



**Department of Vermont Health Access
Pharmacy Benefit Management Program**

**VERMONT
PREFERRED DRUG LIST
and
DRUGS REQUIRING PRIOR
AUTHORIZATION**

Clinical Criteria Manual

November 22, 2011

Preferred Drug List and Drugs Requiring Prior Authorization

The Commissioner for Office of Vermont Health Access shall establish a pharmacy best practices and cost control program designed to reduce the cost of providing prescription drugs, while maintaining high quality in prescription drug therapies. The program shall include:

“A preferred list of covered prescription drugs that identifies preferred choices within therapeutic classes for particular diseases and conditions, including generic alternatives”

From Act 127 passed in 2002

The following pages contain:

1. The therapeutic classes of drugs subject to the Preferred Drug List, the drugs within those categories and the criteria required for Prior Authorization (P.A.) of non-preferred drugs in those categories.
2. The therapeutic classes of drugs which have Clinical Criteria for Prior Authorization may or may not be subject to a preferred agent.
3. Within both of these categories there may be drugs or even drug classes that are subject to Quantity Limit Parameters.

Therapeutic class criteria are listed alphabetically. Within each category the Preferred Drugs are noted in the left-hand columns. Representative non-preferred agents have been included and are listed in the right-hand columns. Any drug not listed as preferred in any of the included categories requires Prior Authorization.

I. THERAPEUTIC CLASS CRITERIA

Acne Medications:

Oral	6
Topical-Anti-infectives	8
Topical-Retinoids	10
Topical-Rosacea	11

Alpha₁-Proteinase Inhibitors..... 12

Alzheimer's Medications:

Cholinesterase Inhib/NMDA Receptor Antagonists	13
--	----

Analgesics:

Cox-2 Inhibitors and NSAIDs	15
Miscellaneous: Transdermal Patch	19
Narcotics-Short Acting	20
Narcotics-Long Acting	23
Long Acting Narcotics - P. A. Request Form	25

Anemia Medications..... 26

Ankylosing Spondylitis-Injectables..... 27

Anti-anxiety: Anxiolytics..... 29

Anticoagulants..... 31

Anticonvulsants..... 33

Anti-depressants:

Miscellaneous	36
SNRIs	38
SSRIs	40
Tricyclics & MAOIs	42

Anti-diabetics:

Insulin	44
Oral	45
Peptide Hormones	48

Anti-emetics:

5-HT₃ Antagonists	49
NK1 Antagonists	51
Other	52

Anti-hyperkinesia and Anti-Narcolepsy:

Short/Intermediate-Acting MPH	53
Long-Acting MPH	53
Short/Intermediate-Acting Amphetamines	53
Long-Acting Amphetamines	53
Non-Stimulant Products	54
Xyrem	56

Anti-hypertensives:

ACE Inhibitors & ACEI Combinations	58
ARBs & ARB Combinations	59
Beta-Blockers	61
Calcium Channel Blockers	63
Renin Inhibitors	65

Anti-infectives:

Antibiotics: Cephalosporins -1st, 2nd and 3rd Gen.	66
Antibiotics: Ketolides	68
Antibiotics: Macrolides	69
Antibiotics: Oxazolidinones	71
Antibiotics: Penicillins (Oral)	72

Antibiotics: Quinolones	73
---	----

Anti-fungal: Allylamines	74
--	----

Anti-fungal: Azoles	76
---	----

Antimalarials: Quinine	78
--	----

Antivirals: Herpes (Oral)	79
---	----

Antivirals: Influenza Medications	80
---	----

Antivirals: Influenza Vaccines	82
--	----

Anti-migraine: Triptans..... 84

Anti-Obesity..... 86

Anti-psychotics:

Atypicals & Combinations	87
--	----

Typicals	92
--------------------------------	----

Bone Resorption Inhibitors..... 93

Bone Resorption Inhibitors Injectable – P.A. Form	96
---	----

Botulinum Toxins..... 97

BPH Agents..... 99

Cardiac Glycosides..... 101

Chemical Dependency..... 102

Buprenorphine - P. A. Request Form	104
--	-----

Vivitrol - P. A. Request Form	105
---	-----

Compounded Products..... 106

Constipation: Chronic, IBS-C or Opioid Induced.... 107

Contraceptives: Vaginal Ring..... 108

Coronary Vasodilators/Antianginals:

Oral and Topical	109
--	-----

Corticosteroids: Oral..... 111

Cough and Cold Preparations..... 112

Cryopyrin-Associated Periodic Syndrome (CAPS)

injectables	113
-----------------------------------	-----

Cystic Fibrosis:

Inhaled Medications	114
---	-----

Specialty Pharmacy Order Form	115
---	-----

Dermatological Agents:

Actinic Keratosis Therapy	116
---	-----

Antibiotics: Topical	117
--	-----

Antifungals: Onychomycosis	118
--	-----

Antifungals: Topical	119
--	-----

Antivirals: Topical	121
---	-----

Corticosteroids	122
---------------------------------------	-----

Genital Wart Therapy	124
--	-----

Immunomodulators	125
--	-----

Scabicides and Pediculicides	126
--	-----

Desmopressin: Intranasal/Oral..... 127

Diabetic Testing Supplies..... 128

Estrogens: Vaginal..... 129

Fibromyalgia Agents..... 130

Gastrointestinals:

Crohn's Disease-Injectables	131
---	-----

H2-blockers	133
-----------------------------------	-----

Inflammatory Bowel Agents (Oral/Rectal)	134
---	-----

Prokinetic Agents	135
---	-----

Continued on next page

Proton Pump Inhibitors	136
Ulcerative Colitis-Injectables	138
Gaucher Disease Medications	139
Gout Agents: Xanthine Oxidase Inhibitors	140
Growth Stimulating Agents	142
Growth Stimulating Agents - P.A./Order Form	144
Hemophilia Factors:	
Specialty Pharmacy Order Form	145
Hepatic Encephalopathy Agents	146
Hepatitis C Medications	147
Hepatitis C (Peg-interferon/Ribavirin)-P.A.Form	149
Hepatitis C Protease Inhibitors-P.A./Order Form	150
Hereditary Angioedema Medications	151
Lipotropics:	
Bile Acid Sequestrants	152
Fibric Acid Derivatives	153
Nicotinic Acid Derivatives	155
Statins	156
Miscellaneous/Combinations	158
Management of Mental Health Medications	160
Miscellaneous	
Carbaglu[®]	161
Elaprase[®] (Hunter's Syndrome Injectable)	162
Glycopyrrolate	163
Lysteda[®]	164
Nuedexta[®]	165
Samsca[®] (for Hyponatremia)	166
Soliris[®] (Paroxysmal Nocturnal Hemoglobinuria Injectable)	167
Somatuline[®] (Acromegaly Injectable)	168
Xenazine[®] (Huntington's Disease with Chorea)	169
Mood Stabilizers	170
Mucosal Coating Agents	171
Multiple Sclerosis Medications	172
Self Injectables Specialty Pharmacy Order Form	174
Nutritionals, enteral	175
Nutritionals, enteral - P.A. Request Form	176
Oncology: Oral (Selected Agents):	
Specialty Pharmacy Order Form	178
Ophthalmics:	
Antibiotics	179
Antihistamines	181
Corticosteroids: Topical	182
Glaucoma Agents/Miotics	183
Immunomodulators	185
Mast Cell Stabilizers	186
NSAIDs	187
Otic: Anti-infectives	188
Over-the-Counter (OTC) Medications	190
Pancreatic Enzyme Products	191
Parkinson's Medications	192
Phosphodiesterase-4 Inhibitors	194

Phosphodiesterase-5 Inhibitors	195
Platelet Inhibitors	197
Psoriasis Injectables	198
Psoriasis Non-biologics	201
Pulmonary:	
Anticholinergics, Inhaled	202
Antihistamines: Intranasal	203
Antihistamines-1st Generation	204
Antihistamines-2nd Generation	205
Beta-Adrenergic Agents	207
Corticosteroids: Inhaled	209
Corticosteroids: Intranasal	211
Leukotriene Modifiers	212
Synagis[®]	213
Synagis[®] - P. A./Order Form	214
Xolair[®]	215
Xolair[®] - P.A. Request Form	216
Pulmonary Arterial Hypertension Medications	217
Renal Disease: Phosphate Binders	218
Rheumatoid, Juvenile and Psoriatic Arthritis Medications	219
Saliva Stimulants	222
Sedative/Hypnotics:	
Benzodiazepine	223
Non-Benzodiazepine, Non-Barbiturate	224
Skeletal Muscle Relaxants: Oral	
Musculoskeletal Agents	226
Antispasticity Agents	226
Smoking Cessation Therapies	228
Testosterone: Topical	229
Thrombopoietin Receptor Agonists	230
Urinary Antispasmodics	231
Vaginal: Anti-infectives	233
Vitamins: Prenatal Vitamins	234

Table of contents for Prior Authorization/Order forms next page

**II. PRIOR AUTHORIZATION REQUEST &
SPECIALTY PHARMACY ORDER FORMS**

Bone Resorption Inhibitors Injectable	237
Buprenorphine	238
Cystic Fibrosis Inhaled	239
Enbrel®	240
General	241
General SPECIALTY	242
Gilenya®	243
Growth Stimulating Agents	244
Hemophilia Factors	245
Hepatitis C Meds (Peg-Interferon/Ribavirin)	246
Hepatitis C Protease Inhibitors	247
Humira®	248
Kineret®	249
Long-Acting Narcotics	250
Multiple Sclerosis Self Injectables	251
Nutritionals	252
Oncology: Oral	254
Remicade®	255
Seroquel®	256
Simponi®	257
Stelara®	258
Synagis®	259
Vivitrol®	260
Xolair®	261

Acne Drugs: Oral

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Brand name minocycline products:

- The patient has had a documented side effect, allergy, or treatment failure with generic minocycline. If a product has an AB rated generic, the trial must be the generic formulation.

Brand name doxycycline products (see below for Oracea[®] and Vibramycin[®] Suspension),:

- The patient has had a documented side effect, allergy, or treatment failure with generic doxycycline. If a product has an AB rated generic, the trial must be the generic formulation.

Oracea[®]:

- The patient has a diagnosis of Rosacea.

AND

- The patient has had a documented side effect, allergy, or treatment failure with doxycycline, minocycline, and tetracycline.

Vibramycin[®] Suspension, Syrup:

- The patient has a medical necessity for a liquid dosage form.

Brand name erythromycin products:

- The patient has had a documented side effect, allergy, or treatment failure with generic erythromycin. If a product has an AB rated generic, the trial must be the generic formulation.

Brand name tetracycline products:

- The patient has had a documented side effect, allergy, or treatment failure with generic tetracycline. If a product has an AB rated generic, the trial must be the generic formulation.

LIMITATIONS:

Minocycline SR products and doxycycline SR products (brand and generic) not covered. Adoxa[®] Pak and doxycycline monohydrate Pak specialty packaging dosage form not covered. Adoxa[®] 150mg cap and doxycycline monohydrate 150 mg cap (brand and generic) not covered.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Acne Drugs: Oral

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
DOXYCYCLINE† 20mg, 50mg, 75mg, 100mg, tab, cap	Adoxa ^{®*} (doxycycline monohydrate) 50 mg, 75 mg, 100 mg tab Monodox ^{®*} (doxycycline monohydrate) 50 mg, 100 mg cap Oracea [®] (doxycycline monohydrate) 40 mg cap Periostat ^{®*} (doxycycline hyclate) 20 mg Vibramycin ^{®*} (doxycycline hyclate) 50 mg, 100 mg cap Vibramycin [®] (doxycycline hyclate) suspension Vibramycin [®] (doxycycline calcium) syrup Vibratab ^{®*} (doxycycline hyclate) 100 mg tab All other brands
E.E.S ^{®†} (erythromycin ethylsuccinate) ERY-TAB [®] (erythromycin base, delayed release) ERYTHROCIN† (erythromycin stearate) ERYTHROMYCIN BASE† ERYTHROMYCIN ETHYLSUCCINATE† (compare to E.E.S [®] , Eryped [®])	Eryped ^{®*} (erythromycin ethylsuccinate) PCE Dispertab [®] (erythromycin base) All other brands
MINOCYCLINE† 50 mg, 75 mg, 100 mg	Minocin ^{®*} (minocycline) 50 mg, 75 mg, 100 mg cap Dynacin ^{®*} (minocycline) 50 mg, 75 mg, 100 mg cap/tab All other brands
TETRACYCLINE† 250 mg, 500 mg cap	All brands
ISOTRETINOIN† 10 mg, 20 mg, 40 mg cap (SOTRET, CLARAVIS, AMNESTEEM)	All other brands

Acne Drugs: Topical-Anti-infectives

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Brand name single ingredient products:

- The patient has had a documented side effect, allergy, or treatment failure with generic benzoyl peroxide, clindamycin, erythromycin, and sodium sulfacetamide. (If a product has an AB rated generic, one trial must be the generic.)

Brand name combination products:

- The patient has had a documented side effect, allergy, or treatment failure with generic erythromycin/benzoyl peroxide and sodium sulfacetamide/sulfur. (If a product has an AB rated generic, one trial must be the generic.)
AND
- The patient has had a documented side effect or treatment failure on combination therapy with the separate generic ingredients of the requested combination product, if applicable.

Azelex[®]

- The diagnosis or indication is acne or rosacea.
AND
- The patient has had a documented side effect, allergy, or treatment failure with two generic topical anti-infective agents (benzoyl peroxide, clindamycin, erythromycin, erythromycin/benzoyl peroxide, sodium sulfacetamide, sodium sulfacetamide/sulfur etc).

LIMITATIONS:

Kits with non-drug products are not covered.

Benzoyl Peroxide Aerosol (Foam) and Benzefoam[®] not covered. Other topical generic benzoyl peroxide preparations preferred.

Clindamycin Aerosol (Foam) and Evoclin[®] not covered. Other topical generic clindamycin preparations preferred.

Sodium sulfacetamine/Sulfur Aerosol (Foam), Rosula[®] and Clarifoam[®] not covered. Other topical generic sodium sulfacetamide/sulfur preparations preferred.

Epiduo[®] (adapalene/benzoyl peroxide) combination not covered. Agents may be prescribed separately.

SE BPO[®] (benzoyl peroxide) foaming cloths dosage form not covered. Other topical generic benzoyl peroxide preparations preferred.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Acne Drugs: Topical - Retinoids

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Brand name tretinoin products:

- The diagnosis or indication is acne vulgaris, actinic keratosis, or rosacea.
AND
- The patient has had a documented side effect, allergy, or treatment failure with a generic topical tretinoin product. If a product has an AB rated generic, the trial must be the generic formulation.

Differin(brand) and adapalene(generic):

- The diagnosis or indication is acne vulgaris, actinic keratosis, or rosacea.
AND
- The patient has had a documented side effect, allergy, or treatment failure with a generic topical tretinoin product.
AND
- If the request is for the brand product, the patient has had a documented intolerance to a generic adapalene product.

Tretinoin (age <10 or >34):

- The diagnosis or indication is acne vulgaris, actinic keratosis, or rosacea.

LIMITATIONS:

Coverage of topical retinoid products will not be approved for cosmetic use (wrinkles, age spots, etc.).

Epiduo Gel, Ziana – These combinations not covered, individual components may be prescribed separately.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Acne Drugs: Topical - Retinoids		<i>Length of Authorization: 1 year</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
<p>TRETINOIN† (<i>specific criteria required for ages <10 or >34</i>) 0.025%, 0.05%, 0.1% C; 0.01%, 0.025% G AVITA® (tretinoin)</p> <p>TAZORAC® (tazarotene) 0.05%, 0.1% C, G</p>	<p>All brand tretinoin products (Atralin® 0.05% G, Retin-A®*, Retin-A Micro® 0.1%, 0.04%, Tretin-X® etc.)</p> <p>adapalene† (compare to Differin®) 0.1% C, G Differin® (adapalene) 0.1% C, G, L; 0.3% G</p> <p>Avage® (tazarotene) ♣ Renova® (tretinoin) ♣ Solage® (tretinoin/mequinol) ♣ Tri-Luma® (tretinoin/hydroquinone/fluocinolone) ♣</p> <p>♣ <i>Not indicated for acne. Coverage of topical retinoid products will not be approved for cosmetic use (wrinkles, age spots, etc.).</i></p>	

C=cream, G=gel

Acne Drugs: Topical - Rosacea

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Brand name metronidazole products and Finacea:

- The diagnosis or indication is acne or rosacea.

AND

- The patient has had a documented side effect, allergy or treatment failure with a generic topical metronidazole product. If a product has an AB rated generic, the trial must be the generic formulation.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Acne Drugs: Topical – Rosacea		<i>Length of Authorization: 1 year</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
METRONIDAZOLE† 0.75% C, G, L	All brand metronidazole products (MetroCream®* 0.75% C, Metrogel®* 0.75% G, Metrogel® 1% G, MetroLotion®* 0.75% L, Noritate® 1% C, Rozex® 0.75% G etc.) Finacea® (azelaic acid) 15% G	

C=cream, G=gel, L=lotion

Alpha₁-Proteinase Inhibitors

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

The indication for use is treatment of alpha₁-proteinase inhibitor deficiency-associated lung disease when all of the following criteria are met:

- Patient's alpha₁-antitrypsin (AAT) concentration < 80 milligrams per deciliter (mg/dl) [or <11 micromolar (μM)]
AND
- Patient has obstructive lung disease as defined by a forced expiratory volume in one second (FEV₁) of 30 – 65 % of predicted or a rapid decline in lung function defined as a change in FEV₁ of > 120 mL/year.
AND
- Medication is being administered intravenously (inhalation administration will not be approved).
AND
- Patient is a non-smoker.
OR
- Patient meets above criteria except lung function has deteriorated beneath above limits while on therapy.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**
- ✓ All requests for alpha₁-proteinase inhibitors (whether billed through the pharmacy or medical benefit (J0256 – all except Glassia[®] or J0257 - Glassia[®])) require Prior Authorization through the MedMetrics Clinical Call Center.

Alpha₁-Proteinase Inhibitors		<i>Length of Authorization: 6 months</i>
NO PA REQUIRED	PA REQUIRED	
	Aralast NP [®] Glassia [®] Prolastin [®] Prolastin-C [®] Zemaira [®]	**Maximum days supply per fill for all drugs is 14 days**

Alzheimer's: Cholinesterase Inhibitors/NMDA Receptor Antagonists

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Cognex Capsule, Galantamine Tablet, Galantamine ER Capsule, Razadyne Tablet, Razadyne ER Capsule:

- The diagnosis or indication for the requested medication is Alzheimer's disease.
AND
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
OR
- The patient had a documented side effect, allergy or treatment failure to Aricept and Exelon.
AND
- If the product has an AB rated generic, the patient has a documented intolerance to the generic.

Donepezil:

- The diagnosis or indication for the requested medication is Alzheimer's disease.
AND
- The patient has a documented intolerance to the brand product.

Galantamine Oral Solution, Razadyne Oral Solution:

- The diagnosis or indication for the requested medication is Alzheimer's disease.
AND
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
OR
- The patient had a documented side effect, allergy or treatment failure to Exelon Oral Solution.
AND
- If the product has an AB rated generic, the patient has a documented intolerance to the generic.

Aricept ODT, donepezil ODT:

- The diagnosis or indication for the requested medication is Alzheimer's disease.
AND
- Medical necessity for a specialty dosage form has been provided.
AND
- If the request is for donepezil ODT, the patient has a documented intolerance to the brand product.

Rivastigmine Oral Capsule:

- The diagnosis or indication for the requested medication is Alzheimer's disease.
AND
- The patient has a documented intolerance to the brand Exelon product.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Alzheimer's: Cholinesterase Inhibitors/NMDA Receptor Antagonists

Length of Authorization: 1 year

Key: § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>CHOLINESTERASE INHIBITORS</u> ARICEPT[®] (donepezil) Tablet <i>(QL = 1 tablet/day)</i> EXELON[®] (rivastigmine) Capsule <i>(QL = 2 capsules/day)</i></p> <p>EXELON[®] (rivastigmine) Oral Solution</p> <p>EXELON[®] (rivastigmine transdermal) Patch <i>(QL = 1 patch/day)</i></p> <p><u>NMDA RECEPTOR ANTAGONIST</u> NAMENDA[®] (memantine) Tablet NAMENDA[®] (memantine) Oral Solution</p>	<p>Cognex[®] (tacrine) Capsule § donepezil† (compare to Aricept[®]) tablet <i>(QL = 1 tablet/day)</i> galantamine† tablet § (compare to Razadyne[®]) galantamine ER† capsule § (compare to Razadyne ER[®]) Razadyne[®] (galantamine) Tablet Razadyne ER[®] (galantamine) Capsule rivastigmine† (compare to Exelon[®]) capsule <i>(QL = 2 capsules/day)</i></p> <p>Aricept[®] ODT (donepezil) <i>(QL = 1 tablet/day)</i> donepezil ODT† (compare to Aricept[®] ODT) <i>(QL = 1 tablet/day)</i></p> <p>galantamine† (compare to Razadyne[®]) Oral Solution Razadyne[®] (galantamine) Oral Solution</p>

Analgesics: COX II and NSAIDs

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Arthrotec:

- The patient has had a documented side effect or treatment failure to two or more preferred generic NSAIDs.
- OR**
- The patient is not a candidate for therapy with a preferred generic NSAID due to one of the following:
 - o The patient is 60 years of age or older
 - o Patient has a history of GI bleed
 - o Patient is currently taking an oral corticosteroid
 - o Patient is currently taking methotrexate
- AND**
- The patient is unable to take the individual components (diclofenac and misoprostol), separately.

Cambia:

- The drug is being prescribed for treatment of acute migraine attacks.
- AND**
- The patient has had a documented side effect or treatment failure to two or more preferred generic NSAIDs, one of which must be generic diclofenac.
- OR**
- The drug is being prescribed for treatment of acute migraine attacks.
- AND**
- The patient has a requirement for an oral liquid dosage form (i.e. swallowing disorder, inability to take oral medications)
- AND**
- The patient has had a documented side-effect or treatment failure with the generic ibuprofen suspension **and** the generic naproxen suspension.

Celebrex:

- The patient does not have a history of a sulfonamide allergy.
- AND**
- The patient has had a documented side effect, allergy, or treatment failure to two or more preferred generic NSAIDs.
- OR**
- The patient is not a candidate for therapy with a preferred generic NSAID due to one of the following
 - o The patient is 60 years of age or older
 - o Patient has a history of GI bleed
 - o Patient is currently taking an anticoagulant (warfarin or heparin)
 - o Patient is currently taking an oral corticosteroid
 - o Patient is currently taking methotrexate

Flector Patch, Pennsaid:

- The diagnosis or indication is osteoarthritis or acute pain caused by minor strains, sprains, and contusions.
- AND**
- The patient has had a documented side-effect or inadequate response to Voltaren gel.
- AND**
- The patient has had a documented side effect or treatment failure with at least two preferred generic NSAIDS.
- OR**
- The patient is not a candidate for therapy with a preferred generic NSAID due to one of the following:
 - The patient is 60 years of age or older
 - Patient has a history of GI bleed
 - Patient is currently taking an oral corticosteroid
 - Patient is currently taking methotrexate
- OR**
- The patient has a documented medical necessity for a topical/transdermal formulation (ex. dysphagia, inability to take oral medications).

Voltaren Gel:

- The diagnosis or indication is osteoarthritis or acute pain caused by minor strains, sprains, and contusions.
- AND**
- The patient has had a documented side effect or treatment failure with at least two preferred generic NSAIDS.
- OR**
- The patient is not a candidate for therapy with a preferred generic NSAID due to one of the following:
 - The patient is 60 years of age or older
 - Patient has a history of GI bleed
 - Patient is currently taking an oral corticosteroid
 - Patient is currently taking methotrexate
- OR**
- The patient has a documented medical necessity for a topical/transdermal formulation (ex. dysphagia, inability to take oral medications).

Vimovo:

- The patient has had a documented side effect or treatment failure to two or more preferred generic NSAIDS.
- OR**
- The patient is not a candidate for therapy with a preferred generic NSAID due to one of the following:
 - The patient is 60 years of age or older
 - Patient has a history of GI bleed
 - Patient is currently taking an oral corticosteroid
 - Patient is currently taking methotrexate
- AND**
- The patient is unable to take naproxen and a preferred proton pump inhibitor, separately.

Zipsor:

- The patient has had a documented intolerance to diclofenac tablets.
- AND**
- The patient has had a documented side effect, allergy, or treatment failure to four or more preferred generic NSAIDS.

All other PA requiring NSAIDs:

- The patient has had a documented side effect or treatment failure to two or more preferred generic NSAIDS. (If a product has an AB rated generic, one trial must be the generic.)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Consider selectivity for cyclooxygenase-2 of the available nonsteroidal anti-inflammatory agents.

In order of most to least selective for COX-2: (preferred agents bold)

Diclofenac (Voltaren[®]) > Mefenamic acid (Ponstel[®]) > **Meloxicam** (Mobic[®]) >
Celecoxib (Celebrex[®]) = **Etodolac** (Lodine[®]) > **Nabumetone** (Relafen[®]) >
Piroxicam (Feldene[®]) > **Ketorolac** (Toradol[®]) > **Ibuprofen** (Motrin[®], Advil[®]) > **Indomethacin** (Indocin[®]) >
Naproxen (Naprosyn[®], Aleve[®]) > **Oxaprozin** (Daypro[®]) > **Aspirin** > **Tolmetin** (Tolectin[®]) > **Fenoprofen**
(Nalfon[®]) > **Ketoprofen** (Orudis[®]) > **Flurbiprofen** (Ansaid[®])¹

¹ Feldman, McMahon in Ann Intern Med. 2000;132:134-143, Do Cyclooxygenase-2 Inhibitors Provide Benefits Similar to Those of Traditional Nonsteroidal Anti-Inflammatory Drugs, with Less Gastrointestinal Toxicity?

Analgesics: COX II AND NSAIDs

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

NSAIDs	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>ORAL</u></p> <p>SINGLE AGENT</p> <p>DICLOFENAC POTASSIUM† (compare to Cataflam®)</p> <p>DICLOFENAC SODIUM† (compare to Voltaren®)</p> <p>DIFLUNISAL† (formerly Dolobid®)</p> <p>ETODOLAC† (formerly Lodine®)</p> <p>FLURBIPROFEN† (formerly Ansaid®)</p> <p>IBUPROFEN† (compare to Motrin®)</p> <p>INDOMETHACIN† (formerly Indocin®, Indocin SR®)</p> <p>KETOPROFEN†</p> <p>KETOPROFEN ER†</p> <p>KETOROLAC† (formerly Toradol®) (QL = 20 doses/5 day supply every 90 days)</p> <p>MECLOFENAMATE SODIUM† (formerly Meclomen®)</p> <p>MELOXICAM† tabs (compare to Mobic®)</p> <p>NABUMETONE† (formerly Relafen®)</p> <p>NAPROXEN† (compare to Naprosyn®)</p> <p>NAPROXEN ENTERIC COATED† (compare to EC-Naprosyn®)</p> <p>NAPROXEN SODIUM† (compare to Anaprox®, Anaprox DS®, Naprelan®)</p> <p>OXAPROZIN† (compare to Daypro®)</p> <p>PIROXICAM† (compare to Feldene®)</p> <p>SULINDAC† (compare to Clinoril®)</p> <p>TOLMETIN SODIUM† (formerly Tolectin®)</p> <p><u>INJECTABLE</u></p> <p>KETOROLAC † Injection (formerly Toradol®) (QL = 1 dose per fill)</p> <p><u>TOPICAL/TRANSDERMAL</u></p> <p><u>NSAID/ANTI-ULCER</u></p>	<p>Anaprox®* (naproxen sodium)</p> <p>Anaprox DS®* (naproxen sodium)</p> <p>Cambia® (diclofenac potassium) packet for oral solution (QL = 9 packets/month)</p> <p>Cataflam®* (diclofenac potassium)</p> <p>Clinoril®* (sulindac)</p> <p>Daypro®* (oxaprozin)</p> <p>EC-Naprosyn®* (naproxen sodium enteric coated)</p> <p>Feldene®* (piroxicam)</p> <p>Fenoprofen 600 mg tablets</p> <p>Indocin® (indomethacin) susp</p> <p>Indocin SR®* (indomethacin) caps</p> <p>mefenamic acid† capsules (compare to Ponstel®)</p> <p>meloxicam suspension</p> <p>Mobic® (meloxicam) suspension</p> <p>Mobic®* (meloxicam) tablets</p> <p>Motrin®* (ibuprofen)</p> <p>Nalfon® (fenoprofen) 200 & 400 mg capsules</p> <p>Naprelan®* (naproxen sodium)</p> <p>Naprosyn®* (naproxen sodium)</p> <p>Ponstel® (mefenamic acid)</p> <p>Voltaren®* (diclofenac sodium)</p> <p>Voltaren XR®* (diclofenac sodium SR)</p> <p>Zipsor® (diclofenac potassium)</p> <p>Flector® (diclofenac) Patch (QL = 2 patches/day)</p> <p>Pennsaid® (diclofenac) Topical Solution</p> <p>Voltaren® (diclofenac) Gel</p> <p>Arthrotec® (diclofenac sodium w/misoprostol)</p> <p>Vimovo® (naproxen/esomeprazole) (QL = 2 tablets/day)</p>
COX II Inhibitors	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
	<p>CELEBREX® (celecoxib) (Quantity limit all strengths = 2 capsules/day)</p>

Note: Please refer to “Dermatologicals: Actinic Keratosis Therapy” for Solaraze®

Analgesics: Miscellaneous: Transdermal Patch

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

LIDODERM®

- The diagnosis or indication is neuropathic pain/post-herpetic neuralgia.
AND
- The patient has had a documented side effect, allergy, treatment failure or contraindication to TWO drugs in the tricyclic antidepressant (TCA) class and/or anticonvulsant class
AND
- The patient has had a documented side effect, allergy, treatment failure or contraindication to Lyrica
OR
- The patient has a medical necessity for a transdermal formulation (ex. dysphagia, inability to take oral medications)

QUTENZA®

- The diagnosis or indication is post-herpetic neuralgia.
AND
- The patient has had a documented side effect, allergy, treatment failure or contraindication to TWO drugs in the tricyclic antidepressant (TCA) class and/or anticonvulsant class
AND
- The patient has had a documented side effect, allergy, treatment failure or contraindication to Lyrica
AND
- The patient has had a documented side effect, allergy, treatment failure or contraindication to Lidoderm
OR
- The patient has a medical necessity for a transdermal formulation (ex. dysphagia, inability to take oral medications)
AND
- The patient has had a documented side effect, allergy, treatment failure or contraindication to Lidoderm

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Analgesics: Miscellaneous: Transdermal Patch <i>Length of Authorization: 6 months</i>	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
	Lidoderm® Patch (lidocaine 5 %) <i>Quantity Limit = 3 patches/day</i> Qutenza® Patch (capsaicin 8 %) <i>Quantity Limit = 4 patches/90 days</i>

Note: Please refer to “Analgesics: Long Acting Narcotics” for Duragesic® and fentanyl patch
 Please refer to “Analgesics: COX II and NSAIDs” for Flector® patch

Analgesics: Narcotics: Short Acting

LENGTH OF AUTHORIZATION: initial approval 3 months, subsequent approval up to 6 months

CRITERIA FOR APPROVAL:

Butorphanol Nasal Spray

- The member has had a documented side effect, allergy, treatment failure, or contraindication to codeine, hydrocodone, morphine, and oxycodone (all 4 generic entities) as single or combination products.
- OR
- The member is unable to use tablet or liquid formulations.

Abstral[®], Actiq[®], fentanyl transmucosal, Fentora[®], Onsolis[®]

- Indication of cancer breakthrough pain (no approval for acute pain or postoperative pain)
- AND
- Documentation that the patient is opioid tolerant (oral morphine \geq 60 mg/day, transdermal fentanyl 25 mcg/hr, oral oxycodone \geq 30 mg/day, oral hydromorphone \geq 8 mg/day or an equianalgesic dose of another opioid for \geq 1 week)
- AND
- The member is on a long-acting opioid formulation
- AND
- The member has had a documented treatment failure with or intolerance to 2 of the following 3 immediate –release breakthrough pain treatment options: morphine, hydromorphone or oxycodone.
- OR
- The member is unable to use tablet or liquid formulations.
- AND
- If the request is for brand name Actiq[®], the member has a documented intolerance to generic fentanyl transmucosal.

Dilaudid[®]-5 Oral Solution

- The member has had a documented side effect, allergy or treatment failure with oxycodone oral solution and morphine oral solution.
- OR
- The member has been started and stabilized on another dosage form of hydromorphone.
- AND
- The member has a medical necessity for a liquid dosage form.

Nucynta[®], Opana[®], Oxymorphone

- The member has had a documented side effect, allergy, or treatment failure to at least two of the following 3 immediate release generic short acting narcotic analgesics – morphine, hydromorphone or oxycodone.
- AND
- If the request is for brand name Opana[®], the member has a documented intolerance to generic oxymorphone.

Oxycodone (generic) Capsules

- The member has a documented intolerance to generic oxycodone tablets.

Ultram[®], Ultracet[®]

- The member has a documented intolerance to the generic formulation.

Rybix ODT[®]

- The member has a medical necessity for a disintegrating tablet formulation (i.e. swallowing disorder)

Ryzolt[®], Tramadol ER, Ultram ER[®]

- The member has had a documented side effect or treatment failure to a preferred short-acting tramadol product. In addition, for approval of Ryzolt[®] or Ultram ER[®], the patient must have a documented intolerance to generic tramadol ER.

Other Short-acting Narcotics

- The member has had a documented side effect, allergy, or treatment failure to at least two medications not requiring prior approval. (If a product has an AB rated generic, one trial must be the generic.)

LIMITATIONS:

Acetaminophen containing products: Daily doses that result in > 4 grams of acetaminophen/day will reject for Prior Authorization. Meperidine 75 mg/ml injection no longer available – 25 mg/ml, 50 mg/ml and 100 mg/ml available. Brand name Demerol 75 mg/ml and 100 mg/2 ml not covered – no generic equivalents.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on the **General Prior Authorization Request Form**.

Analgesics: Narcotics: Short Acting

Length of Authorization: initial approval 3 months, subsequent approval up to 6 months

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (NO PA REQUIRED)	PA REQUIRED
ACETAMINOPHEN W/CODEINE† (compare to Tylenol w/codeine®)	Abstral® (fentanyl) Sublingual Tablets
ACETAMINOPHEN W/HYDROCODONE† (compare to Vicodin®, Lorcet®, Maxidone®, Norco®, Zamicet®, Zydone®) (QL 5/500 = 8 tablets/day, 10/500 = 8 tablets/day, 7.5/750 = 5 tablets/day; 10/325 = 185 ml/day)	Acetaminophen w/codeine: all branded products
ACETAMINOPHEN W/OXYCODONE† (compare to Percocet®) (QL 10/650 = 6 tablets/day)	Acetaminophen w/hydrocodone: all branded products (QL 5/500 = 8 tablets/day, 10/500 = 8 tablets/day, 7.5/750 = 5 tablets/day)
ASPIRIN W/CODEINE†	Acetaminophen w/hydrocodone (compare to Xodol®) (QL=13 tablets/day)
ASPIRIN W/OXYCODONE† (compare to Percodan®)	Acetaminophen w/oxycodone: all branded products (QL 10/650 = 6 tablets/day)
BUTALBITAL COMPOUND W/ CODEINE† (compare to Fiorinal® w/codeine)	Actiq® (fentanyl citrate transmucosal)
CODEINE SULFATE†	Anexsia®* (acetaminophen w/hydrocodone)
DIHYDROCODEINE COMPOUND† (compare to Synalgos-DC®)	Butorphanol Nasal Spray† (Qty Limit = 2 bottles/month)
ENDOCET® (oxycodone w/ acetaminophen)	Capital® w/codeine* (acetaminophen w/codeine)
ENDODAN® (oxycodone w/ aspirin)	Cocet®/ Cocet Plus® (acetaminophen w/codeine) (QL 30/650 or 60/650 = 6 tablets/day)
FIORTAL W/ CODEINE #3® (butalbital w/ codeine)	Combunox®* (oxycodone w/ ibuprofen)
HYDROCODONE† (plain, w/acetaminophen or w/ibuprofen) (some exceptions apply)	Dazidox®* (oxycodone)
HYDROMORPHONE† (compare to Dilaudid®)	Demerol* (meperidine)
MEPERIDINE† (compare to Demerol®) (Maximum 30 tabs or 5 day supply)	Dilaudid®*(hydromorphone)
MORPHINE SULFATE†	Dilaudid-5®(hydromorphone) oral solution
MORPHINE SULFATE SOLN† (compare to Roxanol®)	fentanyl citrate transmucosal† (compare to Actiq®)
OXYCODONE† (plain, w/acetaminophen or w/ibuprofen)	Fentora® (fentanyl citrate buccal tablets)
PENTAZOCINE† (compare to Talwin®)	Fioricet® w/codeine*(butalbital/acetaminophen/caffeine/codeine)
ROXICET® (oxycodone w/ acetaminophen)	Ibudone®* (hydrocodone w/ ibuprofen)
ROXICODONE INTENSOL® (oxycodone)	Liquicet® (hydrocodone w/ acetaminophen)
ROXICODONE® (oxycodone HCL)	Lorcet®* (also HD, PLUS) (hydrocodone w/ acetaminophen)
TRAMADOL† (compare to Ultram®) (Qty Limit = 8 tablets/day)	Lortab®*(hydrocodone w/ acetaminophen)
TRAMADOL/APAP† (compare to Ultracet®) (Qty Limit = 8 tablets/day)	Magnacet® (oxycodone w/ acetaminophen)
	Maxidone®*(hydrocodone w/ acetaminophen)
	Meperidine† (Qty > 30 tabs or 5 day supply)
	Norco®*(hydrocodone w/ acetaminophen)
	Nucynta® (tapentadol)
	Onsolis®(fentanyl buccal soluble film)
	Opana® (oxymorphone)
	Oxycodone† (plain) capsules
	Oxyfast®*(oxycodone)
	OxyIR®*(oxycodone)
	Oxymorphone† (compare to Opana®)
	Panlor DC® (acetaminophen/caffeine/dihydrocodeine)
	Pentazocine w/acetaminophen†
	Pentazocine w/naloxone†
	Percocet®*(oxycodone w/ acetaminophen)
	Percodan®* (oxycodone w/aspirin)
	Reprexain®* (hydrocodone w/ ibuprofen)
	Roxanol®*(morphine sulfate)
	Rybix® ODT (tramadol ODT) (Qty Limit = 8 tablets/day)
	Ryzolt® (tramadol SR) (Qty Limit = 1 tablet/day)
	Synalgos DC®*(dihydrocodeine compound)
	Talwin®* (pentazocine) and branded combinations
	Tramadol ER† (compare to Ultram ER®) (Qty Limit = 1 tablet/day)
	Trezix® (acetaminophen/caffeine/dihydrocodeine)
	Tylenol® #3*,#4*(acetaminophen w/codeine)
	Tylox®*(oxycodone w/ acetaminophen)
	Ultracet® (tramadol w/ acetaminophen) (Qty Limit = 8 tablets/day)
	Ultram®* (tramadol) (Qty Limit = 8 tablets/day)
	Ultram ER® (tramadol SR) (Qty Limit = 1 tablet/day)
	Vicodin®*(hydrocodone w/acetaminophen)
	Vicoprofen®*(hydrocodone w/ ibuprofen)
	Xodol® (hydrocodone w/acetaminophen)
	Xolox® (oxycodone w/ acetaminophen)
	Zamicet®*/ Zydone®* (hydrocodone w/ acetaminophen)

Note: Acetaminophen containing products: (Preferred and PA Required)

Maximum daily dose acetaminophen = 4 grams

Analgesics: Narcotics: Long Acting

LENGTH OF AUTHORIZATION: initial approval 3 months, subsequent approval up to 6 months

PHARMACOLOGY/INDICATION:

Long acting narcotics are potent medications. They are indicated for the management of moderate to severe pain in adults when a continuous, around-the-clock analgesic is needed for an extended period of time.

CLINICAL CONSIDERATIONS:

- Long acting narcotic dosage forms are intended for use in opioid tolerant patients only. These tablet/capsule/topical medication strengths may cause fatal respiratory depression when administered to patients not previously exposed to opioids.
- Long acting narcotics should be prescribed for patients with a diagnosis or condition that requires a continuous, around-the-clock analgesic.
- Long acting narcotics are NOT intended for use as a 'prn' analgesic.
- Long acting narcotics are NOT indicated for pain in the immediate post-operative period (the first 12-24 hours following surgery) or if the pain is mild, or not expected to persist for an extended period of time.
- Long acting narcotics are not intended to be used in a dosage frequency other than FDA approved regimens.
- Patients should not be using other extended release narcotics prescribed by another physician.
- Prescribers should consult the VPMS (Vermont Prescription Monitoring System) to review a patient's Schedule II – IV medication use before prescribing long acting narcotics

CRITERIA FOR APPROVAL:

Transdermal:

Generic Fentanyl Patches

- The patient has a diagnosis or condition that requires a continuous, around-the-clock analgesic.

AND

- The patient has had a documented intolerance to brand name Duragesic.

Butrans Transdermal System

- The patient has a diagnosis of moderate to severe pain, requiring a continuous, around-the-clock analgesic for an extended period of time.

AND

- The patient has had a documented side effect, allergy, or treatment failure to morphine sulfate SR 12 hr **AND** brand Duragesic (fentanyl) patch.

OR

- The prescriber provides compelling clinical information for case specific discussion with DVHA Medical Director who will determine PA decision.

Oral Non-Preferred:

- The patient has a diagnosis or condition that requires a continuous, around-the-clock analgesic.

AND

- The patient has had a documented side effect, allergy, or treatment failure to morphine sulfate SR 12 hr **AND** brand Duragesic (fentanyl) patch. (If a product has an AB rated generic, there must have been a trial of the generic) **Note: A**

history of substance abuse does not warrant approval of Embeda[®] since a clear advantage of this product over other morphine products in this population has not been established.

LIMITATIONS:

- (1) Methadone 40 mg dispersible tablet not approved for retail dispensing.
- (2) Embeda: A history of substance abuse does not warrant approval of Embeda[®] since a clear advantage of this product over other morphine products in this population has not been established.

DOCUMENTATION:

- ✓ Please complete and submit the **Long Acting Narcotics Prior Authorization Request Form.**

Analgesics: Narcotics: Long Acting	
<i>Length of Authorization: initial approval 3 months, subsequent approval up to 6 months</i>	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (NO PA REQUIRED)	PA REQUIRED
<u>TRANSDERMAL</u>	
DURAGESIC ^{®*} (fentanyl patch) 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, (<i>QL=15 patches/30 days</i>)	Butrans (buprenorphine) Transdermal System (<i>QL = 2 patches/14 days</i>)(<i>Maximum 14 day fill</i>) Fentanyl Patch† (compare to Duragesic [®]) 12 mcg/hr, 25 mcg/hr, 50 mcg/hr (<i>QL=15 patches/30 days</i>)
DURAGESIC ^{®*} (fentanyl patch) 75 mcg/hr, 100 mcg/hr (<i>QL= 30 patches/30 days</i>)	Fentanyl Patch† (compare to Duragesic [®]) 75 mcg/hr, 100 mcg/hr (<i>QL=30 patches/30 days</i>)
<u>ORAL</u>	
METHADONE† (compare to Dolophine [®]) 5 mg, 10 mg	Avinza [®] (morphine sulfate XR) (<i>QL= 30 capsules/strength/30 days</i>) Dolophine ^{®*} (methadone)
MORPHINE SULFATE SR 12 hr† (compare to MS Contin [®] , Oramorph SR [®]) (<i>QL=90 tablets/strength/30 days</i>)	Embeda [®] (morphine sulfate/naltrexone hydrochloride) Capsules (<i>QL=2 capsules/day</i>) Exalgo [®] (hydromorphone XR) tablet (<i>QL= 30 tablets/30 days (8 mg tabs), 90 tablets/30 days (12 mg tabs), 120 tablets/30 days (16 mg tabs)</i>) Kadian [®] (morphine sulfate XR) (<i>QL= 60 capsules/strength/30 days</i>) MS Contin ^{®*} (morphine sulfate SR 12 hr) (<i>QL=90 tablets/strength/30 days</i>) Opana ER [®] (oxymorphone ER) (<i>QL=60 tablets/strength/30 days</i>) Oramorph SR ^{®*} (morphine sulfate SR 12 hr) (<i>QL=90 tablets/strength/30 days</i>) OxyContin [®] (Oxycodone ER) (<i>QL= 90 tablets/strength/30 days</i>)



Department of Vermont Health Access
 312 Hurricane Lane, Suite 201
 Williston, Vermont 05495

Agency of Human Services

~ LONG ACTING NARCOTICS ~
 Prior Authorization Request Form

Vermont Medicaid has established coverage limits and criteria for prior authorization of long acting narcotics. These limits and criteria are based on concerns about safety and the potential for abuse and diversion. In order for beneficiaries to receive coverage for this drug, it will be necessary for the prescriber to telephone or complete and fax this form to MedMetrics Health Partners. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name: _____
 Phone #: _____
 Fax #: _____
 Address: _____

Beneficiary:

Name: _____
 Medicaid ID #: _____
 Date of Birth: _____ Sex: _____
 Contact Person at Office: _____

Drug Requested:

Please indicate: Brand Name or Generic Equivalent

Dose /Frequency and Length of Therapy:

Diagnosis or Indication for Use:

Has the member previously tried any of the following preferred medications?

<i>Check all that apply:</i>	<i>Response, check all that apply:</i>
<input type="checkbox"/> Duragesic Patches	<input type="checkbox"/> side-effect <input type="checkbox"/> non-response <input type="checkbox"/> allergy
<input type="checkbox"/> Methadone	<input type="checkbox"/> side-effect <input type="checkbox"/> non-response <input type="checkbox"/> allergy
<input type="checkbox"/> Morphine Sulfate SR 12 hr	<input type="checkbox"/> side-effect <input type="checkbox"/> non-response <input type="checkbox"/> allergy

Is this an initial request or a subsequent request? Initial Subsequent

Prescriber comments:

Prescriber Signature: _____ **Date of this request:** _____

Anemia Medications: Hematopoietic/Erythropoietic Agents

LENGTH OF AUTHORIZATION: 3 months initially, 6 months subsequent requests

CRITERIA FOR APPROVAL:

Aranesp[®], Procrit[®]

- The diagnosis or indication for the requested medication is anemia due to one of the following:
 - Chronic kidney disease/renal failure
 - Post-renal transplant
 - Use of zidovudine for the treatment of human immunodeficiency virus (HIV) (other causes of anemia, such as iron/folate/vitamin B12 deficiency have been eliminated)
 - Surgery patients at high risk for perioperative blood loss
 - Cancer chemotherapy
 - Use of ribavirin or interferon therapy for Hepatitis C
 - Myelodysplastic syndrome

- Hemoglobin level at initiation of therapy is <10 g/dL

OR

- For patients currently maintained on therapy, hemoglobin level is ≤11 g/dL in dialysis patients with chronic kidney disease, ≤10 g/dL in non-dialysis patients with chronic kidney disease, or ≤12 g/dL in patients treated for other indications.

Epogen[®]

- The diagnosis or indication for the requested medication is anemia due to one of the following:
 - Chronic kidney disease/renal failure
 - Post-renal transplant
 - Use of zidovudine for the treatment of human immunodeficiency virus (HIV) (other causes of anemia, such as iron/folate/vitamin B12 deficiency have been eliminated)
 - Surgery patients at high risk for perioperative blood loss
 - Cancer chemotherapy
 - Use of ribavirin or interferon therapy for Hepatitis C
 - Myelodysplastic syndrome

- Hemoglobin level at initiation of therapy is <10 g/dL

OR

- For patients currently maintained on therapy, hemoglobin level is ≤11 g/dL in dialysis patients with chronic kidney disease, ≤10 g/dL in non-dialysis patients with chronic kidney disease, or ≤12 g/dL in patients treated for other indications.

AND

- The patient has had a documented side-effect, allergy, or treatment failure to both Aranesp[®] and Procrit[®]

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Anemia: Hematopoietic/Erythropoietic Agents	
<i>Length of Authorization: 3 months initially, 6 months subsequent request</i>	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED AFTER CLINICAL CRITERIA ARE MET	PA REQUIRED
ARANESP [®] (darbepoetin alfa) PROCIT [®] (epoetin alpha)	Epogen [®] (epoetin alpha)

Ankylosing Spondylitis Medications: Injectables

NOTE: Ankylosing Spondylitis Self-Injectables (Enbrel[®], Humira[®] and Simponi[®]) must be obtained and billed through our specialty pharmacy vendor, ICORE Healthcare. Please see the Enbrel, Humira or Simponi Prior Authorization/Patient Enrollment Form for instructions. ICORE Healthcare may supply Remicade[®] upon request or you may continue to obtain through your usual supplier.

LENGTH OF AUTHORIZATION: Initial PA of 3 months, and 12 months thereafter if medication is well tolerated. Re-evaluate every 12 months.

CRITERIA FOR APPROVAL:

Humira[®]

Patient has a diagnosis of ankylosing spondylitis (AS) and has already been stabilized on Humira[®]

OR

Patient has a confirmed diagnosis of AS, and conventional NSAID treatment and DMARD* therapy (e.g. methotrexate therapy) resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD should be tried.

Notes: Approval should be granted in cases where patients have been treated with infliximab, but have lost response to therapy.

Enbrel[®]

Patient has a diagnosis of ankylosing spondylitis (AS) and has already been stabilized on Enbrel[®]

OR

Diagnosis is AS, and conventional NSAID treatment and DMARD* therapy (e.g. methotrexate therapy) resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD should be tried.

Remicade[®]

Patient has a diagnosis of ankylosing spondylitis (AS) and has already been stabilized on Remicade[®]

OR

Diagnosis is AS, and conventional NSAID treatment and DMARD* therapy (e.g. methotrexate therapy) resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD should be tried.

AND

The prescriber must provide a clinically valid reason why either Humira[®] or Enbrel[®] cannot be used.

Simponi[®]

Patient has a diagnosis of ankylosing spondylitis (AS) and has already been stabilized on Simponi[®]

OR

Patient age \geq 18 years

AND

Diagnosis is AS, and patient has documentation of an inadequate response, adverse reaction or allergic response to methotrexate, or if methotrexate is contraindicated, at least 1 DMARD (other DMARDs include leflunomide, sulfasalazine, gold, antimalarials, minocycline, D-penicillamine, azathioprine, cyclophosphamide and cyclosporine)

AND

The prescriber must provide a clinically valid reason why either Humira[®] or Enbrel[®] cannot be used.

* Patients with a documented diagnosis of active axial involvement should have a trial with twoNSAIDs, but a trial with DMARD is not required. If no active axial skeletal involvement, then an NSAID trial and a DMARD trial are required (unless otherwise contraindicated) prior to receiving Humira[®], Enbrel[®], Remicade[®].or Simponi[®]

DOCUMENTATION:

- ✓ Document clinical information for **Enbrel[®]** or **Humira[®]** on its **Prior Authorization/Patient Enrollment Form** and clinically compelling information supporting the choice of **Simponi[®]** on its **Prior Authorization/Patient Enrollment Form** or **Remicade[®]** on a **Remicade Prior Authorization Request Form**.
- ✓ All requests for infliximab (Remicade[®]) (whether billed through the pharmacy or medical benefit (J1745)) require Prior Authorization through the MedMetrics Clinical Call Center.

Ankylosing Spondylitis: Injectables	
<i>Length of authorization: Initial PA of 3 months; 12 months thereafter</i>	
PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET
<p>ENBREL[®] (etanercept) (<i>Quantity limit = 4 syringes/28 days(50 mg), 8 syringes/28 days (25 mg)</i>)</p> <p>HUMIRA[®] (adalimumab) (<i>Quantity limit = 2 syringes/28 days</i>)</p>	<p>Remicade[®] (infliximab) Simponi[®] (golimumab) (<i>Quantity Limit = 1 syringe/28 days</i>)</p>

Anti-Anxiety: Anxiolytics

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL

Non-preferred Benzodiazepines (except for alprazolam ODT, Klonopin Wafers[®], Niravam[®] and Intensol Products):

- The patient has a documented side effect, allergy, or treatment failure to at least two preferred benzodiazepine medications. (If a product has an AB rated generic, one trial must be the generic formulation.)

alprazolam ODT, Klonopin Wafers[®], and Niravam[®]:

- The patient has a documented side effect, allergy, or treatment failure to at least two preferred benzodiazepine medications. (If a product has an AB rated generic, one trial must be the generic formulation.)

OR

- Patient has a medical necessity for disintegrating tablet administration (i.e. inability to swallow tablets)

AND

- The patient has a documented side effect, allergy, or treatment failure to clonazepam ODT.

Alprazolam Intensol, Diazepam Intensol, Lorazepam Intensol

- Patient has a medical necessity for the specialty dosage form (i.e. swallowing disorder)

AND

- The medication cannot be administered by crushing oral tablets.

Buspar[®] and Vistari[®]:

- The patient has a documented intolerance to the generic formulation.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 160 for a description of the management of mental health drugs.

Anti-Anxiety: Anxiolytics

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>Benzodiazepine</u> ALPRAZOLAM† (compare to Xanax®) ALPRAZOLAM ER†, ALPRAZOLAM XR® (compare to Xanax XR®) CHLORDIAZEPOXIDE† (compare to Librium®) CLONAZEPAM† (compare to Klonopin®) CLONAZEPAM ODT† (compare to Klonopin Wafers®) CLORAZEPATE† tabs (compare to Tranxene T®) DIAZEPAM† (compare to Valium®) LORAZEPAM† (compare to Ativan®) OXAZEPAM† (compare to Serax®)</p> <p><u>Non-Benzodiazepine</u> BUSPIRONE† (compare to Buspar®) HYDROXYZINE HYDROCHLORIDE† (previously Atarax®) HYDROXYZINE PAMOATE† (compare to Vistaril®) MEPROBAMATE† (previously Miltown®)</p>	<p>alprazolam ODT† (compare to Niravam®) Alprazolam Intensol® (alprazolam concentrate) Ativan®* (lorazepam) Diazepam Intensol® (diazepam concentrate) Klonopin®* (clonazepam) Klonopin Wafers®* (clonazepam ODT) Librium®* (chlordiazepoxide) Lorazepam Intensol® (lorazepam concentrate) Niravam® (alprazolam ODT) Serax®* (oxazepam) Tranxene T®* (clorazepate tablets) Tranxene-SD® (clorazepate SR 24 hr tab) Valium®* (diazepam) Xanax®* (alprazolam) Xanax XR®* (alprazolam XR)</p> <p>Buspar®* (buspirone) Vistaril®* (hydroxyzine pamoate)</p>

Anticoagulants

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

Arixtra®

- The patient has a documented intolerance to generic fondaparinux.

Coumadin®

- The patient has been started and stabilized on the requested medication.
- OR**
- The patient has had a documented side effect, allergy or treatment failure to generic warfarin.

Enoxaparin

- The patient has a documented intolerance to brand Lovenox®.

Innohep®

- The diagnosis is treatment of acute, symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism, administered in conjunction with warfarin sodium.

AND

- The patient does not have a bleeding disorder or documented heparin-induced thrombocytopenia (HIT).

AND

- The prescriber must provide a clinically valid reason why one of Lovenox®, Fragmin® or Arixtra® cannot be used.

OR

- The patient has been started and stabilized on the requested medication in conjunction with warfarin.

Pradaxa®

- The diagnosis or indication is atrial fibrillation.

AND

- The patient has been started and stabilized on the requested medication.

OR

- The patient has had a documented side effect, allergy, or contraindication (i.e. drug interactions) to warfarin therapy.

OR

- The patient has not been able to be adherent to coagulation monitoring or has not been able to achieve optimal INR control [INR 2-3] with warfarin therapy, despite dose titration attempts.

OR

- The prescriber has provided another clinically valid reason why generic warfarin cannot be used.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Request Form Prior Authorization**

Anticoagulants*Length of Authorization: 6 months***Key: † Generic product, *Indicates generic equivalent is available without a PA**

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<u>ORAL</u> WARFARIN † (compare to Coumadin®)	Coumadin®* (warfarin) Pradaxa® (dabigatran etexilate) <i>(Quantity Limit = 2 capsules/day)</i>
<u>UNFRACTIONATED HEPARIN</u> HEPARIN †	
<u>LOW MOLECULAR WEIGHT HEPARINS</u> FRAGMIN® (dalteparin) LOVENOX® (enoxaparin) <i>(QL = 2 syringes/day calculated in ml volume)</i>	Enoxaparin † (compare to Lovenox®) <i>(QL = 2 syringes/day calculated in ml volume)</i> Innohep® (tinzaparin)
<u>SELECTIVE FACTOR XA INHIBITOR</u> Fondaparinux† (compare to Arixtra®)	Arixtra®* (fondaparinux)

Anticonvulsants

LENGTH OF AUTHORIZATION: lifetime for seizure disorders*[†]; 1 year for other indications

CRITERIA FOR APPROVAL:

Depakene[®], Depakote[®], Depakote ER[®], Keppra[®] tablets or oral solution, Klonopin[®], Klonopin Wafers[®], Lamictal[®] tablets or chewable tablets, Mysoline[®], Neurontin[®] capsules/tablets/oral solution, Tegretol[®], Tegretol[®] XR (200 & 400 mg), Topamax[®] tablets, Topamax[®] Sprinkles, Trileptal[®] tablets, Zarontin[®], Zonegran[®]

- The patient has been started and stabilized on the requested medication.

OR

- The patient has had a documented intolerance to the generic equivalent of the requested medication.

Banzel[®]

- The diagnosis or indication is treatment of Lennox-Gastaut Syndrome.

AND

- The patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least TWO preferred anticonvulsants (topiramate, lamotrigine, valproic acid)

Felbamate, Felbatol[®]

- A patient information/consent describing aplastic anemia and liver injury has been completed.

AND

- The patient has been started and stabilized on the requested medication. Additionally, if brand is requested, the patient has a documented intolerance to the generic product.

OR

- The diagnosis is adjunctive therapy of partial-onset seizures or Lennox-Gastaut seizures and the patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least THREE preferred anticonvulsants. Additionally, if brand is requested, the patient has a documented intolerance to the generic product.

Diazepam rectal gel

- The patient has been started and stabilized on the requested medication.

OR

- The patient has had a documented intolerance to Diastat rectal gel.

Divalproex sodium capsules (sprinkles), Oxcarbazepine oral suspension (generics)

- The patient has been started and stabilized on the requested medication.

OR

- The patient has had a documented intolerance to the brand name product.

Keppra XR[®], Lamictal XR[®], levetiracetam ER

- The patient has been unable to be compliant with or tolerate twice daily dosing of the immediate release product. Additionally, if brand Keppra XR is requested, the patient has a documented intolerance to the generic product.

Lamictal ODT[®]

- Medical necessity for a specialty dosage form has been provided.

AND

- Lamotrigine chewable tablets cannot be used.

Lyrica[®]

- The patient has a diagnosis of epilepsy.

OR

The patient has had a documented side effect, allergy, or treatment failure to TWO drugs in the tricyclic antidepressant (TCA) class and/or anticonvulsant class, if medication is being used for neuropathic pain.

OR

- The patient has had a documented side effect, allergy, or treatment failure to TWO drugs from the following: gabapentin, tricyclic antidepressant, SSRI antidepressant, SNRI antidepressant, miscellaneous antidepressant, cyclobenzaprine or Savella[®], if medication is being used for fibromyalgia. (this indication not processed via automated step therapy)

Sabril[®]

- The prescriber and patient are registered with the SHARE program.

AND

- The diagnosis is infantile spasms

OR

- The patient is ≥ 16 years old and the indication is adjunctive therapy in refractory complex partial seizures after failure of THREE other preferred anticonvulsants.

Stavzor[®]

- The patient has been started and stabilized on the requested medication.

OR

- The patient has had a documented intolerance to divalproex sodium.

Vimpat[®]

- The patient has been started and stabilized on the requested medication.

OR

- The diagnosis is adjunctive therapy of partial-onset seizures and the patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least TWO preferred anticonvulsants

AND

- If the request is for the oral solution, the patient is unable to use Vimpat tablets (eg. swallowing disorder).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Anticonvulsants*Length of Authorization: lifetime for seizure disorders*[†]; 1 year for other indications***Key:** † Generic product, *Indicates generic equivalent is available without a PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p>ORAL</p> <p>CARBAMAZEPINE† (compare to Tegretol®) CARBAMAZEPINE EXTENDED RELEASE† (compare to Tegretol XR®) CARBATROL® (carbamazepine) CELONTIN® (methsuxamide) CLONAZEPAM† (compare to Klonopin®) CLONAZEPAM ODT† (compare to Klonopin Wafers®) DEPAKOTE SPRINKLES® (divalproex sodium caps)</p> <p>DILANTIN® (phenytoin) DIVALPROEX SODIUM † (compare to Depakote®) DIVALPROEX SODIUM ER† (compare to Depakote ER®) EPITOL† (carbamazepine) ETHOSUXAMIDE† (compare to Zarontin®) GABAPENTIN† 100 mg, 300 mg, 400 mg capsules, 600 mg, 800 mg tablets, 250 mg/5 ml oral solution (compare to Neurontin®) GABITRIL® (tiagabine) LAMOTRIGINE† chew tabs (compare to Lamictal® chew tabs) LAMOTRIGINE† tabs (compare to Lamictal® tabs) LEVETIRACETAM† tabs (compare to Keppra® tabs) LEVETIRACETAM† oral soln (compare to Keppra® oral soln) OXCARBAZEPINE† tablets (compare to Trileptal®) PEGANONE® (ethotoin) PHENYTEK® (phenytoin extended) PHENYTOIN† (compare to Dilantin®) PHENYTOIN EX† cap (compare to Phenytek®) PRIMIDONE† (compare to Mysoline®) TEGRETOL® XR (carbamazepine) 100 mg ONLY TOPIRAMATE† tabs (compare to Topamax® tabs) TOPIRAMATE† sprinkle caps (compare to Topamax® Sprinkles) TRILEPTAL® oral suspension (oxcarbazepine) VALPROIC ACID† (compare to Depakene®) ZONISIMIDE† (compare to Zonegran®)</p> <p>RECTAL</p> <p>DIASTAT® (diazepam rectal gel)</p>	<p>Banzel® (rufinamide) <i>QL = 8 tabs/day (400 mg) and 16 tabs/day (200 mg)</i> Depakene®* (valproic acid) Depakote®* (divalproex sodium) Depakote ER®* (divalproex sodium) divalproex sodium capsules† (compare to Depakote Sprinkles®) felbamate (compare to Felbatol®) Felbatol® (felbamate) Keppra®* (levetiracetam) tablets, oral solution Keppra XR® (levetiracetam extended release) Klonopin®* (clonazepam) Klonopin Wafers®* (clonazepam ODT) Lamictal®* tabs (lamotrigine tabs) Lamictal®* chew tabs (lamotrigine chew tabs) Lamictal ODT® (lamotrigine orally disintegrating tablets) Lamictal XR® tablets (lamotrigine extended release) levetiracetam ER (compare to Keppra XR®) Lyrica® (pregabalin) § (<i>Quantity Limit = 3 capsules/day</i>) Mysoline®* (primidone) Neurontin®* (gabapentin) capsules, tablets and oral solution Oxcarbazepine † oral suspension (compare to Trileptal®) Sabril® (vigabatrin) Stavzor® (valproic acid delayed release) Tegretol®* (carbamazepine) Tegretol XR®* (carbamazepine) (200 and 400 mg strength) Topamax®* (topiramate) tablets Topamax®* (topiramate) Sprinkle Capsules Trileptal®* tablets (oxcarbazepine) Vimpat® (lacosamide) tablets, oral solution Zarontin®* (ethosuxamide) Zonegran®* (zonisamide)</p> <p>Diazepam rectal gel</p>

* For brand name products when generic equivalent preferred, length of authorization is 1 year.

† For generic product when brand name product preferred, length of authorization is 1 year.

Anti-Depressants: Miscellaneous*Length of Authorization: Duration of need for mental health**indications*[^]; 1 year for other indications***Key: † Generic product, *Indicates generic equivalent is available without a PA**

PREFERRED DRUGS (No PA Required)	PA REQUIRED
BUDEPRION [®] SR/BUPROPION SR† (compare to Wellbutrin SR [®]) <i>FDA maximum recommended dose = 400 mg/day</i>	Aplenzin [®] (bupropion hydrobromide) ER tablets <i>Quantity Limit = 1 tablet/day</i>
BUDEPRION XL/BUPROPION XL† (compare to Wellbutrin XL [®]) <i>FDA maximum recommended dose = 450 mg/day</i>	Oleptro [®] (trazodone) ER tablets <i>Quantity Limit = 2 tablets/day (150 mg) or 1 tablet/day (300 mg)</i>
BUPROPION† (compare to Wellbutrin [®]) <i>FDA maximum recommended dose = 450 mg/day</i>	Remeron ^{®*} (mirtazapine) <i>FDA maximum recommended dose = 45 mg/day</i>
MAPROTILINE† (previously Ludiomil [®]) <i>FDA maximum recommended dose = 225 mg/day</i>	Remeron Sol Tab ^{®*} (mirtazapine RDT) <i>FDA maximum recommended dose = 45 mg/day</i>
MIRTAZAPINE† (compare to Remeron [®]) <i>FDA maximum recommended dose = 45 mg/day</i>	Wellbutrin ^{®*} (bupropion) <i>FDA maximum recommended dose = 450 mg/day</i>
MIRTAZAPINE RDT† (compare to Remeron Sol-Tab [®]) <i>FDA maximum recommended dose = 45 mg/day</i>	Wellbutrin SR ^{®*} (bupropion SR) <i>FDA maximum recommended dose = 400mg/day</i>
NEFAZADONE† (previously Serzone [®]) <i>FDA maximum recommended dose = 600 mg/day</i>	Wellbutrin XL ^{®*} (bupropion XL) <i>FDA maximum recommended dose = 450 mg/day</i>
TRAZODONE HCL† (previously Desyrel [®]) <i>FDA maximum recommended dose = 600 mg/day</i>	

* For brand name products when generic equivalent preferred, length of authorization is 1 year.

[^] For generic product when brand name product preferred, length of authorization is 1 year.

Anti-Depressants: SNRIs

LENGTH OF AUTHORIZATION:

Duration of need for mental health indications*; 1 year for other indications

CRITERIA FOR APPROVAL:

Effexor, Venlafaxine ER tablet (brand), Venlafaxine ER capsule (generic):

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or inadequate response to at least 2 different antidepressants from the SSRI, SNRI and/or Miscellaneous Antidepressant categories (may be preferred or non-preferred).

AND

- The patient has had a documented intolerance to the generic product (for Effexor and Venlafaxine ER tablet) or the branded product (for Venlafaxine ER capsule).

Pristiq, Venlafaxine, Venlafaxine ER tablet (generic), Effexor XR capsule:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or inadequate response to at least 2 different antidepressants from the SSRI, SNRI and/or Miscellaneous Antidepressant categories (may be preferred or non-preferred).

Cymbalta:

Depression:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or inadequate response to at least 2 different antidepressants from the SSRI, SNRI and/or Miscellaneous Antidepressant categories (may be preferred or non-preferred).

Generalized Anxiety Disorder:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or inadequate response to at least TWO different antidepressants from the SSRI, SNRI and/or TCA categories (may be preferred or non-preferred) or ONE antidepressant from the SSRI, SNRI and/or TCA categories (may be preferred or non-preferred) and buspirone.

Neuropathic pain:

- The patient has had a documented side effect, allergy, or treatment failure to TWO drugs in the tricyclic antidepressant (TCA) class and/or anticonvulsant class. (this indication not processed via automated step therapy).

Non-neuropathic musculoskeletal pain (osteoarthritis, chronic low back pain):

- The patient has had a documented side effect, allergy, inadequate response or contraindication to acetaminophen (Tylenol®) AND at least TWO nonsteroidal anti-inflammatory drugs (NSAIDs) (oral and/or topical). (this indication not processed via automated step therapy)

Fibromyalgia:

- The patient has had a documented side effect, allergy, or treatment failure to TWO drugs from the following: gabapentin, tricyclic antidepressant, SSRI antidepressant, SNRI antidepressant, miscellaneous antidepressant, cyclobenzaprine, Lyrica® or Savella®. (this indication not processed via automated step therapy)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 160 for a description of the management of mental health drugs.

Anti-Depressants: SNRI Length of Authorization: Duration of need for mental health indications*[^];
1 year for other indications

Key: † Generic product

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
	Cymbalta [®] § (duloxetine) <i>FDA maximum recommended dose = 60 mg/day</i> Effexor [®] (venlafaxine IR) <i>FDA maximum recommended dose = 225 mg/day</i> Effexor XR [®] § (venlafaxine XR) capsule <i>FDA maximum recommended dose = 225 mg/day,</i> <i>Quantity limit = 1 capsule/day (37.5 mg & 75 mg)</i> Pristiq [®] § (desvenlafaxine) <i>FDA maximum recommended dose = 400 mg/day,</i> <i>Quantity limit = 1 tablet/day (50 mg tablet only)</i> Venlafaxine ER [®] † tablet <i>FDA maximum recommended dose = 225 mg/day,</i> <i>Quantity limit = 1 tablet/day (37.5 mg & 75 mg)</i> Venlafaxine ER†§ tablet <i>FDA maximum recommended dose = 225 mg/day,</i> <i>Quantity limit = 1 tablet/day (37.5 mg & 75 mg)</i> Venlafaxine ER† capsule (compare to Effexor XR [®]) <i>FDA maximum recommended dose = 225 mg/day,</i> <i>Quantity limit = 1 capsule/day (37.5 mg & 75 mg)</i> venlafaxine IR †§ (compare to Effexor [®]) <i>FDA maximum recommended dose = 225 mg/day</i>

* For brand name products when generic equivalent preferred, length of authorization is 1 year.

[^] For generic product when brand name product preferred, length of authorization is 1 year.

After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 160 for a description of the management of mental health drugs.

Anti-Depressants: SSRI <i>Length of Authorization: Duration of need for mental health indications*; 1 year for other indications</i>	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
CITALOPRAM† (compare to Celexa®) <i>FDA maximum recommended dose = 40 mg/day</i> FLUOXETINE† (compare to Prozac®) <i>FDA maximum recommended dose = 80 mg/day</i> FLUVOXAMINE† (previously Luvox®) <i>FDA maximum recommended dose = 300 mg/day</i> PAROXETINE tablet† (compare to Paxil®) <i>FDA maximum recommended dose = 60 mg/day</i> SERTRALINE† (compare to Zoloft®) <i>FDA maximum recommended dose = 200 mg/day, Quantity limit = 1.5 tabs/day (25 mg & 50 mg tabs)</i>	Celexa®* (citalopram) <i>FDA maximum recommended dose = 40 mg/day</i> fluoxetine† (pmdd) <i>FDA maximum recommended dose = 80 mg/day</i> fluoxetine† 90 mg (compare to Prozac Weekly®) <i>FDA maximum recommended dose = 90 mg/week</i> Lexapro® (escitalopram) <i>FDA maximum recommended dose = 20 mg/day, Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)</i> Luvox CR® (fluvoxamine CR) <i>FDA maximum recommended dose = 300 mg/day, Quantity limit = 2 capsules/day</i> paroxetine suspension† (compare to Paxil® susp) <i>FDA maximum recommended dose = 60 mg/day</i> Paroxetine CR† (compare to Paxil CR®) <i>FDA maximum recommended dose = 75 mg/day</i> Paxil®* (paroxetine) <i>FDA maximum recommended dose = 60 mg/day</i> Paxil® suspension (paroxetine) <i>FDA maximum recommended dose = 60 mg/day</i> Paxil CR® (paroxetine CR) <i>FDA maximum recommended dose = 75 mg/day</i> Pexeva® (paroxetine) <i>FDA maximum recommended dose = 60 mg/day</i> Prozac®* (fluoxetine) <i>FDA maximum recommended dose = 80 mg/day</i> Prozac Weekly® (fluoxetine) <i>FDA maximum recommended dose = 90 mg/week</i> Sarafem® (fluoxetine pmdd) <i>FDA maximum recommended dose = 80 mg/day</i> Selfemra®† (fluoxetine pmdd) <i>FDA maximum recommended dose = 80 mg/day</i> Zoloft®* (sertraline) <i>FDA maximum recommended dose = 200 mg/day, Quantity limit = 1.5 tabs/day (25 mg & 50 mg tabs)</i>

* For brand name products when generic equivalent preferred, length of authorization is 1 year.

Anti-Depressants: Tricyclics & MAOIs

LENGTH OF AUTHORIZATION: Duration of need for mental health indications*; 1 year for other indications

CRITERIA FOR APPROVAL:

Tricyclics (TCAs) (Brands with generic equivalents):

- The patient has had a documented side effect, allergy, or treatment failure to 2 or more TCAs not requiring prior-authorization. One trial must be the AB rated generic formulation.
- OR**
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
- AND**
- The patient has had a documented intolerance to the generic formulation

Chlordiazepoxide/Amitriptyline 10 mg/25 mg

- The prescriber must provide a clinically valid reason why the individual generic components can not be prescribed.

MAOIs:

Marplan[®]

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
- OR**
- The patient has had a documented side effect, allergy, or treatment failure to phenelzine and tranylcypromine.

Nardil[®], Parnate[®]

- The patient has had a documented intolerance to generic equivalent product..

EMSAM[®]

- The patient has had a documented side effect, allergy, or treatment failure with at least 3 antidepressants from 2 of the major antidepressant classes (Miscellaneous, SNRIs, SSRIs, Tricyclic Antidepressants).
- OR**
- The patient is unable to tolerate oral medications.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 160 for a description of the management of mental health drugs.

Anti-Depressants: Tricyclics & MAOIs

Length of Authorization: Duration of need for mental health indications; 1 year for other indications*

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
TRICYCLICS	
AMITRIPTYLINE† (previously Elavil®) <i>FDA maximum recommended dose = 300 mg/day</i> AMITRIPTYLINE/PERPHEN†.(previously Etrafon®, Triavil®) AMOXAPINE† (previously Asendin®) CHLORDIAZEPOXIDE/AMITRIPTYLINE †5mg/12.5mg (compare to Limbitrol®) CLOMIPRAMINE† (compare to Anafranil®) DESIPRAMINE† (compare to Norpramin®) DOXEPIN† (previously Sinequan®) IMIPRAMINE† (compare to Tofranil®) <i>FDA maximum recommended dose = 300 mg/day</i> IMIPRAMINE PAMOATE† (compare to Tofranil PM®) NORTRIPTYLINE† (previously Aventyl®, compare to Pamelor®) PROTRIPTYLINE† (compare to Vivactil®) TRIMIPRAMINE (compare to Surmontil®)	Anafranil®* (clomipramine) Chlordiazepoxide/Amitriptyline 10 mg/25 mg (formerly Limbitrol DS®) Limbitrol®* (amitriptyline/chlordiazepoxide) Norpramin®* (desipramine) Pamelor®* (nortriptyline) Surmontil®* (trimipramine) Tofranil®* (imipramine) <i>FDA maximum recommended dose = 300 mg/day</i> Tofranil PM®* (imipramine pamoate) Vivactil®* (protriptyline)
MAOIs	
PHENELZINE SULFATE (compare to Nardil®) <i>FDA maximum recommended dose = 90 mg/day</i> TRANYLCPROMINE (compare to Parnate®) <i>FDA maximum recommended dose = 60 mg/day</i>	EMSAM® (selegiline) (<i>QL = 1 patch/day</i>) Marplan® (isocarboxazid) Nardil®* (phenelzine) <i>FDA maximum recommended dose = 90 mg/day</i> Parnate®* (tranylcypromine) <i>FDA maximum recommended dose = 60 mg/day</i>

* For brand name products when generic equivalent preferred, length of authorization is 1 year.

Anti-Diabetics: Insulin

LENGTH OF AUTHORIZATION: lifetime

CRITERIA FOR APPROVAL:

Apidra® or Humalog®

- The patient has had a documented side effect, allergy, or treatment failure to Novolog®

ReliOn R®, ReliOn N® or ReliOn 70/30®

- The patient has had a documented side effect, allergy, or treatment failure to the corresponding Novolin® or Humulin® product

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Insulins		<i>Length of Authorization: lifetime</i>
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
<u>RAPID-ACTING INJECTABLE</u> NOVOLOG® (Aspart)	Apidra® (insulin glulisine) Humalog® (insulin lispro)	
<u>SHORT-ACTING INJECTABLE</u> HUMULIN R® (Regular) NOVOLIN R® (Regular)	ReliOn R® (Regular)	
<u>INTERMEDIATE-ACTING INJECTABLE</u> HUMULIN N® (NPH) NOVOLIN N® (NPH)	ReliOn N® (NPH)	
<u>LONG-ACTING ANALOGS INJECTABLE</u> LANTUS® (insulin glargine) LEVEMIR® (insulin detemir)		
<u>MIXED INSULINS INJECTABLE</u> HUMULIN 70/30® (NPH/Regular) NOVOLIN 70/30® (NPH/Regular) NOVOLOG MIX 70/30® (Protamine/Aspart) HUMALOG MIX 75/25® (Protamine/Lispro) HUMALOG MIX 50/50® (Protamine/Lispro)	ReliOn 70/30® (NPH/Regular)	

Anti-Diabetics: Oral

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

ALPHA GLUCOSIDASE INHIBITORS

- For approval of Precose[®], the patient must have a documented intolerance to generic acarbose.

BIGUANIDES AND COMBINATIONS

Fortamet, Glucophage XR, Glumetza, Metformin ER Osmotic

- The patient has had a documented intolerance to generic metformin XR. (If a product has an AB rated generic, there must have also been a trial of the generic.)

Glucophage, Glucovance, Metaglip

- The patient has had a documented side effect, allergy or treatment failure with at least one preferred biguanide or biguanide combination product. (If a product has an AB rated generic, the trial must be the generic.)

MEGLITINIDES

Nateglinide

- The patient has had a documented intolerance to brand Starlix.

Prandin

- The patient has been started and stabilized on the requested medication.
OR
- The patient has had a documented side effect, allergy or treatment failure with Starlix.

Prandimet

- The patient has been started and stabilized on Prandimet or on stable doses of the separate agents
OR
- The patient has had an inadequate response with repaglinide monotherapy

SECOND GENERATION SULFONYLUREAS

- The patient has had a documented side effect, allergy or treatment failure with glimepiride, and glipizide/glipizide ER, and glyburide/glyburide micronized.

THIAZOLIDINEDIONES AND COMBINATIONS

Actos (pioglitazone), Actoplus Met) and Duetact The patient has been started and stabilized on the requested medication.

- The patient has had a documented side effect, allergy, contraindication or treatment failure with metformin.
OR

Actoplus Met XR

- The patient has been started and stabilized on the requested medication.
OR
- The patient has had a documented treatment failure with generic metformin XR.
OR
- The patient has had a documented treatment failure or has been unable to be adherent to a twice daily dosing schedule of Actoplus Met[®] resulting in a significant clinical impact.

Avandia (rosiglitazone) and combinations

- The patient has been started and stabilized on the requested medication and appears to be benefiting from it and the patient acknowledges that they understand the risks,
OR

- The patient is unable to achieve glycemic control using other medications (including a documented side effect, allergy, contraindication or treatment failure with metformin) and, in consultation with their health care professional, decide not to take pioglitazone for medical reasons and the patient acknowledges that they understand the risks.

DIPEPTIDYL PEPTIDASE (DPP-4) INHIBITORS

Januvia, Onglyza

- The patient has had a documented side effect, allergy, contraindication or treatment failure with metformin.

Janumet

- The patient has had an inadequate response with Januvia or metformin monotherapy.
OR
- The patient has been started and stabilized on Januvia and metformin combination therapy.

Kombiglyze XR

- The patient has had an inadequate response with Onglyza or metformin/metformin XR monotherapy.
OR
The patient has been started and stabilized on Onglyza and metformin/metformin XR combination therapy.

WELCHOL[®]

- See Lipotropics: Bile Acid Sequestrants

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Anti-Diabetics: Oral

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<u>ALPHA GLUCOSIDASE INHIBITORS</u>	
ACARBOSE† (compare to Precose®) GLYSET® (miglitol)	Precose®* (acarbose)
<u>BIGUANIDES AND COMBINATIONS</u>	
<u>SINGLE AGENT</u>	
METFORMIN† (compare to Glucophage®) METFORMIN XR† (compare to Glucophage XR®) RIOMET® (metformin oral solution)	Fortamet® (metformin ER Osmotic) Glucophage®* (metformin) Glucophage XR®* (metformin extended-release) Glumetza® (metformin extended-release) Metformin ER Osmotic† (compare to Fortamet®)
<u>COMBINATION</u>	
GLIPIZIDE/METFORMIN†(compare to Metaglip®) GLYBURIDE/METFORMIN† (compare to Glucovance®)	Glucovance®* (glyburide/metformin) Metaglip®*(glipizide/metformin)
<u>MEGLITINIDES</u>	
<u>SINGLE AGENT</u>	
STARLIX® (nateglinide)	Nateglinide† (compare to Starlix®) Prandin® (repaglinide)
<u>COMBINATION</u>	
	Prandimet® (repaglinide/metformin)
<u>SULFONYLUREAS SECOND GENERATION</u>	
GLIMEPIRIDE† (compare to Amaryl®) GLIPIZIDE† (compare to Glucotrol®) GLIPIZIDE ER† (compare to Glucotrol XL®) GLYBURIDE† (compare to Diabeta®) GLYBURIDE MICRONIZED† (compare to Glynase® PresTab®)	Amaryl®* (glimepiride) Diabeta®* (glyburide) Glucotrol®* (glipizide) Glucotrol XL®* (glipizide extended-release) Glynase® PresTab®* (glyburide micronized)
<u>THIAZOLIDINEDIONES AND COMBINATIONS (after clinical criteria are met)</u>	
<u>SINGLE AGENT</u>	
ACTOS® (pioglitazone) §	Avandia® (rosiglitazone)
<u>COMBINATION</u>	
ACTOPLUS MET® (pioglitazone/metformin) § DUETACT® (pioglitazone/glimepiride) § (Quantity Limit = 1 tablet/day)	Actoplus Met XR (pioglitazone/metformin ER) Avandamet® (rosiglitazone/metformin) Avandaryl® (rosiglitazone/glimeperide)
<u>DIPEPTIDYL PEPTIDASE (DPP-4) INHIBITORS AND COMBINATIONS (after clinical criteria are met)</u>	
<u>SINGLE AGENT</u>	
JANUVIA® (sitagliptin)§ (Quantity limit=1 tab/day) ONGLYZA® (saxagliptin)§ (Quantity limit=1 tab/day)	
<u>COMBINATION</u>	
JANUMET® (sitagliptin/metformin)§ (Quantity limit=2 tabs/day) KOMBIGLYZE XR® (saxagliptin/metformin ER) § (Quantity limit=1 tab/day)	

Note: Please refer to "Lipotropics: Bile Acid Sequestrants" for Welchol®.

Anti-Diabetics: Peptide Hormones

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

BYETTA

- The patient has a diagnosis of diabetes mellitus.
AND
- The patient is at least 18 years of age.
AND
- The patient has had a documented side effect, allergy, or treatment failure with metformin..
AND
- The quantity requested does not exceed 1 pen/month.

SYMLIN

- The patient has a diagnosis of diabetes mellitus.
AND
- The patient is at least 18 years of age.
AND
- The patient is on insulin.

VICTOZA:

- The patient has a diagnosis of diabetes mellitus.
AND
- The patient is at least 18 years of age.
AND
- The patient has had a documented side effect, allergy, contraindication or treatment failure with metformin.
AND
- The patient has had a documented side effect, allergy, or treatment failure to Byetta
AND
- The quantity requested does not exceed 3 pens/month.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Anti-Diabetics: Peptide Hormones		<i>Length of Authorization: 1 year</i>
Key: § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)		
PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	PA REQUIRED	
BYETTA® (exenatide) § <i>(Quantity Limit=1 pen/30 days)</i> SYMLIN® (pramlintide) § (No quantity limit applies)	Victoza® (liraglutide) <i>(Quantity Limit=3 pens/30 days)</i>	

Anti-Emetics: 5-HT₃ Receptor Antagonists

LENGTH OF AUTHORIZATION: 6 months for Chemotherapy/Radiotherapy and 1 time Post-Op

CRITERIA FOR APPROVAL (non-preferred agents):

Aloxi[®], Anzemet[®], Granisetron, Kytril[®]

- The patient has had a documented side effect, allergy, or treatment failure to generic ondansetron. Additionally, after above trial, for approval of Kytril[®] injection, oral solution or tablets, generic granisetron injection, oral solution or tablets must have been tried.

Zofran[®]

- The patient must have a documented side effect, allergy, or treatment failure to the corresponding generic ondansetron product (tablets, orally disintegrating tablets (ODT), oral solution or injection).

Ondansetron oral solution

- The patient is unable to use ondansetron ODT or ondansetron tablets.

Ondansetron 24 mg

- The prescriber provides rationale why generic ondansetron 8 mg tablets cannot be used to achieve the desired dose.

Sancuso[®]

- The patient has a diagnosis of nausea and vomiting associated with cancer chemotherapy.
AND
- The prescriber provides documentation of medical necessity for the transdermal formulation.
OR
- The patient has had a documented side effect, allergy or treatment failure with generic ondansetron.

Zuplenz[®]

- The prescriber provides documentation of medical necessity for the specialty dosage form (i.e. inability to swallow tablets, dysphagia) AND a clinical rationale as to why ondansetron ODT is not a suitable option for the patient.

CRITERIA FOR APPROVAL (quantity limit):

Ondansetron 4 mg and 8 mg

- For nausea and vomiting associated with chemotherapy, 3 tablets for each day of chemotherapy and 3 tablets for each day on days 2-4 after chemotherapy may be approved.
- For hyperemesis gravidarum, three tablets per day of 4 mg or 8 mg may be approved for 3 months.

Anzemet[®]

- For nausea and vomiting associated with chemotherapy, 1 tablet for each day of chemotherapy and 1 tablet for each day on days 2-4 after chemotherapy may be approved.

Kytril[®]

- For nausea and vomiting associated with chemotherapy, 2 tablets for each day of chemotherapy and 2 tablets for each day on days 2-4 after chemotherapy may be approved.

Sancuso®

- For nausea and vomiting associated with chemotherapy, 1 patch for each chemotherapy cycle may be approved.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent, to exceed quantity limits of a preferred agent, or for a diagnosis outside of FDA approval on a **General Prior Authorization Request Form**.

Anti-Emetics: 5-HT₃ Receptor Antagonists	
<i>Length of Authorization: 6 months for Chemotherapy/Radiotherapy, 1 time Post-Op</i>	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
Ondansetron Tablet and Orally Disintegrating Tablet† (compare to Zofran®) 4 mg, 8 mg <i>Quantity Limit = 12 tablets/28 days (4 mg), 6 tablets/28 days (8 mg)</i>	Aloxi® (palonosetron) <i>Quantity Limit = 2 vials/28 days</i>
Ondansetron Injection† (compare to Zofran®)	Anzemet® (dolasetron) <i>Quantity Limit = 4 tablets/28 days (50 mg), 2 tablets/28 days (100 mg)</i>
	Granisetron† (compare to Kytril®) <i>Quantity Limit = 6 tablets/28 days</i>
	Granisetron† (compare to Kytril®) Injectable
	Granisetron† (compare to Kytril®) Oral Solution
	Kytril® (granisetron) <i>Quantity Limit = 6 tablets/28 days</i>
	Kytril® Injectable (granisetron)
	Ondansetron Solution† (compare to Zofran®)
	Ondansetron† 24 mg tablet (previously Zofran®) <i>Quantity Limit = 1 tablet/28 days</i>
	Sancuso® 3.1 mg/24 hrs Transdermal Patch (granisetron) <i>Quantity Limit = 1 patch/28 days</i>
	Zofran®* (ondansetron) Tablet and Orally Disintegrating Tablet <i>Quantity Limit = 12 tablets/28 days (4 mg), 6 tablets/28 days (8 mg)</i>
	Zofran®* (ondansetron) Injection
	Zofran® (ondansetron) Solution
	Zuplenz® (ondansetron) Oral Soluble Film <i>Quantity Limit = 12 films/28 days (4 mg), 6 films/28 days (8 mg)</i>

Anti-Emetics: NK1 Antagonists

LENGTH OF AUTHORIZATION: up to 1 year

CRITERIA FOR APPROVAL:

EMEND® Injection (fosaprepitant) 115 mg Vial

- The medication will be prescribed by an oncology practitioner.
- AND**
- The patient requires prevention of nausea and vomiting associated with moderate to highly emetogenic cancer chemotherapy.
- AND**
- The patient has a medical necessity for the IV administration (i.e. inability to swallow capsules, dysphagia).
- AND**
- The requested quantity does not exceed one 115 mg vial per course of chemotherapy. Patients with multiple courses of chemotherapy per 28 days will be approved quantities sufficient for the number of courses of chemotherapy.

CRITERIA FOR APPROVAL WHEN QUANTITY LIMIT IS EXCEEDED:

EMEND® (aprepitant) 80 mg, 125 mg, Tri-Fold pack

- The medication will be prescribed by an oncology practitioner.
- AND**
- The patient requires prevention of nausea and vomiting associated with moderate to highly emetogenic cancer chemotherapy.
- AND**
- The requested quantity does not exceed one 125 mg and two 80 mg capsules OR one Tri-Fold Pack per course of chemotherapy. Patients with multiple courses of chemotherapy per 28 days will be approved quantities sufficient for the number of courses of chemotherapy.

EMEND® (aprepitant) 40 mg

- The patient requires prevention of postoperative nausea and vomiting.
- AND**
- The requested quantity does not exceed one 40 mg capsule per surgery or course of anesthesia. Patients with multiple surgeries or courses of anesthesia in a 28 day period will be approved quantities sufficient for the number of surgeries or courses of anesthesia.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the need to exceed the established quantity limits on the **General Prior Authorization Request Form.**

Anti-Emetics: NK1 Antagonists		<i>Length of Authorization: up to 1 year</i>
PREFERRED DRUGS (No PA Required)		PA REQUIRED
EMEND® (aprepitant) 40 mg (Qty Limit =1 cap/28 days) * EMEND® (aprepitant) 80 mg (Qty Limit = 2 caps/28 days) * EMEND® (aprepitant) 125 mg (Qty Limit = 1 cap/28 days) * EMEND® (aprepitant) Tri-fold Pack (Qty Limit = 1 pack/28 days)		* EMEND® (fosaprepitant) 115 mg Injection (Qty Limit = 1 vial/28 days)
* <i>To be prescribed by <input type="checkbox"/> oncology practitioners ONLY</i>		

Anti-Emetics: Other

LENGTH OF AUTHORIZATION: 3 months

PHARMACOLOGY:

Marinol[®] is a schedule III cannabinoid agent containing the same active ingredient, tetrahydrocannabinol, as marijuana. While its exact mechanism of action is unknown, it is speculated to inhibit medullary activity as well as suppress prostaglandin and endorphan synthesis. Cesamet[®] is a schedule II synthetic cannabinoid that acts by activating the endocannabinoid receptors, CB1 and CB2, which are involved in nausea/vomiting regulation. Both Marinol[®] and Cesamet[®] are FDA-approved for use in chemotherapy associated nausea and vomiting refractory to conventional antiemetics. In addition, Marinol[®] is indicated for patients with AIDS-related anorexia or wasting syndrome.

CRITERIA FOR APPROVAL:

Dronabinol, Marinol

- The patient has a diagnosis of chemotherapy-induced nausea/vomiting.
AND
- The patient has had a documented side effect, allergy, or treatment failure to **at least 2** antiemetic agents, of which, one must be a **preferred** 5HT3 receptor antagonist. If the request is for Marinol, the patient must additionally have a documented intolerance to generic dronabinol.
OR
- The patient has a diagnosis of AIDS associated anorexia.
AND
- The patient has had an inadequate response, adverse reaction, or contraindication to megestrol acetate. If the request is for Marinol, the patient must additionally have a documented intolerance to generic dronabinol.

Cesamet

- The patient has a diagnosis of chemotherapy-induced nausea/vomiting.
AND
- The patient has had a documented side effect, allergy, or treatment failure to **at least 2** antiemetic agents, of which, one must be a **preferred** 5HT3 receptor antagonist.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Anti-Emetics: Other	
<i>Length of Authorization: Initial approval 3 months, subsequent approval up to 6 months</i>	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
	Dronabinol† (compare to Marinol [®])
	Marinol [®] (dronabinol)
	Cesamet [®] (nabilone)

Anti-Hyperkinesia and Anti-Narcolepsy/Cataplexy

LENGTH OF AUTHORIZATION: Duration of need for mental health indications**†; 1 year for other indications

CRITERIA FOR APPROVAL:

STIMULANTS

Dexmethylphenidate and Focalin®

- The patient has a diagnosis of ADD, ADHD or narcolepsy.
AND
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
OR
- The patient is also on Focalin XR and the prescriber is adding a shorter acting dosage form.
OR
- The patient has had a documented side-effect, allergy, or treatment failure on Methylin® or methylphenidate.
AND
- In addition, for approval of brand name Focalin®, the patient must have had a documented intolerance to generic dexmethylphenidate.

Metadate CD® and Ritalin LA®

- The patient has a diagnosis of ADD, ADHD or narcolepsy.
AND
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
OR
- The patient has had a documented side-effect, allergy, or treatment failure on Focalin XR® or Concerta®.

Methylphenidate ER

- The patient has a diagnosis of ADD, ADHD or narcolepsy.
AND
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
OR
- The patient has had a documented intolerance to brand Concerta®.

Ritalin® and Ritalin SR®

- The patient has a diagnosis of ADD, ADHD or narcolepsy.
AND
- The patient has had a documented intolerance to the preferred equivalent. For Ritalin SR® these are Methylin® ER, Metadate ER® or methylphenidate SR. For Ritalin these are Methylin® or methylphenidate.

Adderall® and Dexedrine CR®

- The patient has a diagnosis of ADD, ADHD or narcolepsy.
AND
- The patient has had a documented intolerance to the preferred generic equivalent.

Methamphetamine and Desoxyn®

- Given the high abuse potential of methamphetamine and Desoxyn®, the patient must have a diagnosis of ADD, ADHD or narcolepsy and have failed all preferred treatment alternatives. In addition, for approval of brand name Desoxyn®, the patient must have had a documented intolerance to generic methamphetamine.

Adderall XR[®], Amphetamine/dextroamphetamine SR 24 HR (generic)

- The patient has a diagnosis of ADD, ADHD or narcolepsy.

AND

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side-effect, allergy, or treatment failure on Vyvanse[®].

AND

- If the request is for the generic product, the patient must have a documented intolerance to the brand name Adderall XR[®].

CNS stimulants for beneficiaries age < 3

- The prescriber must provide a clinically valid reason for the use of the requested medication in a patient < 3 years of age.

NON-STIMULANTS

Intuniv[®]

- The patient has a diagnosis of ADD or ADHD.

AND

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has a documented treatment failure, due to lack of efficacy, to *two* long-acting CNS stimulants (Metadate CD[®], Ritalin LA[®], Focalin XR[®], Adderall XR[®], Concerta[®], Vyvanse[®] and Daytrana[®])

OR

- The patient has had a documented side effect, allergy, or direct contraindication (e.g. comorbid tics, moderate-to-severe anxiety) to *one* long-acting CNS stimulant (Metadate CD[®], Ritalin LA[®], Focalin XR[®], Adderall XR[®], Concerta[®], Vyvanse[®] and Daytrana[®])

OR

- There is a question of substance abuse with the patient or family of the patient.

OR

- The family will choose to decline therapy if a stimulant must be trialed.

OR

- The patient has been trialed on immediate release guanfacine with good response but needs a dosage form with extended duration of therapy.

Kapvay[®]

- The patient has a diagnosis of ADD or ADHD.

AND

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has a documented treatment failure, due to lack of efficacy, to *two* long-acting CNS stimulants (Metadate CD[®], Ritalin LA[®], Focalin XR[®], Adderall XR[®], Concerta[®], Vyvanse[®] and Daytrana[®])

OR

- The patient has had a documented side effect, allergy, or direct contraindication (e.g. comorbid tics, moderate-to-severe anxiety) to *one* long-acting CNS stimulant (Metadate CD[®], Ritalin LA[®], Focalin XR[®], Adderall XR[®], Concerta[®], Vyvanse[®] and Daytrana[®])

OR

- There is a question of substance abuse with the patient or family of the patient.

AND

- The patient has been trialed on clonidine IR with at least a partial response but needs an extended duration formulation to maximize the clinical benefit.

Strattera[®]

- The patient has a diagnosis of ADD or ADHD.
- AND**
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
- OR**
- The patient has a documented treatment failure, due to lack of efficacy, to *two* long-acting CNS stimulants (Metadate CD[®], Ritalin LA[®], Focalin XR[®], Adderall XR[®], Concerta[®], Vyvanse[®] and Daytrana[®])
- OR**
- The patient has had a documented side effect, allergy, or direct contraindication (e.g. comorbid tics, moderate-to-severe anxiety) to *one* long-acting CNS stimulant (Metadate CD[®], Ritalin LA[®], Focalin XR[®], Adderall XR[®], Concerta[®], Vyvanse[®] and Daytrana[®])
- OR**
- There is a question of substance abuse with the patient or family of the patient.
- OR**
- The family will choose to decline therapy if a stimulant must be trialed.
- OR**
- The patient's need for drug therapy is primarily in early AM and evenings in the home environment.

Nuvigil[®]

Narcolepsy, excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (adjunct to standard treatment):

- The patient is > 17 years old.
- AND**
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
- OR**
- The patient has had a documented side-effect, allergy or treatment failure to a CNS stimulant or has a contraindication for use of these agents (e.g. substance abuse history).

Nuvigil[®] **will not be approved** for sleepiness associated with shift work sleep disorder, idiopathic hypersomnolence, excessive daytime sleepiness, fatigue associated with use of narcotic analgesics, or **for ADHD** (for any age patient).

Provigil[®]

Narcolepsy, Excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (adjunct to standard treatment), fatigue associated with multiple sclerosis, fatigue associated with the treatment of depression or schizophrenia:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
- OR**
- The patient has had a documented side-effect, allergy or treatment failure to a CNS stimulant or has a contraindication for use of these agents (e.g. substance abuse history).

ADHD age >12:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
- OR**
- The patient has a documented treatment failure, due to lack of efficacy, to *two* long-acting CNS stimulants or the patient has had a documented side effect, allergy, or direct contraindication (e.g. comorbid tics, moderate-to-severe anxiety, substance abuse) to *one* long-acting CNS stimulant.
- AND**
- The patient has had a documented side-effect, allergy, or treatment failure to Strattera[®].

Provigil[®] **will not be approved** for sleepiness associated with shift work sleep disorder, idiopathic hypersomnolence, excessive daytime sleepiness, fatigue associated with use of narcotic analgesics, or **for ADHD in children age ≤12**.

Xyrem®

- The patient has a diagnosis of narcolepsy/cataplexy.
- AND**
- The patient has been started and stabilized on the medication.
- OR**
- The patient has a documented side effect, allergy, treatment failure, or contraindication to a preferred CNS stimulant or tricyclic antidepressants (e.g., protriptyline, clomipramine).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 160 for a description of the management of mental health drugs.

Anti-Hyperkinesia and Anti-Narcolepsy/Cataplexy

Length of Authorization: Duration of need for mental health indications; 1 year for other indications*

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)

PA REQUIRED

AMPHETAMINE-LIKE STIMULANTS

Short/Intermediate-Acting Methylphenidate Preps

METADATE ER[®] (compare to Ritalin[®] SR)
 METHYLIN[®] (compare to Ritalin[®])
 METHYLIN[®] ER (compare to Ritalin[®] SR)
 METHYLPHENIDATE † (compare to Ritalin[®])
 METHYLPHENIDATE SR † (compare to Ritalin[®] SR)

Dexmethylphenidate † (compare to Focalin[®])
 Focalin[®] (dexmethylphenidate)
 Ritalin[®]* (methylphenidate)
 Ritalin SR[®]* (methylphenidate SR)

Long-Acting Methylphenidate Preps

Oral

CONCERTA[®] (methylphenidate SA OSM IR/ER, 22:78%)
 FOCALIN XR[®] (dexmethylphenidate SR 24 HR IR/ER, 50:50%)

Metadate CD[®] (methylphenidate CR, IR/ER, 30:70%)
 Methylphenidate SA OSM IR/ER, 22:78% † (compare to Concerta[®])
 Ritalin LA[®] (methylphenidate SR 24 HR, IR/ER, 50:50%)

Transdermal Patch

DAYTRANA[®] (methylphenidate patch) (*QL = 1 patch/day*)

Short/Intermediate-Acting Amphetamine Preps

AMPHETAMINE/DETROAMPHETAMINE † (compare to Adderall[®])
 DEXTROAMPHETAMINE † (previously Dexedrine[®])
 DEXTROAMPHETAMINE SR † (compare to Dexedrine CR[®])
 DEXTROSTAT † (dextroamphetamine)

Adderall[®]* (amphetamine/dextroamphetamine)
 Desoxyn[®] (methamphetamine)
 Dexedrine CR[®]* (dextroamphetamine SR)
 Methamphetamine † (compare to Desoxyn[®])

Long-Acting Amphetamine Preps

VYVANSE[®] (lisdexamfetamine) (*QL = 1 capsule/day*)

Adderall XR[®] (amphetamine/dextroamphetamine SR 24 HR, IR/ER, 50:50%) (current users grandfathered)

CNS stimulants (all forms short- & long-acting): PA for beneficiaries < 3 yrs

Amphetamine/dextroamphetamine SR 24 HR, IR/ER, 50:50% † (compare to Adderall XR[®])

NON-STIMULANTS

Intuniv[®] (guanfacine extended release) Tablet
Qty limit = 1 tablet/day

Kapvay[®] (clonidine extended release) Tablet
Qty limit = 4 tablets/day

Nuvigil[®] (armodafinil)
Qty limit: 50 mg = 2 tablets/day
150 mg/250 mg = 1 tablet/day

Provigil[®] (modafinil) (**not approvable for ADHD in children age ≤12**) (*Max days supply = 30 days*)
Qty limit: 100 mg = 1.5 tablets/day
200 mg = 2 tablets/day
Maximum Daily Dose = 400 mg

Strattera[®] (atomoxetine)
FDA maximum recommended dose = 100 mg/day

Xyrem[®] (sodium oxybate)

* For brand name products when generic equivalent preferred, length of authorization is 1 year.

^ For generic product when brand name product preferred, length of authorization is 1 year.

Anti-Hypertensives: ACE Inhibitors and ACEI Combinations

LENGTH OF AUTHORIZATION:

1 year

CRITERIA FOR APPROVAL:

ACE Inhibitors:

- The patient has had a documented side effect, allergy, or treatment failure to all available preferred generic ACEI. If a medication has an AB rated generic, there must have been a trial of the generic formulation.

ACE Inhibitor/Hydrochlorothiazide combinations:

- The patient has had a documented side effect, allergy, or treatment failure to all available preferred generic ACEI/Hydrochlorothiazide combination. If a medication has an AB rated generic, there must have been a trial of the generic formulation.

ACE Inhibitor/Calcium Channel Blocker combination:

- The patient has had a documented side effect, allergy, or treatment failure with a preferred ACEI/Calcium Channel Blocker combination. . If a medication has an AB rated generic, the trial must be the generic formulation.

LIMITATIONS:

Captopril/hydrochlorothiazide combination not covered. Agents may be prescribed separately.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Anti-Hypertensives: ACE Inhibitors and ACEI Combinations

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA Required
<p><u>ACE INHIBITORS:</u> BENAZEPRIL† (compare to Lotensin®) CAPTOPRIL† (previously Capoten®) ENALAPRIL† (compare to Vasotec®) FOSINOPRIL† (previously Monopril®) LISINOPRIL† (compare to Zestril®, Prinivil®) MOEXIPRIL† (compare to Univasc®) QUINAPRIL† (compare to Accupril®) RAMIPRIL† (compare to Altace®) TRANDOLAPRIL† (compare to Mavik®)</p>	Accupril®* (quinapril) Aceon® (perindopril) Altace®* (ramipril) Lotensin®* (benazepril) Mavik®* (trandolapril) perindopril† (compare to Aceon®) Prinivil®* (lisinopril) Univasc®* (moexipril) Vasotec®* (enalapril) Zestril®* (lisinopril)
<p><u>ACE INHIBITOR/HYDROCHLOROTHIAZIDE:</u> BENAZEPRIL/HCTZ† (compare to Lotensin HCT®) ENALAPRIL/HCTZ† (compare to Vaseretic®) FOSINOPRIL/HCTZ† (previously Monopril HCT®) LISINOPRIL/HCTZ† (compare to Zestoretic®, Prinzide®) MOEXIPRIL/HCTZ† (compare to Uniretic®) QUINAPRIL/HCTZ† (compare to Accuretic®)</p>	Accuretic®* (quinapril/HCTZ) Lotensin HCT®* (benazepril/HCTZ) Prinzide®* (lisinopril/HCTZ) Uniretic®* (moexipril/HCTZ) Vaseretic®* (enalapril/HCTZ) Zestoretic®* (lisinopril/HCTZ)
<p><u>ACE INHIBITOR/CALCIUM CHANNEL BLOCKER:</u> amlodipine/benazepril† (compare to Lotrel®)</p>	Lotrel®* (amlodipine/benazepril) Tarka® (trandolapril/verapamil) trandolapril/verapamil† (compare to Tarka®)

Anti-Hypertensives: Angiotensin Receptor Blockers (ARBs) and ARB Combinations

LENGTH OF AUTHORIZATION: 3 years

CRITERIA FOR APPROVAL:

Avapro, Benicar, , Diovan, Losartan, Micardis, Avalide, Benicar HCT, Diovan HCT, , Losartan HCT, Micardis HCT, Azor, Exforge, Exforge HCT

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

Atacand, Edarbi, Teveten

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or treatment failure with a preferred Angiotensin Receptor Blocker (ARB) or ARB combination.

Atacand HCT, Teveten HCT

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or treatment failure with a preferred ARB/Hydrochlorothiazide combination.

Cozaar, Hyzaar (Brands)

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

AND

- The patient has had a documented intolerance with the generic product.

Tribenzor[®]

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

AND

- The patient is unable to comply with taking the individual components (hydrochlorothiazide and Azor[®]) separately.

Twynsta®

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

AND

- The patient is unable to take the individual components (amlodipine and Micardis®) separately.

Valturna

- The patient has a diagnosis of hypertension.

AND

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

OR

- The patient has had a documented treatment failure with Tekturna® alone.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Anti-Hypertensives: ARBs and ARB Combinations	
<i>Length of Authorization: 3 years</i>	
Key: § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)	
PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET
<u>ANGIOTENSIN RECEPTOR BLOCKERS:</u>	
AVAPRO® (irbesartan) § BENICAR® (olmesartan) § DIOVAN® (valsartan) § LOSARTAN† (compare to Cozaar®)§ MICARDIS® (telmisartan) §	Atacand® (candesartan) § Cozaar® (losartan) Edarbi® (azilsartan) Tablet (Qty Limit = 1 tablet/day) Teveten® (eprosartan) §
<u>ANGIOTENSIN RECEPTOR BLOCKER/HYDROCHLOROTHIAZIDE:</u>	
AVALIDE® (irbesartan/hydrochlorothiazide) § BENICAR HCT® (olmesartan/hydrochlorothiazide) § DIOVAN HCT® (valsartan/hydrochlorothiazide) § LOSARTAN/HYDROCHLOROTHIAZIDE † (compare to Hyzaar®)§ MICARDIS HCT® (telmisartan/hydrochlorothiazide) §	Atacand HCT® (candesartan/hydrochlorothiazide)§ Hyzaar® (losartan/hydrochlorothiazide) Teveten HCT® (eprosartan/hydrochlorothiazide) §
<u>ANGIOTENSIN RECEPTOR BLOCKER/CALCIUM CHANNEL BLOCKER:</u>	
AZOR® (olmesartan/amlodipine) § (QL = 1 tablet/day) EXFORGE® (valsartan/amlodipine) § (QL = 1 tab/day)	Twynsta® (amlodipine/telmisartan) (QL = 1 tablet/day)
<u>ANGIOTENSIN RECEPTOR BLOCKER/RENIN INHIBITOR:</u>	
	Valturna® (aliskiren/valsartan) (Qty Limit = 1 tablet/day)
<u>ANGIOTENSIN RECEPTOR BLOCKER/CALCIUM CHANNEL BLOCKER/HYDROCHLOROTHIAZIDE:</u>	
EXFORGE HCT® (amlodipine/valsartan/hydrochlorothiazide) § (QL = 1 tab/day)	Tribenzor® (amlodipine/olmesartan/hydrochlorothiazide) (QL = 1 tablet/day)

Anti-Hypertensives: Beta-Blockers

LENGTH OF AUTHORIZATION: 3 years

CRITERIA FOR APPROVAL

Non-preferred drugs (except Coreg CR[®]):

- The patient has had a documented side effect, allergy, or treatment failure to at least three preferred drugs. (If a medication has an AB rated generic, one trial must be the generic formulation.)

Coreg CR[®]:

Indication: Heart Failure

- The patient has been started and stabilized on Coreg CR[®]. (Note: Samples are not considered adequate justification for stabilization.)
- OR**
- The patient has had a documented side effect, allergy, or treatment failure to metoprolol SR or bisoprolol.
- AND**
- The patient has been unable to be compliant with or tolerate twice daily dosing of carvedilol IR.

Indication: Hypertension

- The patient has been started and stabilized on Coreg CR[®]. (Note: Samples are not considered adequate justification for stabilization.)
- OR**
- The patient has had a documented side effect, allergy, or treatment failure to 3(three) preferred anti-hypertensive beta-blockers.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Anti-Hypertensives: Beta-Blockers

Length of Authorization: 3 years

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>SINGLE AGENT</u> ACEBUTOLOL† (compare to Sectral®) ATENOLOL† (compare to Tenormin®) BETAXOLOL† (compare to Kerlone®) BISOPROLOL FUMARATE† (compare to Zebeta®) CARVEDILOL† (compare to Coreg®) LABETALOL† (compare to Trandate®) METOPROLOL† (compare to Lopressor®) METOPROLOL XL† (compare to Toprol XL®) NADOLOL† (compare to Corgard®) PINDOLOL† (formerly Visken®) PROPRANOLOL† (compare to Inderal®) PROPRANOLOL ER† (compare to Inderal LA®) SOTALOL† (compare to Betapace®, BetapaceAF®) TIMOLOL† (formerly Blocadren®)</p>	<p>Betapace®* (sotalol) Betapace AF®* (sotalol) Bystolic® (nebivolol) (QL = 1 tablet/day for 2.5 mg, 5 mg and 10 mg tablet strengths, 2 tablets/day for 20 mg) Coreg®* (carvedilol) Coreg CR® (carvedilol CR) (QL = 1 tablet/day) Corgard®* (nadolol) Inderal®* (propranolol) Inderal LA®* (propranolol ER) InnoPran XL® (propranolol SR) Kerlone®* (betaxolol) Levatol® (penbutalol) Lopressor®* (metoprolol) Sectral®* (acebutolol) Tenormin®* (atenolol) Toprol XL®* (metoprolol succinate XL) Trandate®* (labetalol) Zebeta®* (bisoprolol)</p>
<p><u>BETA-BLOCKER/DIURETIC COMBINATION</u> ATENOLOL/CHLORTHALIDONE† (compare to Tenoretic®) BISOPROLOL/HYDROCHLOROTHIAZIDE† (compare to Ziac®) METOPROLOL/HYDROCHLOROTHIAZIDE† (compare to Lopressor HCT®) NADOLOL/BENDROFLUMETHIAZIDE† (compare to Corzide®)</p>	<p>Corzide®* (nadolol/bendroflumethiazide) Lopressor HCT®* (metoprolol/hydrochlorothiazide) Propranolol/hydrochlorothiazide† (formerly Inderide®) Tenoretic®* (atenolol/chlorthalidone) Ziac®* (bisoprolol/hydrochlorothiazide)</p>

Anti-Hypertensives: Calcium Channel Blockers

LENGTH OF AUTHORIZATION: 3 years

CRITERIA FOR APPROVAL (except as noted below):

- The patient has had a documented side effect, allergy, or treatment failure to at least three preferred drugs. (If a medication has an AB rated generic, one trial must be the generic formulation.)

Caduet®

- The prescriber must provide a clinically valid reason for the use of the requested medication.

Azor®, Exforge®, Exforge HCT®

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

Tribenzor®

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

AND

- The patient is unable to comply with taking the individual components (hydrochlorothiazide and Azor®) separately.

Twynsta®

- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.

AND

- The patient is unable to take the individual components (amlodipine and Micardis®) separately.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Anti-Hypertensives: Calcium Channel Blockers *Length of Authorization: 3 years*

Key: † Generic product, *Indicates generic equivalent is available without a PA,
 § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<u>SINGLE AGENT</u>	
Dihydropyridines	
AFEDITAB [®] CR † (nifedipine SR, compare to Adalat [®] CC)	Adalat [®] CC* (nifedipine SR)
AMLODIPINE † (compare to Norvasc [®])	Cardene [®] SR (nicardipine SR) (no AB rated generic)
FELODIPINE ER† (previously Plendil [®])	Dynacirc [®] CR (isradipine CR) (no AB rated generic)
NICARDIPINE † (formerly Cardene [®])	Isradipine [®] (formerly Dynacirc [®])
NIFEDIAC [®] CC † (nifedipine SR, compare to Adalat [®] CC)	Nimotop [®] * (nimodipine)
NIFEDICAL [®] XL † (nifedipine SR osmotic, compare to Procardia [®] XL)	Nisoldipine ER† (compare to Sular [®])
NIFEDIPINE IR † (compare to Procardia [®])	Norvasc [®] * (amlodipine)
NIFEDIPINE SR osmotic † (compare to Procardia [®] XL)	Procardia [®] * (nifedipine IR)
NIFEDIPINE SR † (compare to Adalat [®] CC)	Procardia XL [®] * (nifedipine SR osmotic)
NIMODIPINE † (compare to Nimotop [®])	Sular [®] (nisoldipine)
Miscellaneous	
CARTIA [®] XT † (diltiazem SR, compare to Cardizem [®] CD)	Calan [®] * (verapamil)
DILT-CD [®] † (diltiazem SR, compare to Cardizem [®] CD)	Calan [®] SR* (verapamil CR)
DILT-XR [®] † (diltiazem SR, compare to Dilacor [®] XR)	Cardizem [®] * (diltiazem)
DILTIAZEM† (compare to Cardizem [®])	Cardizem [®] CD* (diltiazem SR)
DILTIAZEM ER† (formerly Cardizem [®] SR)	Cardizem [®] LA (diltiazem SR)
DILTIAZEM ER† (compare to Tiazac [®])	Covera-HS [®] (verapamil SR) (no AB rated generic)
DILTIAZEM SR † (compare to Cardizem [®] CD)	Dilacor [®] XR* (diltiazem SR)
DILTIAZEM SR † (compare to Dilacor [®] XR)	Diltiazem ER† /Matzin LA† (compare to Cardizem [®] LA)
TAZTIA [®] XT † (diltiazem ER, compare to Tiazac [®])	Isoptin [®] SR* (verapamil CR)Tiazac [®] * (diltiazem ER)
VERAPAMIL† (compare to Calan [®])	Verelan [®] * (verapamil SR 120 mg, 180 mg, 240 mg and 360 mg)
VERAPAMIL CR† (compare to Calan SR [®] , Isoptin [®] SR)	Verelan [®] PM* (100 mg, 200 mg and 300 mg)
VERAPAMIL SR† 120 mg, 180 mg 240 mg and 360 mg (compare to Verelan [®])	
VERAPAMIL SR† 100 mg, 200 mg, 300mg (compare to Verelan PM [®])	
<u>CALCIUM CHANNEL BLOCKER/OTHER COMBINATION</u>	
(preferred after clinical criteria are met)	
AZOR [®] (olmesartan/amlodipine) § (QL = 1 tablet/day)	Tribenzor [®] (amlodipine/olmesartan/hydrochlorothiazide) (QL = 1 tablet/day)
EXFORGE [®] (valsartan/amlodipine) § (QL = 1 tablet/day)	Twynsta [®] (amlodipine/telmisartan) (QL = 1 tablet/day)
EXFORGE HCT [®] (amlodipine/valsartan/hydrochlorothiazide) § (QL = 1 tab/day)	Caduet [®] (amlodipine/atorvastatin)

Anti-hypertensives: Renin Inhibitors

LENGTH OF AUTHORIZATION: 3 years

CRITERIA FOR APPROVAL:

Tekturna[®]:

- The patient has a diagnosis of hypertension.
- AND**
- The patient has had a documented side effect, allergy, or treatment failure with an Angiotensin Receptor Blocker (ARB). *Note:* Approval of an ARB requires a documented side effect, allergy, or treatment failure with an Angiotensin Converting Enzyme (ACE) inhibitor.

Amturnide[®], Tekalmo[®], Tekturna HCT[®]:

- The patient has a diagnosis of hypertension.
- AND**
- The patient has had a documented side effect, allergy, or treatment failure with an Angiotensin Receptor Blocker (ARB). *Note:* Approval of an ARB requires a documented side effect, allergy, or treatment failure with an Angiotensin Converting Enzyme (ACE) inhibitor.
- OR**
- The patient has had a documented treatment failure with Tekturna[®] alone.

Valturna[®]:

- The patient has a diagnosis of hypertension.
- AND**
- The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.
- OR**
- The patient has had a documented treatment failure with Tekturna[®] alone.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of this medication on a **General Prior Authorization Request Form**.

Anti-hypertensives: Renin Inhibitors		<i>Length of Authorization: 3 years</i>
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
	<p><u>Single Agent</u> Tekturna[®] (aliskiren) (<i>Qty Limit = 1 tablet/day</i>)</p> <p><u>Combination</u> Amturnide[®] (aliskiren/amlodipine/hydrochlorothiazide) (<i>Qty Limit = 1 tablet/day</i>)</p> <p>Tekamlo[®] (aliskiren/amlodipine) (<i>Qty Limit = 1 tablet/day</i>)</p> <p>Tekturna HCT[®] (aliskiren/hydrochlorothiazide) (<i>Qty Limit = 1 tablet/day</i>)</p> <p>Valturna[®] (aliskiren/valsartan) (<i>Qty Limit = 1 tablet/day</i>)</p>	

Anti-Infectives: Antibiotics: Cephalosporins

LENGTH OF AUTHORIZATION: for the date of service, only: no refills

CRITERIA FOR APPROVAL:

Duricef[®], Keflex[®]:

- The patient has had a documented side effect, allergy, or treatment failure to generic cefadroxil and cephalixin.

Lorabid[®] capule/suspension:

- The patient is completing a course of therapy which was initiated in the hospital.
- OR**
- The patient has had a documented side effect, allergy, or treatment failure to at least two of the following medications: cefaclor/ER, cefprozil, and cefuroxime (for the capsule) or the patient has had a documented side effect, allergy, or treatment failure to at least two of the following medications: cefaclor suspension, cefprozil suspension and Ceftin[®] suspension (for the suspension).

Ceftin[®] tablets, Cefzil[®] tablets:

- The patient has had a documented side effect, allergy, or treatment failure to at least two of the following medications: cefaclor/ER, cefprozil, and cefuroxime. If a product has an AB rated generic, one trial must be the generic formulation.

Ceftin suspension, Cefzil[®] suspension:

- The patient has had a documented side effect, allergy, or treatment failure to at least two of the following medications: cefaclor suspension, cefprozil suspension and cefuroxime suspension. If a product has an AB rated equivalent that is preferred, one trial must be the preferred formulation.

Spectracef[®] tablet, Cedax[®] Capsule, Cefditoren tablet:

- The patient is completing a course of therapy which was initiated in the hospital.
- OR**
- The patient has had a documented side effect, allergy, or treatment failure to both cefpodoxime and Omnicef[®].
- AND**
- If the request is for Spectracef[®], the patient has a documented intolerance with generic cefditoren tablets

Cefpodoxime suspension, Cedax[®] suspension:

- The patient is completing a course of therapy which was initiated in the hospital.
- OR**
- The patient has had a documented side effect or treatment failure to both, brand Omnicef[®] and Suprax[®] suspension.

Vantin[®] tablets:

- The patient is completing a course of therapy which was initiated in the hospital and the patient is unable to use generic cefpodoxime.
- OR**
- The patient has had a documented side effect or treatment failure to both brand Omnicef[®] and cefpodoxime.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Anti-Infectives: Antibiotics: Cephalosporins

Length of Authorization: Date of service only. No refills.

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)

PA REQUIRED

1st GENERATION:

CEFADROXIL† (compare to Duricef®)

CEPHALEXIN† (compare to Keflex®)

IV drugs are not managed at this time.

Duricef®* (cefadroxil)

Keflex®* (cephalexin)

2nd GENERATION:

TABLETS/CAPSULES

CEFACTOR† CAPSULE

CEFACTOR ER† TABLET

CEFPROZIL† (compare to Cefzil®) TABLET

CEFUROXIME † (compare to Ceftin®) TABLET

SUSPENSION

CEFACTOR† SUSPENSION

CEFPROZIL† (compare to Cefzil®)

SUSPENSION

CEFUROXIME† (compare to Ceftin®)

SUSPENSION

IV drugs are not managed at this time.

Ceftin®* (cefuroxime) tablet

Cefzil®* (cefprozil) tablet

Lorabid® (loracarbef) capsule

Ceftin®* (cefuroxime) suspension

Cefzil®* (cefprozil) suspension

Lorabid® (loracarbef) suspension

3rd GENERATION:

CAPSULES/TABLETS

CEFDINIR† (compare to Omnicef®) CAPSULE

CEFPODOXIME PROXETIL† (compare to Vantin®) TABLET

OMNICEF® (cefdinir) CAPSULE

SUPRAX® (cefixime) TABLET

SUSPENSION

CEFDINIR† (compare to Omnicef®)

SUSPENSION

OMNICEF® (cefdinir) SUSPENSION

SUPRAX® (cefixime) SUSPENSION

IV drugs are not managed at this time.

Cedax® (ceftibuten) capsule

Cefditoren† (compare to Spectracef®) tablet

Spectracef® (cefditoren) tablet

Vantin®* (cefpodoxime) tablet

Cedax® (ceftibuten) suspension

Cefpodoxime proxetil† (formerly Vantin®) suspension

Anti-Infectives: Antibiotics: Ketolides

LENGTH OF AUTHORIZATION: Date of service only, no refills

CRITERIA FOR APPROVAL:

- The member is continuing a course of therapy initiated while an inpatient at a hospital.

OR

- The diagnosis or indication for the requested medication is community-acquired pneumonia.

AND

- The member is at least 18 years of age at the time of the request.

AND

- The member has no contraindication or a history of hypersensitivity or serious adverse event, from any macrolide antibiotic.

AND

- Infection is due to documented *Streptococcus pneumoniae* (including multi-drug resistant [MDRSP*] *s.pneumoniae*), *Haemophilus influenzae*, *Moraxella catarrhalis*, *Chlamydomphila pneumoniae*, or *Mycoplasma pneumoniae*.

AND

- The member does not have any of the following medical conditions: myasthenia gravis, hepatitis or underlying liver dysfunction, history of arrhythmias (e.g. QTc prolongation, or antiarrhythmic therapy), uncorrected hypokalemia or hypomagnasemia, clinically significant bradycardia, a history of therapy with Class IA (e.g. quinidine or procainamide) or Class III (e.g. dofetilide) antiarrhythmic medications.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**.

*MDRSP includes penicillin-resistant *S. pneumoniae* isolates (PRSP) that are resistant to ≥ 2 of the following antibiotics: penicillin, 2nd generation cephalosporins, macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.

Anti-Infectives: Antibiotics: Ketolides		<i>Length of Authorization: Date of Service Only; no refills</i>
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
n/a	Ketek® (telithromycin)	

Anti-Infectives: Antibiotics: Macrolides

LENGTH OF AUTHORIZATION:for the date of service, only; no refills (azithromycin/Zithromax packets)

Up to 6 months: refills.permissable with extended duration PA approvals (other medications).

CRITERIA FOR APPROVAL (NON-PREFERRED AGENTS)(EXCEPT AS BELOW):

- The patient has a documented side-effect, allergy, or treatment failure to at least two of the preferred medications. (If a product has an AB rated generic, one trial must be the generic.)
- OR**
- The patient is completing a course of therapy with the requested medication that was initiated in the hospital.

CRITERIA FOR APPROVAL OF AZITHROMYCIN/ZITHROMAX PACKETS:

- Is there a clinically valid reason why the dose cannot be obtained using generic azithromycin tablets?
- AND**
- If the request is for brand Zithromax, the patient has a documented intolerance to the generic product.

CRITERIA FOR APPROVAL OF AZITHROMYCIN FOR > 5 DAY SUPPLY:

- The patient has a diagnosis of Lyme Disease AND has had a documented side effect, allergy, or treatment failure to at least two of the following: doxycycline, amoxicillin, or a 2nd generation cephalosporin. For early Lyme disease, without neurologic or rheumatologic (arthritis) complications, the length of authorization is up to 10 days. For neurologic or rheumatologic Lyme disease, the length of authorization is up to 28 days
- OR**
- The patient has a diagnosis of Cystic Fibrosis. (length of authorization up to 6 months)
- OR**
- The patient has a diagnosis of HIV/immunocompromised status and azithromycin is being used for MAC or Toxoplasmosis treatment or prevention.(length of authorization up to 6 months)
- OR**
- The patient has a diagnosis of bacterial sinusitis AND has had a documented side effect, allergy, or treatment failure to penicillin, amoxicillin, or sulfamethoxazole/trimethoprim (Bactrim). (length of authorization up to 10 days)
- OR**
- The patient has a diagnosis of severe bronchiectasis with frequent exacerbations (length of authorization up to 6 months)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting provision of a non-preferred agent or more than the stated quantity limits on a **General Prior Authorization Request Form**.

Anti-Infectives: Antibiotics: Macrolides

Length of Authorization: Date of service, only; no refills for generic and brand azithromycin packets; up to 6 months (others) Refills permissible with extended duration PA approvals

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p>AZITHROMYCIN† tabs, liquid (≤ 5 day supply) (compare to Zithromax®) (Maximum 10 days therapy/30 days)</p> <p>CLARITHROMYCIN† (compare to Biaxin®)</p> <p>E.E.S®† (erythromycin ethylsuccinate) ERY-TAB® (erythromycin base, delayed release) ERYTHROCIN† (erythromycin stearate) ERYTHROMYCIN BASE† ERYTHROMYCIN ETHYLSUCCINATE† (compare to E.E.S®) ERYTHROMYCIN W/SULFISOXAZOLE† (compare to Pediazole®)</p> <p>IV drugs are not managed at this time.</p>	<p>azithromycin† tablets and liquid (if > 5 day supply) (compare to Zithromax®) (Maximum 10 days therapy/30 days) Azithromycin† packet (compare to Zithromax®) (<i>QL = 2 grams/fill</i>) Biaxin®* (clarithromycin) Biaxin XL® (clarithromycin SR) Clarithromycin SR† (compare to Biaxin® XL)</p> <p>Dynabac® (dirithromycin)</p> <p>Eryped® (erythromycin ethylsuccinate) PCE Dispertab® (erythromycin base) Pediazole®* (erythromycin-sulfisoxazole)</p> <p>Zithromax®* (azithromycin) tablets and liquid <i>QL = 5 days supply/RX, maximum 10 days therapy/30 days</i> Zithromax® (azithromycin) packet (<i>QL=2 grams/fill</i>) Zmax® Suspension (azithromycin extended release for oral suspension) <i>QL = 5 days supply/RX, maximum 10 days therapy/30 days</i></p>

Anti-Infectives: Antibiotics: Oxazolidinones

LENGTH OF AUTHORIZATION: 28 days

CRITERIA FOR APPROVAL:

- The patient has been started on intravenous or oral linezolid in the hospital and will be finishing the course of therapy in an outpatient setting **AND** the quantity requested does not exceed 56 tablets per 28 days.

OR

- The patient has a documented blood, tissue, sputum, or urine culture that is positive for Vancomycin-Resistant Enterococcus (VRE) species or Methicillin-Resistant Staphylococcus species **AND** the quantity requested does not exceed 56 tablets per 28 days.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent and quantities exceeding the established limit on a **General Prior Authorization Request Form**.

Anti-Infectives: Antibiotics: Oxazolidinones	
<i>Length of authorization: 28 days</i>	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
IV form of this medication not managed at this time	Zyvox® (linezolid) <i>QL = 56 tablets per 28 days</i> Zyvox® (linezolid) suspension

Anti-infectives: Antibiotics: Penicillins (Oral)

LENGTH OF AUTHORIZATION: For the date of service only; no refills

CRITERIA FOR APPROVAL:

Augmentin and Augmentin ES:

- The patient has had a documented side effect, allergy, or treatment failure to the generic formulation of the requested medication.

OR

- The patient is < 12 weeks of age and requires the 125 mg/5 mL strength of Augmentin.

Amoxicillin/Clavulanate XR, Augmentin XR, Moxatag:

- The prescriber must provide a clinically valid reason for the use of the requested medication. Additionally, for approval of brand Augmentin XR, the patient must have a documented intolerance to generic Amoxicillin/Clavulanate XR

DOCUMENTATION

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Anti-Infectives: Antibiotics: Penicillins (oral)	
<i>Length of Authorization: Date of service only. No refills.</i>	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
AMOXICILLIN† (compare to Amoxil [®] , Trimox [®] , DisperMox [®])	Amoxicillin/clavulanate† (compare to Augmentin XR [®]) tablets
AMOXICILLIN/CLAVULANATE† (compare to Augmentin [®])	Augmentin ^{®*} (amoxicillin/clavulanate) chewable tablets, tablets, suspension
AMPICILLIN† (compare to Principen [®])	Augmentin ES ^{®*} (amoxicillin/clavulanate) suspension
DICLOXACILLIN†	Augmentin XR [®] (amoxicillin/clavulanate) tablets
PENICILLIN VK† (compare to Veetids [®])	Moxatag [®] (amoxicillin extended release) tablet <i>QL = 1 tablet/day</i>
	* PA will be granted for 125 mg/5 mL strength for patients < 12 weeks of age

Anti-Infectives: Antibiotics: Quinolones

LENGTH OF AUTHORIZATION: for the date of service, no refills

CRITERIA FOR APPROVAL:

Noroxin[®]:

- The patient is completing a course of therapy with the requested medication that was initiated in the hospital.
- OR**
- The patient has had a documented side effect, allergy, or treatment failure to ciprofloxacin immediate-release tablets/solution or ofloxacin.

Cipro[®], Cipro XR[®], ciprofloxacin ER, ProQuin XR[®]:

- The patient has had a documented side effect, allergy, or treatment failure to generic ciprofloxacin immediate-release tablets or oral solution.
- AND**
- If the request is for Cipro XR, the patient has had a documented intolerance to generic ciprofloxacin ER.

Avelox[®], Factive[®]:

- The patient is completing a course of therapy with the requested medication that was initiated in the hospital.
- OR**
- The patient has had a documented side effect, allergy, or treatment failure to Levaquin.

Levofloxacin (generic):

- The patient has a documented intolerance with the brand Levaquin[®]

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred quinolone on a **General Prior Authorization Request Form**.

Anti-Infectives: Antibiotics: Quinolones

Length of Authorization: Date of service only. No refills.

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
CIPROFLOXACIN† (compare to Cipro [®]) CIPRO [®] OS (ciprofloxacin oral solution) LEVAQUIN [®] (levofloxacin) tabs,sol OFLOXACIN† IV drugs are not managed this time	Avelox [®] (moxifloxacin HCL) Avelox [®] ABC PACK (moxifloxacin HCL) Cipro [®] * (ciprofloxacin) Cipro [®] XR (ciprofloxacin) ciprofloxacin ER† (compare to Cipro [®] XR) Factive [®] (gemifloxacin) levofloxacin † (compare to Levaquin [®]) tabs, sol Noroxin [®] (norfloxacin) ProQuin XR [®] (ciprofloxacin extended-release)

Anti-Infectives: Antifungals: Allylamines

LENGTH OF AUTHORIZATION: Up to 3 months

Onychomycosis (terbinafine):

Fingernails: 2 tablets (500mg) per day for 1 week/month for 2 months (pulse) or 1 tablet (250mg) per day for 6 weeks

Toenails: 2 tablets (500mg) per day for 1 week per month for 3 months (pulse) or 1 tablet (250mg) per day for 12 weeks

Tinea capitis: 6 weeks

Tinea pedis/Tinea cruris/Tinea corporis: up to 250 mg/day for up to 1 month (30 tabs/month)

Other indications: 3 months

CRITERIA FOR APPROVAL

Terbinafine Tablets:

- The patient has a diagnosis of a fingernail/toenail onychomycosis infection (confirmed with a positive KOH stain, PAS stain, or fungal culture or physician clinical judgment).
AND
- The patient meets at least 1 of the following criteria:
 - Pain to affected area that limits normal activity
 - Diabetes Mellitus
 - Patient is immunocompromised
 - Patient has diagnosis of systemic dermatosis
 - Patient has significant vascular compromise**AND**
- The quantity requested does not exceed 30 tablets per month for a maximum of 3 months.
OR
- The patient has a diagnosis of a *Tinea capitis* infection (confirmed with a positive KOH stain, PAS stain, or fungal culture).
AND
- The quantity requested does not exceed 30 tablets per month for a maximum of 6 weeks.
OR
- The patient has a diagnosis of a *Tinea pedis*, *Tinea cruris*, or *Tinea corporis* infection (confirmed with a positive KOH stain, PAS stain, or fungal culture).
AND
- The patient has a documented side-effect, allergy, or treatment failure to at least **THREE** different topical antifungal medications (one of the trials **must** have included a topical terbinafine product).
AND
- The quantity requested does not exceed 30 tablets per month for a maximum of 1 month.
- For approval of Lamisil[®], the patient must have a documented intolerance to generic terbinafine.

Lamisil Granules:

- The patient has a diagnosis of a *Tinea capitis* infection (confirmed with a positive KOH stain, PAS stain, or fungal culture).
AND
- The patient has a requirement for an oral liquid dosage form.
AND
- The patient had a documented side effect, allergy, or treatment failure with Griseofulvin suspension

LIMITATIONS:

Coverage of Onychomycosis agents will **NOT** be approved solely for cosmetic purposes.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting provision of the non-preferred agent or more than the stated quantity limits on a **General Prior Authorization Request Form**.

Anti-Infectives: Antifungals: Allylamines	
<i>Length of Authorization: Up to 3 months</i>	
Key: † Generic product	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
	terbinafine† (compare to Lamisil®) tablets (<i>QL: 30 tab/month post PA approval</i>)
	Lamisil® (terbinafine) granules (<i>QL: 125 mg packet (1 or 2 per day depending on dose) 187.5 mg packet (1 per day) post PA approval</i>)
	Lamisil® tablets (terbinafine) (<i>QL: 30 tab/month post PA approval</i>)

Please Note: Griseofulvin suspension is available without restrictions or PA for treatment of *Tinea Capitis* infections.

Anti-Infectives: Antifungals: Azoles

LENGTH OF AUTHORIZATION: Up to 3 months

Onychomycosis (Sporanox/itraconazole):

Fingernails: 2 capsules (200mg) twice daily for 1 week per month for 2 months (pulse) or
2 capsules (200mg) per day for 6 weeks

Toenails: 2 capsules (200mg) twice daily for 1 week per month for 3 months (pulse) or
2 capsules (200mg) per day for 12 weeks

Other medications/indications: 3 months

CRITERIA FOR APPROVAL ITRACONAZOLE/SPORANOX®:

- The patient has a diagnosis of invasive aspergillosis, blastomycosis, or histoplasmosis
OR
- The patient has a diagnosis of a fingernail/toenail onychomycosis infection (confirmed with a positive KOH stain, PAS stain, fungal culture or physician clinical judgment) **AND** has a documented side-effect, allergy, contraindication, or treatment failure to oral terbinafine **AND** meets at least 1 of the following criteria:
 - Pain to affected area that limits normal activity
 - Diabetes Mellitus
 - Patient is immunocompromised
 - Patient has diagnosis of systemic dermatosis
 - Patient has significant vascular compromise**OR**
- The patient is completing a course of therapy with the requested medication that was initiated in the hospital.
OR
- The patient has a documented side-effect, allergy, or treatment failure to at least **ONE** of the preferred medications.
- For approval of Sporanox® capsules, the patient must have a documented intolerance to generic itraconazole. For approval of Sporanox® solution, the patient must have a medical necessity for a liquid dosage form.

LIMITATIONS:

Coverage of Onychomycosis agents will **NOT be approved solely for cosmetic purposes.**

CRITERIA FOR APPROVAL OF VORICONAZOLE/VFEND®:

- Patient has a diagnosis of invasive aspergillosis.
OR
- The patient is completing a course of therapy with the requested medication that was initiated in the hospital.
OR
- The patient has a documented side-effect, allergy, or treatment failure to **ONE** of the preferred medications **AND** itraconazole.
- For approval of Vfend® tablets, the patient must have a documented intolerance to generic voriconazole. For approval of Vfend® solution, the patient must have a medical necessity for a liquid dosage form.

CRITERIA FOR APPROVAL OF NOXAFIL:

- The patient has a diagnosis of HIV/immunocompromised status (neutropenia secondary to chemotherapy, hematopoietic stem cell transplant recipients) **AND** Noxafil is being used for the prevention of invasive *Aspergillus/Candida* infections.
- OR**
- The patient is completing a course of therapy with the requested medication that was initiated in the hospital.
- OR**
- The patient has a documented side-effect, allergy, or treatment failure to **ONE** of the preferred medications **AND** itraconazole **AND** the patient is being treated for oropharyngeal candidiasis.

CRITERIA FOR APPROVAL OF DIFLUCAN® (BRAND):

- For approval of Diflucan® brand name product, the patient must have a documented intolerance to generic fluconazole.

CRITERIA FOR APPROVAL OF ORAVIG:

- The indication for use is treatment of oropharyngeal candidiasis.
- AND**
- The patient has had a documented side effect, allergy, treatment failure/inadequate response to both nystatin suspension and clotrimazole troche.
- OR**
- The patient is unable to be compliant with the nystatin suspension and/or clotrimazole troche dosing schedules.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting provision of a non-preferred agent on a **General Prior Authorization Request Form**.

Anti-Infectives: Antifungals: Azoles	
<i>Length of Authorization: Up to 3 months (see above)</i>	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
FLUCONAZOLE† (compare to Diflucan®) tabs, suspension	Diflucan®* (fluconazole) tabs, suspension
KETOCONAZOLE† (formerly Nizoral®) tabs	itraconazole† (compare to Sporanox®) caps
CLOTRIMAZOLE Troche† (compare to Mycelex®)	Noxafil® (posaconazole)
	Oravig® (miconazole) buccal tabs (<i>QL=1 tab/day; 14 tabs per RX ONLY</i>)
	Sporanox® (itraconazole) caps, solution
	VFend® (voriconazole) tabs, suspension
	voriconazole† (compare to VFend®) tabs
IV drugs are not managed at this time.	

Anti-Infectives: Antimalarials: Quinine

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The diagnosis or indication is for the treatment of malaria. (Use for leg cramps not permitted.)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**.

Anti-Infectives: Antimalarials: Quinine		<i>Length of Authorization: 1 year</i>
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
	Qualaquin [®] (quinine sulfate)	

Anti-Infectives: Antivirals: Herpes: Oral

LENGTH OF AUTHORIZATION: for duration of prescription, up to 6 months

CRITERIA FOR APPROVAL (NON-PREFERRED AGENTS except Valacyclovir):

Famvir, Zovirax

- The patient has a documented side effect or allergy, or treatment failure (at least one course of ten or more days) with acyclovir **AND** Valtrex.

Famciclovir

- The patient has a documented side effect or allergy, or treatment failure (at least one course of ten or more days) with acyclovir **AND** Valtrex.
AND
- The patient has a documented intolerance to brand name Famvir®.

Valacyclovir

- The patient has a documented intolerance to brand name Valtrex®.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

<p>Anti-Infectives: Antivirals: Herpes: Oral <i>Length of Authorization: up to 6 months</i> Key: † Generic product, *Indicates generic equivalent is available without a PA § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr style="background-color: black; color: white;"> <th style="text-align: left; padding: 2px;">PREFERRED DRUGS (No PA Required)</th> <th style="text-align: left; padding: 2px;">PA REQUIRED</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;"> ACYCLOVIR† (compare to Zovirax®) VALTREX® (valacyclovir) </td> <td style="padding: 2px;"> Famvir® (famciclovir) § famciclovir† (compare to Famvir®) valacyclovir † (compare to Valtrex®) Zovirax®* (acyclovir) § </td> </tr> </tbody> </table>	PREFERRED DRUGS (No PA Required)	PA REQUIRED	ACYCLOVIR† (compare to Zovirax®) VALTREX® (valacyclovir)	Famvir® (famciclovir) § famciclovir† (compare to Famvir®) valacyclovir † (compare to Valtrex®) Zovirax®* (acyclovir) §
PREFERRED DRUGS (No PA Required)	PA REQUIRED			
ACYCLOVIR† (compare to Zovirax®) VALTREX® (valacyclovir)	Famvir® (famciclovir) § famciclovir† (compare to Famvir®) valacyclovir † (compare to Valtrex®) Zovirax®* (acyclovir) §			

Anti-Infectives: Antivirals: Influenza Medications

Dosing information below is to be used in combination with the CDC and Vermont Department of Health recommendations:

<http://www.cdc.gov/flu/>

<http://healthvermont.gov/prevent/flu/index.aspx>

Antiviral medications with activity against influenza viruses are an important adjunct to influenza vaccine in the control of influenza.

- Influenza antiviral prescription drugs can be used to **treat** influenza or to **prevent influenza**.
- Two FDA-approved influenza antiviral medications are recommended for use in the United States during the 2011-2012 influenza season: **oseltamivir** (Tamiflu[®]) and **zanamivir** (Relenza[®]).
- Oseltamivir and zanamivir are chemically related antiviral medications known as neuraminidase inhibitors that have activity against both influenza A and B viruses.
- The greatest benefit is when antiviral treatment is started within 48 hours of influenza illness onset.
- Antiviral treatment may still be beneficial in patients with severe, complicated, or progressive illness, and in hospitalized patients when administered more than 48 hours from illness onset.
- Annual influenza vaccination is the best way to prevent influenza because vaccination can be given well before influenza virus exposures occur, and can provide safe and effective immunity throughout the influenza season. However, antiviral medications are **70% to 90%** effective in preventing influenza and are useful adjuncts to vaccination.
- CDC does not recommend widespread or routine use of antiviral medications for chemoprophylaxis so as to limit the possibilities that antiviral resistant viruses could emerge.

LENGTH OF AUTHORIZATION: for duration of the prescription

CRITERIA FOR APPROVAL (Tamiflu, Relenza):

Tamiflu and Relenza will **NOT** require prior-authorization **at this time** when prescribed within the following quantity limits:

Relenza (zanamivir): 20 blisters per 30 days

Tamiflu (oseltamivir): 75 mg or 45 mg: 10 capsules per 30 days

30 mg: 20 capsules per 30 days

Suspension (6 mg/ml): 180 ml (3 bottles) per 30 days

Antiviral Medication Dosing Recommendations for Treatment and Chemoprophylaxis of Influenza, 2011 – 2012 Influenza Season.

Agent, group		Treatment (5 days)	Chemoprophylaxis (7 days, 14 days or longer in long term care)
Oseltamivir (Tamiflu[®])			
Adult		75-mg capsule twice per day	75-mg capsule once per day
Children ≥ 12 months	≤15 kg	30 mg twice daily	30 mg once per day
	>15-23 kg	45 mg twice daily	45 mg once per day
	>23-40 kg	60 mg twice daily	60 mg once per day
	>40 kg	75 mg twice daily	75 mg once per day
Zanamivir (Relenza[®])*			
Adult		10 mg (two 5 mg inhalations) twice daily	10 mg (two 5-mg inhalations) once daily
Children		10 mg (two 5 mg inhalations) twice daily (for 7 years or older)	10 mg (two 5-mg inhalations) once daily (for 5 years or older)

*Zanamivir, an inhaled medication, can induce bronchospasm and is not recommended for treatment for patients with underlying pulmonary disease such as asthma or chronic obstructive pulmonary disease.

LIMITATIONS:

Amantadine, Flumadine[®] and rimantadine are not CDC recommended for use in influenza treatment or chemoprophylaxis at this time and are not covered for this indication. For information regarding amantadine see “Parkinsons Medications”. Flumadine[®]/rimantadine is not covered for any indication.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General** **Prior Authorization Request Form.**

Anti-Infectives: Antivirals: Influenza Medications

Length of Authorization: up to 6 weeks

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS	PA REQUIRED
RELENZA [®] (zanamivir)(QL= 20 blisters/30 days) TAMIFLU [®] (oseltamivir)(QL = 10 caps/30 days (45 mg & 75 mg caps), 20 caps/30 days (30 mg caps), 180 ml (6 mg/ml)/30 days (suspension))	

Anti-Infectives: Antivirals: Influenza Vaccines

LENGTH OF AUTHORIZATION:

NOTE: Seasonal Influenza Nasal Vaccine is provided free of charge and without PA for patients ages 2 – 18 by the Vermont Department of Health. Prescribers should contact the Vermont Department of Health for supply.

1 dose for children and adults aged 2-49 years, including children aged 2-8 years who have been previously vaccinated with influenza vaccine.

2 doses total, given at least one month apart, for children age 2-8 years who have not been previously vaccinated with influenza vaccine.

INDICATION: Seasonal Influenza Nasal Vaccine

Seasonal influenza nasal vaccine (live attenuated) is FDA approved for influenza prevention in healthy people 2 - 49 years of age who are not pregnant. It is different from the standard influenza vaccines, which contain inactivated viruses and are administered intramuscularly. Theoretically, viruses from the live vaccine may be transmitted to other people. The Advisory Committee on Immunization Practices (ACIP) publishes guidelines specifying groups of people who will benefit most from influenza vaccination, such as those with chronic medical conditions, nursing home residents, and pregnant women. However, the intranasal formulation is contraindicated in many patients that would benefit from influenza vaccination, due to the fact it is a live vaccine.

CRITERIA FOR APPROVAL (Flumist):

- Flumist is being requested for influenza prophylaxis during flu season,

AND
- The patient is between the ages of 19 and 49 years old,

AND
- Prescriber provides documentation of a contraindication to an intramuscular injection (e.g., currently on warfarin; history of thrombocytopenia) or other compelling information to support the use of this dosage form.

EXCLUDED FROM APPROVAL:

- Hypersensitivity (severe allergy) to any FluMist[®] component including eggs and egg products.
- Children and adolescents aged 2 – 17 years receiving aspirin therapy (increased risk of Reye's Syndrome).
- History of Guillain-Barre Syndrome.
- People with a medical condition that places them at high risk for complications from influenza, including those with chronic heart or lung disease, such as asthma or reactive airways disease; people with medical conditions such as diabetes or kidney failure; or people with illnesses that weaken the immune system, or who take medications that can weaken the immune system.
- Children <5 years old with a history of recurrent wheezing
- Pregnant women

Requests will be evaluated on a case-by-case basis, in the event of vaccine shortage and/or the issuing of prioritization orders from the Department of Public Health and Centers for Disease Control.

Age Group	Vaccination Status	Dosage Schedule
Children age 2 –8 years	Not previously vaccinated with seasonal influenza vaccine or received only one dose in 2010/11 and it was first time vaccination	2 doses (0.2 mL* each at least one month apart)
Children age 2 – 8 years	Previously vaccinated with seasonal influenza vaccine	1 dose (0.2 mL*) per season
Children & Adults age 9-49	Not Applicable	1 dose (0.2 mL*) per season

* administered as 0.1 mL per nostril

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of Flumist[®] on the **General Prior Authorization Request Form**.

Anti-Infectives: Antivirals: Influenza Vaccines	
<i>Length of Authorization: up to 6 weeks</i>	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>SEASONAL Influenza Vaccine Injection</u> <u>(Trivalent Inactivated Vaccine)</u> <u>(includes H1N1 for 2011-2012)</u> AFLURIA[®] 2011- 2012 Injection AGRIFLU[®] 2011- 2012 Injection FLUARIX[®] 2011- 2012 Injection FLULAVAL[®] 2011- 2012 Injection FLUVIRIN[®] 2011- 2012 Injection FLUZONE[®] 2011 - 2012 Injection</p> <p><u>SEASONAL Influenza Nasal Vaccine</u> <u>(Live Attenuated Influenza Vaccine)</u> <u>(includes H1N1 for 2011-2012)</u></p>	<p>FluMist[®] Nasal</p>

Anti-Migraine: Triptans

LENGTH OF AUTHORIZATION:

6 months

CRITERIA FOR APPROVAL (non-preferred agents):

Oral: Amerge, Axert, Frova, Imitrex, Maxalt, Relpax, Zomig:

- The patient has had a documented side-effect, allergy or treatment failure to Sumatriptan, Naratriptan and Maxalt-MLT.

Maxalt-MLT:

- The patient has had a documented side effect, allergy, or treatment failure with Sumatriptan and Naratriptan.

Naratriptan:

- The patient has had a documented side effect, allergy, or treatment failure with Sumatriptan.

Treximet:

- The patient had a documented side effect, allergy, or treatment failure with 2 preferred Triptans
AND
- The patient is unable to take the individual components (sumatriptan and naproxen) separately

Nasal Spray: Zomig:

- The patient has had a documented side-effect, allergy or treatment failure Imitrex® Nasal Spray.

Nasal Spray or Injection: Sumatriptan

- The patient has had a documented intolerance to brand Imitrex®.

CRITERIA FOR APPROVAL (to exceed quantity limit):

- The patient is taking a medication for migraine prophylaxis

LIMITATIONS:

Sumavel DosePro® not covered as no Federal Rebate offered.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting provision of a non-preferred agent or more than the stated quantity limits on a **General Prior Authorization Request Form**.

Anti-Migraine: Triptans

Length of Authorization: 6 months

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>SINGLE AGENT</u></p> <p><u>ORAL</u></p> <p>SUMATRIPTAN† (compare to Imitrex®) <i>Quantity Limit = 18 tablets/month (25 mg), 9 tablets/month (50 mg, 100 mg)</i></p> <p>After Sumatriptan Trial</p> <p>NARATRIPTAN† (compare to Amerge®) <i>(Quantity Limit = 9 tablets/month)</i></p> <p>After Sumatriptan and Naratriptan Trials</p> <p>MAXALT-MLT® (rizatriptan ODT) <i>Quantity Limit = 12 tablets/month</i></p> <p><u>NASAL SPRAY</u></p> <p>IMITREX® (sumatriptan) <i>Quantity Limit = 12 units/month (5 mg nasal spray), 6 units/month (20 mg nasal spray)</i></p> <p><u>INJECTABLE</u></p> <p>IMITREX® (sumatriptan) <i>Quantity Limit = 4 injections/month (4 or 6 mg injection)</i></p> <p><u>COMBINATION PRODUCT</u></p>	<p>Amerge® (naratriptan) <i>Quantity Limit = 9 tablets/month</i></p> <p>Axert® (almotriptan) <i>Quantity Limit = 6 tablets/month</i></p> <p>Frova® (frovatriptan) <i>Quantity Limit = 9 tablets/month</i></p> <p>Imitrex®* (sumatriptan) <i>Quantity Limit = 18 tablets/month (25 mg), 9 tablets/month (50 mg, 100 mg)</i></p> <p>Maxalt® (rizatriptan) tablet <i>Quantity Limit = 12 tablets/month</i></p> <p>Relpax® (eletriptan) <i>Quantity Limit = 12 tablets/month</i></p> <p>Zomig® (zolmitriptan) <i>Quantity Limit = 12 tablets/month (2.5 mg tablets or orally disintegrating tablets), 6 tablets/month (5 mg tablets or orally disintegrating tablets)</i></p> <p>Sumatriptan† (compare to Imitrex®) <i>Quantity Limit = 12 units/month (5 mg nasal spray), 6 units/month (20 mg nasal spray)</i></p> <p>Zomig® (zolmitriptan) <i>Quantity Limit =, 12 units/month (5 mg nasal spray)</i></p> <p>sumatriptan† (compare to Imitrex®) <i>Quantity Limit = 4 injections/month (4 or 6 mg injection)</i></p> <p>Treximet® (sumatriptan/naproxen) <i>Quantity Limit = 9 tablets/month</i></p>

Anti-Obesity Agents

Effective 10/12/2011, anti-obesity agents (weight loss agents) are no longer a covered benefit for all Vermont Pharmacy Programs. This change is resultant from Drug Utilization Review (DUR) Board concerns regarding safety and efficacy of these agents.

Antipsychotics: Atypical and Combination

LENGTH OF AUTHORIZATION: Duration of need *^ (except as noted below)
Seroquel \leq 50 mg/day = 1 year

CRITERIA FOR APPROVAL:

NON-PREFERRED TABLETS:

Fanapt[®], Invega[®] and Saphris[®]:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
OR
- The patient has had a documented side effect, allergy or treatment failure with at least two preferred products.

Clozaril[®], Risperdal[®]:

- The patient has a documented intolerance to the generic equivalent.

Latuda[®]

- The patient is pregnant and the diagnosis is schizophrenia,
OR
- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
OR
- The patient has had a documented side effect, allergy or treatment failure with at least two preferred products.

Seroquel[®] < or = 50 mg/day (Adults 18 years and older):

- The patient is being prescribed > 50 mg/day with combinations of tablet strengths.
OR
- The indication for use is Adjunct treatment of Major Depressive Disorder (MDD) and the patient has had a documented inadequate response to at least 2 different antidepressants from the SSRI, SNRI, TCA, MAOI and/or Miscellaneous Antidepressant categories. Trazodone dosed at < 150 mg/day would not be considered a trial for this indication.
OR
- The indication for use is any anxiety disorder (panic, agoraphobia, social phobia, obsessive-compulsive disorder, PTSD, Acute Stress Disorder, Generalized Anxiety Disorder) and the patient has had a documented inadequate response to at least 2 different antidepressants from the SSRI, SNRI, TCA, MAOI and/or Miscellaneous Antidepressant categories or at least 1 antidepressant from the SSRI, SNRI, TCA, MAO and/or Miscellaneous Antidepressant categories and bupropion. Trazodone dosed at < 150 mg/day and bupropion would not be considered trials for this indication.
OR
- The indication for use is a mental health indication (other than the two above indications or a sleep disorder).

Note: Seroquel in doses of \leq 50 mg/day will not be approved for indications of insomnia, for sleep or as an hypnotic.

Seroquel XR®:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
OR
- The indication for use schizophrenia or bipolar disorder (bipolar mania, bipolar depression, bipolar maintenance).
AND
- The patient has not been able to be adherent to a twice daily dosing schedule of Seroquel® immediate release resulting in a significant clinical impact
OR
- The indication for use is Adjunct treatment of Major Depressive Disorder (MDD) and the patient has had a documented inadequate response to at least 2 different antidepressants from the SSRI, SNRI, TCA, MAOI and/or Miscellaneous Antidepressant categories. Trazodone dosed at < 150 mg/day would not be considered a trial for this indication.
AND
- The patient has not been able to be adherent to a twice daily dosing schedule of Seroquel® immediate release resulting in a significant clinical impact

Abilify®, Olanzapine, Zyprexa®:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
OR
- The patient has had a documented side effect, allergy or treatment failure with at least two preferred products (indications other than Major Depressive Disorder (MDD))
- AND
- If the request is for generic olanzapine, the patient has a documented intolerance to brand Zyprexa.
OR
- The indication for use is Adjunct treatment of Major Depressive Disorder (MDD) and the patient has had a documented inadequate response to at least 2 different antidepressants from the SSRI, SNRI, TCA, MAOI and/or Miscellaneous Antidepressant categories. Trazodone dosed at < 150 mg/day would not be considered a trial for this indication.
AND
- The patient has had a documented side effect, allergy or treatment failure with one preferred atypical antipsychotic product being used as adjunctive therapy.
- AND
- If the request is for generic olanzapine, the patient has a documented intolerance to brand Zyprexa.

NON-PREFERRED ORAL SOLUTIONS (except Risperdal®):

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
OR
- The patient has had a documented side effect, allergy or treatment failure with at least one preferred product.

Risperdal®:

- The patient has a documented intolerance to the generic product risperidone.

NON-PREFERRED SHORT-ACTING INJECTABLE PRODUCTS:

- Medical necessity for a specialty dosage form has been provided.
AND
- The patient has had a documented side effect, allergy, or treatment failure with Geodon IM.

LONG-ACTING INJECTIONS:

- Medical necessity for a specialty dosage form has been provided (swallowing disorder, non-compliance with oral medications, etc.)
- For approval of Invega Sustenna®, the patient must also have had a documented side effect, allergy, or treatment failure with Risperdal® Consta.
- For approval of Zyprexa Relprevv®, the prescriber must also provide clinical rationale why Risperdal® Consta is not a suitable option for this patient.

ORALLY DISINTEGRATING TABLETS:

- Medical necessity for a specialty dosage form has been provided.
AND
- If the request is for a generic product with a brand equivalent, the patient has a documented intolerance to brand product.

COMBINATION PRODUCTS:

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)
OR
- The patient has had a documented side effect, allergy or treatment failure with two preferred products (Geodon, risperidone, and Seroquel).
OR
- The prescriber provides a clinically valid reason for the use of the requested medication.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**
- ✓ Document clinically information supporting the prescribing of Seroquel in doses of ≤ 50 mg/day on a **Seroquel Prior Authorization Request Form.**

After a 4-month lapse in use of a non-preferred agent, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 160 for a description of the management of mental health drugs.

Antipsychotics: Atypical and Combination Length of authorization: Duration of Need**

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)

PA REQUIRED

TABLETS/CAPSULES

CLOZAPINE† (compare to Clozaril®)
FDA maximum recommended dose = 900 mg/day
 GEODON® (ziprasidone)
FDA maximum recommended dose = 160 mg/day
 RISPERIDONE† (compare to Risperdal®)
FDA maximum recommended dose = 16 mg/day
 SEROQUEL® (quetiapine) > 50 mg/day
 SEROQUEL® (quetiapine) ≤ 50 mg/day (children < 18 years old)
FDA maximum recommended dose = 800 mg/day

Abilify® (aripiprazole)
FDA maximum recommended dose = 30 mg/day, Quantity limit = 1.5 tabs/day (5 mg, 10 mg & 15 mg tabs)
 Clozaril®* (clozapine)
FDA maximum recommended dose = 900 mg/day
 Fanapt® (iloperidone)
FDA maximum recommended dose = 24 mg/day, Quantity limit = 2 tablets/day
 Invega® (paliperidone)
FDA maximum recommended dose = 12 mg/day, Quantity limit = 1 tab/day (3mg, 9mg), 2 tabs/day (6mg)
 Latuda® (lurasidone)
FDA maximum recommended dose = 80 mg/day, Quantity limit = 1 tablet/day
 Olanzapine† (compare to Zyprexa®)
FDA maximum recommended dose = 20 mg/day, Quantity limit = 1.5 tabs/day (2.5 mg, 5 mg, 7.5 mg & 10 mg tabs)
 Risperdal®* (risperidone)
FDA maximum recommended dose = 16 mg/day
 Saphris® (asenapine) sublingual tablet
FDA maximum recommended dose = 20 mg/day
 Seroquel® (quetiapine) ≤ 50 mg/day (adults ≥ 18 years old)
 Seroquel XR® (quetiapine XR)
FDA maximum recommended dose = 800 mg/day, Quantity Limit = 1 tab/day (150 mg & 200 mg tablet strengths), 2 tabs/day (50 mg strength)
 Zyprexa® (olanzapine)
FDA maximum recommended dose = 20 mg/day, Quantity limit = 1.5 tabs/day (2.5 mg, 5 mg, 7.5 mg & 10 mg tabs)

ORAL SOLUTIONS

RISPERIDONE† (compare to Risperdal®) oral solution
FDA maximum recommended dose = 16 mg/day

Abilify® (aripiprazole) oral solution
FDA maximum recommended dose = 25 mg/day
 Risperdal® (risperidone) oral solution
FDA maximum recommended dose = 16 mg/day

SHORT-ACTING INJECTABLE PRODUCTS

GEODON® IM (ziprasidone intramuscular injection)
FDA maximum recommended dose = 40 mg/day

Abilify® IM (aripiprazole intramuscular injection)
FDA maximum recommended dose = 30 mg/day
 Zyprexa® IM (olanzapine intramuscular injection)
FDA maximum recommended dose = 30 mg/day

LONG-ACTING INJECTABLE PRODUCTS

Table continued on next page

Invega Sustenna® (paliperidone palmitate)
FDA maximum recommended dose = 234 mg/month
 Risperdal® Consta (risperidone microspheres)
FDA maximum recommended dose = 50 mg/14 days
 Zyprexa Relprevv® (olanzapine pamoate)
FDA maximum recommended dose = 600 mg/month, Quantity limit = 1 vial/28 days (405 mg) or 2 vials/month (210 or 300 mg)
Table continued on next page

ORALLY DISINTEGRATING TABLETS	
	<p>Abilify[®] Discmelt (aripiprazole) <i>FDA maximum recommended dose = 30 mg/day,</i> <i>Quantity limit = 2 tabs/day (10 mg & 15 mg tabs)</i></p> <p>FazaClo[®] (clozapine orally disintegrating tablets) <i>FDA maximum recommended dose = 900 mg/day</i></p> <p>Olanzapine orally disintegrating tablets† (compare to Zyprexa Zydis[®]) <i>FDA maximum recommended dose = 20 mg/day,</i> <i>Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)</i></p> <p>Risperdal[®] M-Tab (risperidone orally disintegrating tablets) <i>FDA maximum recommended dose = 16 mg/day</i></p> <p>Risperidone† ODT (compare to Risperdal[®] M-Tab) <i>FDA maximum recommended dose = 16 mg/day</i></p> <p>Zyprexa Zydis[®] (olanzapine orally disintegrating tablets) <i>FDA maximum recommended dose = 20 mg/day,</i> <i>Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)</i></p>
COMBINATION PRODUCTS	
	<p>Symbyax[®] (olanzapine/fluoxetine) <i>FDA maximum recommended dose = 18 mg/75 mg (per day)</i></p>

* For brand name products when generic equivalent preferred, length of authorization is 1 year.

^ For generic product when brand name product preferred, length of authorization is 1 year.

Antipsychotics: Typical

LENGTH OF AUTHORIZATION: Duration of need for mental health indications*

CRITERIA FOR APPROVAL:

ORAL

- The patient has had a documented side effect, allergy or treatment failure with at least two preferred products. (If a product has an AB rated generic, one trial must be the generic.)

LONG ACTING INJECTABLE PRODUCTS

- For approval of Haldol[®] deconaoate, the patient has a documented intolerance to the generic product.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 160 for a description of the management of mental health drugs.

Antipsychotics: Typical		<i>Length of authorization: Duration of need for mental health indication*s</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
<u>ORAL TABLETS/CAPSULES</u>		
CHLORPROMAZINE† (formerly Thorazine [®])	Haldol [®] * (haloperidol)	
FLUPHENAZINE† (formerly Prolixin [®])	Loxitane [®] * (loxapine)	
HALOPERIDOL† (compare to Haldol [®])	Navane [®] * (thiothixene) 2 mg, 5 mg, 10 mg	
LOXAPINE† (compare to Loxitane [®])		
MOBAN [®] (molindone)		
NAVANE [®] (thiothixene) (20 mg ONLY)		
PERPHENAZINE† (formerly Trilafon [®])		
THIORIDAZINE† (formerly Mellaril [®])		
THIOTHIXENE† (compare to Navane [®])		
TRIFLUOPERAZINE† (formerly Stelazine [®])		
 <u>LONG ACTING INJECTABLE PRODUCTS</u>		
fluphenazine decanoate† (formerly Prolixin [®] decanoate)	Haldol [®] decanoate* (haloperidol decanoate)	
haloperidol decanoate † (compare to Haldol [®] decanoate)		

* For brand name products when generic equivalent preferred, length of authorization is 1 year.

Bone Resorption Inhibitors

LENGTH OF AUTHORIZATION: 3 years

CRITERIA FOR APPROVAL:

Actonel[®], Actonel[®] w/calcium :

- The patient has a diagnosis/indication of Paget's Disease

AND

- The patient has had a documented side effect, allergy, or treatment failure (at least a six-month trial) to generic alendronate.

OR

- The patient has a diagnosis/indication of postmenopausal osteoporosis, osteoporosis in men or glucocorticoid induced osteoporosis.

AND

- The patient has had a documented side effect, allergy, or treatment failure (at least a 1 year trial) to generic alendronate[®]. Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with an oral bisphosphonate.

Altelia[®], Boniva[®] Oral

- The patient has a diagnosis/indication of postmenopausal osteoporosis.

AND

- The patient has had a documented side effect, allergy, or treatment failure (at least a 1 year trial) to generic alendronate[®]. Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with an oral bisphosphonate.

Calcitonin Nasal Spray (generic), Fortical[®]:

- The patient has had a documented intolerance to brand Miacalcin.

Fosamax[®] Tablet:

- The patient has had a documented intolerance to generic alendronate.

Fosamax[®] Oral Solution:

- The patient has a requirement for an oral liquid dosage form.

Fosamax Plus D[®]:

- There is a clinical reason why the patient is unable to take generic alendronate and vitamin D separately.

Didronel[®], Etidronate, Skelid[®]:

- The patient has a diagnosis/indication of Paget's Disease

AND

- The patient has had a documented side effect, allergy, or treatment failure (at least a six-month trial) to generic alendronate. If a medication has an AB rated generic, there must have also been a trial of the generic formulation.

Forteo[®]:

- The patient has a diagnosis/indication of postmenopausal osteoporosis in females or primary or hypogonadal osteoporosis in males.
AND
- The patient has had a documented side effect, allergy, or treatment failure to an oral bisphosphonate. Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with an oral bisphosphonate.
AND
- The prescriber has verified that the patient has been counseled about osteosarcoma risk.
AND
- The quantity requested does not exceed 1 pen (3 mL) per 28 days.

Boniva[®] Injection:

- The patient has a diagnosis/indication of postmenopausal osteoporosis.
AND
- The patient has had a documented side effect or treatment failure to a preferred bisphosphonate. Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with an oral bisphosphonate.
AND
- The quantity requested does not exceed four (4) 3 mg doses per year.

Prolia[®] Injection:

- The patient has a diagnosis/indication of postmenopausal osteoporosis
AND
- The patient has had a documented side effect, allergy, or treatment failure to a preferred bisphosphonate. Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with an oral bisphosphonate.
AND
- The quantity requested does not exceed 1 syringe per 6 months.

Reclast[®] Injection:

- The patient has a diagnosis/indication of Paget's disease of bone.
OR
- The patient has a diagnosis/indication of postmenopausal osteoporosis.
OR
- The patient is male with a diagnosis of osteoporosis.
OR
- The patient has a diagnosis of glucocorticoid induced osteoporosis.
AND
- The patient has had a documented side effect or treatment failure to a preferred bisphosphonate. Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with an oral bisphosphonate.
AND
- The quantity requested does not exceed a single 5 mg dose per year.

Xgeva[®] Injection:

- The patient has been started and stabilized on the requested medication
OR
- The diagnosis or indication is bone metastases from solid tumors (e.g. prostate, breast, thyroid, non-small lung cancer)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of Boniva IV, Forteo, Prolia, Reclast or Xgeva on a Bone Resorption Inhibitor **Injectable Prior Authorization Request Form**.
- ✓ Document clinically compelling information supporting the choice of other non-preferred agents on a **General Prior Authorization Request Form**

Bone Resorption Inhibitors		<i>Length of Authorization: 3 years</i>
Key: † Generic product,		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
<u>ORAL BISPHOSPHONATE</u>		
TABLETS/CAPSULES		
ALENDRONATE† (compare to Fosamax®)	Actonel® (risedronate) Actonel® w/calcium (risedronate/calcium) Altrelvia (risedronate) Delayed Release Tablet <i>(Quantity Limit = 4 tablets/28 days)</i> Boniva® (ibandronate) <i>(Quantity Limit = 150 mg tablet/1 tablet per 28 days)</i> Didronel® (etidronate) Etidronate† (compare to Didronel®) Fosamax®* (alendronate) Fosamax Plus D® (alendronate/vitamin D) Skelid® (tiludronate)	
ORAL SOLUTION		
	Fosamax® Oral Solution (alendronate)	
<u>INJECTABLE BISPHOSPHONATE</u>		
	Boniva Injection (ibandronate) <i>(QL=3 mg/3 months (four doses)/year)</i> Reclast® Injection (zoledronic acid) <i>(QL=5 mg (one dose)/year)</i>	
<u>INJECTABLE RANKL INHIBITOR</u>		
	Prolia® Injection (denosumab) <i>(QL=60 mg/6 months (two doses)/year)</i> Xgeva® (denosumab) <i>(QL=120 mg/28 days)</i>	
<u>CALCITONIN NASAL SPRAY</u>		
MIACALCIN® (calcitonin)	Calcitonin† Nasal Spray (compare to Miacalcin®) Fortical®† (calcitonin)	
<u>PARATHYROID HORMONE INJECTION</u>		
	Forteo® (teriparatide) <i>(Quantity Limit = 1 pen (3 ml)/28 days)</i>	



Department of Vermont Health Access
 312 Hurricane Lane, Suite 201
 Williston, Vermont 05495

Agency of Human Services

~ BONE RESORPTION INHIBITORS INJECTABLE ~
 Prior Authorization Request Form

Vermont Medicaid has established criteria for prior authorization of ossification enhancing injectables. For beneficiaries to receive coverage for these agents, it will be necessary for the prescriber to telephone or complete and fax this form to MedMetrics Health Partners. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name: _____
 Phone #: _____
 Fax #: _____
 Address: _____
 Contact Person at Office: _____

Beneficiary:

Name: _____
 Medicaid ID #: _____
 Date of Birth: _____ Sex: _____

Will this medication be billed through the: **pharmacy benefit** or **medical benefit** (J-code or other code)? **(Please check one)**

Administering Provider if other than Prescriber: (name): _____ NPI #: _____

Pharmacy (if known): _____ Phone: _____ &/or FAX: _____

Drug requested: Boniva IV Forteo Prolia Reclast Xgeva

Dose & frequency: _____

Diagnosis/indication:

- Treatment of postmenopausal osteoporosis Treatment of male osteoporosis
- Paget's Disease Treatment of glucocorticoid induced osteoporosis
- Bone metastases from solid tumors (tumor type: _____)
- Other (Please Explain) _____

Has the member previously tried the following preferred medication?

<i>Drug:</i>	<i>Response:</i>
<input type="checkbox"/> Alendronate Oral	<input type="checkbox"/> side-effect <input type="checkbox"/> treatment failure* dates of use: _____

*Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with the bisphosphonate.

Prescriber comments: _____

Prescriber Signature: _____

Date of this request: _____

Botulinum Toxins

LENGTH OF AUTHORIZATION: initial approval 3 months, subsequent approval up to 12 months

CRITERIA FOR APPROVAL:

BOTOX (onabotulinumtoxinA):

- The indication for use is:
 - Strabismus and blepharospasm associated with dystonia, including essential blepharospasm, VII cranial nerve disorders/hemifacial spasm
 - Focal dystonias, including cervical dystonia, spasmodic dysphonia, oromandibular dystonia
 - Limb spasticity (e.g., due to cerebral palsy, multiple sclerosis, or other demyelinating CNS diseases)
 - Focal spasticity (e.g., due to hemorrhagic stroke, anoxia, traumatic brain injury)
 - Axillary Hyperhidrosis (if member has failed an adequate trial of topical therapy)
 - Overactive bladder or detrusor overactivity (if member has failed an adequate trial of at least TWO urinary antispasmodics (either short- or long-acting formulations))
 - Chronic migraine (>15 days per month with headache lasting 4 hours a day or longer) and the member has failed or has a contraindication to an adequate trial of at least TWO medications for migraine prophylaxis from at least two different classes (tricyclic antidepressants, beta-blockers, calcium channel blockers or anticonvulsants)
- AND**
- The patient is >12 years of age if for blepharospasm or strabismus, >16 years of age for cervical dystonia, and >18 years of age for hyperhidrosis, chronic migraine or overactive bladder/detrusor overactivity.

Dysport (abobotulinumtoxinA):

- The patient has a diagnosis of cervical dystonia or spasmodic torticollis
- AND**
- The patient is ≥18 years of age
- AND**
- The patient has had a treatment failure with BOTOX®.

Myobloc (rimabotulinumtoxinB):

- The patient has a diagnosis of focal dystonias, including cervical dystonia, spasmodic dysphonia, oromandibular dystonia
- AND**
- The patient is ≥16 years of age

Xeomin (incobotulinumtoxinA):

- The patient has a diagnosis of cervical dystonia or blepharospasm.
- AND**
- The patient is ≥18 years of age
- AND**
- The patient has had a documented intolerance or treatment failure with BOTOX®.

LIMITATIONS:

Coverage of botulinum toxins will not be approved for cosmetic use (e.g., glabellar lines, vertical glabellar eyebrow furrows, facial rhytides, horizontal neck rhytides, etc.). (BOTOX® Cosmetic (onabotulinumtoxinA) is not covered)

IMPORTANT NOTE:

Botulinum neurotoxins are used to treat various disorders of focal muscle spasm and excessive muscle contractions, such as focal dystonias. When injected intramuscularly, botulinum neurotoxins produce a presynaptic neuromuscular blockade by preventing the release of acetylcholine from the nerve endings. As a consequence of the chemistry and clinical pharmacology of each botulinum neurotoxin product, botulinum neurotoxins are not interchangeable, even among same serotype products. Units of biological activity are unique to each preparation and cannot be compared or converted into units of another. It is important that providers recognize there is no safe dose conversion ratio—i.e., one unit of BOTOX® (onabotulinumtoxinA, formerly type A) does not equal one unit of Myobloc® (rimabotulinumtoxinB, formerly type B) does not equal one unit of Dysport (abobotulinumtoxinA) does not equal one unit of Xeomin (incobotulinumtoxinA). Failure to understand the unique characteristics of each formulation of botulinum neurotoxin can result in under or over dosage. It is expected that use of these products will be based on each product's individual dosing, efficacy and safety profiles.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the request of the agent on a **General Prior Authorization Request Form.**
- ✓ All requests for botulinum toxin (whether billed through the pharmacy or medical benefit) require Prior Authorization through the MedMetrics Clinical Call Center.

Botulinum Toxins	
<i>Length of Authorization: initial approval 3 months, subsequent approval up to 12 months</i>	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
	BOTOX® (onabotulinumtoxinA) Myobloc® (rimabotulinumtoxinB) Available after a BOTOX® treatment failure for select indications: Dysport® (abobotulinumtoxinA) Xeomin® (incobotulinumtoxinA)

BPH Agents

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Alpha Blockers

- **Cardura[®], Cardura XL[®]:** The patient has had a documented side effect, allergy or treatment failure with two alpha blockers, one of which must be generic doxazosin.
- **Flomax[®]:** The patient has had a documented side effect, allergy or treatment failure with two preferred alpha blockers, one of which must be generic tamsulosin.
- **Rapaflo[®], Uroxatral[®]:** The patient has had a documented side effect, allergy or treatment failure with two preferred alpha blockers.

Androgen Hormone Inhibitors

- **Avodart:** The patient has a diagnosis of BPH (benign prostatic hypertrophy) AND the patient has a documented side effect, allergy or treatment failure to generic finasteride.
- **Proscar:** The patient has a diagnosis of BPH (benign prostatic hypertrophy) AND the patient has a documented intolerance to generic finasteride.
- **Finasteride for males age < 45:** The patient has a diagnosis of BPH (benign prostatic hypertrophy)

Combination Product

- **Jalyn:** The patient has a diagnosis of BPH (benign prostatic hypertrophy) AND the patient has a documented treatment failure/inadequate response to combination therapy with generic tamsulosin and finasteride.

LIMITATIONS:

Coverage of androgen hormone inhibitors will not be approved for cosmetic use in men or women (male-pattern baldness/alopecia or hirsutism). (This includes Propecia[®] (finasteride) whose only FDA approved indication is for treatment of male pattern hair loss.)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

BPH Agents*Length of authorization: 1 year***Key: † Generic product, *Indicates generic equivalent is available without a PA****PREFERRED DRUGS (No PA Required)****PA REQUIRED****ALPHA BLOCKERS**

DOXAZOSIN† (compare to Cardura®)

TAMSULOSIN† (compare to Flomax®)

Quantity Limit = 2 capsules/day

TERAZOSIN† (previously Hytrin®)

Cardura®* (doxazosin)

Cardura XL® (doxazosin)

Quantity Limit = 1 tablet/day

Flomax®* (tamsulosin)

*Quantity Limit = 2 capsules/day*Rapaflo® (silodosin) *Quantity Limit = 1 capsule/day*

Uroxatral® (alfuzosin)

*Quantity Limit = 1 tablet/day***ANDROGEN HORMONE INHIBITORS**FINASTERIDE† (compare to Proscar®) (*QL = 1 tablet/day*)Avodart® (dutasteride) (*QL = 1 capsule/day*)finasteride† (compare to Proscar®) females; males age < 45 (*QL = 1 tablet/day*)Proscar®* (finasteride) (*QL = 1 tablet/day*)**COMBINATION PRODUCT**Jalyn® (dutasteride/tamsulosin) (*QL = 1 capsule/day*)

Cardiac Glycosides

LENGTH OF AUTHORIZATION: not applicable

CRITERIA FOR APPROVAL: not applicable

Cardiac Glycosides

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
DIGOXIN† DIGOXIN† Oral Solution LANOXIN® (digoxin)	

Chemical Dependency: Alcohol and Opiate Dependency

LENGTH OF AUTHORIZATION:

Vivitrol - 6 months, no renewal

All others – Up to 1 year

CRITERIA FOR APPROVAL:

Alcohol/Opiate Dependency: Revia, Antabuse

- The patient has had a documented intolerance to the generic equivalent product.

Alcohol/Opiate Dependency: Vivitrol

- Diagnosis of alcohol dependency
AND
- An inadequate response, adverse reaction, or contraindication to 1 out of 3 oral formulations used for alcohol dependence including: oral naltrexone, acamprosate, and disulfiram OR a compelling clinical reason for use (e.g. multiple hospital admissions for alcohol detoxification)
AND
- Patient should be opiate free for > 7 – 10 days prior to initiation of Vivitrol
OR
- Diagnosis is prevention of relapse to opioid dependency
AND
- The patient has failed Suboxone therapy or is not a candidate for Suboxone therapy (eg. Patient is opiate free and prescriber wishes to prevent relapse to opioid dependence without using maintenance therapy) or patient requires injectable therapy (compliance, tolerance, etc).
AND
- Patient should be opiate free for > 7 – 10 days prior to initiation of Vivitrol
ALSO
- Available only through the Pharmacy Benefit (J-Code 2315 blocked from Medical Benefit) from a pharmacy provider that will deliver directly to the physician's office (Medicare Part B to be billed first if applicable)

Opiate Dependency: Suboxone, Subutex, Buprenorphine

- Diagnosis of opiate dependence confirmed (will not be approved for alleviation of pain).
AND
- Prescriber has an DATA 2000 waiver ID number (“X-DEA license”) in order to prescribe
AND
- A “Pharmacy Home” for all prescriptions has been selected (Pharmacy located or licensed in VT)
AND
- Patients new to Suboxone (no claims in last 60 days) will be prescribed Suboxone Film (not SL tablet).
AND
- Patients new to Suboxone (no claims in last 60 days) will be subject to a quantity limit of 16 mg/day.
AND
- Requests for Suboxone SL tablet after documented intolerance of Suboxone Film must include a completed MedWatch form that will be submitted by DVHA to the FDA.
AND
- If buprenorphine (compare to Subutex) is being requested,
 - Patient is either pregnant and history from OB provider has been submitted (duration of PA will be one 1 month post anticipated delivery date)
OR
 - Patient is breastfeeding a methadone dependent baby and history from the neonatologist or pediatrician has been submitted.

AND

- If the request is for brand Subutex, the patient has a documented intolerance to generic buprenorphine and the prescriber has included a completed MedWatch form that will be submitted by DVHA to the FDA..

Smoking Cessation Products: See “Smoking Cessation Therapies”

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of Vivitrol[®] or Suboxone[®]/Subutex[®]/buprenorphine on the **Vivitrol[®] or Buprenorphine Prior Authorization Request Forms.**
- ✓ Document clinically compelling information supporting the choice of Revia[®] on a **General Prior Authorization Request Form.**

Chemical Dependency: Alcohol and Opiate Dependency	
<i>Length of authorization: Vivitrol 6 months, no renewal; all others up to 1 year</i>	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>ALCOHOL DEPENDENCY</u></p> <p>CAMPRAL[®] (acamprosate) DISULFIRAM† 250 mg, 500 mg tab (compare to Antabuse[®]) NALTREXONE oral † (compare to Revia[®])</p>	<p>Antabuse[®]* (disulfiram) Revia[®]* (naltrexone oral) Vivitrol[®] (naltrexone for extended-release injectable suspension) (<i>QL = 1 injection (380 mg) per 30 days</i>)</p>
<p><u>OPIATE DEPENDENCY</u></p> <p>NALTREXONE oral † (compare to Revia[®])</p> <p><u>Preferred Agent after Clinical Criteria are Met</u></p> <p>SUBOXONE[®] sublingual FILM (buprenorphine/nalaxone) <i>QL = 3 films per day (all strengths)</i> <i>(Maximum Daily Dose = 24 mg/day (if currently prescribed 24 mg Suboxone SL tablet)</i> <i>(Maximum daily Dose = 16 mg/day (new Suboxone users)</i></p> <p>*Maximum days supply for Suboxone is 14 days*</p> <p>Note: Methadone for opiate dependency may only be prescribed through a Methadone Maintenance Clinic</p>	<p>buprenorphine† sublingual TABLET(compare to Subutex[®]) <i>QL = 3 tablets per day (2 mg strength)</i> <i>or 2 tablets/day (8 mg strength)</i> <i>(Maximum Daily Dose = 16 mg/day)</i></p> <p>Revia[®]* (naltrexone oral)</p> <p>Suboxone[®] sublingual TABLET (buprenorphine/nalaxone) <i>QL = 3 tablets per day (all strengths)</i> <i>(Maximum Daily Dose = 24 mg/day (current users of this dose)</i> <i>(Maximum daily Dose = 16 mg/day (new users)</i></p> <p>Subutex[®] sublingual Tablet (buprenorphine) <i>QL = 3 tablets per day (2 mg strength)</i> <i>or 2 tablets/day (8 mg strength)</i> <i>(Maximum Daily Dose = 16 mg/day)</i></p> <p>**Maximum days supply for Suboxone/Subutex/buprenorphine is 14 days**</p> <p>For Prevention of Relapse to Opioid Dependency</p> <p>Vivitrol[®] (naltrexone for extended-release injectable suspension) (<i>QL = 1 injection (380 mg) per 30 days</i>)</p>

~BUPRENORPHINE ~
 Prior Authorization Request Form

Vermont Medicaid has established criteria for prior authorization of buprenorphine (Suboxone[®], Subutex[®]). These criteria are based on concerns about safety and the potential for abuse and diversion. All requests must be submitted using this fax form.

Submit request via Fax (only): 1-866-767-2649

Prescribing physician:

 Name: _____
 Phone #: _____
 Fax #: _____
 Address: _____

Beneficiary:

 Name: _____
 Medicaid ID #: _____
 Date of Birth: _____ Sex: _____

Contact Person at Office: _____

► Please answer the following questions:

Is buprenorphine being prescribed for opiate dependency?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Does the prescriber signing this form have a DATA 2000 waiver ID number ("X-DEA license")?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Has the prescriber queried the VPMS (Vermont Prescription Monitoring System) to review patient's scheduled II-IV medication history?	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not signed up
A "Pharmacy Home" for ALL prescriptions has been selected AND discussed with patient? (Pharmacy must be located/licensed in VT) Pharmacy Name: _____ Pharmacy Phone #: _____	<input type="checkbox"/> Yes <input type="checkbox"/> No
Has patient filled a Suboxone RX in last 60 days	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Don't know
Request is for the following medication: Sublingual FILM	<input type="checkbox"/> Suboxone [®] (buprenorphine/naloxone)
Request is for the following medication: Sublingual TABLET	<input type="checkbox"/> Suboxone [®] (buprenorphine/naloxone) <input type="checkbox"/> Buprenorphine (compare to Subutex [®])
Anticipated maintenance dose/frequency: (target dose of no more than 16 mg/day) (maximum 14 day supply per prescription fill) Dose: _____ Frequency: _____ (recommended once daily)	
If this request is for Buprenorphine (compare to Subutex [®]), please answer the following questions: Is the member pregnant? (please provide history from OB provider) If yes, anticipated date of delivery: _____	<input type="checkbox"/> Yes <input type="checkbox"/> No
Is the member breastfeeding a methadone dependent baby? (please provide history from neonatologist or pediatrician)	<input type="checkbox"/> Yes <input type="checkbox"/> No
Would you have referred your patient to a methadone clinic if this option was conveniently located and available?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Additional clinical information to support PA request:	

Prescriber Signature: _____ (stamps not acceptable)

Prescriber X-DEA License #: _____ **Date of request:** _____

~VIVITROL~

Prior Authorization Request Form

Vermont Medicaid has established criteria for prior authorization of Vivitrol (naltrexone for IM extended release suspension). These criteria are based on concerns about safety. In order for beneficiaries to receive coverage for Vivitrol, it will be necessary for the prescriber to complete and fax this prior authorization request to MedMetrics Health Partners. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via Fax: 1-866-767-2649

Prescribing physician:

Name: _____

Phone #: _____

Fax #: _____

Address: _____

Contact Person at Office: _____

Beneficiary:

Name: _____

Medicaid ID #: _____

Date of Birth: _____ Sex: _____

Administering physician:

Name: _____

Address: _____

Pharmacy (required): _____ **Phone:** _____ **&/or FAX:** _____

QUALIFICATIONS

MDs	Prescribers must secure direct delivery of Vivitrol from the pharmacy to the physician's office. Pharmacies may not dispense Vivitrol directly to the patient. Vivitrol may not be billed through the Medical Benefit as a J-Code J2315.
------------	---

PROCESS

► Please answer the following questions:

Patient diagnosis ?	<input type="checkbox"/> Alcohol dependence <input type="checkbox"/> Prevention of relapse to opioid dependency
Has the patient been opiate free for > 7 – 10 days	<input type="checkbox"/> Yes <input type="checkbox"/> No
For alcohol dependence: (1) Has the patient tried any of the following? Please document below.	<input type="checkbox"/> Yes <input type="checkbox"/> No
oral naltrexone: <input type="checkbox"/> side-effect <input type="checkbox"/> non-response <input type="checkbox"/> allergy acamprosate: <input type="checkbox"/> side-effect <input type="checkbox"/> non-response <input type="checkbox"/> allergy disulfiram: <input type="checkbox"/> side-effect <input type="checkbox"/> non-response <input type="checkbox"/> allergy	<input type="checkbox"/> Yes <input type="checkbox"/> No
(2) Has patient had a recent hospital admission for alcohol detoxification?	If yes, date: ____/____/____
For prevention of relapse to opioid dependency	<input type="checkbox"/> Yes <input type="checkbox"/> No
(1) Has the patient failed buprenorphine therapy?	<input type="checkbox"/> Yes <input type="checkbox"/> No
(2) Is the patient not a candidate for buprenorphine therapy?	<input type="checkbox"/> Yes <input type="checkbox"/> No
(3) Patient requires injectable therapy?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Comments and additional patient history:	

Prescriber Signature: _____ **Date of request:** _____

Compounded Products

Review Guidelines for Appropriateness of Compounded Products

Compounding of medication may be allowed:

- For making a strength of a medication when specific doses are not commercially available and a significantly different dosage form is clinically needed.
- For preparation of a medication that has been withdrawn from the marketplace due to economic concerns, NOT safety.
- For those patients that cannot swallow or have trouble swallowing and require a different dosage form than is currently available.
- For those patients who have sensitivity to dyes, preservatives, or fillers in commercial products and require allergy-free medications.
- For children who require liquid medications.

A compound drug will only be covered if it is

- Considered medically necessary according to specified criteria as detailed below **and**
- Commercially available alternative agents have been previously tried with therapeutic failure or patient intolerance (Exception: Compounded injections of 17-alpha hydroxyprogesterone caproate are covered due to physicians' prior success with this compounded product and the FDA and CMS allowance)

Medically necessary criteria for a compound drug

- All ingredients are FDA approved for medical use in the United States (for example, domperidone has not been approved by the FDA for any indication in the United States).
- It is not a copy of a commercially available FDA approved product.
- It is not a substitution for an available FDA approved product (for example, there are multiple commercially available hormonal products for use in menopause. Bioidentical individualized hormonal products will not be covered). (see also exception for 17-alpha hydroxyprogesterone caproate injection above)
- One or more prescription ingredients is included in the compound; a compound whose primary active ingredient is OTC will only be covered if that particular OTC is covered under the beneficiary's program
- Safety and effectiveness of use for the prescribed indication is supported by FDA approval or adequate medical and scientific evidence or medical literature.

An ingredients is not covered if it is

- From a manufacturer that does not offer Federal Rebate
- Considered a "bulk chemical or powder". CMS has clarified that bulk products are not considered covered outpatient drugs because they are not prescription drug products approved under section 505,505(j), or 507 of the Federal Food Drug and Cosmetic Act.
- Bulk powders used to compound products for the prevention of pre-term labor will continue to be covered after Prior Authorization when this practice is acceptable to the FDA.

Contraceptives: Vaginal Ring

LENGTH OF AUTHORIZATION: not applicable

CRITERIA FOR APPROVAL: not applicable

Contraceptives: Vaginal Ring	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
NUVARING [®] (etonogestrel/ethinyl estradiol vaginal ring)	

Coronary Vasodilators/Antianginals: Oral and Topical

LENGTH OF AUTHORIZATION: 3 years

CRITERIA FOR APPROVAL:

Dilatrate-SR[®], Imdur[®]:

- The patient has had a side effect, allergy, or treatment failure to at least two of the following medications: isosorbide dinitrate ER tablet, isosorbide mononitrate ER tablet, nitroglycerin ER capsule or Nitro-time[®]. If a product has an AB rated generic, one trial must be the generic formulation.

Ismo[®], Isordil[®], Monoket[®], Isosorbide dinitrate SL tablet:

- The patient has had a side effect, allergy, or treatment failure to at least two of the following medications: isosorbide dinitrate tablet or isosorbide mononitrate tablet. If a product has an AB rated generic, one trial must be the generic formulation.

Nitro-Dur[®]:

- The patient has had a side effect, allergy, or treatment failure to Nitrek[®] or generic nitroglycerin transdermal patches.

Bidil[®]:

- The prescriber provides a clinically valid reason why the patient cannot use isosorbide dinitrate and hydralazine as separate agents.

Ranexa[®]:

- The patient has had a diagnosis/indication of chronic angina.
- AND
- The patient has had a documented side effect, allergy, or treatment failure with at least one medication from two of the following classes: beta-blockers, maintenance nitrates, or calcium channel blockers.
- AND
- The patient does not have any of the following conditions:
 - Hepatic insufficiency
 - Concurrent use of medications which may interact with Ranexa[®]:
 - CYP450 3A4 inducers (rifampin, rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, St. John's wort)
 - CYP450 3A4 inhibitors (diltiazem, verapamil, ketoconazole, protease inhibitors, grapefruit juice, macrolide antibiotics)
 - Note: doses of digoxin or drugs metabolized by CYP450 2D6 (TCAs, some antipsychotics) may need to be adjusted if used with Ranexa[®].
- AND
- The dose requested does not exceed 3 tablets/day (500 mg) or 2 tablets/day (1000 mg).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Coronary Vasodilators/Antianginals: Oral and Topical

Length of Authorization: 3 years

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)

PA REQUIRED

ORAL

ISOSORBIDE DINITRATE† tab (compare to Isordil®)
 ISOSORBIDE DINITRATE† ER tablet
 ISOSORBIDE MONONITRATE† tab (compare to, Ismo®, Monoket®)
 ISOSORBIDE MONONITRATE† ER tab (compare to Imdur®)
 NITROGLYCERIN† SL tablet
 NITROGLYCERIN† ER capsule
 NITROLINGUAL PUMP SPRAY®
 NITROGLYCERIN SPRAY LINGUAL† (compare to Nitroglycerin Pump Spray®)
 NITROMIST® Lingual Spray
 NITROQUICK® (nitroglycerin SL tablet)
 NITROSTAT® (nitroglycerin SL tablet)
 NITRO-TIME® (nitroglycerin ER capsule)

Dilatrate-SR® (isosorbide dinitrate SR cap)
 Imdur®* (isosorbide mononitrate ER tablet)
 Ismo®* (isosorbide mononitrate tablet)
 Isosorbide dinitrate SL tablet
 Isordil®* (isosorbide dinitrate tab)
 Monoket®* (isosorbide mononitrate tablet)

 BiDil® (isosorbide dinitrate/hydralazine)

 Ranexa® (ranolazine) (*QL = 3 tablets/day (500 mg), 2 tablets/day (1000 mg)*)

TOPICAL

NITREK® (nitroglycerin transdermal patch)
 NITRO-BID® (nitroglycerin ointment)
 NITROGLYCERIN TRANSDERMAL PATCHES† (compare to Nitro-Dur®)

Nitro-Dur®* (nitroglycerin transdermal patch)

Corticosteroids: Oral

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL (NON-PREFERRED):

- The patient has been started and stabilized on the requested medication.

OR

- The patient has a documented side effect, allergy, or treatment failure to at least two preferred medications. If a product has an AB rated generic, one trial must be the generic formulation.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Corticosteroids: Oral	
<i>Length of authorizations: 1 year</i>	
Key : † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
BUDESONIDE 24HR (compare to Entocort EC [®])	Celestone [®] (betamethasone) oral solution
CORTISONE ACETATE†	Cortef ^{®*} (hydrocortisone)
DEXAMETHASONE†	Flo-Pred [®] (prednisolone) oral suspension
DEXPAK [®] tabs (dexamethasone taper pack)	Medrol ^{®*} (methylprednisolone)
ENTOCORT EC ^{®*} (budesonide 24 hr cap)	Millipred [®] (prednisolone) oral solution
HYDROCORTISONE† (compare to Cortef [®])	Orapred [®] oral solution* (prednisolone) (age ≥ 12 yrs)
METHYLPREDNISOLONE† (compare to Medrol [®])	Orapred [®] ODT (prednisolone) (age ≥ 12 yrs)
ORAPRED [®] oral solution/ODT (prednisolone sod phosphate) (age < 12 yrs)	Pediapred ^{®*} (prednisolone)
PREDNISOLONE† tablets/liquid (compare to Pediapred [®] , Prelone [®])	Prelone ^{®*} (prednisolone)
PREDNISONE†	Veripred [®] 20 oral solution (prednisolone sodium phosphate)

Cough and Cold Preparations

LENGTH OF AUTHORIZATION: date of service only, no refills

CRITERIA FOR APPROVAL:

Tussionex[®], TussiCaps[®], Hydrocodone/chlorpheniramine suspension (generic)

- The patient has had a documented side effect, allergy, or treatment failure to two of the following generically available cough or cough/cold products: hydrocodone/homatropine (compare to Hycodan[®]), promethazine/codeine (previously Phenergan[®] with Codeine), guaifenesin/codeine (Cheratussin AC[®]).or benzonatate.

AND

- The patient is 6 years old of age or greater.

AND

- The quantity requested does not exceed 60 ml (Tussionex[®]) or 12 capules (TussiCaps[®]).

AND

- If the request is for Tussionex[®], the patient has a documented intolerance to generic hydrocodone/chlorpheniramine suspension.

All Other Brands

- The prescriber must provide a clinically valid reason for the use of the requested medication including reasons why any of the generically available preparations would not be a suitable alternative.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **Prior Authorization Request Form.** **General**

Cough and Cold Preparations		<i>Length of Authorization: date of service only, no refills</i>
Key: † Generic product		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
All generics MUCINEX [®] (guaifenesin)	Hydrocodone/chlorpheniramine (compare to Tussionex [®]) (<i>QL = 60 ml</i>) Tussionex [®] (hydrocodone/chlorpheniramine) (<i>QL = 60 ml</i>) TussiCaps [®] (hydrocodone/chlorpheniramine) (<i>QL = 12 capsules/RX</i>) All other brands	
PA required for Age < 2 years old for all products (brand and generic)	Age < 2 years old for all products (brand and generic)	

Cryopyrin-Associated Periodic Syndromes (CAPS) Injectables

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The diagnosis or indication for the requested medication is Cryopyrin-Associated Periodic Syndrome (CAPS)
OR
- The diagnosis or indication for the requested medication is Familial Cold Autoinflammatory Syndrome (FCAS)
OR
- The diagnosis or indication for the requested medication is Muckle-Wells Syndrome (MWS)
AND
- The patient is > 4 years old (Ilaris[®]) or > 12 years old (Arcalyst[®])
AND
- If the request is for Arcalyst[®], the patient must have a documented side effect, allergy, treatment failure or a contraindication to Ilaris[®] (canakinumab)

Note: Medical Records to support the above diagnosis must accompany the Prior Authorization Request.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of Arcalyst[®] or Ilaris[®] on a **General Prior Authorization Form.**
- ✓ All requests for canakinumab (Ilaris[®]) (whether billed through the pharmacy or medical benefit (J0638)) or rilonacept (Arcalyst[®]) (whether billed through the pharmacy or medical benefit (J2793)) require Prior Authorization through the MedMetrics Clinical Call Center.

CAPS Injectables		<i>Length of Authorization: 1 year</i>
PREFERRED AFTER CLINICAL CRITERIA ARE MET	PA REQUIRED	
Ilaris [®] (canakinumab) (<i>QL=1 vial/56 days</i>)	Arcalyst [®] (rilonacept) (<i>QL = 2 vials for loading dose, then 1 vial per week</i>)	

Cystic Fibrosis: Inhalation Medications

NOTE: TOBI[®] and Pulmozyme[®] must be obtained and billed through our specialty pharmacy vendor, ICORE Healthcare. Please see the Cystic Fibrosis Prior Authorization/Patient Enrollment Form for instructions. ICORE Healthcare will not be supplying Cayston[®] at this time (obtainable through several other specialty pharmacies).

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The diagnosis or indication is cystic fibrosis.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of Cayston on a **General Prior Authorization Request Form**.
- ✓ Document clinical information for Pulmozyme[®] and TOBI[®] on its **Prior Authorization/Patient Enrollment Form**.

Cystic Fibrosis: Inhalation Medications		<i>Length of Authorization: 1 year</i>
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
TOBI [®] (tobramycin) inhalation solution <i>(Quantity Limit = 56 vials/56 days; maximum days supply = 56 days)(2 vials/day for 28 days, then 28 days off)</i>	Cayston [®] (aztreonam) inhalation solution <i>(Quantity Limit = 84 vials/56 days; maximum days supply = 56 days)(3 vials/day for 28 days, then 28 days off)</i> Pulmozyme [®] (dornase alfa) inhalation solution <i>(Quantity Limit =60/30 days; maximum days supply=30 days)</i>	



VERMONT CYSTIC FIBROSIS MEDICATION – Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address		City	
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address		City	
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

Please Note: Cayston® and pancreatic enzymes are not obtained through ICORE Specialty Pharmacy.

3 Department of Vermont Health Access PRIOR AUTHORIZATION REQUEST/PRESCRIPTION CYSTIC FIBROSIS INHALATION MEDICATION

Patient Diagnosis:

Cystic Fibrosis Other: _____

(Requires Review by DVHA Medical Director)

Product:

Pulmozyme® (dornase alfa inhalation) 1 mg/ml 2.5 ml ampules

Administer via nebulizer once daily.
Dispense # 30 Refill ____ times

Administer via nebulizer twice daily.
Dispense # 60 Refill ____ times

TOBI® (tobramycin solution for inhalation) 300 mg/5 ml ampules

Administer via nebulizer twice daily,
alternating 28 days on and 28 days off

Dispense # 56 Refill ____ times

Deliver product to: Patient's home MD office Clinic

Prescriber's Signature: _____ **Date:** _____

Dermatological Agents: Actinic Keratosis Therapy

LENGTH OF AUTHORIZATION: 16 weeks

CRITERIA FOR APPROVAL:

Imiquimod (generic) cream:

- The patient has had a documented intolerance to brand Aldara®.

Efudex:

- The patient has had a documented intolerance with generic topical fluorouracil 5% cream or solution

Solaraze Gel:

- The diagnosis or indication is actinic keratosis
- AND**
- The patient has had a documented side effect, allergy, contraindication or treatment failure with generic topical fluorouracil product.

Zyclara Cream:

- The diagnosis or indication is actinic keratosis on the face or scalp
- AND**
- The patient has had a documented side effect, allergy, or treatment failure with 5-fluorouracil and Aldara® or generic imiquimod 5% cream.
- OR**
- The treatment area is greater than 25 cm² on the face or scalp.
- AND**
- The patient has had a documented side effect, allergy, or treatment failure with 5-fluorouracil.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**

Dermatological Agents: Actinic Keratosis Therapy	
<i>Length of Authorization: 16 weeks</i>	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
ALDARA® (imiquimod) 5 % Cream FLUOROURACIL† (compare to Efudex®) 5% cream, 5%, 2% solution CARAC® (fluorouracil) 0.5% cream FLUOROPLEX® (fluorouracil) 1% cream	Efudex®* (fluorouracil) 5% cream, solution Imiquimod† (compare to Aldara®) 5 % cream Solaraze® (diclofenac sodium) 3 % Gel <i>Qty Limit = 1 tube/30 days</i> Zyclara (imiquimod) 3.75 % Cream <i>Qty Limit = 56 packets/6 weeks</i>

Dermatological Agents: Antibiotics: Topical

LENGTH OF AUTHORIZATION: for the date of service, no refills

CRITERIA FOR APPROVAL:

Altabax®:

- The patient is being treated for impetigo.
- AND
- The patient has had a documented side effect, allergy, or treatment failure with mupirocin ointment
- AND
- MRSA (methicillin resistant staph aureus) has been ruled out by culture

Bactroban® Cream or Ointment:

- The patient has had a documented intolerance with mupirocin ointment

Cortisporin® Cream or Ointment:

- The patient has had a documented side-effect, allergy or treatment failure with at least one preferred generic topical antibiotic

Neosporin® / Polysporin®:

- The patient has had a documented intolerance with a generic equivalent of the requested medication

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**

Dermatological Agents: Antibiotics: Topical	
<i>Length of Authorization: for date of service, no refills</i>	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>Single Agent</u> BACITRACIN† GENTAMICIN† Cream or Ointment MUPIROCIN OINTMENT† (compare to Bactroban®)</p> <p><u>Combination Products</u> BACITRACIN-POLYMYXIN† NEOMYCIN-BACITRACIN-POLYMYXIN†</p>	<p>Altabax® (retapamulin) <i>QL = 1 tube</i> Bactroban® (mupirocin) Cream or Ointment</p> <p>Cortisporin® Cream (neomycin-polymyxin-hydrocortisone) Cortisporin® Ointment(bacitracin-neomycin-polymyxin-hydrocortisone) Neosporin®* (neomycin-bacitracin-polymyxin) Polysporin®* (bacitracin-polymixin)</p> <p>All other branded products</p>

Note: Bactroban® Nasal Ointment is not included in this managed category.

Dermatological Agents: Antifungals: Onychomycosis

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL (CICLOPIROX/PENLAC SOLUTION):

- The patient has a diagnosis of a fingernail/toenail onychomycosis infection (confirmed with a positive KOH stain, PAS stain, or fungal culture or physician clinical judgment).

AND

- The patient meets at least 1 of the following criteria:
 - Pain to affected area that limits normal activity
 - Diabetes Mellitus
 - Patient is immunocompromised
 - Patient has diagnosis of systemic dermatosis
 - Patient has significant vascular compromise

- For approval of Penlac[®], the patient must have a documented intolerance to generic ciclopirox.

LIMITATIONS:

Coverage of Onychomycosis agents will **NOT be approved solely for cosmetic purposes.**
Kits with multiple drug products or non-drug items not covered.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting provision of the non-preferred agent on a **General Prior Authorization Request Form.**

Dermatological Agents: Antifungals: Onychomycosis	
<i>Length of Authorization: 1 year</i>	
Key: † Generic product	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
	ciclopirox† 8 % solution (compare to Penlac [®] Nail Lacquer) (<i>QL=1 bottle (6.6 ml)/90 days</i>)
	Penlac [®] Nail Lacquer (ciclopirox 8 % solution) (<i>QL=1 bottle (6.6 ml)/90 days</i>)

Dermatological Agents: Antifungals: Topical

LENGTH OF AUTHORIZATION:

Up to 3 months

All drugs (except Vusion): All indications: 3 months

Vusion: Diaper dermatitis: up to 50 g/month (1 tube) for up to 1 month

CRITERIA FOR APPROVAL:

All Brands (except Vusion)

- The patient has had a documented side effect, allergy, or treatment failure to at least TWO different preferred generic topical antifungal agents. (If a product has an AB rated generic, one trial must be the generic equivalent of the requested product.)

OR

- The patient has a contraindication that supports the need for a specific product or dosage form of a brand topical antifungal.

Vusion®:

- The patient has a diagnosis of diaper dermatitis complicated by documented candidiasis

AND

- The patient is at least 4 weeks of age.

AND

- The patient has had two trials (with two different preferred antifungal agents) used in combination with a zinc oxide diaper rash product resulting in documented side effects, allergy, or treatment failures.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**

Dermatological Agents: Antifungals: Topical *Length of Authorization: up to 3 months*

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p>Single Agent</p> <p>CICLOPIROX † (compare to Loprox[®]) 0.77% C, Sus, G; 1% Sh</p> <p>CLOTRIMAZOLE † (formerly Lotrimin[®]) 1% C, S</p> <p>ECONAZOLE † (formerly Spectazole[®]) 1% C</p> <p>KETOCONAZOLE † (compare to Kuric[®], Nizoral[®]) 2% C, 2% Sh</p> <p>MICONAZOLE † all generic/OTC products</p> <p>NYSTATIN † O, C, P (compare to Mycostatin[®], Nystop[®], Pedi-Dri[®], Nyamyc[®])</p> <p>TOLNAFTATE † (compare to Tinactin[®]) 1% C, P, Sp, S</p>	<p>Ertaczo[®] (sertaconazole) 2% C</p> <p>Exelderm[®] (sulconazole) 1% C, S</p> <p>Extina[®] (ketoconazole) 2% F</p> <p>Kuric^{®*} (ketoconazole) 2% C</p> <p>Lamisil RX/OTC[®] (terbinafine) 1% C, S, Sp, G</p> <p>Loprox^{®*} (ciclopirox) 0.77% C, S, G; 1% Sh</p> <p>Lotrimin AF^{®*} OTC (clotrimazole) 1% C, S, L</p> <p>Mentax[®]/ Lotrimin Ultra[®] OTC (butenafine) 1% C</p> <p>Mycostatin^{®*} (nystatin) C, P</p> <p>Naftin[®] (naftifine) 1% C, G</p> <p>Nizoral^{®*} (ketoconazole) 2% Sh</p> <p>Nizoral A-D[®] OTC (ketoconazole) 1% Sh</p> <p>Nystop[®], Pedi-Dri[®], Nyamyc^{®*} (nystatin) P</p> <p>Oxistat[®] (oxiconazole) 1% C, L</p> <p>Tinactin[®]/Tinactin AT OTC* (tolnaftate) 1% C, P, Sp, S</p> <p>Xolegel[®] (ketoconazole) 2% G</p> <p>All other branded products</p>
<p>Combination Products</p> <p>CLOTRIMAZOLE W/BETAMETHASONE † (compare to Lotrisone[®]) C, L</p> <p>NYSTATIN W/TRIAMCINOLONE † (formerly Mycolog II[®]) C, O</p>	<p>Lotrisone^{®*} (clotrimazole w/betamethasone) C, L</p> <p>Vusion[®] (miconazole w/zinc oxide) O (QL=50 g/30 days)</p> <p>All other branded products</p>

C=cream, F=foam, G=gel, L=lotion, P=powder, S=solution, Sh=shampoo, Sp=spray, Sus=suspension

Note: Please refer to “Anti-Infectives: Antifungals: Topical: Onychomycosis” for ciclopirox solution and Penlac[®] Nail Lacquer

Dermatological Agents: Antivirals: Topical

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

Denavir[®]:

- The patient has a diagnosis of oral herpes simplex infection.

Zovirax[®]:

- If prescribed for the treatment of oral herpes simplex infection, the patient has had a documented side effect, allergy, or treatment failure (at least one course of four or more days) with Denavir[®].

LIMITATIONS:

Xerese[®] (acyclovir/hydrocortisone) 5-1% cream combination not covered. Agents may be prescribed separately.

** Topical antiviral therapy offers minimal clinical benefit in the treatment of genital herpes and its use is discouraged by the CDC so topical antiviral therapy will not be approved for this indication. **

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**

Dermatological Agents: Antivirals: Topical <i>Length of Authorization: 6 months</i>	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
ABREVA OTC (docosanol) 10% C	Denavir [®] (penciclovir) 1% C Zovirax [®] (acyclovir) 5% C, O

C=cream, O=ointment

Dermatological Agents: Corticosteroids

LENGTH OF AUTHORIZATION: For the duration of prescription (up to 6 months)

CRITERIA FOR APPROVAL (NON-PREFERRED AGENTS):

- The patient has a documented side effect, allergy, or treatment failure to at least two different preferred agents of *similar* potency. (If a product has an AB rated generic, one trial must be the generic.)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Dermatological Agents: Corticosteroids

Length of Authorization: up to 6 months

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>LOW POTENCY</u></p> <p>ALCLOMETASONE 0.05% C, O† (compare to Aclovate®) DESONIDE† 0.05% C, L, O (compare to DesOwen®) FLUOCINOLONE 0.01% C, S† (formerly Synalar®) HYDROCORTISONE† 0.5%, 1%, 2.5% C; 1%, 2.5% L, 0.5%, 1%, 2.5% O HYDROCORTISONE ACETATE† 1% C; 1% O (all generics)</p>	<p>Aclovate®* (alclometasone) 0.05% C, O Balneol® (hydrocortisone) 0.25% L Capex® (fluocinolone) 0.01% shampoo Desonate® (desonide) 0.05% G DesOwen®* (desonide) 0.05% C, L, O Hytone®* (hydrocortisone) 1%, 2.5% C Nucort 2% lotion (hydrocortisone acetate) Verdeso® (desonide) 0.05% F All other brands</p>
<p><u>MEDIUM POTENCY</u></p> <p>BETAMETHASONE DIPROPIONATE† 0.05% L (formerly Diprosome®) BETAMETHASONE VALERATE† 0.1% C, L (compare to Beta-Val®) DESOXIMETASONE† 0.05% C (compare to Topicort®) FLUOCINOLONE† 0.025% C, O (formerly Synalar®) FLUTICASONE † 0.05% C; 0.005% O (compare to Cutivate®) HYDROCORTISONE BUTYRATE† 0.1% C, O, S (compare to Locoid®) HYDROCORTISONE VALERATE† 0.2% C, O (compare to Westcort®) MOMETASONE FUROATE† 0.1% C, L, O (compare to Elocon®) TRIAMCINOLONE ACETONIDE† 0.025%, 0.1% C, L, O (compare to Aristocort®; formerly Kenalog®)</p>	<p>Aristocort®* (triamcinolone) 0.1% C Beta-Val®* (betamethasone valerate) 0.1% C, L Cloderm® (clocortolone) 0.1% C Cordran® (all products) Cutivate®*(fluticasone) 0.05% C; 0.005% O Cutivate® (fluticasone) 0.05% L Dermatop® (prednicarbate) 0.1% C, O Elocon®* (all products) Locoid®* (hydrocortisone butyrate) 0.1% C, O, S Locoid® (hydrocortisone butyrate) 0.1% L Luxiq® (betamethasone valerate) F prednicarbate† (compare to Dermatop®) 0.1% C, O Topicort®* (desoximetasone) 0.05% C Trianex®* (triamcinolone) 0.05% O Westcort®* (hydrocortisone valerate) all products All other brands</p>
<p><u>HIGH POTENCY</u></p> <p>AMCINONIDE† (formerly Cyclocort®) AUGMENTED BETAMETHASONE† 0.05% C (compare to Diprolene® AF) BETAMETHASONE VALERATE† 0.1% O (formerly Beta-Val®) DESOXIMETASONE† 0.05% G; 0.25% C, O (compare to Topicort®) FLUOCINONIDE† 0.05% C, G, O, S (compare to Lidex®) TRIAMCINOLONE ACETONIDE† 0.5% C, O (formerly Aristocort®)</p>	<p>Apexicon E® (diflorasone) 0.05% C Diflorasone diacetate 0.05% C (compare to Apexicon E®) Diprolene® AF* (augmented betamethasone) 0.05% C Halog® (halcinonide) all products Lidex®* (fluocinonide) 0.05% C Topicort®* (desoximetasone) 0.05% G; 0.25% C, O All other brands</p>
<p><u>VERY HIGH POTENCY</u></p> <p>AUGMENTED BETAMETHASONE† 0.05% L, O (compare to Diprolene®) AUGMENTED BETAMETHASONE † 0.05% G (compare to Alphatrex®) CLOBETASOL PROPIONATE† (compare to Temovate®/Cormax®) CLOBETASOL PROPIONATE† 0.05% F (compare to Olux®) DIFLORASONE DIACETATE† 0.05% O (compare to Psorcon E/Apexicon®) HALOBETASOL PROPRIONATE† (compare to Ultravate®)</p>	<p>Alphatrex®* (augmented betamethasone) 0.05% G Apexicon®* (diflorasone) 0.05% O Clobex® (clobetasol propionate) 0.05% L, shampoo, spray Cormax®* (clobetasol propionate) 0.05% C, O, S Diprolene®* (augmented betamethasone) 0.05% L, O Olux®*/Olux E® (clobetasol propionate) 0.05% F Psorcon-E®* (diflorasone diacetate) 0.05% C Temovate®* (clobetasol propionate) 0.05% C, G, O, S Vanos® (fluocinonide) 0.1% C Ultravate®* (halobetasol propionate) 0.05% C, O All other brands</p>

C=cream, F=foam, G=gel, L=lotion, O=ointment, S=solution

Dermatological Agents: Genital Wart Therapy

LENGTH OF AUTHORIZATION: up to 16 weeks

Veregen, imiquimod: up to 16 weeks

Zyclara: up to 8 weeks

All other products: up to 1 month

CRITERIA FOR APPROVAL:

Condylox[®] gel, Veregan[®]:

- The patient has had a documented side effect, allergy, or treatment failure with Aldara[®].

Condylox^{®*} solution:

- The patient has had a documented intolerance to generic podofilox solution.

Imiquimod (generic) cream:

- The patient has had a documented intolerance to brand Aldara[®].

Zyclara[®] cream:

- The diagnosis or indication is external genital/perianal warts or condyloma acuminata

AND

- The patient has had a documented side effect or treatment failure with Aldara[®]

DOCUMENTATION:

✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Dermatological Agents: Genital Wart Therapy <i>Length of Authorization: up to 16 weeks</i>	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
ALDARA [®] (imiquimod 5%)	Imiquimod [†] 5 % (compare to Aldara [®]) cream
PODOFILOX SOLUTION [†] (compare to Condylox [®])	Condylox [®] Gel (podofilox gel) Condylox ^{®*} solution (podofilox solution) Veregan [®] (sinecatechins ointment) <i>(Quantity limit = 15 grams (1 tube)/per 30 days)</i> Zyclara [®] (imiquimod 3.75%) Cream <i>(Quantity limit = 56 packets/per 8 weeks)</i>

Dermatological Agents: Immunomodulators

At the September 2006 meeting of the DUR Board, the class of topical immunomodulators was reviewed for efficacy and safety. Included in this review was the January 20, 2006, U.S. Food and Drug Administration (FDA) updated labeling and March 17, 2005 FDA Public Health Advisory regarding Elidel[®] Cream (pimecrolimus) and Protopic[®] Ointment (tacrolimus). The labeling changes include a BOXED WARNING about the possible risk of cancer and a medication guide that is to be distributed with each prescription to ensure that the parents of patients using these medications are aware of this concern. Although a causal link has not been established, rare reports of cancer (e.g. skin and lymphoma) have been reported in patients who had been receiving these products. The FDA has advised that Protopic[®] and Elidel[®] be used only as labeled. The new labeling clarifies that these drugs are recommended for use as *second-line* treatments for the short-term and non-continuous chronic treatment of mild to moderate (Elidel[®] Cream) or moderate to severe (Protopic[®] Ointment) atopic dermatitis. The FDA also advises clinicians to avoid use in children less than 2 years of age.

LENGTH OF AUTHORIZATION: up to 1 year

CRITERIA FOR APPROVAL:

Age < 2 years (requests will be approved for up to 6 months):

- The patient has a diagnosis of atopic dermatitis (eczema). AND
- The patient has had a documented side effect, allergy, or treatment failure with at least one moderate to high potency topical corticosteroid within the last 6 months. AND
- The quantity requested does not exceed 30 grams/fill and 90 grams/6 months.

Age > 2 years (requests will be approved for up to 1 year):

- The patient has a diagnosis of atopic dermatitis (eczema). AND
- The patient has had a documented side effect, allergy, or treatment failure with at least one moderate to high potency topical corticosteroid within the last 6 months. AND
- The quantity requested does not exceed 30 grams/fill and 90 grams/6 months.

Dermatological Agents: Immunomodulators <i>Length of Authorization: up to 1 year</i>	
§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)	
NO PA REQUIRED <i>(For age > 2 after prerequisite trial of one topical corticosteroid)</i>	PA REQUIRED
<p>ELIDEL[®] Cream (pimecrolimus) § <i>(Quantity Limit = 30 grams/fill and 90 grams/6 months)</i></p> <p>PROTOPIC[®] Ointment (tacrolimus) § <i>(Quantity Limit = 30 grams/fill and 90 grams/6 months)</i></p> <p>Note: Protopic ointment concentration limited to 0.03% for age < 16 years old.</p>	<p>Elidel[®] Cream (pimecrolimus) age < 2 years <i>(Quantity Limit = 30 grams/fill and 90 grams/6 months)</i></p> <p>Protopic[®] Ointment (tacrolimus) age < 2 years <i>(Quantity Limit = 30 grams/fill and 90 grams/6 months)</i></p> <p>Note: Protopic ointment concentration limited to 0.03% for age < 16 years old.</p>

Dermatological Agents: Scabicides and Pediculicides

LENGTH OF AUTHORIZATION: date of service only, no refills

CRITERIA FOR APPROVAL:

- The patient has had a documented side effect or allergy to permethrin or treatment failure with two treatments of permethrin.
- For approval of Elimite[®] Cream or Ovide[®] Lotion, the patient must have a documented intolerance to the generic equivalent product.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Dermatological Agents: Scabicides and Pediculicides <i>Length of Authorization: date of service only, no refills</i> Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
EURAX [®] (crotamiton) <i>C, L</i> NIX [®] (permethrin) <i>CR, G, Sp</i> PERMETHRIN† (compare to Elimite [®]) <i>C</i> PERMETHRIN† <i>L</i> PIPERONYL BUTOXIDE AND PYRETHRINS† <i>G, S, Sh</i> RID [®] (piperonyl butoxide and pyrethrins) <i>G, Sh, Sp</i> All other brand and generic Scabicides and Pediculicides	Elimite ^{®*} (permethrin 5 %) <i>C</i> Lindane† <i>L, Sh</i> Malathion † <i>L</i> (compare to Ovide [®]) Ovide [®] (malathion) <i>L</i> Ulesfia [®] (benzoyl alcohol 5%) <i>L</i>

C=cream, CR=crème rinse, G=gel, L=lotion, S=solution, Sh=shampoo, Sp=spray

Desmopressin: Intranasal/Oral

LENGTH OF AUTHORIZATION: 2 years

CRITERIA FOR APPROVAL: Intranasal

- The diagnosis or indication for the requested medication is (1) Diabetes Insipidus, (2) hemophilia type A, or (3) Von Willebrand disease
- AND**
- If the request is for brand DDAVP, the patient has a documented intolerance to generic desmopressin spray or solution.

CRITERIA FOR APPROVAL: non-preferred oral

- The diagnosis or indication for the requested medication is (1) Diabetes Insipidus and/or (2) primary nocturnal enuresis
- AND**
- The patient has had a documented intolerance to generic desmopressin tablets

LIMITATIONS:

Desmopressin intranasal formulations will not be approved for the treatment of primary nocturnal enuresis (PNE) due to safety risks of hyponatremia. Oral tablets may be prescribed for this indication.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Desmopressin: Intranasal		<i>Length of Authorization: 2 years</i>
<small>Key: † Generic product, *Indicates generic equivalent is available without a PA</small>		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
<u>Intranasal</u>	DDAVP® (desmopressin) Nasal Solution or Spray 0.01% Desmopressin † Nasal Solution or Spray 0.01 % (compare to DDAVP®) Minirin † (desmopressin) Nasal Spray 0.01% Stimat® (desmopressin) Nasal Solution 1.5 mg/ml	
<u>Oral</u>		
desmopressin†	DDAVP®* (desmopressin) tablets	

Diabetic Testing Supplies

LENGTH OF AUTHORIZATION: 5 years

CRITERIA FOR APPROVAL:

- The prescriber demonstrates that the patient has a medical necessity for clinically significant features that are not available on any of the preferred meters/test strips.

LIMITATIONS:

Talking monitors are not covered under the pharmacy benefit.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Diabetic Testing Supplies		<i>Length of Authorization: 5 years</i>
PREFERRED PRODUCTS (No PA Required)	PA REQUIRED	
<p><u>DIABETIC MONITORS/METERS</u> FREESTYLE LITE[®] SYSTEM KIT FREESTYLE FLASH[®] SYSTEM KIT FREESTYLE FREEDOM[®] SYSTEM KIT FREESTYLE FREEDOM LITE[®] SYSTEM KIT ONE TOUCH[®] ULTRA 2 KIT ONE TOUCH[®] ULTRA MINI KIT ONE TOUCH[®] ULTRA SMART KIT PRECISION XTRA[®] METER</p> <p><u>DIABETIC TEST STRIPS</u> FREESTYLE^{®*} FREESTYLE LITE^{®*} ONE TOUCH[®] BASIC* ONE TOUCH[®] SURESTEP* ONE TOUCH[®] FAST TAKE* ONE TOUCH[®] UL[®]TRA* PRECISION XTRA^{®*} PRECISION XTRA[®] BETA KETONE (10 count)</p>	<p>Accucheck[®] Ascensia[®] Assure[®] Exactech[®] Prodigy[®]</p> <p>All other brands and store brands</p> <p>Accucheck[®] Ascensia[®] Assure[®] Exactech[®] Prodigy[®]</p> <p>All other brands and store brands</p>	

* 50 and 100 count package sizes

Estrogens: Vaginal

LENGTH OF AUTHORIZATION: not applicable

CRITERIA FOR APPROVAL: not applicable

Estrogens: Vaginal	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>Estradiol</u> ESTRACE VAGINAL[®] Cream ESTRING[®] Vaginal Ring VAGIFEM[®] Vaginal Tablets</p> <p><u>Conjugated Estrogens</u> PREMARIN VAGINAL[®] Cream</p> <p><u>Estradiol Acetate</u> FEMRING[®] Vaginal Ring</p>	

Fibromyalgia Agents

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Savella®:

- The diagnosis or indication is treatment of fibromyalgia.
- AND**
- The patient has had a documented side effect, allergy, or treatment failure to TWO drugs from the following: gabapentin, tricyclic antidepressant, SSRI antidepressant, SNRI antidepressant, miscellaneous antidepressant, cyclobenzaprine or Lyrica®.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Fibromyalgia Agents		<i>Length of Authorization: 1 year</i>
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
	Savella® (milnacipran) tablet, titration pack <i>Quantity Limit = 2 tablets/day</i>	

Note: Please refer to “Anticonvulsants” for clinical criteria for **Lyrica®** and “Anti-Depressants – SNRIs” for clinical criteria for **Cymbalta®**.

Gastrointestinals: Crohn's Disease Medications: Injectables

NOTE: Crohn's Disease Self-Injectables (Humira® and Cimzia®) must be obtained and billed through our specialty pharmacy vendor, ICORE Healthcare. Please see the Humira and Cimzia Prior Authorization/Patient Enrollment Form for instructions. ICORE Healthcare may supply Remicade® upon request or you may continue to obtain through your usual supplier. ICORE Healthcare will not be supplying Tysabri® at this time – please continue to obtain through your usual supplier.

LENGTH OF AUTHORIZATION: Initial PA of 3 months, and 12 months thereafter if medication is well tolerated. Re-evaluate every 12 months.

CRITERIA FOR APPROVAL:

Humira® , Remicade®:

Patient has a diagnosis of Crohn's disease and has already been stabilized on the medication.

OR

Diagnosis is moderate to severe Crohn's disease and at least 2 of the following drug classes resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure (i.e. resistant or intolerant to steroids or immunosuppressants): aminosalicylates, antibiotics, corticosteroids, and immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.

Note: Humira® and Cimzia have been shown to be effective in patients who have been treated with infliximab but have lost response to therapy.

Cimzia®:

Patient has a diagnosis of Crohn's disease and has already been stabilized on Cimzia®

OR

Patient age > 18 years

AND

Diagnosis is moderate to severe Crohn's disease and at least 2 of the following drug classes resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure (i.e. resistant or intolerant to steroids or immunosuppressants): aminosalicylates, antibiotics, corticosteroids, and immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.

AND

The prescriber must provide a clinically valid reason why Humira® cannot be used.

Tysabri®:

Patient has a diagnosis of Crohn's disease and has already been stabilized on Tysabri®.

OR

Diagnosis is moderate to severe Crohn's disease and at least 2 of the following drug classes resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure (i.e. resistant or intolerant to steroids or immunosuppressants): aminosalicylates, antibiotics, corticosteroids, and immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.

AND

The patient has a documented side effect, allergy, treatment failure, or contraindication to BOTH, Remicade® and Humira®.

DOCUMENTATION:

- ✓ Document clinical information for **Humira®** on its **Prior Authorization/Patient Enrollment Form** and clinically compelling information supporting the choice of **Remicade®** on a **Remicade Prior Authorization Request Form** or **Cimzia®** on its **Prior Authorization/Patient Enrollment Form** or **Tysabri®** on a **General Prior Authorization Request Form**.

- ✓ All requests for infliximab (Remicade®) (whether billed through the pharmacy or medical benefit (J1745)) or natalizumab (Tysabri®) billed through the medical benefit as J2323 require Prior Authorization through the MedMetrics Clinical Call Center.

Crohn's Disease: Injectables	
<i>Length of authorization: Initial PA of 3 months; 12 months thereafter</i>	
PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET
HUMIRA® (adalimumab) <i>Quantity limit = 6 syringes/28 days for the first month (Crohn's starter kit); 2 syringes/28 days subsequently</i> REMICADE® (infliximab)	Cimzia® (certolizumab pegol) <i>Quantity limit = 1 kit/28 days (starter X 1, then regular)</i> Tysabri® (natalizumab)

Gastrointestinals: Histamine-2 Receptor Antagonists

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Axid[®] capsule, nizatidine capsule, Pepcid[®] tablet, ranitidine capsule, Tagamet[®] tablet, Zantac[®] tablets:

- The patient has had a documented side effect, allergy, or treatment failure to at least one preferred medication. If a medication has an AB rated generic, the trial must be the generic formulation. For approval of ranitidine capsules, the patient must have had a trial of ranitidine tablets.

Axid[®] Oral Solution, Famotidine Oral Suspension, Nizatidine Oral Solution, Pepcid[®] Oral Suspension, Zantac[®] Effervescent, Zantac[®] Oral Syrup:

- The patient has had a documented side effect, allergy, or treatment failure to ranitidine syrup or cimetidine oral solution. If a medication has an AB rated generic, there must have been a trial of the generic formulation.

Gastrointestinals: Histamine-2 Receptor Antagonists

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
CIMETIDINE† (compare to Tagamet [®]) tablet FAMOTIDINE† (compare to Pepcid [®]) tablet RANITIDINE† (compare to Zantac [®]) tablet	Axid [®] (nizatidine) capsule § nizatidine† (compare to Axid [®]) capsule § Pepcid [®] * (famotidine) tablet§ ranitidine† capsule § Tagamet [®] * tablet § Zantac [®] * tablet §
<u>SYRUP & SPECIAL DOSAGE FORMS</u> CIMETIDINE † ORAL SOLUTION RANITIDNE † syrup (compare to Zantac [®])	Axid [®] (nizatidine) Oral Solution § famotidine† (compare to Pepcid [®]) oral suspension § Nizatidine †Oral Solution (compare to Axid [®]) Pepcid [®] (famotidine) Oral Suspension § Zantac (ranitidine) Effervescent [®] § Zantac [®] * (ranitidine) Syrup§

Gastrointestinals: Inflammatory Bowel Agents (Oral and Rectal Products)

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Azulfidine^{®*}, Colazal^{®*}, Rowasa^{®*}:

- The patient has had a documented intolerance to the generic equivalent of the requested medication.

Asacol HD[®]:

- The patient has had a documented side effect, allergy, or treatment failure with two (2) preferred oral mesalamine products.

Sfrowasa[®]:

- The patient has had a documented intolerance to mesalamine enema.

LIMITATIONS:

Kits with non-drug products are not covered.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Gastrointestinals: Inflammatory Bowel Agents (Oral and Rectal Products)

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<u>MESALAMINE PRODUCTS</u>	
Oral	
APRISO [®] (mesalamine capsule extended-release)	Asacol HD [®] (mesalamine tablet delayed release)
ASACOL [®] (mesalamine tablet delayed-release)	
LIALDA [®] (mesalamine tablet extended-release)	
PENTASA [®] (mesalamine cap CR)	
Rectal	
CANASA [®] (mesalamine suppository)	Rowasa ^{®*} (mesalamine enema)
MESALAMINE ENEMA† (compare to Rowasa [®])	Sfrowasa [®] (mesalamine enema sulfite free)
<u>OTHER</u>	
BALSALAZIDE† (compare to Colazal [®])	Azulfidine ^{®*} (sulfasalazine)
DIPENTUM [®] (olsalazine)	Colazal ^{®*} (balsalazide)
SULFASALAZINE† (compare to Azulfidine [®])	

Gastrointestinals: Proton Pump Inhibitors

LENGTH OF AUTHORIZATION: up to 1 year

CRITERIA FOR APPROVAL:

lansoprazole ODT, Nexium powder for suspension, Prevacid Solutabs (for patients \geq 12 years old), Prilosec packet, Protonix packet

- The patient has a requirement for an oral liquid dosage form. In addition, for approval of lansoprazole ODT, the patient has a documented intolerance to brand Prevacid Solutabs.

Other non-preferred medications:

- The member has had a documented side effect, allergy, or treatment failure to Kapidex/Dexilant capsules, Omeprazole RX 20 mg or 40 mg generic capsules AND Pantoprazole generic tablets.
- If the request is for Prevacid 24 hr OTC or lansoprazole generic RX capsules, the patient must also have a documented intolerance to brand Prevacid RX.

CRITERIA FOR APPROVAL (twice daily dosing):

- Gastroesophageal Reflux Disease (GERD) – If member has had an adequate trial (e.g. 8 weeks) of standard once daily dosing for GERD, twice daily dosing may be approved.
- Zollinger-Ellison (ZE) syndrome – Up to triple dose PPI may be approved.
- Hypersecretory conditions (endocrine adenomas or systemic mastocytosis) – Double dose PPI may be approved.
- Erosive Esophagitis, Esophageal stricture, Barrett's esophagitis (complicated GERD) – Double dose PPI may be approved.
- Treatment of ulcers caused by H. Pylori – Double dose PPI may be approved for up to 2 weeks.
- Laryngopharyngeal reflux – Double dose PPI may be approved.

LIMITATIONS:

Zegerid[®] (omeprazole/sodium bicarbonate) RX capsules, powder for suspension not covered as no Federal Rebate offered.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Gastrointestinals: PPIs

Length of Authorization: 1 year

Key: † Generic product

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED, any dose
<p><u>ORAL CAPULES/TABLETS</u> KAPIDEX[®]/DEXILANT[®] (dexlansoprazole) capsules (<i>Quantity limit=1 cap/day</i>) OMEPRAZOLE† 20 mg or 40 mg RX capsule (compare to Prilosec[®]) (<i>Quantity limit = 1 capsule/day</i>) PANTOPRAZOLE† tablets (compare to Protonix[®]) (<i>Quantity limit=1 tab/day</i>)</p>	<p>Aciphex[®] (rabeprazole) tablets § (<i>Quantity limit=1 tab/day</i>) lansoprazole generic RX (compare to Prevacid[®]) capsules (<i>Quantity limit = 1 cap/day</i>) Nexium[®] (esomeprazole) capsules § (<i>Quantity limit=1 cap/day</i>) omeprazole †* generic 10 mg RX (compare to Prilosec[®]) capsules § (<i>Quantity limit=1 cap/day</i>) omeprazole †* generic OTC tablets § (<i>Quantity limit=1 tab/day</i>) omeprazole magnesium† generic OTC 20 mg capsules§ (<i>Quantity limit=1 cap/day</i>) omeprazole/sodium bicarb capsules RX (compare to Zegerid[®] RX)§ (<i>Quantity limit=1 cap/day</i>) Prevacid[®] RX (lansoprazole) capsules § (<i>Quantity limit=1 cap/day</i>) Prevacid[®] 24 hr OTC (lansoprazole) capsules (<i>Quantity limit=1 cap/day</i>) Prilosec OTC[®] 20mg (omeprazole magnesium) tablets (<i>Quantity limit = 1 tablet/day</i>) Prilosec[®]* RX (omeprazole) capsules § (<i>Quantity limit=1 cap/day</i>) Protonix[®]* (pantoprazole) tablets (<i>Quantity limit=1 tab/day</i>) Zegerid OTC[®] (omeprazole/sodium bicarb)caps § (<i>Quantity limit=1 cap/day</i>)</p>
<p><u>SUSPENSION & SPECIAL DOSAGE FORMS</u> PREVACID SOLUTABS[®]* (lansoprazole) (<i>Quantity limit=1 tab/day</i>)</p> <p><u>COMBINATION</u> PREVPAC[®] (lansoprazole w/ H.pylori anti-bacterials) (<i>No Quantity limit applies</i>)</p>	<p>lansoprazole ODT† generic RX (compare to Prevacid[®] Solutabs) (<i>Quantity limit=1 tab/day</i>) Nexium[®] (esomeprazole) powder for suspension (<i>Quantity limit=1 packet/day</i>) Prilosec (omeprazole magnesium) packet (<i>Quantity limit=2 packets/day</i>) Protonix[®] (pantoprazole) packet (<i>Quantity limit=1 packet/day</i>)</p>

*No PA required for patients < 16 years

♦ No PA required for patients < 12 years

Gastrointestinals: Ulcerative Colitis Medications: Injectables

ICORE Healthcare may supply Remicade[®] upon request or you may continue to obtain through your usual supplier.

LENGTH OF AUTHORIZATION: Initial PA of 3 months, and 12 months thereafter if medication is well tolerated. Re-evaluate every 12 months.

CRITERIA FOR APPROVAL:

Remicade[®]

Patient has a diagnosis of Ulcerative Colitis and has already been stabilized on Remicade[®].

OR

The patient has a diagnosis of Ulcerative Colitis and has had a documented side effect, allergy, or treatment failure with at least 2 of the following 3 agents: aminosalicylates (e.g. sulfasalazine, mesalamine, etc.), corticosteroids, or immunomodulators (e.g. azathioprine, 6-mercaptopurine, cyclosporine, etc.).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of **Remicade[®]** on a **Remicade Prior Authorization Request Form**.

- ✓ All requests for infliximab (Remicade[®]) (whether billed through the pharmacy or medical benefit (J1745)) require Prior Authorization through the MedMetrics Clinical Call Center.

Gastrointestinals: Ulcerative Colitis Medications: Injectables	
<i>Length of authorization: Initial PA of 3 months; 12 months thereafter</i>	
PREFERRED AGENTS (No PA Required)	PA REQUIRED
	Remicade [®] (infliximab)

Gaucher Disease Medications

LENGTH OF AUTHORIZATION: initial approval 6 months, subsequent approval 1 year

CRITERIA FOR APPROVAL:

- The diagnosis or indication is Gaucher disease (GD) type I.
AND
- The diagnosis has been confirmed by molecular or enzymatic testing.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a PA required agent on a **General Prior Authorization Request Form.**

Gaucher Disease Medications	
<i>Length of Authorization: initial approval 6 months, subsequent approval 1 year</i>	
NO PA REQUIRED	PA REQUIRED
	Cerezyme® (imiglucerase for injection) Vpriv® (velaglucerase alfa for injection) **Maximum days supply per fill for all drugs is 14 days**

Gout Agents

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Colcryst[®]:

- The diagnosis or indication for the requested medication is Familial Mediterranean Fever (FMF)
OR
- The diagnosis or indication for the requested medication is gout
AND
- The patient has had a documented side effect or treatment failure with at least one drug from the NSAID class.
OR
- The patient is not a candidate for therapy with at least one drug from the NSAID class due to one of the following:
 - The patient is 60 years of age or older
 - Patient has a history of GI bleed
 - Patient is currently taking an anticoagulant (warfarin or heparin)
 - Patient is currently taking an oral corticosteroid
 - Patient is currently taking methotrexate

Krystexxa[®]:

- The diagnosis or indication is treatment of chronic gout.
AND
- The patient has had a documented side effect, allergy, treatment failure or a contraindication to BOTH allopurinol and febuxostat. NOTE: Treatment failure is defined as inability to reduce serum uric acid levels to < 6 mg/dl with allopurinol doses of 600 mg/day taken consistently. Additionally, renal impairment is not considered a contraindication to allopurinol use.

Note: after preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval.

Uloric[®]:

- The diagnosis or indication is treatment of gout.
AND
- The patient has had a documented side effect, allergy, treatment failure or a contraindication to allopurinol. NOTE: Treatment failure is defined as inability to reduce serum uric acid levels to < 6 mg/dl with allopurinol doses of 600 mg/day taken consistently. Additionally, renal impairment is not considered a contraindication to allopurinol use.

Zyloprim[®]:

- The patient has had a documented intolerance to generic allopurinol.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.
- ✓ All requests for pegloticase (Krystexxa[®]) (J2507) (must be billed through the medical benefit) require Prior Authorization through the MedMetrics Clinical Call Center.

Gout Agents:*Length of Authorization: 1 year***Key: † Generic product, *Indicates generic equivalent is available without a PA**

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<u>SINGLE INGREDIENT COLCHICINE</u>	Colcrys® (colchicine) tablet <i>QL = 3 tablets/day (gout) or 4 tablets/day (FMF)</i>
<u>SINGLE INGREDIENT URICOSURIC AGENTS</u> PROBENECID†	
<u>XANTHINE OXIDASE INHIBITORS</u> ALLOPURINOL† (compare to Zyloprim®)	Uloric® (febuxostat) <i>QL (40 mg tablets) = 1 tablet/day</i> Zyloprim®* (allopurinol)
<u>COMBINATION PRODUCTS</u> COLCHICINE/PROBENECID†	
<u>PEG-URICASE AGENTS</u>	Krystexxa (pegloticase) Vials for IV Infusion <i>QL = 2 vials/28 days</i>

Note: Please see Analgesics: Cox-II Inhibitors and NSAID for preferred NSAID options

Growth Stimulating Agents

NOTE: These drugs must be obtained and billed through our specialty pharmacy vendor, ICORE Healthcare. Please see Growth Stimulating Agents Prior Authorization/Enrollment Form for instructions.

GROWTH HORMONE

► See next pages for growth hormone products.

LENGTH OF AUTHORIZATION: Up to 1 year

CRITERIA FOR APPROVAL:

PEDIATRIC:

1) The patient must have one of the following indications for growth hormone:

- Turner syndrome confirmed by genetic testing.
- Prader-Willi Syndrome confirmed by genetic testing.
- Growth deficiency due to chronic renal failure.
- Patient who is Small for Gestational Age (SGA) due to Intrauterine Growth Retardation (IUGR) and catch up growth not achieved by age 2 (Birth weight less than 2500g at gestational age of <37 weeks or a birth weight or length below the 3rd percentile for gestational age).

OR

- Pediatric Growth Hormone Deficiency confirmed by results of two provocative growth hormone stimulation tests (insulin, arginine, levodopa, propranolol, clonidine, or glucagon) showing results (peak level) <10ng/ml.

2) The requested medication must be prescribed by a pediatric endocrinologist (or pediatric nephrologist if prescribed for growth deficiency due to chronic renal failure).

3) Confirmation of non-closure of epiphyseal plates (x-ray determining bone age) must be provided for females > age 12 and males > age 14.

4) Initial requests can be approved for 6 months. Subsequent requests can be approved for up to 1 year with documentation of positive response to treatment with growth hormone.

ADULT:

The patient must have one of the following indications for growth hormone:

- Panhypopituitarism due to surgical or radiological eradication of the pituitary.

OR

- Adult Growth Hormone Deficiency confirmed by one growth hormone stimulation test (insulin, arginine, levodopa, propranolol, clonidine, or glucagon) showing results (peak level) <5ng/ml. Growth hormone deficient children must be retested after completion of growth.

LIMITATIONS:

Coverage of Growth Hormone products will not be approved for patients who have Idiopathic Short Stature.

GENOTROPIN[®], HUMATROPE[®], NUTROPIN[®], NUTROPIN[®] AQ, OMNITROPE[®], SAIZEN[®], TEV-TROPIN[®]

- The patient has a documented side effect, allergy, or treatment failure to Norditropin

➤ **INCRELEX[®]**

INDICATION: Long-term treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (Primary IGFD)

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

- Member has growth hormone gene deletion AND neutralizing antibodies to growth hormone, OR primary insulin-like growth factor (IGF-1) deficiency (IGFD), defined by the following:
 - Height standard deviation score < -3 AND
 - Basal IGF-1 standard deviation score < -3 AND
 - Normal or elevated growth hormone level
- Member is ≥ 2 years old (safety and efficacy has not been established in patients younger than 2), AND
- Member has open epiphysis, AND
- Member is under the care of an endocrinologist or other specialist trained to diagnose and treat growth disorders.

➤ **SEROSTIM[®]**

INDICATION: AIDS associated wasting/anorexia

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

- A diagnosis of AIDS associated wasting/anorexia

➤ **ZORBTIVE[®]**

INDICATION: Short Bowel Syndrome

LENGTH OF AUTHORIZATION: 4 weeks

CRITERIA FOR APPROVAL:

- A diagnosis of short bowel syndrome
- Concomitant use of specialized nutritional support (specialty TPN)
- Prescription by gastroenterologist (specialist)

DOCUMENTATION:

- ✓ Document information for the indication of the use of these medications on a **Growth Stimulating Agents Prior Authorization/Enrollment Form.**

Growth Stimulating Agents		<i>Length of Authorization: up to 1 year</i>
PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	
NORDITROPIN [®]	Genotropin [®] Humatrope [®] Nutropin [®] /Nutropin [®] AQ Omnitrope [®] Saizen [®] Tev-Tropin [®] <u>Specialized Indications – See Specific Criteria</u> Increlex [®] (mecasermin) Serostim [®] Zorbtive [®]	



GROWTH STIMULATING AGENTS - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address		City	
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address		City	
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

3

Department of Vermont Health Access GROWTH STIMULATING AGENTS PRIOR AUTHORIZATION REQUEST

Patient Diagnosis: _____

Requested DVHA **PREFERRED** Growth Stimulating Agent

Norditropin®

Growth Hormone Stimulation Test # 1	Test:	result:
Growth Hormone Stimulation Test # 2	Test:	result:
Patient's Height:		
Patient's Bone Age:		
Patient's Chronological Age:		
Growth Velocity:		
IGF-1 results:		

Please explain the medical necessity for a '**NON-PREFERRED**' product:

Genotropin® Humatrope® Nutropin® Omnitrope® Saizen® Tev-Tropin®

Medical justification: _____

Request is for a '**SPECIALIZED INDICATION**' product: (Criteria in Clinical Criteria Manual)

Increlex® Serostim® Zorbitive®

Other information/ Prescriber comments: _____

4

PRESCRIPTION

Norditropin® Nordiflex Norditropin® Cartridge Norditropin® Flexpro

Other Product: (Please Specify) _____

Dosage Form / Strength: _____

Dose/Route & Frequency (Sig): _____

Dispense Quantity: One month supply or _____ Refill X _____

Needles/syringes: quantity sufficient for drug supply with refills as above

Deliver product to: Patient's home MD office Clinic

Prescriber's Signature: _____ **Date:** _____



HEMOPHILIA FACTORS - Patient Enrollment and Prescription Form

Complete form in its entirety and fax to number listed below

1

PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address		City	
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2

PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address		City	
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

3

Department of Vermont Health Access PRESCRIPTION HEMOPHILIA FACTORS

Patient Diagnosis:	
<input type="checkbox"/> Hemophilia A – Factor VIII Disease	
<input type="checkbox"/> Hemophilia B – Factor IX Disease	
<input type="checkbox"/> von Willebrand Disease	
Patient Weight (kg):	Native Factor Level:
Product Name:	
Dose / Frequency Instructions:	
# of doses ordered: _____ Refills: _____ If doses of different units are ordered, specific number of doses of each	
Reason(s) for Use:	
<input type="checkbox"/> Prophylaxis only <input type="checkbox"/> Episodic only <input type="checkbox"/> Prophylaxis and PRN	
<input type="checkbox"/> Acute Bleeding Episode <input type="checkbox"/> Surgical Prophylaxis <input type="checkbox"/> Dental Procedure	
Recent bleed while on Prophylaxis:	
Date of bleed: ____/____/____	
Location of bleed: _____ Severity of bleed: _____	
# of Doses already administered prior to this order: _____ IU/Dose: _____	
Deliver product to: <input type="checkbox"/> Patient's home <input type="checkbox"/> MD office <input type="checkbox"/> Clinic	
<input type="checkbox"/> Needles/syringes: quantity sufficient for factor supply	
Prescriber's Signature: _____	Date: _____

Hepatic Encephalopathy Agents

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Xifaxan 550 mg Tablets®

- Patient has a diagnosis of hepatic encephalopathy
- AND**
- Patient has had a documented side effect, allergy, treatment failure or contraindication to lactulose

Hepatic Encephalopathy Agents	
<i>Length of Authorization: 1 year</i>	
Key: † Generic product	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>Osmotic Laxatives</u> LACTULOSE†</p> <p><u>Antibiotics</u> METRONIDAZOLE† 250 mg Tablets NEOMYCIN SULFATE† 500 mg Tablets</p>	<p>Xifaxan® (rifaximin) 550 mg Tablets (Qty limit = 2 tablets/day)</p>

Note: Xifaxan (rifaximin) 200 mg tablets – *Quantity Limit = 9 tablets/RX (only FDA approved for traveler’s diarrhea indication)*

Hepatitis C Medications

NOTE: These drugs must be obtained and billed through our specialty pharmacy vendor, ICORE Healthcare. Please see Hepatitis C Medications (Peg-Interferon/Ribavirin) Prior Authorization/Enrollment Form and Hepatitis C Protease Inhibitors Prior Authorization/Enrollment Form for instructions.

LENGTH OF AUTHORIZATION: Ribavirin/Peg-interferon = 48 weeks; Incivek = 12 weeks; Victrelis = 44 weeks (ICORE Specialty will monitor lab results and determine final duration of therapy)

CRITERIA FOR APPROVAL:

Preferred Ribavirin and Pegasys

- The diagnosis or indication for the requested medication is Hepatitis.

AND

- The prescriber is, or has consulted with, a Hepatologist, Gastroenterologist, or Infectious Disease Specialist.

Non-preferred Ribavirin Brands/Strengths

- The patient has a documented intolerance to generic ribavirin 200 mg tablets or capsules.

Rebetol® Oral Solution

- The patient is unable to use generic ribavirin 200 mg tablets or capsules

Peg-Intron® or Infergen®

- The patient has had a documented side effect, allergy, or treatment failure to Pegasys®.

Incivek® (telaprevir)

- The diagnosis or indication for the requested medication is hepatitis C (genotype 1) infection and the patient has already been started and stabilized on the requested medication in combination with pegylated interferon and ribavirin. (Note: samples are not considered adequate justification for started and stabilized).

OR

- The patient has a confirmed diagnosis of chronic hepatitis C (genotype 1) infection

AND

- The patient is ≥ 18 years of age

AND

- The prescriber is, or has consulted with, a Hepatologist, Gastroenterologist, or Infectious Disease Specialist.

AND

- The patient has not previously failed therapy with Incivek or Victrelis

AND

- The requested medication will be used in combination with pegylated interferon and ribavirin.

Victrelis® (boceprevir)

- The diagnosis or indication for the requested medication is hepatitis C (genotype 1) infection and the patient has already been started and stabilized on the requested medication in combination with pegylated interferon and ribavirin. (Note: samples are not considered adequate justification for started and stabilized).

OR

- The patient is ≥ 18 years of age

AND

- The patient has a confirmed diagnosis of chronic hepatitis C (genotype 1) infection

AND

- The prescriber is, or has consulted with, a Hepatologist, Gastroenterologist, or Infectious Disease Specialist.

AND

- The patient has not previously failed therapy with Incivek or Victrelis

AND

- The patient has or will be pre-treated with ribavirin and peginterferon therapy for at least 4 weeks prior to initiating Victrelis

AND

- The requested medication will be used in combination with pegylated interferon and ribavirin.

DOCUMENTATION:

- ✓ Document information for the indication of the use of these medications on a **Hepatitis C Medications (Peg-Interferon/Ribavirin) Prior Authorization/Patient Enrollment Form** and **Hepatitis C Protease Inhibitors Prior Authorization/Patient Enrollment Form**.

Hepatitis C Medications	
<i>Length of Authorization: up to 48 weeks</i>	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET
<u>RIBAVIRIN</u> Tablets/Capsules RIBAVIRIN† 200 mg tablets or capsules Oral Solution	Copegus®* (ribavirin 200 mg tablet) Ribapak® 400 mg/600 mg Dose Pack (ribavirin) Rebetol®* (ribavirin 200 mg capsule) All other strengths/brands of ribavirin tablets/capsules Rebetol® (ribavirin 40 mg/ml) oral solution
<u>INTERFERON</u> PEGASYS® (peg-interferon alpha-2a) (QL = 4 vials/28 days) PEGASYS CONVENIENCE PACK® (peg-interferon alfa-2a) (QL = 1 kit/28 days)	Peg-Intron®/ Peg-Intron Redipen® (peg-interferon alpha-2b) (QL=4 pens per 28 days) Peg-Intron Redipen Pak 4® (peg-interferon alpha-2b) (QL=1 kit (4 pens) per 28 days) Infergen® (interferon alphacon-1)
<u>HEPATITIS C PROTEASE INHIBITORS</u> INCIVEK® (telaprevir) (QL = 6 tablets/day) VICTRELIS® (boceprevir) (QL = 12 capsules/day)	



HEPATITIS C MEDICATIONS – Peg-Interferon/Ribavirin

Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA <u>or</u>			
Street Address			City
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address			City
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

**3 Department of Vermont Health Access
HEPATITIS C MEDICATIONS – Peg-Interferon/Ribavirin
PRIOR AUTHORIZATION REQUEST**

Patient Diagnosis:	Genotype:
If requesting prescriber is not a Hepatologist, Gastroenterologist or ID Specialist, has one of these specialties been consulted on this case? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Specialist name: _____ Specialist Type: _____	
Requested DVHA PREFERRED Oral Hepatitis C Product? <input type="checkbox"/> Ribavirin 200 mg Tab (compare to Copegus®) <input type="checkbox"/> Ribavirin 200 mg Cap (compare to Rebetol®)	
For any DVHA NON-PREFERRED Oral Hepatitis C Product or Strength, please explain the medical necessity for this product: Product: _____ Medical justification: _____	
Requested DVHA PREFERRED Injectable Hepatitis C Product? <input type="checkbox"/> Pegasys® Prefilled Syringe <input type="checkbox"/> Pegasys® Single Dose Vial	
For any DVHA NON-PREFERRED Injectable Hepatitis C Product, please explain the medical necessity for this product: Product: _____ Medical justification: _____	
Patient will also be receiving (Please complete Hepatitis C Protease Inhibitors PA Form) <input type="checkbox"/> Incivek® <input type="checkbox"/> Victrelis® <input type="checkbox"/> Neither	
4 PRESCRIPTION	
Oral: <input type="checkbox"/> Ribavirin 200 mg <input type="checkbox"/> Tablet <u>or</u> <input type="checkbox"/> Capsule <input type="checkbox"/> Other (Specify): _____ Dose: _____ Frequency: _____ Qty: <u>28 days supply</u> Refill X: _____	
Injectable: <input type="checkbox"/> Pegasys® Prefilled Syringe 180 mcg/0.5 ml “Convenience Kit” (4 syringes/box) <u>or</u> <input type="checkbox"/> Pegasys® 180 mcg/1 ml Single Dose Vial <u>or</u> <input type="checkbox"/> Other (choose): <input type="checkbox"/> PEG-Intron® RediPen <input type="checkbox"/> PEG-Intron® Kit <input type="checkbox"/> Infergen® Specify Strength of above: _____ Sig: Dose/Route/Frequency: _____ Dispense Quantity: <u>28 days supply</u> Refill X: _____	
<input type="checkbox"/> Needles/syringes: quantity sufficient for drug supply with refills as above	
Deliver product to: <input type="checkbox"/> Patient's home <input type="checkbox"/> MD office <input type="checkbox"/> Clinic	
Prescriber's Signature: _____ Date: _____	



HEPATITIS C PROTEASE INHIBITORS (INCIVEK®/VICTRELIS®)

- Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1

PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA <u>or</u>			
Street Address			City
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2

PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address			City
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:

Fax Number: 866-364-2673

Phone Number: 800-327-1392

3

Department of Vermont Health Access HEPATITIS C PROTEASE INHIBITORS PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:	Genotype:
If requesting prescriber is not a Hepatologist, Gastroenterologist or ID Specialist, has one of these specialties been consulted on this case? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Specialist name: _____ Specialist Type: _____	

Requested Hepatitis C Protease Inhibitor?

Incivek®: 375 mg tablet Victrelis®: 200 mg capsule

Patient is treatment naive? Yes No

If no, previous response to peg-interferon/ribavirin

Null responder Partial responder Relapser

Patient has had previous therapy with Incivek® or Victrelis®? Yes No

If yes, please specify: _____ (agent) ___/___/___ (date) _____ (response)

Most recent HCV-RNA level: _____ IU/mL Date: ___/___/___

Patient has cirrhosis? Yes No

Ribavirin/peg-interferon will be used concomitantly Yes No

Ribavirin/peg-interferon PA form included Yes No

or

Patient has had started Ribavirin/peg-interferon therapy Yes No

If yes, date therapy initiated: ___/___/___

Prescriber Additional Comments:

4

PRESCRIPTION

Incivek®: 375 mg tablet Sig: 750 mg PO TID with food Qty: 168 tablets (28 days)

Victrelis®: 200 mg capsule Sig: 800 mg PO TID with food Qty: 336 capsules (28 days)

Refill X _____ Note: TID is q 7 – 9 hours

**** HCV-RNA levels will be required per protocol (required for certain refills) ****

Deliver product to: Patient's home MD office Clinic

Prescriber's Signature: _____ Date: _____

Hereditary Angioedema Medications

LENGTH OF AUTHORIZATION: initial approval 6 months, subsequent approval 1 year

CRITERIA FOR APPROVAL:

Berinert:

- The diagnosis or indication is **treatment** of an acute Hereditary Angioedema (HAE) attack. (Approval may be granted so that 2 doses may be kept on hand).

Cinryze:

- The diagnosis or indication is **prophylaxis** of Hereditary Angioedema (HAE) attacks.
- The patient has had a documented side effect, allergy, treatment failure or a contraindication to androgen therapy (i.e. danazol). **AND**
- The medication is to be used for the **treatment** of an acute Hereditary Angioedema (HAE) attack. **OR**

Kalbitor:

- The diagnosis or indication is **treatment** of an acute Hereditary Angioedema (HAE) attack. (Approval may be granted so that 2 doses may be kept on hand).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Hereditary Angioedema Medications	
<i>Length of Authorization: initial approval 6 months, subsequent approval 1 year</i>	
NO PA REQUIRED	PA REQUIRED
	Berinert® (human C1 inhibitor) Cinryze® (human C1 inhibitor) <i>(QL = 16 vials/28 days for prophylaxis; 4 vials per fill for acute attacks)</i> Kalbitor® (ecallantide) <i>(QL = 6 vials (2 packs) per fill)</i>

Lipotropics: Bile Acid Sequestrants

LENGTH OF AUTHORIZATION: 3 years

CRITERIA FOR APPROVAL:

Questran^{®*}

- The patient has had a documented intolerance to cholestyramine powder.

Questran Light^{®*}

- The patient has had a documented intolerance to cholestyramine light powder.

Colestid^{®*}

- The patient has had a documented intolerance to colestipol tablets or granules.

Welchol[®]

- If being prescribed for lipid reduction, the patient has had a documented side effect, allergy, or treatment failure to cholestyramine and colestipol.

OR

- If being prescribed for additional improved glycemic control, the patient must have been unable to obtain a satisfactory hemoglobin A1C reduction with metformin and one other oral anti-diabetic agent.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Lipotropics: Bile Acid Sequestrants		<i>Length of Authorization: 3 years</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
CHOLESTYRAMINE† powder (compare to Questran [®]) CHOLESTYRAMINE LIGHT† powder (compare to Questran Light [®]) PREVALITE† powder (cholestyramine light)	Questran ^{®*} powder (cholestyramine) Questran Light ^{®*} powder (cholestyramine light)	
COLESTIPOL† tablets, granules (compare to Colestid [®])	Colestid ^{®*} tablets, granules (colestipol) Welchol [®] (colesevelam)	

Lipotropics: Fibric Acid Derivatives

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Lopid[®]*

- The patient has had a documented intolerance to generic gemfibrozil.

Tricor[®], TriLipix[®]

- The patient has been started and stabilized on either Tricor[®] or TriLipix[®] (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient is taking a statin concurrently.

OR

- The patient has had a documented side effect, allergy, or treatment failure to gemfibrozil.

Antara[®], fenofibrate, fenofibrate micronized, fenofibric acid, Fenoglide[®], Fibracor[®], Lipofen[®], Lofibra[®] and Triglide[®]

- The patient is taking a statin concurrently and has had a documented side effect, allergy, or treatment failure with Tricor[®] or TriLipix[®]. (If a product has an AB rated generic, there must have been a trial with the generic formulation.)

OR

- The patient has had a documented side effect, allergy, or treatment failure to gemfibrozil and Tricor[®] or TriLipix[®]. (If a product has an AB rated generic, there must have been a trial with the generic formulation.)

(Note regarding fibrates: For patients receiving statin therapy, fenofibrate appears less likely to increase statin levels and thus may represent a safer choice than gemfibrozil for coadministration in this group of patients - *Am J Med* 2004;116:408-416)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Lipotropics: Fibric Acid Derivatives

Length of Authorization: 1 year.

Key: † Generic product, *Indicates generic equivalent is available without a PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)

PA REQUIRED

GEMFIBROZIL† (compare to Lopid®) 600 mg

On statin concurrently or after gemfibrozil trial

TRICOR® (fenofibrate nanocrystallized) §
48 mg, 145 mg

Quantity Limit = 1 tablet/day

TRILIPIX (fenofibric acid) §

45 mg, 135 mg delayed release capsule

Quantity Limit = 1 capsule/day

Antara® (fenofibrate micronized) § 43 mg, 130 mg
fenofibrate tablets†(compare to Lofibra® tablets) §
54 mg, 160 mg

fenofibrate micronized capsule†(compare to
Lofibra® capsules) § 67 mg, 134 mg, 200 mg
fenofibric acid § 35 mg, 105 mg

Quantity Limit = 1 capsule/day

Fenoglide® (fenofibrate MeltDose) § 40 mg, 120 mg

Fibricor® (fenofibric acid) § 35 mg, 105 mg

Quantity Limit = 1 capsule/day

Lipofen® (fenofibrate) § 50 mg, 150 mg

Lofibra® (fenofibrate micronized) Capsules § 67mg,
134 mg, 200 mg

Lofibra® (fenofibrate) Tablets § 54 mg, 160 mg

Lopid®* (gemfibrozil) § 600 mg

Triglide® (fenofibrate) § 50 mg, 160 mg

Lipotropics: Nicotinic Acid Derivatives

LENGTH OF AUTHORIZATION: not applicable

CRITERIA FOR APPROVAL: not applicable

Lipotropics: Nicotinic Acid Derivatives	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>Immediate Release Products</u> NIACIN† NIACOR®† (niacin)</p> <p><u>Extended Release Products</u> NIASPAN® (niacin extended release)</p>	

Lipotropics: Statins

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

HIGH POTENCY STATINS

Crestor[®]

- The patient has had a documented side effect, allergy, or contraindication to generic simvastatin.

OR

- The patient has had an inadequate response to a six week trial of simvastatin 40 mg OR requires LDL reduction of $\geq 45\%$

Lipitor[®], Livalo[®]

- The patient has had a documented side effect, allergy, or contraindication to generic simvastatin.

OR

- The patient has had an inadequate response to a six week trial of simvastatin 40 mg OR requires LDL reduction of at least 45%

AND

- The patient has had a documented side effect, allergy or inadequate response to a six week trial of at least 20 mg per day of Crestor[®]

Simvastatin 80 mg Tablets

- The patient has been taking this dose for 12 or more months without evidence of muscle toxicity.

Zocor[®]

- The patient has had documented side effect, allergy, or treatment failure to BOTH generic simvastatin and Crestor[®]

OTHER STATINS

Altoprev[®], Lescol[®], Lescol[®] XL, Mevacor[®], Pravachol[®]

- The patient has had a documented side effect, allergy, or treatment failure to BOTH generic lovastatin and pravastatin.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Lipotropics: Statins

Length of Authorization: 1 year Key: †

Generic product, *Indicates generic equivalent is available without a PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)

PA REQUIRED

HIGH POTENCY STATINS

SIMVASTATIN† (compare to Zocor®) (QL = 1 tablet/day of 5 mg, 10 mg, 20 mg and 40 mg)

Lipitor® (atorvastatin) (QL = 1 tablet/day)
 Livalo (pitavastatin) (QL = 1 tablet/day)
 Simvastatin† 80 mg tablets (compare to Zocor®) (QL = 1 tablet/day)
 Zocor®* (simvastatin) (QL = 1 tablet/day)

AFTER GENERIC SIMVASTATIN TRIAL (6 week trial of simvastatin of 40 mg/day)

CRESTOR® (rosuvastatin calcium) §
 (QL = 1 tablet/day)

OTHER STATINS

LOVASTATIN† (compare to Mevacor®) (QL = 1 tab/day (10 & 20 mg), 2 tab/day (40 mg))

Altoprev® (aka: Altocor®) (lovastatin) (QL = 1 tablet/day)
 Lescol® (fluvastatin) (QL = 1 tablet/day)
 Lescol® XL (fluvastatin XL) (QL = 1 tablet/day)
 Mevacor®* (lovastatin) (QL = 1 tab/day (10 & 20 mg), 2 tabs/day (40 mg))
 Pravachol®* (pravastatin) (QL = 1 tab/day)

PRAVASTATIN† (compare to Pravachol®) (QL = 1 tablet/day)

Note: Please refer to “Lipotropics: Miscellaneous/Combinations” for statin combinations and Lovaza®.

Lipotropics: Miscellaneous/Combinations

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Lovaza[®]

- The patient has been started and stabilized on this medication (Note: samples are not considered adequate justification for stabilization.)
- OR**
- The patient has triglyceride levels > 500 mg/dL
- AND**
- The patient has a documented contraindication, side effect, allergy, or treatment failure to a fibric acid derivative and niacin.

Caduet[®]

- The prescriber must provide a clinically valid reason for the use of the requested medication.

Advicor[®]

- The patient is unable to take the individual drug components separately.

Vytorin[®]

- The patient has had an inadequate response to BOTH generic simvastatin and Crestor[®].
- AND**
- If the request is for Vytorin 10/80, the patient has been taking this dose for 12 or more months without evidence of muscle toxicity.

Zetia[®]

- The patient has a documented side effect, allergy or contraindication (eg. drug interaction) to a statin.
- OR**
- The patient has a diagnosis of homozygous sitosterolemia.
- OR**
- The patient has had an inadequate response to BOTH generic simvastatin and Crestor[®].

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Lipotropics: Miscellaneous/Combination*Length of Authorization: 1 year*

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<u>MISCELLANEOUS</u>	
	Lovaza [®] (omega-3-acid ethyl esters)
<u>CHOLESTEROL ABSORPTION INHIBITORS/COMBINATIONS</u>	
	Vytorin [®] (ezetimibe/simvastatin) (<i>QL = 1 tablet/day</i>) Zetia [®] (ezetimibe) (<i>Qty Limit = 1 tablet/day</i>)
<u>OTHER STATIN COMBINATIONS</u>	
SIMCOR [®] (simvastatin/extended release niacin) (<i>Qty Limit = 1 tablet/day</i>) ±	Advicor [®] (lovastatin/extended release niacin) (<i>Qty Limit = 1 tablet/day</i>) Caduet [®] (atorvastatin/amlodipine) (<i>Qty Limit = 1 tablet/day</i>)

± Recommended to be used only when goal is not met in patients previously having experience with any niacin derivative or statin.

Management of Mental Health Medications

1. Patients on certain existing non-preferred mental health drugs as of 01/01/06 were “grandparented” and their mental health drug use was not subject to the Preferred Drug List (PDL).

Patients of any age who were using:

- antipsychotics,
- antidepressants,
- mood stabilizers,
- and/or CNS Stimulants/ADD/ADHD drugs

were grandfathered so as not to risk destabilization. Changes in therapy or lapses in therapy of greater than 4 (four) months resulted in the application of the PDL.

Use of sedative hypnotics and/or anxiolytics by patients using antipsychotics, antidepressants, mood stabilizers, and/or CNS Stimulants/ADD/ADHD drugs was also grandfathered until such time as there was a change or lapse in the sedative hypnotic/anxiolytic treatment of greater than 4(four) months. If patients end all antipsychotics, antidepressants, mood stabilizers, or CNS Stimulants/ADD/ADHD drug treatment but continue sedative hypnotic or anxiolytic treatment, non-preferred sedative hypnotic or anxiolytic drugs will not be subject to PA for one year from the end of the antipsychotics, antidepressants, mood stabilizers, or CNS Stimulants/ADD/ADHD drug treatment unless there is a change or lapse in the sedative hypnotic/anxiolytic treatment of greater than 4(four) months. In either case, if there is a change or lapse in sedative hypnotic/anxiolytic therapy of greater than 4(four) months, the PDL will apply.

2. The PDL applies to new patients, patients who are prescribed a change in therapy, and patients who have had a lapse in therapy of greater than 4 (four) months.

The PDL represents a clinically effective array of mental health products that are cost effective. The classes include:

- SSRI Antidepressants
- SNRI Antidepressants
- Miscellaneous Antidepressants
- Tricyclic and MAOI Antidepressants
- Atypical Antipsychotics
- Typical Antipsychotics
- Mood Stabilizers (including some anticonvulsants)
- CNS Stimulants/ADD/ADHD Drugs (Antihyperkinesia medications)
- Sedative Hypnotics
- Anxiolytics

3. The PDL also may include FDA maximum recommended adult daily doses.

With some exceptions, prior authorization will be required if FDA maximum recommended daily doses are exceeded by 25%. These FDA maximum recommended daily doses were not applied to current patients on 01/01/06. As part of drug utilization review (DUR) activities, prescribers may be contacted by mail where patients are prescribed quantities above these doses.

4. The prescribing of brands when generic equivalents are available will require prior authorization.

Patients on current therapies (brand where generic equivalent available) were allowed to continue these drugs without prior authorization until October 2, 2006. Prescribers were contacted by mail and provided with lists to assist them in identifying patients who might readily transition to a preferred generic and those who would require a PA. New patients and patients who are prescribed a change in therapy require a PA for the use of a branded drug when a generic equivalent is available. A prior authorization granted for a brand name medication when a generic equivalent exists will expire after one year after which a new PA must be obtained for continuation of the brand.

Miscellaneous: Carbaglu®

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The diagnosis or indication for the requested medication is hyperammonemia due to N-acetylglutamate synthetase (NAGS) deficiency

AND

- The prescriber is a specialist in metabolic disorders (e.g., medical geneticist) or prescriber is in consultation with a specialist

Note: after preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Miscellaneous: Carbaglu®		<i>Length of Authorization: 1 year</i>
NO PA REQUIRED	PA REQUIRED	
	Carbaglu® dispersible tablets (carglumic acid) <i>(Maximum days supply per fill = 14 days)</i>	

Miscellaneous: Elaprase® (Hunter's Syndrome Injectable)

NOTE: Elaprase® must be obtained and billed through our specialty pharmacy vendor, ICORE Healthcare. Please see General Specialty Prior Authorization/Patient Enrollment Form for instructions.

LENGTH OF AUTHORIZATION: 1 year

CLINICAL CONSIDERATIONS:

How supplied: 6 mg glass vials (one vial per package)
Dose: 0.5 mg/kg every week

CRITERIA FOR APPROVAL:

- The diagnosis or indication for the requested medication is Hunter's Syndrome.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of Elaprase® on a **General Specialty Prior Authorization/Patient Enrollment Form.**

This drug must be billed through the OVHA POS prescription processing system using NDC values by our specialty pharmacy vendor, ICORE Healthcare.

J code (J1743) will NOT be accepted in the Medical Benefit.

Miscellaneous; Elaprase®		<i>Length of Authorization: 1 year</i>
NO PA REQUIRED	PA REQUIRED	
		Elaprase® (idursulfase) (<i>QL = calculated weekly dose</i>)

Miscellaneous: Glycopyrrolate

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Cuvposa®:

- The diagnosis or indication for the requested medication is Sialorrhea or a neurologic condition associated with excessive drooling (e.g. cerebral palsy, mental retardation, Parkinson’s disease).

AND

- The dose cannot be obtained from the tablet formulation.

AND

- (For patients >18 years of age) The patient has had a documented side effect, allergy, treatment failure, or a contraindication to scopolamine patches.

Robinul®, Robinul Forte®:

- The patient has had a documented intolerance to generic glycopyrrolate.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Miscellaneous: Glycopyrrolate		<i>Length of Authorization: 1 year</i>
NO PA REQUIRED	PA REQUIRED	
GLYCOPYRROLATE 1 mg, 2 mg tablets (compare to Robinul®, Robinul Forte®)	Cuvposa® oral solution (glycopyrrolate)* Maximum days supply per fill is 30 days Robinul® 1 mg tablet (glycopyrrolate) Robinul® Forte 2 mg tablet (glycopyrrolate)	

Miscellaneous: Lysteda®

LENGTH OF AUTHORIZATION: 1 year

CLINICAL CONSIDERATIONS:

Dose: Lysteda is dosed as two 650 mg tablets three times daily for up to 5 days during menstruation.

CRITERIA FOR APPROVAL:

- The diagnosis or indication is clinically significant heavy menstrual bleeding
- **AND**
- The patient has been started and stabilized on oral tranexamic acid within the previous 360 days
- **OR**
- The patient does not have a contraindication to therapy with oral tranexamic acid (i.e., active thrombotic disease, history of thrombosis/thromboembolism, or an intrinsic risk of thrombosis/thromboembolism), and if oral tranexamic acid is to be used concomitantly with an estrogen containing hormonal contraceptive product, the risks of combination therapy have been discussed with the patient.
- **AND**
- The patient has had a documented side effect, allergy, contraindication, or an inadequate response with at least one oral contraceptive or progestin containing product despite an adequate trial of at least 90 days, or a rationale for why these products cannot be used (e.g. actively attempting to conceive).
- **AND**
- The patient has had a documented side effect, allergy, contraindication, or an inadequate response with at least one regular scheduled (not PRN) NSAID or a rationale for why these products cannot be used (e.g. actively attempting to conceive).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Miscellaneous: Lysteda®		<i>Length of Authorization: 1 year</i>
NO PA REQUIRED	PA REQUIRED	
	Lysteda® tablets (tranexamic acid) <i>Quantity limit = 30 tablets/28 days</i>	

Miscellaneous: Nuedexta®

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The diagnosis or indication is pseudobulbar affect (PBA) secondary to amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS)
- AND**
- The patient does not have any contraindications to use:

Concomitant use with quinidine, quinine, or mefloquine
History of quinidine, quinine or mefloquine-induced thrombocytopenia, hepatitis
MAOI use within 14 days of starting Nuedexta
Prolonged QT interval, congenital long QT syndrome, Torsades de Pointes, or heart failure
Complete atrioventricular (AV) block or patients at high risk for AV block
Concomitant use with drugs that prolong QT interval and are metabolized by CYP2D6 (eg. thioridazine, pimozide)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Miscellaneous: Nuedexta®		<i>Length of Authorization: 1 year</i>
NO PA REQUIRED	PA REQUIRED	
	Nuedexta® capsules (dextromethorphan/quinidine) <i>Quantity limit = 2 capsules/day</i>	

Miscellaneous: Samsca® (for Hyponatremia)

LENGTH OF AUTHORIZATION: 1 month initially, subsequent approvals up to 1 year

CLINICAL CONSIDERATIONS:

How supplied: 15 or 30 mg tablets

Dose: Initial, 15 mg once daily;

After at least 24 hours, titrate dose up to 30 mg once daily to a maximum of 60 mg once daily to achieve desired sodium level;

Maximum dose, 60 mg once daily

Patients should be in a hospital for initiation and reinitiation of tolvaptan therapy to evaluate its therapeutic response. Doses can be administered without regard to meals. Avoid fluid restriction during the first 24 hours of therapy. Patients taking tolvaptan should be advised to continue ingesting fluids in response to thirst.

Initiate and Reinitiate in a Hospital and Monitor Serum Sodium

<p>Samsca® should be initiated and reinitiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable.</p>
--

CRITERIA FOR APPROVAL:

- The agent is being used for the treatment of euvolemic or hypervolemic hyponatremia
AND
- Despite optimal fluid restriction, the patient's serum sodium < 120 mEq/L or the patient is symptomatic with a serum sodium < 125 mEq/L.
AND
- The treatment will be initiated or is being reinitiated in a hospital setting where serum sodium can be monitored

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Miscellaneous: Samsca®	<i>Length of Authorization: 1 month initially, subsequent approvals up to 1 year</i>
NO PA REQUIRED	PA REQUIRED
	<p>Samsca® tablets (tolvaptan) <i>Quantity limit = 15 mg tablets (1 tablet/day), 30 mg tablets (2 tablets/day)</i></p>

Miscellaneous: Soliris® (Paroxysmal Nocturnal Hemoglobinuria Injectable)

LENGTH OF AUTHORIZATION: initial approval 3 months, subsequent approval 1 year

CLINICAL CONSIDERATIONS:

How supplied: 10 mg/mL (30 mL)

Dose: 600 mg IVF every 7 days x 4 weeks, followed by 900 mg IVF 7 days later and 900 mg IVF every 14 days thereafter

CRITERIA FOR APPROVAL:

- The patient has a diagnosis of paroxysmal nocturnal hemoglobinuria documented by flow cytometry.
AND
- The patient has received the meningococcal vaccine prior to therapy.
AND
- The request is for a quantity limit of 20 vials (of 300 mg/30 mL) total with initial approval duration of 3 months and a quantity limit of 6 vials per 28 days with recertification approvals.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.
- ✓ All requests for eculizumab (whether billed through the pharmacy or medical benefit (J1300)) require Prior Authorization through the MedMetrics Clinical Call Center.

Miscellaneous: Soliris®

Length of Authorization: initial approval 3months, subsequent approval 1 year

NO PA REQUIRED

PA REQUIRED

Soliris® (eculizumab) (*Quantity Limit = 20 vials total/12 weeks initially; 6 vials/28 days subsequently*)

Miscellaneous: Somatuline® (Acromegaly Injectable)

LENGTH OF AUTHORIZATION: 1 year

CLINICAL CONSIDERATIONS:

How supplied: 60, 90 or 120 mg pre-filled syringes

Dose: initial dose is 90 mg deep subcutaneous every 4 weeks x 3 months, then dose adjusted to between 60 mg and 120 mg every 4 weeks based on lab values and symptoms

CRITERIA FOR APPROVAL:

- The diagnosis or indication for the requested medication is Acromegaly.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

This drug must be billed through the DVHA POS prescription processing system using NDC values.

J code or other code will NOT be accepted for processing through medical benefit.

Miscellaneous: Somatuline®		<i>Length of Authorization: 1 year</i>
NO PA REQUIRED	PA REQUIRED	
		Somatuline® Depot Injection (lanreotide) (<i>QL = 0.2 ml/28 days (60 mg syringe), 0.3 ml/28 days (90 mg syringe) and 0.5 ml/28 days (120 mg syringe)</i>)

Miscellaneous: Xenazine® (for Huntington's Disease with chorea)

LENGTH OF AUTHORIZATION: 1 month initially, subsequent approvals up to 1 year

CLINICAL CONSIDERATIONS:

How supplied: 12.5 or 25 mg tablets

Dose: initial dose is 12.5 mg/day increasing by 12.5 mg/day at weekly intervals

CRITERIA FOR APPROVAL:

- The diagnosis or indication for the requested medication is Huntington's disease with chorea.

AND

- Age \geq 18 years.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Miscellaneous: Xenazine® <i>subsequent approvals up to 1 year</i>	<i>Length of Authorization: 1 month initially,</i>
NO PA REQUIRED	PA REQUIRED
	Xenazine® tablets (tetrabenazine) <i>Quantity limit = 50 mg/day at initial approval (12.5 mg tablets ONLY), up to 100 mg/day at subsequent approvals (12.5 mg or 25 mg tablets)</i> <i>Maximum 1 month supply per fill</i>

Mood Stabilizers (See also Anticonvulsants)

LENGTH OF AUTHORIZATION: Duration of Need*

CRITERIA FOR APPROVAL:

Lithobid®:

- The patient has had a documented side effect, allergy, or treatment failure with the generic equivalent of the requested medication.

Equetro®:

- The patient has had a documented side effect, allergy, or treatment failure with a carbamazepine product from the anticonvulsant therapeutic drug category

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

After a 4-month lapse in use of a non-preferred agent, or if there is a change in therapy, a look-back through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 160 for a description of the management of mental health drugs.

Mood Stabilizers		<i>Length of authorization: Duration of Need*</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
LITHIUM CARBONATE† (formerly Eskalith®) LITHIUM CARBONATE SR† (compare to Lithobid®, formerly Eskalith CR®) LITHIUM CITRATE SYRUP†	Equetro® (carbamazepine SR) Lithobid®* (lithium carbonate SR)	

* For brand name products with generic equivalents, length of authorization is 1 year.

Mucosal Coating Agents

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

MuGard

- Patient is receiving radiation and/or chemotherapy.
- AND**
- The patient has had a documented side effect, allergy or treatment failure with at least one oral mucosal coating agent (e.g. aluminum hydroxide suspension, Mylanta®) or a topical anesthetic (e.g. viscous lidocaine or diphenhydramine solutions) or combinations of similar agents.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Mucosal Coating Agents		<i>Length of Authorization: 6 months</i>
Key: † Generic product		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
ALUMINUM HYDROXIDE† (formerly Amphojel®) GELCLAIR® (povidone sodium hyaluronate glycyrrhetic acid gel) MYLANTA/DIPHENYDRAMINE/LIDOCAINE VISCOUS (aka “Magic Mouthwash”) Or other similar single or combination products	MuGard® (mucoadhesive oral wound rinse) <i>(QL = 4 bottles/month)</i>	

Multiple Sclerosis Medications

NOTE: Multiple Sclerosis Self-Injectables (Avonex[®], Betaseron[®], Copaxone[®], Extavia[®] and Rebif[®]) must be obtained and billed through our specialty pharmacy vendor, ICORE Healthcare. Please see Multiple Sclerosis Patient Enrollment/Order Form for instructions. ICORE Healthcare will not be supplying Tysabri[®] at this time – please continue to obtain through your usual supplier. Gilenya[®] must be obtained and billed through our specialty pharmacy vendor, ICORE Healthcare. Please see Gilenya[®] Patient Enrollment/PA Form for instructions. ICORE Healthcare will not be supplying Ampyra[®] at this time.

LENGTH OF AUTHORIZATION: Initial PA of 3 months, and 12 months thereafter if medication is well tolerated. Re-evaluate every 12 months.

CRITERIA FOR APPROVAL:

Ampyra[®]

Patient has a diagnosis of multiple sclerosis.

AND

Patient age \geq 18 years.

Extavia[®]

Patient has a diagnosis of multiple sclerosis.

AND

The provider provides a clinical reason why Betaseron cannot be prescribed.

Gilenya[®]

Patient has a diagnosis of relapsing multiple sclerosis.

AND

The patient has had a documented side effect, allergy, inadequate response, or contraindication to at least one preferred self-injectable MS drug.

AND

Patient has tolerated first dose under observation.

Tysabri[®]

Patient has a diagnosis of relapsing multiple sclerosis and has already been stabilized on Tysabri[®].

OR

Diagnosis is relapsing multiple sclerosis and the patient has a documented side effect, allergy, treatment failure, or contraindication to at least two preferred drugs.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of Ampyra[®] or Tysabri[®] on a **General Prior Authorization Request Form**.
- ✓ Document clinical information for **Gilenya[®]** on its **Prior Authorization/Patient Enrollment Form**

Multiple Sclerosis Medications

Length of authorization: Initial PA of 3 months; 12 months thereafter

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>INJECTABLES</u></p> <p><u>Interferons</u> AVONEX[®] (interferon beta-1a) BETASERON[®] (interferon beta-1b) REBIF[®] (interferon beta-1a)</p> <p><u>Other</u> COPAXONE[®] (glatiramer) (<i>QL = 1 kit/30 days</i>)</p> <p><u>ORAL</u></p>	<p>Extavia[®] (interferon beta-1b)</p> <p>Tysabri[®] (natalizumab)</p> <p>Ampyra[®] (dalfampridine) tablet (<i>QL = 2 tablets/day, maximum 30 day supply per fill</i>)</p> <p>Gilenya[®] (fingolimod) capsule (<i>QL = 1 capsule/day, maximum 28 day supply per fill</i>)</p>



MULTIPLE SCLEROSIS SELF INJECTABLES - Patient Enrollment/Order Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address		City	
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address		City	
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

**3 Department of Vermont Health Access
 PRESCRIPTION
 MULTIPLE SCLEROSIS SELF INJECTABLES**

Patient Diagnosis: _____

Product:

- Avonex 30 mcg/0.5 ml Prefilled Syringe (4 per box)
- Avonex 30 mcg Kit (Single Dose Vials) (4 per box)
- Betaseron 0.3 mg Prefilled Syringe
- Copaxone 20 mg Prefilled Syringe (30 per kit)
- Rebif Titration Pack X 1 (**Therapy initiation ONLY-No Refills**) (contains 6 - 8.8 mcg and 6 – 22 mcg Prefilled Syringes)
- Rebif 22 mcg/0.5 ml Prefilled Syringes
- Rebif 44 mcg/0.5 ml Prefilled Syringes

(Please Note: This form not to be used for Tysabri PA request or ordering)

Quantity:	Refills:
------------------	-----------------

Dose / Route/ Frequency Instructions (Sig): _____

Deliver product to: Patient's home MD office Clinic

Needles/syringes: quantity sufficient for drug supply with refills as above

Prescriber's Signature: _____ **Date:** _____

Nutritionals: Enteral (Oral)

LENGTH OF AUTHORIZATION: 6 months

CRITERIA FOR APPROVAL:

Caloric and/or protein intake is not obtainable through regular liquefied or pureed foods.

AND

Requested nutritional supplement will be taken by mouth (not administered via tube feeding)

AND

Patient has experienced unplanned weight loss or is extremely low weight (see further definitions below)

OR

Patient has demonstrated nutritional deficiency identified by low serum protein levels (albumin or pre-albumin levels to be provided).

UNPLANNED WEIGHT LOSS/LOW WEIGHT

Adult:

- involuntary loss of $\geq 10\%$ of body weight within 6 months
- involuntary loss of $\geq 5\%$ of body weight within 1 month
- loss of $\geq 2\%$ of body weight within one week
- BMI of $\leq 18.5 \text{ kg/m}^2$

Elderly: (≥ 65):

- involuntary loss of $\geq 10\%$ of body weight within 6 months
- involuntary loss of $\geq 5\%$ of body weight within 3 months
- loss of $\geq 2\%$ of body weight within one month

Children:

- $< 70\%$ of expected weight-for-height
- $< 85\%$ of expected height-for-age
- mid-upper arm circumference/head circumference ratio < 0.25

LIMITATIONS:

Infant formulas are not covered under the pharmacy benefit.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **Nutritionals Prior Authorization Request Form**.

Nutritionals: Enteral (Oral)		<i>Length of authorization: 6 months</i>
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
	All Note: Nutritional supplements administered via tube feeds are provided through the Medical Benefit. Please see guidelines at http://ovha.vermont.gov/forproviders/copy_of_GOC13.pdf	



Department of Vermont Health Access
 312 Hurricane Lane, Suite 201
 Williston, Vermont 05495

Agency of Human Services

~NUTRITIONALS ~
ORAL NUTRITION TAKEN BY MOUTH
 Prior Authorization Request Form

Effective February 2002, Vermont Medicaid established coverage limits and criteria for prior authorization of Nutritional supplements. These limits and criteria are based on concerns about safety and appropriate use. In order for beneficiaries to receive coverage for nutritionals, it will be necessary for the prescriber to telephone or complete and fax this form to MedMetrics Health Partners. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name: _____
 Phone #: _____
 Fax #: _____
 Address: _____

Beneficiary:

Name: _____
 Medicaid ID #: _____
 Date of Birth: _____ Sex: _____
 Contact Person at Office: _____

Diagnosis: _____

Baseline: Date: ___/___/___ Height: _____ Weight: _____ BMI: _____

Current: Date: ___/___/___ Height: _____ Weight: _____ BMI: _____

Children: Mid-Upper Arm Circumference: _____ Head Circumference: _____

Laboratory Values: Date: ___/___/___ Albumin: _____ Pre-Albumin: _____

Answer the following questions:

Caloric/protein intake is <u>not</u> obtainable through regular liquefied or pureed foods.	<input type="checkbox"/> Agree <input type="checkbox"/> Disagree
Requested nutritional supplement will be taken by <u>mouth</u> (not administered via tube feeding)	<input type="checkbox"/> Yes <input type="checkbox"/> No
Oral nutritional supplement is being requested due to:	<input type="checkbox"/> Unplanned weight loss (see complete definition by age in clinical criteria manual) <input type="checkbox"/> Low serum protein levels (nutritional deficiency as defined by albumin or pre-albumin levels)
Underlying cause of unplanned weight loss or low serum protein levels: Circle or describe specifics: <ul style="list-style-type: none"> ▪ Increased metabolic need resulting from severe trauma (i.e.: burns, infection, major bone fractures) ▪ Malabsorption syndrome (as related to cystic fibrosis, renal disease, short gut syndrome, Crohn's disease and other unspecified disorders of the gut) 	<input type="checkbox"/> Yes <input type="checkbox"/> No
	<input type="checkbox"/> Yes <input type="checkbox"/> No

<ul style="list-style-type: none"> ▪ Nutritional wasting due to chronic disease (i.e.: cancer, AIDS, conditions resulting in dysphagia, pulmonary insufficiency, renal disease) 	<input type="checkbox"/> Yes <input type="checkbox"/> No
<ul style="list-style-type: none"> ▪ Other: Explain: _____ _____ 	<input type="checkbox"/> Yes <input type="checkbox"/> No
Additional clinical information to support PA request:	

Requested Supplement: _____
Strength & Frequency: _____
Anticipated duration of supplementation: _____

Prescriber Signature: _____ **Date of this request:** _____



ORAL ONCOLOGY/SELECT ADJUNCT - Patient Enrollment/Order Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address			City
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address			City
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

**3 Department of Vermont Health Access
PRESCRIPTION
ORAL ONCOLOGY/SELECT ADJUNCT**

Patient Diagnosis: _____

BSA(m2) _____ Patient height (cm) _____ Patient weight(kg) _____

Maintenance Therapy # of Refills _____

Cycle Specific Therapy NO REFILLS Cycle # _____

Treatment / Dosage Change Reason : Toxicity Progression of Disease

Change in BSA Other: _____

MEDICATION	Normalized Dose	Strength/ Frequency/ Route of Administration	QTY
<input type="checkbox"/> ARIMIDEX*			
<input type="checkbox"/> AROMASIN*			
<input type="checkbox"/> CASODEX			
<input type="checkbox"/> FEMARA*			
<input type="checkbox"/> GLEEVEC			
<input type="checkbox"/> HEXALEN			
<input type="checkbox"/> LUPRON DEPOT*			
<input type="checkbox"/> MERCAPTOPYRINE*			
<input type="checkbox"/> MESNEX			
<input type="checkbox"/> NEULASTA*			
<input type="checkbox"/> NEUPOGEN*			
<input type="checkbox"/> SPRYCEL			
<input type="checkbox"/> SUTENT			
<input type="checkbox"/> TARCEVA			
<input type="checkbox"/> TEMODAR			
<input type="checkbox"/> TRETINOIN			
<input type="checkbox"/> VESANOID			
<input type="checkbox"/> XELODA			
Other:			

Additional RX Instructions: _____

Prescriber's Signature: _____ Date: _____

* Not required to use ICORE

Ophthalmics: Antibiotics

LENGTH OF AUTHORIZATION: duration of therapy requested

CRITERIA FOR APPROVAL:

Aminoglycosides:

- **Single Agent:** The patient has had a documented side effect, allergy or treatment failure with at least one preferred ophthalmic aminoglycoside. (If a product has an AB rated generic, there must have also been a generic formulation)
- **Combination Product:** The patient has had a documented intolerance with generic tobramycin/dexamethasone ophthalmic.

Macrolides:

- The patient has had a documented side effect, allergy or treatment failure with generic erythromycin. (If a product has an AB rated generic, there must have also been a trial of the generic formulation)

Miscellaneous Antibiotics:

- The patient has had a documented side effect, allergy or treatment failure with at least TWO preferred ophthalmic miscellaneous antibiotics. (If a product has an AB rated generic, there must have also been a trial of the generic formulation)

Quinolones:

- The patient has had a documented side effect, allergy or treatment failure with ciprofloxacin or ofloxacin.

AND

- If the request is for Quixin, the patient also has a documented intolerance to generic levofloxacin 0.5 %.

OR

- The request is for Vigamox or Zymar as part of a regimen to prevent postoperative infection in patients receiving any ophthalmologic surgery.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Ophthalmics: Antibiotics

Length of Authorization: duration of therapy requested

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>QUINOLONES</u> CIPROFLOXACIN HCL† (compare to Ciloxan®) OFLOXACIN† (compare to Ocuflor®)</p>	Besivance® (besifloxacin) Ciloxan®*(ciprofloxacin) Iquix® (levofloxacin 1.5 %) (preservative free) levofloxacin† 0.5 % (compare to Quixin®) Moxeza® (moxifloxacin 0.5%) (preservative free) Ocuflor®*(ofloxacin) Quixin® (levofloxacin 0.5 %) Vigamox® (moxifloxacin 0.5%) (preservative free) Zymar® (gatifloxacin 0.3%) Zymaxid® (gatifloxacin 0.5%)
<p><u>MACROLIDES</u> ERYTHROMYCIN† ROMYCIN† (erythromycin)</p>	Azasite® (azithromycin) All other brands
<p><u>AMINOGLYCOSIDES</u> <u>Single Agent</u> AK-TOB† (tobramycin) GENOPTIC† (gentamicin) GENTAK† (gentamicin) GENTAMICIN† TOBRAMYCIN † sol (compare to Tobrex®)</p> <p><u>Combination</u> TOBRAMYCIN W/DEXAMETHASONE† (compare to Tobradex®)</p>	Tobrex® sol* (tobramycin) Tobrex® gel (tobramycin) Tobradex®* (tobramycin/dexamethasone) TobraDex ST® (tobramycin/dexamethasone) Zylet® (tobramycin/loteprednol) Pred-G® (gentamicin/prednisolone) All other brands
<p><u>MISCELLANEOUS</u> <u>Single Agent</u> BACITRACIN SULFACETAMIDE SODIUM (compare to Bleph-10®)</p> <p><u>Combination</u> AK-POLY-BAC† (bacitracin/polymyxin) BACITRACIN ZINC W/POLYMYXIN B (compare to Polysporin®) NEOMYCIN/POLYMYXIN W/BACITRACIN (compare to Neosporin®) NEOMYCIN/POLYMYXIN W/DEXAMETHASONE (compare to Maxitrol®) NEOMYCIN/POLYMYXIN W/GRAMICIDIN (compare to Neosporin®) NEOMYCIN/POLYMYXIN W/HYDROCORTISONE NEOMYCIN/POLYMYXIN/BACITRACIN/HYDROCORTISONE POLYMYXIN B W/TRIMETHOPRIM (Polytrim®) SULFACETAMIDE W/PREDNISOLONE ACETATE (compare to Blephamide®) SULFACETAMIDE W/PREDNISOLONE SOD PHOSPHATE</p>	Bleph-10®* (sulfacetamide) All other brands Blephamide® (sulfacetamide/prednisolone acetate) Maxitrol®* (neomycin/polymyxin/dexamethasone) Neosporin®* (neomycin/polymyxin/gramicidin or (neomycin/polymyxin/bacitracin) Poly-pred® (neomycin/polymyxin B/prednisolone acetate) Polysporin®* (bacitracin/polymyxin B) Polytrim®* (polymyxin B/trimethoprim) All other brands

Ophthalmics: Antihistamines

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Pataday[®]/Patanol[®]

- The patient has had a documented side effect, allergy, or treatment failure to ketotifen.

Azelastine, Bepreve[®], Elestat[®], Epinastine, Optivar[®], Zaditor[®] RX

- The patient has had a documented side effect, allergy, or treatment failure to Pataday[®] or Patanol[®].
- If the product has a generic equivalent, the patient must also have had a documented intolerance to the generic equivalent.

Lastacaft[®], Emadine[®]

- The patient is pregnant and the diagnosis is allergic conjunctivitis

OR

- The patient has had a documented side effect, allergy, or treatment failure to ketotifen.

AND

- The patient has had a documented side effect, allergy, or treatment failure to Patanol[®]/Pataday[®]

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Ophthalmics: Antihistamines		<i>Length of Authorization: 1 year</i>
Key: † Generic product. § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
KETOTIFEN† 0.025 % (eg. Alaway [®] , Zaditor [®] OTC, others) <i>(QL = 1 bottle/month)</i> After trial of ketotifen 0.025 % PATADAY [®] § (olopatadine 0.2%)/PATANOL [®] § (olopatadine 0.1%) <i>(QL = 1 bottle/month)</i>	Azelastine † (compare to Optivar [®]) <i>(QL = 1 bottle/month)</i> Bepreve [®] (bepotastine besilate) <i>(QL = 1 bottle/month)</i> Elestat [®] (epinastine) <i>(QL = 1 bottle/month)</i> Epinastine† (compare to Elestat [®]) <i>(QL = 1 bottle/month)</i> Emadine [®] (emedastine) <i>(QL = 2 bottles/month)</i> Lastacaft [®] (alcaftadine) <i>(QL = 1 bottle/month)</i> Optivar [®] (azelastine) <i>(QL = 1 bottle/month)</i> Zaditor [®] RX (ketotifen 0.025 %) <i>(QL = 1 bottle/month)</i>	

Ophthalmics: Corticosteroids: Topical

LENGTH OF AUTHORIZATION: up to 3 months

CRITERIA FOR APPROVAL:

- The patient has had a documented side effect, allergy, or treatment failure with one preferred generic ophthalmic corticosteroid. (If a product has an AB rated generic, there must have been a trial of the generic formulation)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Ophthalmics: Corticosteroids: Topical		<i>Length of Authorization: up to 3 months</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
DEXAMETHASONE SODIUM PHOSPHATE 0.1% Sol† FLUOROMETHOLONE 0.1% S† PREDNISOLONE ACETATE 1% S†	Alex® (loteprednol) 0.2% S Durezol® (difluprednate) 0.05% E FML® (fluorometholone) 0.1% O FML Forte® (fluorometholone) 0.25% S FML Liquifilm®/Flarex® (fluorometholone) 0.1% S Lotemax® (loteprednol) 0.5% S Pred Forte®/Omnipred® (prednisolone acetate) 1% S Pred Mild® (prednisolone acetate) 0.12% S Vexol® (rimexolone) 1% S All other brands	

E=emulsion, S=suspension, Sol=solution

Ophthalmics: Glaucoma Agents / Miotics

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

ALPHA 2 ADRENERGIC AGENTS

- The patient has had a documented side effect, allergy or treatment failure with at least one preferred ophthalmic alpha 2 adrenergic agent. If the request is for brimonidine tartrate 0.15%, the patient must have a documented intolerance of brand name Alphagan P 0.15%.

BETA BLOCKERS

- The patient has had a documented side effect, allergy or treatment failure with at least one preferred ophthalmic beta blocker.

PROSTAGLANDIN INHIBITORS (Lumigan, Travatan, and Travatan Z)

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy or treatment failure with a preferred beta blocker.

PROSTAGLANDIN INHIBITORS (Latanoprost, Xalatan)

- The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)

OR

- The patient has had a documented side effect, allergy or treatment failure with a preferred ophthalmic beta blocker.

AND

- The patient has had a documented side effect, allergy or treatment failure with Lumigan and Travatan/Travatan Z.

AND

- If the request is for Latanoprost, the patient has a documented intolerance to the brand product.

CARBONIC ANHYDROUS INHIBITORS

Single Agent:

- The patient has had a documented side effect, allergy or treatment failure with a preferred carbonic anhydrous inhibitor.

Combination Product:

- The patient has had a documented intolerance to the generic equivalent product.

MISCELLANEOUS

- The patient has had a documented side effect, allergy or treatment failure with a preferred miscellaneous ophthalmic agent. If a product has an AB rated generic, there must have also been a trial of the generic formulation)

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Ophthalmics: Glaucoma Agents / Miotics

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<u>ALPHA 2 ADRENERGIC</u>	
<p><u>Single Agent</u> ALPHAGAN P[®] 0.1 %, 0.15 % (brimonidine tartrate) BRIMONIDINE TARTRATE† 0.2 % (formerly Alphagan[®])</p> <p><u>Combination</u> COMBIGAN[®] (brimonidine tartrate/timolol maleate)</p>	<p>apraclonidine† (compare to Iopidine[®]) (no PA required for patients ≤ 10 years of age) brimonidine tartrate 0.15 % † (compare to Alphagan P[®]) Iopidine[®] (apraclonidine) (no PA required for patients ≤ 10 years of age)</p>
<u>BETA BLOCKERS</u>	
<p>BETAXOLOL HCL† (compare to Betoptic[®]) BETOPTIC S[®] (betaxolol suspension) CARTEOLOL HCL† (compare to Ocupress[®]) LEVOBUNOLOL HCL† (compare to Betagan[®]) METIPRANOLOL† (compare to Optipranolol[®]) TIMOLOL MALEATE† (compare to Istalol[®], Timoptic[®]) TIMOLOL MALEATE †gel (compare to Timotic XE[®])</p>	<p>Betagan^{®*} (levobunolol) Betimol[®] (timolol) Istalol^{®*} (timolol) Optipranolol^{®*} (metipranolol) Timoptic^{®*} (timolol maleate) Timoptic XE^{®*} (timolol maleate gel)</p>
<u>PROSTAGLANDIN INHIBITORS</u>	
<p><i>NOTE: COVERAGE OF A 'PREFERRED' PI AGENT IS CONTINGENT UPON A 1ST-LINE TRIAL OF AT LEAST ONE PREFERRED BETA-BLOCKER.. COVERAGE OF A 'NON-PREFERRED' PI AGENT IS CONTINGENT UPON A SIMILAR FIRST-LINE TRIAL <u>AS WELL AS</u> A FAILED TRIAL OF BOTH LUMIGAN AND TRAVATAN/TRAVATAN Z.</i></p>	
<p>LUMIGAN[®] 0.01 %/0.03 % (bimatoprost) § TRAVATAN[®]/TRAVATAN Z[®] (travoprost) §</p>	<p>Latanoprost† (compare to Xalatan[®]) Xalatan[®] (latanoprost)</p>
<u>CARBONIC ANHYDROUS INHIBITORS</u>	
<p><u>Single Agent</u> DORZOLAMIDE 2 % (compare to Trusopt[®])</p> <p><u>Combination</u> DORZOLAMIDE w/TIMOLOL (compare to Cosopt[®])</p>	<p>Azopt[®] (brinzolamide 1%) Trusopt^{®*} (dorzolamide 2%)</p> <p>Cosopt^{®*} (dorzolamide w/timolol)</p>
<u>MISCELLANEOUS</u>	
<p>DIPIVEFRIN HCL† (compare to Propine[®]) ISOPTO[®] CARBACHOL (carbachol) ISOPTO[®] CARPINE (pilocarpine) PILOCARPINE HCL† (formerly Pilocar[®]) PILOPINE[®] (pilocarpine) PHOSPHOLINE IODIDE[®] (echothiophate) PROPINE[®] (dipivefrin)</p>	<p>Miochol-E[®] (acetylcholine) Miostat[®] (carbachol)</p>

Ophthalmics: Immunomodulators

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The patient has a diagnosis of moderate to severe keratoconjunctivitis sicca (dry eye syndrome)

AND

- The patient has had a documented side effect, allergy, or treatment failure to an artificial tear product.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Ophthalmics: Immunomodulators		<i>Length of Authorization: 1 year</i>
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
	Restasis [®] (cyclosporine ophthalmic emulsion) 0.05% (<i>QL=60 vials per 30 days</i>).	

Ophthalmics: Mast Cell Stabilizers

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The patient has had a documented side effect, allergy, or treatment failure with generic cromolyn sodium.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Ophthalmics: Mast Cell Stabilizers		<i>Length of Authorization: 1 year</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
CROMOLYN SODIUM † (compare to Crolo [®] m)	Alamast [®] (pemirolast potassium) Alocril [®] (nedocromil sodium) Alomide [®] (lodoxamide) Crolo [®] m* (cromolyn sodium)	

Ophthalmics: Non-Steroidal Anti-inflammatory Drugs (NSAIDS)

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Acuvail®

- The patient has had a documented side effect, allergy, or treatment failure to Acular® or Acular LS®

OR

- The patient has a documented hypersensitivity to the preservative benzalkonium chloride.

Bromfenac, Diclofenac, Nevanac®, Voltaren®, Xibrom®,

- The patient has had a documented side effect, allergy, or treatment failure to Acular® or Acular LS®. In addition, if a product has an AB rated generic, there must have also been a trial of the generic formulation.

Ketorolac 0.4 %/0.5 %

- The patient has had a documented intolerance to brand Acular®/Acular LS® ophthalmic solution.

Ocufen®

- The patient has had a documented intolerance to generic flurbiprofen ophthalmic solution.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Ophthalmics: NSAIDs		<i>Length of Authorization: 1 year</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
ACULAR® (ketorolac 0.5% ophthalmic sol.) ACULAR LS® (ketorolac 0.4% ophthalmic sol.) FLURBIPROFEN 0.03% ophthalmic sol. † (compare to Ocufen®)	Acuvail (ketorolac 0.45 %) Ophthalmic Solution <i>(Quantity Limit = 30 unit dose packets/15 days)</i> Bromfenac † 0.09 % ophthalmic sol (compare to Xibrom®) Diclofenac† 0.1% ophthalmic sol (compare to Voltaren®) Ketorolac † 0.4 % ophthalmic sol (compare to Acular LS®) Ketorolac † 0.5 % ophthalmic sol (compare to Acular®) Nevanac® ophthalmic susp. (nepafenac 0.1%) Ocufen®* ophthalmic sol. (flurbiprofen 0.03%) Voltaren® (diclofenac 0.1% ophthalmic sol.) Xibrom® ophthalmic sol. (bromfenac 0.09%)	

Otic: Anti-Infectives

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Cetraxal[®]

- The patient has a documented side effect, allergy, or treatment failure to one of the following: any generic neomycin/polymyxin B/hydrocortisone product, Ciprodex[®] otic suspension, or generic ofloxacin otic solution.

Cipro-HC[®], Coly-Mycin S[®], Cortisporin TC[®]

- The patient has had a documented side effect, allergy, or treatment failure to neomycin/polymyxin B sulfate/hydrocortisone and one other preferred product.

Cortisporin[®] Otic, :

- The patient has had a documented side effect, allergy, or treatment failure to the generic product.

Acetasol HC, Acetic Acid/Hydrocortisone[†], Vosol HC[®], Auralgan[®], Myoxin, Otic Care[®], Otic Edge[®], PR Otic[®], Treagan[®], TriOxin[®], Zinotic[®]/Zinotic ES[®] :

- The patient has had a documented side effect, allergy, or treatment failure to at least TWO preferred otic anti-infectives.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Otic: Anti-Infectives

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>Anti-infective Single Agent</u></p> <p>OFLOXACIN† 0.3% Otic Soln (previously Floxin®)</p>	<p>Cetraxal (ciprofloxacin 0.2%) otic solution (Quantity limit = 14 unit dose packages/7 days)</p>
<p><u>Anti-infective/Corticosteroid Combination</u></p> <p>CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%) otic suspension</p> <p>NEOMYCIN/POLYMYXIN B SULFATE/HYDROCORTISONE† (compare to Cortisporin otic®)</p> <p>CORTOMYCIN† (neomycin/polymyxin B sulfate/hydrocortisone) Otic soln, susp</p>	<p>Cipro-HC® (ciprofloxacin 0.2%/hydrocortisone 1%) otic suspension</p> <p>Coly-Mycin S®/Cortisporin TC® (neomycin/colistin/thonzium/hydrocortisone)</p> <p>Cortisporin otic®* (neomycin/polymyxin B sulfate/hydrocortisone) otic solution/suspension</p>
<p><u>Miscellaneous Agents</u></p> <p>ACETIC ACID† Otic soln</p> <p>ACETIC ACID-ALUMINUM ACETATE† Otic soln</p> <p>VOSOL® (Acetic Acid 2%) Otic soln</p>	<p>Acetasol HC† (acetic acid 2%/hydrocortisone 1% otic soln)</p> <p>Acetic Acid/Hydrocortisone† Otic Soln</p> <p>Auralgan®/Otic Care®/ Otic Edge®/PR Otic®/Treagan® (acetic acid/antipyrine/benzocaine/polycosanol)</p> <p>TriOxin®/ Myoxin (benzocaine/chloroxylenol/hydrocortisone susp)</p> <p>Vosol HC® (acetic acid 2%/hydrocortisone 1% otic soln)</p> <p>Zinotic®/Zinotic ES® (chloroxylenol/glycerin/pramoxine/zinc acetate)</p>

Managed on Preferred Drug List (PDL) <small>Refer to PDL categories listed below for details</small>	Limited to Generics Only	Class Not Covered
Anti-diabetics: Insulin	Analgescics, Oral	Alternative Medicines
Analgescics: NSAIDs	Antacids	Analgescics - Topical
Anti-Obesity Agents (All*)	Antidiarrheals	Anesthetics - Local, Topical & Oral
Cough and Cold Preparations	Antiemetics	Antiflatulents
Acne Drugs: Topical Anti-infectives	Antipruritics - Topical	Antihistamines -Topical
Dermatological Agents: Antivirals: Topical	Antiseptics, Topical (Chlorine/Dioxide)	Anti-infectives-Throat
Dermatological Agents: Corticosteroids	Decongestants, Nasal & Oral	Antiseborrheic Products
Dermatological Agents: Antifungals: Topical	Digestive Enzymes (example: Acidophilus)	Antiseptics - Mouth/Throat
Dermatological Agents: Antibiotics: Topical	Emollient/Keratolytic/Antimicrobial Agents	Antiseptics & Disinfectives
Dermatological Agents: Scabicides and Pediculocides	Fluoride Dental Products	Bulk Chemicals
Diabetic Testing Supplies	Glucosamine-Chondroitin	Charcoal Antibate
Gastrointestinals: Histamine-2 Receptor Antagonists	Hematopoietic Agents - Folic Acid/Folates	Contact Lens Solution
Gastrointestinals: Proton Pump Inhibitors	Iron Preparations - Ferrous Sulfate/Ferrous Gluconate	Depigmenting Agents
Nutritionals, Oral Liquid	Laxatives	Hair Growth Agents
Ophthalmics: Antihistamines	Melatonin (as a Single Agent only)	Hematopoietic Agents - Cobalamins & Mixtures
Pulmonary: Antihistamines: 1 st Generation	Minerals	Homeopathic Products
Pulmonary: Antihistamines: 2 nd Generation	Calcium	Infant Foods (refer to WIC)
Smoking Cessation Therapies	Magnesium/Magnesium SR (brand Mag Tab SR [®] OK)	Liniments
Vitamins: Prenatal Vitamins	Sodium	Minerals
	Ophthalmics	Manganese
	Artificial Tears and Lubricants	Potassium (OTC)
	Decongestants	Trace Minerals
	Hyperosmolar Products	Zinc
	Oral Electrolyte Solution	Mouthwashes
	OTC Agents - Miscellaneous	Nutritional Substances, Miscellaneous
	Proteins/Amino Acids	Nutritional Substitutes - Sweeteners
	Rectal Local Anesthetics	Pigmenting Agents
	Sleep Aids	Scar Treatment Products
	Tar Products	Shampoos
	Vaginal Anti-infectives	Skin Cleansers
	Vitamins	Skin Protectants
	Multiple Vitamins with Minerals	Soaps
	Multivitamins (see next line)	Sunscreens
	(Aquadek [®] , Source CF [®] and Vitamax [®] brands covered)	Throat Lozenges
	Pediatric Vitamins	Topicals, Miscellaneous
	Vitamin B Complex, B1, B2, B3, B5, B6	Vitamins
	Vitamin D	Vitamin A
		B-Complex with <u>Minerals</u> , B7, B12 ORAL
		Coiflavonoids
		Statin
		Vitamin C
		Vitamin E
		Wound Dressings

Last Updated 10/17/2011

Pancreatic Enzyme Products

LENGTH OF AUTHORIZATION: not applicable

CRITERIA FOR APPROVAL: not applicable

Pancreatic Enzyme Products	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
CREON [®] 3,000 (lipase units) DR Capsule CREON [®] 6,000 (lipase units) DR Capsule CREON [®] 12,000 (lipase units) DR Capsule CREON [®] 24,000 (lipase units) DR Capsule PANCREAZE [®] 4,200 (lipase units) DR Capsule PANCREAZE [®] 10,500 (lipase units) DR Capsule PANCREAZE [®] 16,800 (lipase units) DR Capsule PANCREAZE [®] 21,000 (lipase units) DR Capsule ZENPEP [®] 5,000 (lipase units) DR Capsule ZENPEP [®] 10,000 (lipase units) DR Capsule ZENPEP [®] 15,000 (lipase units) DR Capsule ZENPEP [®] 20,000 (lipase units) DR Capsule	

Note: All products must be newly FDA approved
 Abbreviations: DR=delayed release

Parkinson's Medications

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Sinemet[®], Sinemet[®] CR, Mirapex[®], Parcopa[®], Parlodel[®], Requip[®], Eldepryl[®]

- The patient has had a documented intolerance to the generic product.

Amantadine tablets

- The patient has had a documented intolerance to generic amantadine capsules.

Azilect[®]

- The diagnosis or indication is Parkinson's disease.
- AND
- The patient has had a documented side effect, allergy, or treatment failure with selegiline.
- AND
- The dose requested does not exceed 1 mg/day

Mirapex ER[®], Requip XL[®]

- The diagnosis or indication is Parkinson's disease. Requests will not be approved for Restless Leg Syndrome (RLS)
- AND
- The patient has had an inadequate response (i.e. wearing off effect or "off" time) with the immediate release product..
- OR
- The patient has not been able to be adherent to a three times daily dosing schedule of the immediate release release product resulting in a significant clinical impact.

Tasmar[®]

- The diagnosis or indication is Parkinson's disease.
- AND
- The patient has had a documented side effect, allergy, or treatment failure with Comtan[®].

Zelapar[®]

- The diagnosis or indication is Parkinson's disease.
- AND
- The patient is on current therapy with levodopa/carbidopa.
- AND
- Medical necessity for disintegrating tablet administration is provided (i.e. inability to swallow tablets or drug interaction with oral selegiline).
- AND
- The dose requested does not exceed 2.5 mg/day.

LIMITATIONS:

To prevent the use of amantadine in influenza treatment/prophylaxis, days supply \leq 10 days will require PA.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Parkinson's Medications	
<i>Length of Authorization: 1 year</i>	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
<u>DOPAMINE PRECURSOR/DOPA DECARBOXYLASE INHIBITORS</u> CARBIDOPA/LEVODOPA† (compare to Sinemet®) CARBIDOPA/LEVODOPA† ER (compare to Sinemet® CR) CARBIDOPA/LEVODOPA† ODT (compare to Parcopa®)	Parcopa®* (carbidopa/levodopa ODT) Sinemet®* (carbidopa/levodopa) Sinemet CR®*(carbidopa/levodopa ER)
<u>DOPAMINE AGONISTS (ORAL)</u> BROMOCRIPTINE† (compare to Parlodel®) PRAMIPEXOLE † (compare to Mirapex®) ROPINIROLE† (compare to Requip®)	Mirapex®* (pramipexole) Mirapex ER® (pramipexole ER) <i>QL = 1 tab/day</i> Parlodel®* (bromocriptine) Requip®* (ropinirole) Requip XL® (ropinirole XL) <i>QL = 1 tab/day (all strengths except 12 mg), QL = 2 tabs/day (12 mg)</i>
<u>COMT INHIBITORS</u> COMTAN® (entacapone)	Tasmar® (tolcapone)
<u>MAO-B INHIBITORS</u> SELEGILINE† (compare to Eldepryl®)	Azilect® (rasagiline) (<i>QL = 1 mg/day</i>) Eldepryl®* (selegiline) Zelapar® (selegiline ODT) (<i>QL = 2.5 mg/day</i>)
<u>OTHER</u> AMANTADINE†capsules (formerly Symmetrel®) (PA required for ≤ 10 day supply) STALEVO® (carbidopa/levodopa/entacapone)	Amantadine† tablets (formerly Symmetrel®) (Quantity limit PA also required for ≤ 10 day supply)

ODT = orally disintegrating tablets

Phosphodiesterase-4 (PDE-4) Inhibitor Medications

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The indication for the requested medication is treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
AND
- The patient has had a documented side effect, allergy, treatment failure, or a contraindication to at least one inhaled long-acting anticholinergic **AND** at least one inhaled long-acting beta-agonist.
AND
- The patient has had a documented side effect, allergy, treatment failure, or a contraindication to at least one inhaled corticosteroid.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Phosphodiesterase-4 (PDE-4) Inhibitors		<i>Length of Authorization: 1 year</i>
NO PA REQUIRED	PA REQUIRED	
	Daliresp [®] tablet (roflumilast) <i>Quantity limit = 1 tablet/day</i>	

Phosphodiesterase-5 (PDE-5) Inhibitor Medications

Effective 7/1/06, phosphodiesterase-5 (PDE-5) inhibitors are no longer a covered benefit for all Vermont Pharmacy Programs for the treatment of erectile dysfunction. This change is resultant from changes set into effect on January 1, 2006 and as detailed in Section 1903(i)(21)(K) of the Social Security Act (the Act), precluding Medicaid Federal Funding for outpatient drugs used for the treatment of sexual or erectile dysfunction. Sildenafil will remain available for coverage via prior authorization for the treatment of Pulmonary Arterial Hypertension.

LENGTH OF AUTHORIZATION: Revatio IV: Date of service

All Others: 1 year

CRITERIA FOR APPROVAL:

Adcirca[®] (tadalafil) 20 mg, Revatio[®] (sildenafil citrate) 20 mg:

- Clinical diagnosis of pulmonary hypertension
- AND**
- No concomitant use of organic nitrate-containing products

Viagra[®] (sildenafil citrate) 25 mg, 50 mg, and 100 mg:

- Clinical diagnosis of pulmonary hypertension
- AND**
- No concomitant use of organic nitrate-containing products
- AND**
- Inadequate response to Revatio (sildenafil) 20 mg or currently maintained on a sildenafil dose of 25 mg TID or higher

Revatio IV[®]

- Clinical diagnosis of pulmonary hypertension
- AND**
- No concomitant use of organic nitrate-containing products
- AND**
- The patient has a requirement for an injectable dosage form.
- AND**
- Arrangements have been made for IV bolus administration outside of an inpatient hospital setting.

DOCUMENTATION:

- ✓ Document clinical information supporting the choice of agent on a **General Prior Authorization Request Form**.

Phosphodiesterase 5 (PDE-5) Inhibitors

Length of Authorization: Date of Service or 1 year

PREFERRED DRUGS (No PA Required)

PA REQUIRED

Adcirca[®] (tadalafil)
(Quantity Limit = 2 tablets/day)
Revatio[®] (sildenafil citrate) tablet
(Quantity Limit = 3 tablets/day)
Revatio[®] (sildenafil citrate) vial
(Quantity Limit = 3 vials/day, maximum 14 days supply per fill)
Viagra[®] (sildenafil citrate)
(Quantity Limit = 3 tablets/day)

Note: Please refer to "Pulmonary Arterial Hypertension Medications" for Endothelium Receptor Antagonists and Prostanoids.

Platelet Inhibitors

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Agrylin[®], Persantine[®], Pletal[®]:

- The patient has had a documented intolerance to the generic formulation of the medication.

LIMITATIONS:

Plavix[®] 300mg is not an outpatient dose and is not covered in the pharmacy benefit..

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Platelet Inhibitors		<i>Length of Authorization: 1 year</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
<u>AGGREGATION INHIBITORS</u>		
CILOSTAZOL† (compare to Pletal [®])	Plavix [®] 300 mg (clopidogrel bisulfate)	
EFFIENT [®] (prasugrel) Tablet <i>QL = 1 tablet/day</i>	Pletal [®] * (cilostazol)	
PLAVIX [®] 75 mg (clopidogrel bisulfate)		
TICLOPIDINE† (previously Ticlid [®])		
<u>OTHER</u>		
AGGRENOX [®] (dipyridamole/Aspirin)	Agrylin [®] * (anagrelide)	
ANAGRELIDE† (compare to Agrylin [®])	Persantine [®] * (dipyridamole)	
ASPIRIN†		
DIPYRIDAMOLE† (compare to Persantine [®])		

Psoriasis Medications: Injectables

NOTE: Psoriasis Self-Injectables (Enbrel® and Humira®) must be obtained and billed through our specialty pharmacy vendor, ICORE Healthcare. Stelara® may either be obtained and billed through our specialty pharmacy vendor, ICORE Healthcare or through the medical benefit. Please see the Enbrel, Humira or Stelara Prior Authorization/Patient Enrollment Form for instructions. ICORE Healthcare may supply Remicade® upon request or you may continue to obtain through your usual supplier. ICORE Healthcare will not be supplying Amevive® at this time – please continue to obtain through your usual supplier.

LENGTH OF AUTHORIZATION: Initial PA of 3 months (Stelara 4 months), and 12 months thereafter upon recertification

CRITERIA FOR APPROVAL:

Enbrel®

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis and has already been stabilized on Enbrel®

OR

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis affecting > 10% of the body surface area (BSA) and/or has involvement of the palms, soles, head and neck, or genitalia and has had a documented side effect, allergy, inadequate treatment response, or treatment failure to at least 2 different categories of therapy [i.e. at least 2 topical agents and at least 1 oral systemic agent, (unless otherwise contraindicated)] from the following categories:

Topical agents: emollients, keratolytics, corticosteroids, calcipotriene, tazarotene, etc.

Systemic agents: methotrexate, sulfasalazine, azathioprine, cyclosporine, tacrolimus, mycophenylate mofetil, etc.

Phototherapy: ultraviolet A and topical psoralens (topical PUVA), ultraviolet A and oral psoralens (systemic PUVA, narrow band ultraviolet B (NUVA), etc.

Humira®

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis and has already been stabilized on Humira®

OR

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis affecting > 10% of the body surface area (BSA) and/or has involvement of the palms, soles, head and neck, or genitalia and has had a documented side effect, allergy, inadequate treatment response, or treatment failure to at least 2 different categories of therapy [i.e. at least 2 topical agents and at least 1 oral systemic agent, (unless otherwise contraindicated)] from the following categories:

Topical agents: emollients, keratolytics, corticosteroids, calcipotriene, tazarotene, etc.

Systemic agents: methotrexate, sulfasalazine, azathioprine, cyclosporine, tacrolimus, mycophenylate mofetil, etc.

Phototherapy: ultraviolet A and topical psoralens (topical PUVA), ultraviolet A and oral psoralens (systemic PUVA, narrow band ultraviolet B (NUVA), etc.

Amevive[®]

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis and has already been stabilized on Amevive[®]

OR

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis affecting > 10% of the body surface area (BSA) and/or has involvement of the palms, soles, head and neck, or genitalia and has had a documented side effect, allergy, inadequate treatment response, or treatment failure to at least 2 different categories of therapy [i.e. at least 2 topical agents and at least 1 oral systemic agent, (unless otherwise contraindicated)] from the following categories:

Topical agents: emollients, keratolytics, corticosteroids, calcipotriene, tazarotene, etc.

Systemic agents: methotrexate, sulfasalazine, azathioprine, cyclosporine, tacrolimus, mycophenolate mofetil, etc.

Phototherapy: ultraviolet A and topical psoralens (topical PUVA), ultraviolet A and oral psoralens (systemic PUVA, narrow band ultraviolet B (NUVA), etc.

AND

The prescriber must provide a clinically valid reason why either Enbrel[®] or Humira[®] cannot be used.

Remicade[®]

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis and has already been stabilized on Remicade[®]

OR

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis affecting > 10% of the body surface area (BSA) and/or has involvement of the palms, soles, head and neck, or genitalia and has had a documented side effect, allergy, inadequate treatment response, or treatment failure to at least 2 different categories of therapy [i.e. at least 2 topical agents and at least 1 oral systemic agent, (unless otherwise contraindicated)] from the following categories:

Topical agents: emollients, keratolytics, corticosteroids, calcipotriene, tazarotene, etc.

Systemic agents: methotrexate, sulfasalazine, azathioprine, cyclosporine, tacrolimus, mycophenolate mofetil, etc.

Phototherapy: ultraviolet A and topical psoralens (topical PUVA), ultraviolet A and oral psoralens (systemic PUVA, narrow band ultraviolet B (NUVA), etc.

AND

The prescriber must provide a clinically valid reason why either Enbrel[®] or Humira[®] cannot be used.

Stelara[®]

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis and has already been stabilized on Stelara[®]

OR

The prescription must be written by a dermatologist

AND

The patient has a documented diagnosis of moderate to severe plaque psoriasis affecting > 10% of the body surface area (BSA) and/or has involvement of the palms, soles, head and neck, or genitalia and has had a documented side effect, allergy, inadequate treatment response, or treatment failure to at least 2 different categories of therapy [i.e. at least 2 topical agents and at least 1 oral systemic agent, (unless otherwise contraindicated)] from the following categories:

Topical agents: emollients, keratolytics, corticosteroids, calcipotriene, tazarotene, etc.

Systemic agents: methotrexate, sulfasalazine, azathioprine, cyclosporine, tacrolimus, mycophenylate mofetil, etc.

Phototherapy: ultraviolet A and topical psoralens (topical PUVA), ultraviolet A and oral psoralens (systemic PUVA, narrow band ultraviolet B (NUVA), etc.

AND

The prescriber must provide a clinically valid reason why either Enbrel® or Humira® cannot be used.

DOCUMENTATION:

- ✓ Document clinical information for **Enbrel®**, **Humira®** or **Stelara®** on its **Prior Authorization/Patient Enrollment Form** and clinically compelling information supporting the choice of **Remicade®** on a **Remicade Prior Authorization Request Form** and **Amevive®** on a **General Prior Authorization Request Form**.
- ✓ All requests for infliximab (Remicade®) (whether billed through the pharmacy or medical benefit (J1745)) or ustekinumab (Stelara®) (whether billed through the pharmacy or medical benefit (J3357)) or alefacept (Amevive®) (J0215) (billed through the medical benefit) require Prior Authorization through the MedMetrics Clinical Call Center.

Psoriasis Medications: Injectables

Length of authorization: Initial PA of 3 months (Stelara 4 months); 12 months thereafter

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

ENBREL® (etanercept)
Quantity limit = 8 syringes/28 days for the first 3 months; then 4 syringes/28 days(50 mg) or 8 syringes/28 days (25 mg) subsequently

HUMIRA® (adalimumab)
Quantity limit = 4 syringes/28 days for one month month; 2 syringes/28 days subsequently

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Amevive® (alefacept)
Remicade® (infliximab)
Stelara® (ustekinumab)
*(Quantity limit = 45 mg (0.5 ml) or 90 mg (1 ml) per dose)
(90 mg dose only permitted for pt weight > 100 kg)*

Psoriasis: Non-Biologics

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Calcitrene Ointment

- The patient has a documented intolerance to Calcipotriene ointment.

Dovonex Solution

- The patient has a documented intolerance to the generic product.

Taclonex Ointment or Scalp Suspension

- The patient has had an inadequate response to a 24 month trial of a betamethasone dipropionate product and Dovonex (or generic calcipotriene), simultaneously, with significant non-adherence issues.
- AND**
- The patient has had a documented side effect, allergy, or treatment failure with Tazorac 0.05% or 0.1% cream or gel.

Note: If approved, initial fill of Taclonex[®] will be limited to 60 grams.

Vectical Ointment

- The patient ≥ 18 years of age
- AND**
- The patient has a diagnosis of mild-to-moderate plaque psoriasis
- AND**
- The patient has demonstrated inadequate response, adverse reaction or contraindication to calcipotriene

LIMITATIONS:

Kits with non-drug products or combinations of 2 drug products are not covered.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Psoriasis: Non-Biologics		<i>Length of Authorization: 1 year</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
<u>ORAL</u>		
CYCLOSPORINE† (all brand and generic) METHOTREXATE† (all brand and generic) OXSORALEN-ULTRA [®] (methoxsalen) SORIATANE [®] (acitretin) capsules		
<u>TOPICAL</u>		
CALCIPOTRIENE† Solution (compare to Dovonex [®]) CALCIPOTRIENE [®] OINTMENT (formerly Dovonex [®]) DOVONEX [®] (calcipotriene cream) PSORiatec [®] , DRITHO-SCALP [®] (anthralin cream) TAZORAC [®] (tazarotene cream, gel)	Calcitrene [®] (calcipotriene) ointment Dovonex ^{®*} Solution (calcipotriene) Taclonex [®] (calcipotriene/betamethasone ointment/scalp suspension) <i>(QL for initial fill = 60 grams)</i> Vectical [®] Ointment (calcitriol) <i>(Quantity Limit = 200 g (2 tubes)/week)</i>	

Pulmonary: Anticholinergics

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Duoneb Nebulizer

- The patient has a documented intolerance to generic ipratropium/albuterol nebulizer.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Anticholinergics Length of Authorization: 1 year	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>METERED DOSE INHALER (SINGLE AGENT)</u> ATROVENT HFA[®] (ipratropium) <i>Quantity Limit = 2 inhalers/25 days</i> SPIRIVA[®] (tiotropium) <i>Quantity Limit = 1 capsule/day</i></p> <p><u>NEBULIZER (SINGLE AGENT)</u> IPRATROPIUM SOLN FOR INHALATION</p> <p><u>METERED DOSE INHALER (COMBINATION)</u> COMBIVENT[®] (ipratropium/albuterol) <i>Quantity Limit = 2 inhalers/30 days</i></p> <p><u>NEBULIZER (COMBINATION)</u> IPRATROPIUM/ALBUTEROL[†] (compare to Duoneb[®])</p>	<p style="text-align: center; padding-top: 100px;">Duoneb^{®*} (ipratropium/albuterol)</p>

Pulmonary: Antihistamines: Intranasal

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

ASTELIN, ASTEPRO, AZELASTINE, PATANASE

- The diagnosis or indication for the requested medication is allergic rhinitis.
AND
- The patient has had a documented side effect, allergy, or treatment failure to loratadine (OTC) **OR** cetirizine (OTC) **AND** a preferred nasal glucocorticoid.
AND
- If the request is for azelastine (generic), the patient has had a documented intolerance to brand Astelin.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Antihistamines: Intranasal		<i>Length of Authorization: 1 year</i>
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
	Astelin® (azelastine) Nasal Spray <i>Quantity Limit = 1 bottle (30 ml)/25 days</i>	
	azelastine (compare to Astelin®) Nasal Spray <i>Quantity Limit = 1 bottle (30 ml)/25 days</i>	
	Astepro® (azelastine) Nasal Spray <i>Quantity Limit = 1 bottle (30 ml)/25 days</i>	
	Patanase® (olopatadine 0.6%) Nasal Spray <i>Quantity Limit = 1 bottle (31 gm)/25 days</i>	

Pulmonary: Antihistamines: 1st Generation

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

- The prescriber must provide a clinically valid reason for the use of the requested medication including reasons why any of the generically available products would not be a suitable alternative.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Antihistamines: 1st Generation		<i>Length of Authorization: 1 year</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
All generic antihistamines	All brand antihistamines (example: Benadryl [®])	
All generic antihistamine/decongestant combinations	All brand antihistamine/decongestant combinations (example: Deconamine SR [®] , Rynatan [®] , Ryna-12 [®])	

Pulmonary: Antihistamines: 2nd Generation

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

SINGLE AGENT TABLET

FEXOFENADINE 60MG/180 MG TABLETS

- The diagnosis or indication for the requested medication is allergic rhinitis or chronic idiopathic urticaria.
AND
- The patient has had a documented side effect, allergy, or treatment failure to loratadine (OTC) **AND** cetirizine (OTC).

CLARINEX TABLETS, CLARITIN TABLETS, LEVOCETIRIZINE TABLETS, XYZAL TABLETS

- The diagnosis or indication for the requested medication is allergic rhinitis or chronic idiopathic urticaria.
AND
- The patient has had a documented side effect, allergy, or treatment failure to loratadine (OTC) **AND** cetirizine (OTC).
AND
- The patient has had a documented side effect, allergy, or treatment failure to fexofenadine.
AND
- If the request is for Xyzal, the patient must also have a documented intolerance to levocetirizine tablets.

CHEWABLE/ORALLY DISINTEGRATING TABLET

CERTIRIZINE CHEWABLE TABLETS, CLARINEX REDITABS, CLARITIN CHEWABLE TABLETS, CLARITIN REDITABS, ZYRTEC ALLERGY OTC DISINTEGRATING TABLETS

- The diagnosis or indication for the requested medication is allergic rhinitis or chronic idiopathic urticaria.
AND
- The patient has had a documented side effect, allergy, or treatment failure to loratadine (OTC) rapidly disintegrating tablets or requires less than a 10 mg dose of loratadine.

SINGLE AGENT ORAL LIQUID

CLARINEX SYRUP, CLARITIN OTC SYRUP, LEVOCETIRIZINE SOLUTION, XYZAL SOLUTION, ZYRTEC CHILDREN'S ALLERGY ORAL LIQUID

- The diagnosis or indication for the requested medication is allergic rhinitis or chronic idiopathic urticaria.
AND
- The patient has had a documented side effect, allergy, or treatment failure to loratadine syrup **AND** cetirizine syrup.
AND
- If the request is for Xyzal, the patient must also have a documented intolerance to levocetirizine solution.

COMBINATION WITH PSEUDOEPHEDRINE

CETIRIZINE D, CLARINEX-D, CLARITIN-D

- The diagnosis or indication for the requested medication is allergic rhinitis.
AND
- The patient has had a documented side effect, allergy, or treatment failure to loratadine-D (OTC).

LIMITATIONS: Many Allegra[®] and Zyrtec[®] brand products as well as Claritin[®] capsules are not covered as no Federal Rebate is offered.

Fexofenadine/pseudoephedrine combination products (brand and generic) are not covered – individual components may be prescribed separately.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Antihistamines: 2nd Generation

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

§ Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>SINGLE AGENT TABLET</u></p> <p>LORATADINE † (OTC) (Allergy Relief[®], Alavert[®]) (compare to Claritin[®]) 10 mg tablet CETIRIZINE † OTC (formerly Zyrtec[®]) 5 mg, 10 mg tablets</p> <p>After loratadine OTC and cetirizine OTC trials FEXOFENADINE † 60 mg, 180 mg (OTC) tablets (formerly Allegra[®])</p>	<p>Clarinetx[®] (desloratadine) 5 mg tablet Claritin^{®*} tablets OTC (loratadine) 10 mg Levocetirizine † (compare to Xyzal[®]) 5 mg tablet Xyzal[®] (levocetirizine) 5 mg tablet</p> <p>All other brands</p>
<p><u>COMBINATION WITH PSEUDOEPHEDRINE</u></p> <p>LORATADINE/PSEUDOEPHEDRINE SR 12hr 5 mg/120 MG † (OTC) (Alavert Allergy/Sinus[®]) (compare to Claritin D[®] 12 hr)</p> <p>LORATADINE/PSEUDOEPHEDRINE SR 24hr 10 mg/240 MG † (OTC) (compare to Claritin D[®] 24 hr)</p>	<p>Cetirizine/Pseudoephedrine SR 12hr 5 mg/120 mg OTC † Clarinetx-D[®] 12 hr (desloratadine/pseudoephedrine 2.5 mg/120 mg) Clarinetx-D[®] 24 hr (desloratadine/pseudoephedrine 5 mg/240 mg) Claritin-D 12 hr^{®*§} (loratadine/pseudoephedrine 5 mg/120 mg) Claritin-D 24 hr^{®*§} (loratadine/pseudoephedrine 10 mg/240 mg)</p> <p>All other brands</p>
<p><u>SINGLE AGENT ORAL LIQUID</u></p> <p>LORATADINE † (OTC) syrup (Allergy Relief[®]) (compare to Claritin[®]) CETIRIZINE † (OTC, RX) syrup</p>	<p>Clarinetx Syrup[®] (desloratadine) Claritin OTC Syrup^{®*} (loratadine) Levocetirizine (compare to Xyzal[®]) Solution Xyzal[®] (levocetirizine) Solution Zyrtec^{®*} Children's Allergy (cetirizine) (only one NDC)</p> <p>All other brands</p>
<p><u>CHEWABLE/ORALLY DISINTEGRATING TABLET</u></p> <p>LORATADINE † (OTC) (Allergy Relief[®], Alavert[®]) rapidly disintegrating tablet (RDT) (compare to Claritin[®]) 10 mg</p>	<p>Cetirizine † OTC Chewable Tablets 5 mg, 10 mg Clarinetx Reditabs^{®§} (desloratadine) 2.5 mg, 5 mg Claritin (loratadine) OTC Chewable Tablets^{®§} 5 mg Claritin (loratadine) OTC Reditabs^{®§} 5 mg, 10 mg* Zyrtec Allergy[®] OTC (cetirizine orally disintegrating tablet) 10 mg</p> <p>All other brands</p>

Pulmonary: Beta-Adrenergic Agents

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Metered Dose Inhalers (Short-Acting)

For prior-authorization of a non-preferred short-acting beta-adrenergic MDI, the patient must:

- Be started and stabilized on the requested medication.
- OR
- Have a documented side effect, allergy, or treatment failure to Xopenex®.

Metered Dose Inhalers (Long-Acting)

Effective 11/1/06, prior-authorization will be required for long-acting beta-adrenergic (LABA) MDIs for patients who have not been on a controller medication in the past 6 months or who do not have a diagnosis of COPD.

For prior-authorization of a long-acting beta-adrenergic MDI, the patient must have:

- A diagnosis of COPD
- OR
- A diagnosis of asthma and prescribed an inhaled corticosteroid as a controller medication.

Accuneb® nebulizer solution 0.63 mg/ml and 1.25 mg/ml

- The patient must have had a documented intolerance to the generic formulation.

Levalbuterol nebulizer solution (age ≤ 12 years)

- The patient must have had a documented intolerance to the brand Xopenex nebulizer solution.

Levalbuterol nebulizer solution (age > 12 years)

- The patient must have had a documented side effect, allergy, or treatment failure to albuterol nebulizer.
- AND
- The patient must have had a documented intolerance to the brand Xopenex nebulizer solution.

Xopenex® nebulizer solution (age >12 years)

- The patient must have been started and stabilized on the requested medication.
- OR
- The patient must have had a documented side effect, allergy, or treatment failure to albuterol nebulizer.

Brovana® or Perforomist® Nebulizer Solution

- The patient must have a diagnosis of COPD.
- AND
- The patient must be unable to use a non-nebulized long-acting bronchodilator or anticholinergic (Foradil®, Serevent® or Spiriva®) due to a physical limitation

Terbutaline, Brethine® tablets

- The medication is not being prescribed for the prevention/treatment of preterm labor.
- AND
- If Brethine is requested, the patient must have had a documented side effect, allergy, or treatment failure to generic terbutaline tablets.

Vospire ER® tablets

- The patient must have had a documented side effect, allergy, or treatment failure to generic albuterol ER tablets.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Beta-Adrenergic Agents		<i>Length of Authorization: 1 year</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
<u>METERED-DOSE INHALERS (SHORT-ACTING)</u>		
XOPENEX [®] HFA (levalbuterol) MAXAIR [®] Autohaler (pirbuterol)	Proair [®] HFA (albuterol) Proventil [®] HFA (albuterol) Ventolin [®] HFA (albuterol)	
<u>METERED-DOSE INHALERS (LONG-ACTING)</u>		
SEREVENT [®] DISKUS (salmeterol) (<i>after criteria for LABA are met</i>) <i>Quantity Limit = 60 blisters/30 days</i> FORADIL [®] (formoterol) (<i>after criteria for LABA are met</i>) <i>Quantity Limit = 60 capsules/30 days</i>		
<u>NEBULIZER SOLUTIONS (SHORT-ACTING)</u>		
ALBUTEROL † 0.63 mg/ml and 1.25 mg/ml neb solution (compare to Accuneb [®]) ALBUTEROL † 0.83 mg/ml neb solution XOPENEX [®] neb solution (levalbuterol) (age ≤ 12 years)	Accuneb ^{**} (albuterol sulfate neb solution 0.63 mg/ml and 1.25 mg/ml) Levalbuterol † neb solution (compare to Xopenex [®]) (all ages) Xopenex [®] neb solution (levalbuterol) (age >12 years)	
<u>NEBULIZER SOLUTIONS (LONG-ACTING)</u>		
	Brovana [®] (arformoterol) <i>QL = 2 vial/day</i> Perforomist [®] (formoterol) <i>QL = 2 vial/day</i>	
<u>TABLETS/SYRUP (SHORT-ACTING)</u>		
ALBUTEROL tablets/syrup † METAPROTERENOL tablets/syrup †	Brethine ^{**} (terbutaline) terbutaline tablets † (compare to Brethine [®])	
<u>TABLETS (LONG-ACTING)</u>		
ALBUTEROL ER tablets †	Vospire ER ^{**} (albuterol)	

Pulmonary: Corticosteroids/Combinations: Inhaled

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Metered-dose inhalers (single agent):

- The patient has been started and stabilized on the medication.
- OR**
- The patient has had a documented side effect, allergy, or treatment failure to at least two preferred agents.

Budesonide Inh Suspension (all ages):

- The patient requires a nebulizer formulation.
- AND**
- The patient has a documented intolerance to the brand product.

Pulmicort Respules[®] (age > 12 years):

- The patient requires a nebulizer formulation.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Corticosteroids/Combinations: Inhal

Length of Authorization: 1 year

Key: § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)

PREFERRED DRUGS (No PA Required)

PA REQUIRED

METERED-DOSE INHALERS (SINGLE AGENT)

ASMANEX[®] 220 mcg/inh (mometasone furoate)
(*QL = 0.72 gm (3 inhalers)/90 days*)

ASMANEX[®] 110 mcg/inh (mometasone furoate)
(*QL = 0.405 gm (3 inhalers)/90 days*)

FLOVENT DISKUS[®] (fluticasone propionate)
(*QL = 3 inhalers/90 days*)

FLOVENT HFA[®] (fluticasone propionate)
(*QL = 36 gm (3 inhalers)/90 days*)

PULMICORT FLEXHALER[®] (budesonide)
(*QL = 6 inhalers/90 days*)

QVAR[®] 40 mcg/inh (beclomethasone)
(*QL = 17.4 gm (2 inhalers)/90 days*)

QVAR[®] 80 mcg/inh (beclomethasone)
(*QL = 58.4 gm (8 or 6 inhalers)/90 days*)

Aerobid[®] (flunisolide)

Aerobid M[®] (flunisolide/menthol)

Alvesco[®] (ciclesonide)

(*QL = 18.3 gm (3 inhalers)/90 days*) (80 mcg/inh)

(*QL = 36.6 gm (6 inhalers)/90 days*) (160 mcg/inh)

METERED-DOSE INHALERS (COMBINATION PRODUCT)

ADVAIR[®] DISKUS (fluticasone/salmeterol)
(*QL = 3 inhalers/90 days*)

ADVAIR[®] HFA (fluticasone/salmeterol)
(*QL = 36 gm (3 inhalers)/90 days*)

DULERA[®] (mometasone/formoterol)
(*QL = 39 gm (3 inhalers)/90 days*)

SYMBICORT[®] (budesonide/formoterol)
(*QL = 30.6 gm (3 inhalers)/90 days*)

NEBULIZER SOLUTIONS

PULMICORT RESPULES[®] (budesonide) (age ≤ 12 yrs)

Budesonide Inh Suspension (compare to Pulmicort Respules[®]) (all ages)

Pulmicort Respules[®] (budesonide) (age > 12 years)

Pulmonary: Corticosteroids: Intranasal

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Beconase AQ[®], Flonase[®], Flunisolide 25 mcg/spray, Flunisolide 29 mcg/spray, Omnaris[®], Rhinocort Aqua[®], triamcinolone, Veramyst[®]:

- The patient has had a documented side effect, allergy, or treatment failure to all three preferred nasal glucocorticoids. If a product has an AB rated generic, the generic must additionally be tried before approval of the brand.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Pulmonary: Corticosteroids: Intranasal		<i>Length of Authorization:</i>
<i>1 year</i>		
Key: † Generic product		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
FLUTICASONE Propionate† (compare to Flonase [®]) <i>QL = 16 gm (1 inhaler)/30 days</i> NASACORT AQ [®] (triamcinolone) <i>QL = 16.5 gm (1 inhaler)/30 days</i> NASONEX [®] (mometasone) <i>QL = 17 gm (1 inhaler)/30 days</i>	Beconase AQ [®] (beclomethasone) <i>QL = 50 gm (2 inhalers)/30 days</i> Flonase ^{®*} (fluticasone propionate) <i>QL = 16 gm (1 inhaler)/30 days</i> flunisolide † 25 mcg/spray (previously Nasalide [®]) <i>QL = 50 ml (2 inhalers)/30 days</i> flunisolide† 29 mcg/spray (formerly Nasarel [®]) <i>QL = 50 ml (2 inhalers)/30 days</i> Omnaris [®] (ciclesonide) <i>QL = 12.5 gm (1 inhaler)/30 days</i> Rhinocort Aqua [®] (budesonide) <i>QL = 8.6 gm (1 inhaler)/30 days</i> triamcinolone † (compare to Nasacort AQ [®]) <i>QL = 16.5 gm (1 inhaler)/30 days</i> Veramyst [®] (fluticasone furoate) <i>QL = 10 gm (1 inhaler)/30 days</i>	

Pulmonary: Leukotriene Modifiers

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Singulair®

- The diagnosis or indication for the requested medication is asthma.
- OR**
- The diagnosis or indication for the requested medication is allergic rhinitis.
- AND**
- The patient has had a documented side effect, allergy, or treatment failure to a second generation non-sedating antihistamine **AND** a nasal corticosteroid.
- OR**
- The diagnosis or indication for the requested medication is urticaria.
- AND**
- The patient has had a documented side effect, allergy, or treatment failure to at least TWO preferred 2nd generation antihistamines (i.e. loratadine (OTC), cetirizine (OTC), fexofenadine).

Zafirlukast, Accolate®

- The diagnosis or indication for the requested medication is asthma.
- AND**
- If the request is for Accolate, the patient has a documented intolerance to generic zafirlukast.

Zyflo CR®

- The diagnosis or indication for the requested medication is asthma.
- AND**
- The patient has had a documented side effect, allergy, or treatment failure to Accolate® or Singulair®.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Pulmonary: Leukotriene Modifiers	
<i>Length of Authorization: 1 year</i>	
Key: § Indicates drug is managed via automated Step Therapy (prerequisite drug therapy automatically screened for upon claims processing)	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><i>Note: Children 5 years old and under not subject to PA criteria for Singulair®.</i></p>	<p>Accolate® (zafirlukast) <i>Quantity Limit = 2 tablets/day</i></p> <p>Singulair® (montelukast sodium) § <i>Quantity Limit = 1 tablet or packet per day</i></p> <p>zafirlukast (compare to Accolate®) § <i>Quantity Limit = 2 tablets/day</i></p> <p>Zyflo CR® (zileuton SR) <i>Quantity Limit = 4 tablets/day</i></p>

Asthma Diagnosis: POS looks back for beta agonist rescue inhaler or inhaled corticosteroids/corticosteroid combinations for inferred diagnosis.

Allergic Rhinitis Diagnosis: POS looks back for second generation non-sedating antihistamine and nasal corticosteroid.

Pulmonary: Synagis®

NOTE: Synagis® must be obtained and billed through our specialty pharmacy vendor for Synagis®, Wilcox Home Infusion. Please see Synagis Prior Authorization/Enrollment Form for instructions.

LENGTH OF AUTHORIZATION: Only one dose (based on recipient weight) will be approved per thirty-day period. Dose is given once monthly between November 1st and March 31st (up to 5 doses depending on gestational age).

INDICATION:

Palivizumab is indicated for the prevention of RSV lower respiratory tract disease in selected infants and children with chronic lung disease of prematurity (CLD [formerly called bronchopulmonary dysplasia]) or with a history of preterm birth (< 35 weeks' gestation) or with congenital heart disease.

CRITERIA FOR APPROVAL:

- Infants born at 28 weeks of gestation or earlier (i.e., ≤ 28 weeks, 6 days) and under twelve months of age at the start of the RSV season (maximum 5 doses).
- Infants born at 29-32 weeks (i.e., between 29 weeks, 0 days and 31 weeks, 6 days) of gestation and under 6 months of age at the start of the RSV season (maximum 5 doses).
- Infants born at 32-35 weeks (i.e., between 32 weeks, 0 days and 34 weeks, 6 days) of gestation who have at least one of the following risk factors and who have not reached 3 months of age: (dosing continues in the RSV season through the end of the month the infant reaches 3 months old – maximum 3 doses)
 - Infant attends child care
 - One of more siblings (or other child permanently in house) < 5 years of age
- Children under 24 months of age with chronic lung disease of prematurity (bronchopulmonary dysplasia) who have received medical therapy (supplemental oxygen, bronchodilator, diuretic or chronic corticosteroid therapy) within 6 months prior to the start of the RSV season (maximum 5 doses).
- Children under 24 months of age with hemodynamically significant cyanotic or acyanotic heart disease (CHD) (maximum 5 doses):
 - Receiving medication to control congestive heart failure
 - Moderate to severe pulmonary hypertension
 - Have cyanotic heart disease
- Infants under 12 months of age with either: (dosing continues in the RSV season through the end of the month the infant reaches 12 months old -maximum 5 doses)
 - Congenital abnormalities of the airways
 - Neuromuscular condition compromising handling of respiratory tract secretions

EXCLUDED FROM APPROVAL:

- Infants and children with hemodynamically insignificant heart disease.
- Infants with lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure.
- Infants with mild cardiomyopathy who are not receiving medical therapy.
- Established RSV disease.

This drug must be obtained and billed through our specialty pharmacy vendor for Synagis®, Wilcox Home Infusion, and processed through the DVHA POS prescription processing system using NDC values.

Under no circumstances will claims processed through the medical benefit be accepted.

DOCUMENTATION:

Document clinically compelling information supporting the use of Synagis on the **Synagis® Prior Authorization/Patient Enrollment Form.**



Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name		Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #		
Allergies: <input type="checkbox"/> NKA or _____				
Street Address			City	
State	County	Zip Code		
Parent/Guardian		Day Telephone	Night Telephone	
Emergency Contact		Relationship	Telephone	

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address			City
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	
Supervising Physician's Name (If Required for Mid-Level Practitioner)		NPI Number	

WILCOX MEDICAL

Wilcox Home Infusion
250 Stratton Road
Rutland, Vermont 05701
A subsidiary of **bio scrip**
Form Last Updated 09/2010

Fax Completed Form to:

Fax Number: 802-775-7824 ☎

Phone Number: 800-639-1210 ☎

**3 Department of Vermont Health Access PRIOR AUTHORIZATION REQUEST
SYNAGIS® (PALIVIZUMAB)**

Gestational Age: weeks: _____ days: _____	Current Weight: (kg)	Dose: 15mg / kg (weight verified monthly)
Diagnosis:		
<input type="checkbox"/> Infants born at 28 weeks of gestation or earlier (i.e., ≤ 28 weeks, 6 days) and under 12 months of age at the start of the RSV season (maximum 5 doses)		
<input type="checkbox"/> Infants born at 29 - 32 weeks (i.e., between 29 weeks, 0 days and 31 weeks, 6 days) of gestation and under 6 months of age at the start of the RSV season (maximum 5 doses)		
<input type="checkbox"/> Infants born at 32 - 35 weeks (i.e., between 32 weeks, 0 days and 34 weeks, 6 days) of gestation who have at least one of the following risk factors and who have not reached 3 months of age: (dosing continues in the RSV season through the end of the month the infant reaches 3 months old – maximum 3 doses)		
<input type="checkbox"/> Infant attends child care <input type="checkbox"/> One or more siblings (or other child permanently in house) < 5 years of age		
<input type="checkbox"/> Children under 24 months of age with chronic lung disease of prematurity (bronchopulmonary dysplasia) who have received medical therapy (supplemental oxygen, bronchodilator, diuretic or chronic corticosteroid therapy) within 6 months prior to the start of the RSV season (maximum 5 doses)		
<input type="checkbox"/> Treatment: _____ <input type="checkbox"/> Dates of Use: _____		
<input type="checkbox"/> Children under 24 months of age with hemodynamically significant cyanotic or acyanotic heart disease(CHD)		
<input type="checkbox"/> Receiving medication to control congestive heart failure		
<input type="checkbox"/> Moderate to severe pulmonary hypertension (maximum 5 doses)		
<input type="checkbox"/> Have cyanotic heart disease		
<input type="checkbox"/> Infants under 12 months of age with either: (dosing continues in the RSV season through the end of the month the infant reaches 12 months old – maximum 5 doses)		
<input type="checkbox"/> Congenital abnormalities of the airways		
<input type="checkbox"/> Neuromuscular condition compromising handling of respiratory tract secretions		
<input type="checkbox"/> Other: _____		

NICU HISTORY

Did the patient spend time in the NICU?
 Yes No (If yes, please attach the NICU summary)

Was RSV prophylaxis recommended by the NICU/Hospital physician for this patient?
 Yes No

Was a NICU/Hospital /Clinic dose administered?
 Yes, Date(s): _____ No

4 PRESCRIPTION

Synagis (palivizumab) 50 and/or 100 mg vials and supplies for administration.
 Sig: Inject 15 mg/kg IM once every 4 weeks; expected date of first home injection: _____
 Dispense Quantity: Quantity sufficient for prophylaxis thru 03/2010
 Deliver product to: MD office Patient's home Clinic
 Home health nurse to administer injection Home Health Agency: _____
 If delivery is to clinic, please give location: _____
 Pediatric Anaphylaxis: Administer 0.01 ml/kg (max 0.3ml) of 1:1000 epinephrine solution subcutaneously or intramuscularly, and contact EMS or physician, as appropriate.
 Other: _____
 Sig: _____
 Physician will monitor patient's response to therapy. Any complications in therapy will be reported to the physician either by the patient's caregiver, or the skilled nursing service (If other than physician's office or Wilcox Home Infusion)
Prescriber's Signature: _____ **Date:** _____
Supervising Physician's Signature: _____
 This order is valid for the entire upcoming season if signed prior to the November dose, or for the remainder of the present season if signed after November.

~ XOLAIR ~

Prior Authorization Request Form

Vermont Medicaid has established coverage limits and criteria for prior authorization of Xolair. In order for beneficiaries to receive Medicaid coverage for Xolair, it will be necessary for the prescriber to telephone or complete and fax this prior authorization request to MedMetrics Health Partners. Please complete this form as directed and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing Physician:

 Name: _____
 Phone #: _____
 Fax #: _____
 Address: _____
 Specialty: _____
 Contact Person at Office: _____

Beneficiary:

 Name: _____
 Medicaid ID #: _____
 Date of Birth: _____ Sex: _____
 Patient Diagnosis: Moderate/Severe Persistent Asthma
 Other: _____

If requesting prescriber is not a pulmonologist, allergist, or immunologist, date of last visit to one (required yearly):

Specialist name: _____ **Specialist Type:** _____ **Date:** _____

- Initial Prior Authorization Request:** Please complete all portions of form below
- Subsequent PA Request:** Has patient shown marked clinical improvement **Yes** **No**

List all previous therapies tried and failed for this condition:

Therapy	Specific Drug	Reason for Discontinuation
Inhaled Corticosteroid		
Chronic Oral Corticosteroid		
Leukotriene Receptor Antagonist		
Long-Acting Beta Agonist		

Has the member tested positive to at least one perennial aeroallergen by a skin or blood test (i.e. RAST, CAP, intracutaneous test)? **Yes** **No**
 Please explain: _____

Is the member's IgE level ≥ 30 and ≤ 700 IU/ml? **Yes** **No** Please provide IgE level: _____

Prescriber Signature: _____ **Date of this request:** _____

Pulmonary Arterial Hypertension Medications

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Flolan[®]

- Clinical diagnosis of pulmonary hypertension
- AND
- The patient has had a documented intolerance to the generic epoprostenol.

Pulmonary Arterial Hypertension Medications <i>Length of Authorization: N/A</i> Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
<p><u>ENDOTHELIAL RECEPTOR ANTAGONISTS</u></p> <p>LETAIRIS[®] (ambrisentan) Tablet <i>Quantity Limit = one tablet/day</i></p> <p>TRACLEER[®] (bosentan) Tablet <i>Quantity Limit = 2 tablets/day</i></p> <p><u>PROSTANOIDS</u></p> <p>Injection EPOPROSTENOL † (compare to Flolan[®]) REMODULIN[®] (treprostinil sodium injection) VELETRI[®] (epoprostinil)</p> <p>Inhalation TYVASO[®] (treprostinil inhalation solution) VENTAVIS[®] (iloprost inhalation solution)</p> <p>**Maximum days supply for all drugs is 30 days**</p>	<p>Flolan^{®*} (epoprostenol)</p>

Note: Please refer to “Phosphodiesterase Inhibitor Medications” for Adcirca[®] and Revatio[®].

Renal Disease: Phosphate Binders

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Eliphos, PhosLo

- The patient must have a documented intolerance to the generic equivalent calcium acetate capsule or tablet.

Renvela Oral Suspension Packet

- The patient has a requirement for a liquid dosage form.

Renvela tablet

- The patient must have a documented side effect, allergy, or inadequate response to Renagel[®] (sevelamer hydrochloride).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **Prior Authorization Request Form.** **General**

Renal Disease: Phosphate Binders		<i>Length of Authorization: 1 year</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
CALCIUM ACETATE † (compare to PhosLo [®] , Eliphos [®]) capsule, tablet FOSRENOL [®] (lanthanum carbonate) RENAGEL [®] (sevelamer hydrochloride) tablet	Eliphos ^{®*} (calcium acetate) tablet PhosLo ^{®*} (calcium acetate) capsule Renvela [®] (sevelamer carbonate) Oral Suspension packet (<i>QL = 2 packs/day (0.8 g strength only)</i>) Renvela [®] (sevelamer carbonate) tablet	

Rheumatoid, Juvenile Idiopathic & Psoriatic Arthritis Medications: Injectables

NOTE: Rheumatoid, Juvenile Idiopathic and Psoriatic Arthritis Self-Injectables (Cimzia[®], Enbrel[®], Humira[®], Kineret[®] and Simponi) must be obtained and billed through our specialty pharmacy vendor, ICORE Healthcare. Please see the Cimzia, Enbrel, Humira, Kineret or Simponi Prior Authorization/Patient Enrollment Form for instructions. ICORE Healthcare may supply Remicade[®] upon request or you may continue to obtain through your usual supplier. ICORE Healthcare will not be supplying Actemra[®] or Orencia[®] at this time – please continue to obtain through your usual supplier.

LENGTH OF AUTHORIZATION: Initial PA of 3 months, and 12 months thereafter if medication is well tolerated. Re-evaluate every 12 months.

CRITERIA FOR APPROVAL:

Humira[®]

Patient has a diagnosis of rheumatoid arthritis (RA), juvenile idiopathic arthritis or psoriatic arthritis and has already been stabilized on Humira[®]

OR

Diagnosis is RA, juvenile idiopathic arthritis or psoriatic arthritis, and methotrexate therapy resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD¶ *should be tried prior to approving Humira[®].

Note: Approval should be granted in cases where patients have been treated with infliximab, but have lost response to therapy.

Enbrel[®]

Patient has a diagnosis of RA, juvenile RA (JRA), or psoriatic arthritis and has already been stabilized on Enbrel[®]

OR

Diagnosis is RA, JRA, or psoriatic arthritis, and methotrexate therapy resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD¶ *should be tried prior to approving Enbrel[®].

Actemra[®]

Patient has a diagnosis of RA or juvenile RA (JRA) and has already been stabilized on Actemra[®]

OR

Patient age \geq 18 years (RA) or \geq 2 years (JRA).

AND

Diagnosis is RA or juvenile RA (JRA) and patient has documentation of an inadequate response, adverse reaction or allergic response to methotrexate, or if methotrexate is contraindicated, at least 1 other DMARD¶ (other DMARDs include leflunomide, sulfasalazine, gold, antimalarials, minocycline, D-penicillamine, azathioprine, cyclophosphamide and cyclosporine)

AND

The prescriber must provide a clinically valid reason why either Humira[®] or Enbrel[®] cannot be used. For RA, patient must have had an inadequate response to one or more TNF inhibitors.

Cimzia[®]

Patient has a diagnosis of RA and has already been stabilized on Cimzia[®]

OR

Patient age \geq 18 years

AND

Diagnosis is RA and patient has documentation of an inadequate response, adverse reaction or allergic response to methotrexate, or if methotrexate is contraindicated, at least 1 DMARD (other DMARDs include leflunomide, sulfasalazine, gold, antimalarials, minocycline, D-penicillamine, azathioprine, cyclophosphamide and cyclosporine)

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

Remicade®

Patient has a diagnosis of RA or psoriatic arthritis and has already been stabilized on Remicade®

OR

Diagnosis is RA or psoriatic arthritis, and methotrexate therapy resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD* should be tried prior to approving Remicade®.

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

Simponi®

Patient has a diagnosis of RA or psoriatic arthritis and has already been stabilized on Simponi®

OR

Patient age \geq 18 years

AND

Diagnosis is RA or psoriatic arthritis, and patient has documentation of an inadequate response, adverse reaction or allergic response to methotrexate, or if methotrexate is contraindicated, at least 1 DMARD* (other DMARDs include leflunomide, sulfasalazine, gold, antimalarials, minocycline, D-penicillamine, azathioprine, cyclophosphamide and cyclosporine)

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

Kineret®

Patient has a diagnosis of RA and has already been stabilized on Kineret®

OR

Diagnosis is RA or psoriatic arthritis, and methotrexate therapy resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD should be tried prior to approving Kineret®.

Note: Kineret® may be used as monotherapy or concomitantly with DMARDs, other than TNF antagonists. Kineret® should not be administered concomitantly with any TNF antagonists (i.e. Enbrel®, Humira®, or Remicade®).

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

Orencia®

Patient has a diagnosis of RA or juvenile RA (JRA) and has already been stabilized on Orencia®

OR

Diagnosis is RA or juvenile RA (JRA) and methotrexate therapy resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD¶ should be tried prior to approving Orencia®. **Note:** Orencia® may be used as monotherapy or concomitantly with DMARDs, other than TNF antagonists. Orencia® should not be administered concomitantly with TNF antagonists (i.e. Enbrel®, Humira®, or Remicade®) and is not recommended for use with Kineret®.

AND

The prescriber must provide a clinically valid reason why either Humira® or Enbrel® cannot be used.

¶ Patients with systemic juvenile arthritis (SJRA/SJIA) and fever are not required to have a trial of a DMARD, including methotrexate. Patients with systemic juvenile arthritis without fever should have a trial of methotrexate, but a trial of another DMARD in case of a contraindication to methotrexate, is not required before Enbrel®, Humira®, Actemra®, or Orencia® is approved.

* Patients with psoriatic arthritis with a documented diagnosis of active axial involvement should have a trial of NSAID therapy, but a trial with DMARD is not required before a TNF-blocker is approved. If no active axial skeletal involvement, then an NSAID trial and a DMARD trial are required (unless otherwise contraindicated) prior to receiving Humira®, Enbrel®, Remicade® or Simponi®

DOCUMENTATION:

- ✓ Document clinical information for Cimzia®, Enbrel®, Humira®, Kineret® or Simponi® on its **Prior Authorization/Patient Enrollment Form** and clinically compelling information supporting the choice of Remicade® on a **Remicade Prior Authorization Request Form** or Actemra® or Orencia® on a **General Prior Authorization Request Form**.
- ✓ All requests for infliximab (Remicade®) (whether billed through the pharmacy or medical benefit (J1745)) or tocilizumab (Actemra®) (J3262) or abatacept (Orencia) (J0129) (both are billed through the medical benefit) require Prior Authorization through the MedMetrics Clinical Call Center.

Rheumatoid, Juvenile Idiopathic and Psoriatic Arthritis: Injectables	
<i>Length of authorization: Initial PA of 3 months; 12 months thereafter</i>	
PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET	NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET
ENBREL® (etanercept) <i>(Quantity limit = 4 syringes/28 days(50 mg) and 8 syringes/28 days (25 mg))</i> HUMIRA® (adalimumab) <i>(Quantity limit = 4 syringes/28 days)</i>	Actemra® (tocilizumab) <i>(Qty limit = 4 vials/28 days (80 mg vial), 3 vials/28 days (200 mg vial) or 2 vials/28 days (400 mg vial))</i> Cimzia® (certolizumab pegol) <i>(Quantity limit = 1 kit/28 days (starter X 1, then regular))</i> Kineret® (anakinra) <i>(Quantity limit = 1 syringe/day)</i> Orencia® (abatacept) Remicade® (infliximab) Simponi® (golimumab) <i>(Qty limit = 1 syringe/28 days)</i>

Saliva Stimulants

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

SALAGEN®

- The patient has had a documented side effect, allergy, or treatment failure to generic pilocarpine.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Saliva Stimulants		<i>Length of Authorization: 1 year</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
PILOCARPINE† (compare to Salagen®) EVOXAC® (cevimeline)	Salagen®* (pilocarpine)	

Sedative Hypnotics: Benzodiazepine

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

The patient has had a documented side effect, allergy, or treatment failure with two preferred benzodiazepine sedative/hypnotics. If a product has an AB rated generic, one trial must be the generic.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 160 for a description of the management of mental health drugs.

Sedative Hypnotics: Benzodiazepine		<i>Length of Authorization: 1 year</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
ESTAZOLAM† (compare to Prosom®) FLURAZEPAM† (formerly Dalmane®) TEMAZEPAM 15 mg, 30 mg † (compare to Restoril®)	Doral® (quazepam) Halcion® (triazolam) Prosom®* (estazolam) Restoril®* (temazepam) temazepam† 7.5 mg, 22.5 mg (compare to Restoril®) triazolam † (compare to Halcion®)	

Sedative Hypnotics: Non-benzodiazepine, Non-barbiturate

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Ambien®:

The patient has had a documented intolerance to generic zolpidem.

Ambien CR®, Lunesta®, Zolpidem CR:

The patient has had a documented side effect, allergy or treatment failure to generic zolpidem. If the request is for Ambien CR 6.25 mg, there has also been a documented intolerance to the generic. If the request is for Zolpidem CR 12.5 mg, there has also been a documented intolerance to the brand product.

Edluar®:

The patient has a medical necessity for a disintegrating tablet formulation (i.e. swallowing disorder).

AND

The patient has a documented intolerance to Zolpimist®.

Rozerem®: The patient has had a documented side effect, allergy, contraindication or treatment failure to generic zolpidem.

OR

There is a question of substance abuse with the patient or family of the patient.

Note: If approved, initial fill of Rozerem® will be limited to a 14 day supply.

Silenor®: The patient has had a documented side effect, allergy, contraindication or treatment failure to generic zolpidem.

AND

The patient has had a documented intolerance with generic doxepin or there is another clinically valid reason why a generic doxepin (capsule or oral solution) cannot be used.

Somnote®: The patient has had a documented side effect, allergy, or treatment failure with two preferred medications from the sedative hypnotic: benzodiazepine and/or sedative hypnotic: non-benzodiazepine, non-barbiturate classes.

Sonata®:

The patient has had a documented intolerance to generic zaleplon

Zolpimist®:

The patient has a medical necessity for a non-oral dosage form (i.e. swallowing disorder).

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

MANAGEMENT OF MENTAL HEALTH DRUGS: See page 160 for a description of the management of mental health drugs.

Sedative Hypnotics: Non-benzodiazepine, Non-barbiturate	
<i>Length of Authorization: 1 year</i>	
Key: † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
CHLORAL HYDRATE † syrup	Ambien®* (zolpidem) (<i>Quantity Limit = 1 tab/day</i>)
ZOLPIDEM † (compare to Ambien®) (<i>Quantity Limit = 1 tab/day</i>)	Ambien CR® (zolpidem) (<i>Quantity Limit = 1 tab/day</i>)
ZALEPLON † (compare to Sonata®) (<i>Quantity limit = 1 capsule/day (5 mg) or 2 capsules/day (10 mg)</i>)	Edluar® (zolpidem) sublingual tablet (<i>Quantity Limit = 1 tab/day</i>)
	Lunesta® (eszopiclone) (<i>Quantity Limit = 1 tab/day</i>)
	Rozerem® (ramelteon) (<i>Quantity Limit = 1 tab/day</i>)
	Silenor® (doxepin) (<i>Quantity limit = 1 tab/day</i>)
	Somnote® (chloral hydrate capsule)
	Sonata® (zaleplon) (<i>Quantity limit = 1 cap/day (5 mg) or 2 caps/day (10 mg)</i>)
	Zolpidem CR† (compare to Ambien CR®) (<i>Quantity Limit = 1 tab/day</i>)
	Zolpimist® (zolpidem) Spray (5 mg/spray) (<i>Quantity Limit = 1 canister/30 days</i>)

Skeletal Muscle Relaxants: Oral

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

MUSCULOSKELETAL AGENTS:

Amrix, cyclobenzaprine ER, cyclobenzaprine 7.5 mg, Fexmid

- The prescriber must provide a clinically valid reason why a preferred generic cyclobenzaprine cannot be used. If a branded specialty cyclobenzaprine product is requested, the patient must also have a documented intolerance to the generic equivalent.

Brand skeletal muscle relaxants with generics available (Flexeril, Parafon Forte DSC, Robaxin):

- The patient has had a documented side effect, allergy or treatment failure with two different preferred musculoskeletal agents (One trial must be the AB rated generic).

carisoprodol, carisoprodol/ASA, carisoprodol/ASA/codeine, Soma, metaxolone, Skelaxin:

- The patient has had a documented side effect, allergy or treatment failure with two different preferred musculoskeletal agents. Additionally, if a brand name product is requested where an AB rated generic exists, the patient must also have had a documented intolerance to the generic product.

orphenadrine/ASA/caffeine

- The prescriber must provide a clinically valid reason why generic orphenadrine in combination with aspirin (or another analgesic) cannot be used.

ANTISPASTICITY AGENTS:

Dantrium, Zanaflex tablets:

- The patient must have a documented side effect, allergy, or treatment failure with the AB rated generic product.

Zanaflex capsules:

- The prescriber must provide a clinically valid reason why generic tizanidine tablets cannot be used.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **Prior Authorization Request Form.** **General**

Skeletal Muscle Relaxants: Oral

Length of Authorization: 1 year

Key: † Generic product, *Indicates generic equivalent is available without a PA

PREFERRED DRUGS (No PA Required)

PA REQUIRED

Musculoskeletal Agents

Single Agent

CHLORZOXAZONE† (compare to Parafon Forte DSC®)

CYCLOBENZAPRINE† (compare to Flexeril®)

METHOCARBAMOL† (compare to Robaxin®)

ORPHENADRINE CITRATE ER† (previously Norflex®)

Amrix® (cyclobenzaprine sustained-release)

carisoprodol 250 mg

carisoprodol† 350 mg (compare to Soma®)

cyclobenzaprine ER† (compare to Amrix®)

cyclobenzaprine 7.5 mg† (compare to Fexmid®)

Fexmid® (cyclobenzaprine)

Flexeril®* (cyclobenzaprine)

metaxalone† (compare to Skelaxin®)

Parafon Forte DSC®* (chlorzoxazone)

Robaxin®* (methocarbamol)

Skelaxin® (metaxalone)

Soma® (carisoprodol)

Combination Product

carisoprodol, ASA† (previously Soma Compound®)

carisoprodol, ASA, codeine† (previously Soma Compound with Codeine®)

Orphenadrine, ASA, caffeine† (previously Norgesic®, Norgesic Forte®)

ASA = aspirin

Antispasticity Agents

BACLOFEN† (previously Lioresal®)

DANTROLENE† (compare to Dantrium®)

TIZANIDINE† (compare to Zanaflex®) tablets

Dantrium®* (dantrolene)

Zanaflex®* (tizanidine) capsules

Zanaflex®* (tizanidine) tablets

**Effective 11/1/06: All carisoprodol products (brand and generic) move to "PA REQUIRED"*

Smoking Cessation Therapies

LENGTH OF AUTHORIZATION: up to 16 weeks (2 x 8 weeks) for nicotine replacement OR up to 24 weeks (2 x 12 weeks) for oral therapy (per rolling 365 days)

CRITERIA FOR APPROVAL:

nicotine patch OTC/Rx, Nicotine System Kit

- The patient has had a documented intolerance to Nicoderm CQ patch.

nicotine gum

- The patient has had a documented intolerance to Nicorette gum.

nicotine lozenge

- The patient has had a documented side effect or allergy to Nicorette lozenge or Commit lozenge.

Nicotrol Inhaler

- The patient has had a documented treatment failure with BOTH Nicoderm CQ patch and Nicorette gum.

Nicotrol Nasal Spray

- The prescriber must provide a clinically valid reason for the use of the requested medication.

Zyban

- The patient has had a documented side effect or allergy to bupropion SR.

Smoking Cessation Counseling is encouraged with the use of smoking cessation therapies

Vermont QUIT LINE (available free to all patients) 1-877-YES-QUIT (937-7848)

GETQUIT™ Support Plan available free to all Chantix® patients 1-877-CHANTIX (242-6849)

DOCUMENTATION:

- Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form.**

Smoking Cessation Therapies		<i>Length of Authorization: see table</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
<u>NICOTINE REPLACEMENT (Maximum duration is 16 weeks (2 x 8 weeks)/365 days)♣</u>		
NICODERM CQ PATCH® NICORETTE GUM® COMMIT LOZENGE® NICORETTE LOZENGE®	nicotine patch OTC† nicotine patch RX† (compare to Habitrol®) Nicotine System Kit® nicotine gum† Nicotine lozenge† Nicotrol inhaler® Nicotrol Nasal Spray®	
<u>ORAL THERAPY</u>		
BUPROPION SR† (compare to Zyban®) CHANTIX® (varenicline) (Limited to 18 years and older, quantity Limit = 2 tabs/day, maximum duration 24 weeks (2 x 12 weeks)/365 days)♣	Zyban®* (bupropion SR) (maximum duration 24 weeks (2 x 12 weeks)/365 days)♣	

♣ For approval of therapy beyond the established maximum duration, the prescriber must provide evidence that the patient is engaged in a smoking cessation counseling program.

Testosterone: Topical

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Andoderm[®], Axiron[®], Fortesta[®], Testim[®]

- The patient has had a documented side effect, allergy, or treatment failure to AndroGel[®] Gel or Pump.

LIMITATIONS:

Coverage of testosterone products is limited to males.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Testosterone: Topical		<i>Length of Authorization: 1 year</i>
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
<p>ANDROGEL[®] GEL (testosterone 1% gel packets) <i>Quantity limit = 2.5 gm packet (1 packet/day)</i> <i>5 gm packet (2 packets/day)</i></p> <p>ANDROGEL[®] PUMP (testosterone pump bottles) <i>Quantity limit = 1 % (4 bottles/30 days)</i> <i>1.62% (2 bottles/30days)</i></p>	<p>Androderm[®] Transdermal 2.5 mg, 5 mg (testosterone patch) <i>Quantity limit = 1 patch/day/strength</i></p> <p>Axiron (testosterone 2% solution) 90 ml Pump Bottle <i>Quantity limit = 2 bottles/30 days</i></p> <p>Fortesta[®] (testosterone 2 % Gel) 60 gm Pump Bottle <i>Quantity limit = 2 bottles/30 days</i></p> <p>Testim[®] Gel 5 gm (testosterone 1% gel tube) <i>Quantity limit = 2 tubes/day</i></p>	
* Maximum days supply all products is 30 days *	* Maximum days supply all products is 30 days *	

Thrombopoietin Receptor Agonists

LENGTH OF AUTHORIZATION: initial approval 3 months, subsequent approvals 6 months

CRITERIA FOR APPROVAL:

- The patient is at least 18 years of age.
- **AND**
- The diagnosis or indication is chronic immune (idiopathic) thrombocytopenic purpura (ITP).
- **AND**
- The patient's platelet count is less than 30,000/ μL ($< 30 \times 10^9/\text{L}$) or the patient is actively bleeding.
- **AND**
- The patient has had a documented side effect, allergy, treatment failure or a contraindication to therapy with corticosteroids.
- **OR**
- The patient has a documented insufficient response following splenectomy.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the use of a non-preferred agent on the **General Prior Authorization Request Form**

Thrombopoietin Receptor Agonists	
<i>Length of Authorization: initial approval 3 months, subsequent approvals 6 months</i>	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
	Nplate [®] (romiplostim) Promacta [®] (eltrombopag)

Urinary Antispasmodics

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL: (for patients >21 and <65 years of age):

Please note: Patients <21 years of age are exempt from all ORAL Urinary Antispasmodics PA requirements (Exception: An adequate trial of oxybutynin/oxybutynin XL will be required before approval of Ditropan/Ditropan XL will be granted for all patients) and patients ≥ 65 years of age are exempt from the short acting oxybutynin trial requirement.

Ditropan, flavoxate, Enablex, Vesicare

- The patient has had a documented side effect, allergy, or treatment failure with generic oxybutynin.

Detrol, Detrol LA, Ditropan XL, Oxybutynin XL, Sanctura, Sanctura XR, trospium (generic), Toviaz

- The patient has had a documented side effect, allergy, or treatment failure with generic oxybutynin.
AND
- The patient has had a documented side effect, allergy, or treatment failure with 2 preferred long-acting agents. If a medication has an AB rated generic, there must have also been a trial of the generic formulation.

Gelnique, Oxytrol

- The patient is unable to swallow a solid oral formulations (e.g. patients with dysphagia)
OR
- The patient is unable to be compliant with solid oral dosage forms.

DOCUMENTATION:

- ✓ Document clinically information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Urinary Antispasmodics	
<i>Length of Authorization: 1 year</i>	
Key : † Generic product, *Indicates generic equivalent is available without a PA	
PREFERRED DRUGS (No PA Required)	PA REQUIRED
SHORT-ACTING AGENTS	
OXYBUTYNIN† (compare to Ditropan®)	Ditropan®* (oxybutynin) Flavoxate † (formerly Urispas®)
LONG-ACTING AGENTS (after clinical criteria are met)	
<u>Twice Daily</u> (<i>Qty Limit = 2 per day</i>)	Detrol® (tolterodine) Sanctura® (trospium) Trospium† (Sanctura®)
<u>Once Daily</u> (<i>Qty Limit = 1 per day</i>) ENABLEX® (darifenacin) VESICARE® (solifenacin)	Detrol LA® (tolterodine) Ditropan XL® (oxybutynin XL) oxybutynin XL† (compare to Ditropan® XL) Sanctura XR® (trospium) Toviaz® (fesoterodine)
<u>Transdermal/Topical</u>	Gelnique® (oxybutynin topical gel) (<i>Qty limit = 1 sachet/day</i>) Oxytrol® (oxybutynin transdermal) (<i>Qty limit = 8 patches/28 days</i>)
<p><i>Note:</i></p> <ul style="list-style-type: none"> ◆Patients under the age of 65 must fail an adequate trial of generic oxybutynin before approval will be granted for either Vesicare® or Enablex®. ◆ A therapeutic failure on two preferred long acting products is required before a PA will be approved on any non-preferred long acting medication. ◆Recipients < 21 years of age are exempt from all ORAL PA Requirements.(Exception: An adequate trial of oxybutynin/oxybutynin XL will be required before approval of Ditropan® / Ditropan® XL will be granted) 	

Vaginal Anti-Infectives

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

Cleocin[®], Clindesse[®]:

- The patient has had a documented side effect, allergy, or treatment failure to generic clindamycin vaginal (clindamycin vaginal or Clindamax).

Metrogel Vaginal[®]:

- The patient has had a documented side effect, allergy, or treatment failure to generic metronidazole vaginal gel 0.75 % or Vandazole.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **General Prior Authorization Request Form**.

Vaginal Anti-Infectives		<i>Length of Authorization: 1 year</i>
Key: † Generic product, *Indicates generic equivalent is available without a PA		
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
<u>CLINDAMYCIN</u>		
CLINDAMYCIN VAGINAL† (clindamycin vaginal cream 2%) CLINDAMAX† (clindamycin vaginal cream 2%)	Cleocin ^{®*} (clindamycin vaginal cream 2%) Clindesse [®] (clindamycin vaginal cream 2%) Cleocin [®] Vaginal Ovules (clindamycin vaginal suppositories)	
<u>METRONIDAZOLE</u>		
METRONIDAZOLE VAGINAL GEL 0.75% † VANDAZOLE† (metronidazole vaginal 0.75%)	Metrogel Vaginal ^{®*} (metronidazole vaginal gel 0.75%)	

Vitamins: Prenatal Multivitamins

LENGTH OF AUTHORIZATION: 1 year

CRITERIA FOR APPROVAL:

All Non-Preferred

- The prescriber must provide a clinically valid reason for the use of the requested medication including reasons why any of the preferred products would not be a suitable alternative.

DOCUMENTATION:

- ✓ Document clinically compelling information supporting the choice of a non-preferred agent on a **Prior Authorization Request Form.** **General**

Vitamins: Prenatal Multivitamins		<i>Length of Authorization: 1 year</i>
PREFERRED DRUGS (No PA Required)	PA REQUIRED	
PRENAPLUS® PRENATAL PLUS/IRON® PRENATAL PLUS® PRENATE PLUS®	All others	

II. PRIOR AUTHORIZATION REQUEST & SPECIALTY PHARMACY ORDER FORMS

- ▶ [**Bone Resorption Inhibitors Injectable Prior Authorization Request Form**](#)
- ▶ [**Buprenorphine Prior Authorization Request Form**](#)
- ▶ [**Cystic Fibrosis Medication Order Form**](#)
- ▶ [**Enbrel[®] Prior Authorization Request/Order Form**](#)
- ▶ [**General Prior Authorization Request Form**](#)
- ▶ [**General SPECIALTY Prior Authorization Request/Order Form**](#)
- ▶ [**Gilenya[®] Prior Authorization Request/Order Form**](#)
- ▶ [**Growth Stimulating Agents Prior Authorization Request/Order Form**](#)
- ▶ [**Hemophilia Factors Order Form**](#)
- ▶ [**Hepatitis C \(Peg-Interferon/Ribavirin\) Prior Authorization Request/Order Form**](#)
- ▶ [**Hepatitis C Protease Inhibitors Prior Authorization Request/Order Form**](#)
- ▶ [**Humira[®] Prior Authorization Request/Order Form**](#)
- ▶ [**Kineret[®] Prior Authorization Request/Order Form**](#)
- ▶ [**Long Acting Narcotics Prior Authorization Request Form**](#)
- ▶ [**Multiple Sclerosis Self Injectables Order Form**](#)
- ▶ [**Nutritionals Prior Authorization Request Form**](#)
- ▶ [**Oncology: Oral \(Select Agents\) Order Form**](#)
- ▶ [**Remicade[®] Prior Authorization Request Form**](#)
- ▶ [**Seroquel[®] Prior Authorization Request/Order Form**](#)

- ▶ [Simponi[®] Prior Authorization Request/Order Form](#)
- ▶ [Stelara[®] Prior Authorization Request/Order Form](#)
- ▶ [Synagis[®] Prior Authorization Request/Order Form](#)
- ▶ [Vivitrol[®] Prior Authorization Request Form](#)
- ▶ [Xolair[®] Prior Authorization Request Form](#)



Department of Vermont Health Access
 312 Hurricane Lane, Suite 201
 Williston, Vermont 05495

Agency of Human Services

~ BONE RESORPTION INHIBITORS INJECTABLE ~

Prior Authorization Request Form

Vermont Medicaid has established criteria for prior authorization of ossification enhancing injectables.. For beneficiaries to receive coverage for these agents, it will be necessary for the prescriber to telephone or complete and fax this form to MedMetrics Health Partners. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name: _____
 Phone #: _____
 Fax #: _____
 Address: _____
 Contact Person at Office: _____

Beneficiary:

Name: _____
 Medicaid ID #: _____
 Date of Birth: _____ Sex: _____

Will this medication be billed through the: **pharmacy benefit** or **medical benefit** (J-code or other code)? **(Please check one)**

Administering Provider if other than Prescriber: (name): _____ NPI #: _____

Pharmacy (if known): _____ Phone: _____ &/or FAX: _____

Drug requested: Boniva IV Forteo Prolia Reclast Xgeva

Dose & frequency: _____

Diagnosis/indication:

- Treatment of postmenopausal osteoporosis Treatment of male osteoporosis
- Paget's Disease Treatment of glucocorticoid induced osteoporosis
- Bone metastases from solid tumors (tumor type: _____)
- Other (Please Explain) _____

Has the member previously tried the following preferred medication?

<i>Drug:</i>	<i>Response:</i>
<input type="checkbox"/> Alendronate Oral	<input type="checkbox"/> side-effect <input type="checkbox"/> treatment failure* dates of use: _____

*Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with the bisphosphonate.

Prescriber comments: _____

Prescriber Signature: _____

Date of this request: _____

~BUPRENORPHINE ~
 Prior Authorization Request Form

Vermont Medicaid has established criteria for prior authorization of buprenorphine (Suboxone[®], Subutex[®]). These criteria are based on concerns about safety and the potential for abuse and diversion. All requests must be submitted using this fax form.

Submit request via Fax (only): 1-866-767-2649

Prescribing physician:

 Name: _____
 Phone #: _____
 Fax #: _____
 Address: _____

Beneficiary:

 Name: _____
 Medicaid ID #: _____
 Date of Birth: _____ Sex: _____

Contact Person at Office: _____

► Please answer the following questions:

Is buprenorphine being prescribed for opiate dependency?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Does the prescriber signing this form have a DATA 2000 waiver ID number ("X-DEA license")?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Has the prescriber queried the VPMS (Vermont Prescription Monitoring System) to review patient's scheduled II-IV medication history?	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not signed up
A "Pharmacy Home" for ALL prescriptions has been selected AND discussed with patient? (Pharmacy must be located/licensed in VT) Pharmacy Name: _____ Pharmacy Phone #: _____	<input type="checkbox"/> Yes <input type="checkbox"/> No
Has patient filled a Suboxone RX in last 60 days	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Don't know
Request is for the following medication: Sublingual FILM	<input type="checkbox"/> Suboxone [®] (buprenorphine/naloxone)
Request is for the following medication: Sublingual TABLET	<input type="checkbox"/> Suboxone [®] (buprenorphine/naloxone) <input type="checkbox"/> Buprenorphine (compare to Subutex [®])
Anticipated maintenance dose/frequency: (target dose of no more than 16 mg/day) (maximum 14 day supply per prescription fill) Dose: _____ Frequency: _____ (recommended once daily)	
If this request is for Buprenorphine (compare to Subutex [®]), please answer the following questions: Is the member pregnant? (please provide history from OB provider) If yes, anticipated date of delivery: _____	<input type="checkbox"/> Yes <input type="checkbox"/> No
Is the member breastfeeding a methadone dependent baby? (please provide history from neonatologist or pediatrician)	<input type="checkbox"/> Yes <input type="checkbox"/> No
Would you have referred your patient to a methadone clinic if this option was conveniently located and available?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Additional clinical information to support PA request:	

Prescriber Signature: _____ (stamps not acceptable)

Prescriber X-DEA License #: _____ **Date of request:** _____



VERMONT CYSTIC FIBROSIS MEDICATION – Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address		City	
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address		City	
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

Please Note: Cayston® and pancreatic enzymes are not obtained through ICORE Specialty Pharmacy.

3 Department of Vermont Health Access PRIOR AUTHORIZATION REQUEST/PRESCRIPTION CYSTIC FIBROSIS INHALATION MEDICATION

Patient Diagnosis:

Cystic Fibrosis Other: _____

(Requires Review by DVHA Medical Director)

Product:

Pulmozyme® (dornase alfa inhalation) 1 mg/ml 2.5 ml ampules

Administer via nebulizer once daily.
Dispense # 30 Refill ____ times

Administer via nebulizer twice daily.
Dispense # 60 Refill ____ times

TOBI® (tobramycin solution for inhalation) 300 mg/5 ml ampules

Administer via nebulizer twice daily,
alternating 28 days on and 28 days off

Dispense # 56 Refill ____ times

Deliver product to: Patient's home MD office Clinic

Prescriber's Signature: _____ **Date:** _____



ENBREL® (etanercept) - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address			City
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address			City
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

3 Department of Vermont Health Access ENBREL® (etanercept) PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:

Rheumatoid Arthritis Psoriatic Arthritis Juvenile Idiopathic Arthritis
 Ankylosing Spondylitis Plaque Psoriasis

If requesting prescriber is not a Rheumatologist or Dermatologist, has one of these specialties been consulted on this case? **Yes** **No**

Specialist name: _____ Specialist Type: _____

List previous medications/therapies tried and failed for this condition: (include oral, injectable, topical, phototherapy etc.)

Therapy (and dates)	Reason for discontinuation
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

Prescriber Additional Comments: _____

4 PRESCRIPTION

Dosage Form and Quantity:

Enbrel 25 mg prefilled syringe Dispense Quantity: _____
or
 Enbrel 25 mg multi-use vial Dispense Quantity: _____
or
 Enbrel 50mg prefilled syringe Dispense Quantity: _____
or
 Enbrel 50mg SureClick autoinjector Dispense Quantity: _____

Sig: Dose/Route/Frequency: _____

Refill X: _____

Deliver product to: Patient's home MD office Clinic

Prescriber's Signature: _____ **Date:** _____



Department of Vermont Health Access
 312 Hurricane Lane, Suite 201
 Williston, Vermont 05495

Agency of Human Services

~ GENERAL ~

Prior Authorization Request Form

In order for beneficiaries to receive Medicaid coverage for medications that require prior authorization, the prescriber must telephone or complete and fax this form to MedMetrics Health Partners. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Beneficiary:

Name: _____

Name: _____

Phone #: _____

Medicaid ID #: _____

Fax #: _____

Date of Birth: _____ Sex: _____

Address: _____

Contact Person at Office: _____

Will this medication be billed through the: **pharmacy benefit** or **medical benefit** (J-code or other code)? **(Please check one)**

Administering Provider if other than Prescriber: (name): _____ NPI #: _____

Pharmacy (if known): _____ Phone: _____ &/or FAX: _____

1. Drug Requested: _____ **Strength, Route & Frequency:** _____ **Length of therapy:** _____

Brand Name **Generic Equivalent**

2. Patient's diagnosis for use of this medication: _____

3. Previous history of a medical condition, allergies or other pertinent medical information, that necessitates the use of this medication: _____

Was patient seen by any other provider for this condition? YES / NO What specialty? _____

4. Please list preferred medications previously tried and failed for this condition:

Name of medication	Reason for failure	Date
_____	_____	_____
_____	_____	_____
_____	_____	_____

5. Please list pertinent laboratory test(s) or procedure(s) if applicable:

Procedure	Findings	Date
_____	_____	_____
_____	_____	_____

6. Other Information/ comments:

Prescriber Signature: _____

Date of this request: _____



"GENERAL" SPECIALTY - Prior Authorization and Patient Enrollment Form

USE WHEN NO DRUG SPECIFIC FORM EXISTS - Complete form in its entirety and fax to number listed below

PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address		City	
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address		City	
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

3

**Department of Vermont Health Access
"GENERAL" SPECIALTY MEDICATIONS (Not drug specific)
PRIOR AUTHORIZATION REQUEST**

Patient Diagnosis: _____

Drug Requested: _____

Strength, Route & Frequency: _____

Length of therapy: _____

Previous history of a medical condition, allergies or other pertinent medical information, that necessitates the use of this particular medication: _____

Was patient seen by any other provider for this condition? Yes No

Specialist name: _____ Specialist Type: _____

Medications previously tried and failed for this condition:

Name of medication	Type of failure	Date
_____	_____	_____
_____	_____	_____
_____	_____	_____

Please list pertinent laboratory test(s) or procedure(s) if applicable:

Procedure/Test	Findings	Date
_____	_____	_____
_____	_____	_____

Other Information/ comments: _____

4

PRESCRIPTION

Drug Name/Strength: _____

Sig: Dose: _____ Route: _____ Frequency: _____

Qty: _____ Refill X: _____

Deliver product to: Patient's home MD office Clinic

Prescriber's Signature: _____ Date: _____



GROWTH STIMULATING AGENTS - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address			City
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address			City
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

**3 Department of Vermont Health Access
 GROWTH STIMULATING AGENTS
 PRIOR AUTHORIZATION REQUEST**

Patient Diagnosis: _____

Requested DVHA **PREFERRED** Growth Stimulating Agent
 Norditropin®

Growth Hormone Stimulation Test # 1	Test:	result:
Growth Hormone Stimulation Test # 2	Test:	result:
Patient's Height:		
Patient's Bone Age:		
Patient's Chronological Age:		
Growth Velocity:		
IGF-1 results:		

Please explain the medical necessity for a '**NON-PREFERRED**' product:
 Genotropin® Humatrope® Nutropin® Omnitrope® Saizen® Tev-Tropin®
 Medical justification: _____

Request is for a '**SPECIALIZED INDICATION**' product: (Criteria in Clinical Criteria Manual)
 Increlex® Serostim® Zorbtive®

Other information/ Prescriber comments: _____

4 PRESCRIPTION

Norditropin® Nordiflex Norditropin® Cartridge Norditropin® Flexpro
 Other Product: (Please Specify) _____

Dosage Form / Strength: _____

Dose/Route & Frequency (Sig): _____

Dispense Quantity: One month supply or _____ Refill X _____

Needles/syringes: quantity sufficient for drug supply with refills as above

Deliver product to: Patient's home MD office Clinic

Prescriber's Signature: _____ **Date:** _____



HEMOPHILIA FACTORS - Patient Enrollment and Prescription Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address		City	
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address		City	
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

3 Department of Vermont Health Access PRESCRIPTION HEMOPHILIA FACTORS

Patient Diagnosis:	
<input type="checkbox"/> Hemophilia A – Factor VIII Disease	
<input type="checkbox"/> Hemophilia B – Factor IX Disease	
<input type="checkbox"/> von Willebrand Disease	
Patient Weight (kg):	Native Factor Level:
Product Name:	
Dose / Frequency Instructions:	
# of doses ordered: _____ Refills: _____ If doses of different units are ordered, specific number of doses of each	
Reason(s) for Use:	
<input type="checkbox"/> Prophylaxis only <input type="checkbox"/> Episodic only <input type="checkbox"/> Prophylaxis and PRN	
<input type="checkbox"/> Acute Bleeding Episode <input type="checkbox"/> Surgical Prophylaxis <input type="checkbox"/> Dental Procedure	
Recent bleed while on Prophylaxis:	
Date of bleed: ____/____/____	
Location of bleed: _____ Severity of bleed: _____	
# of Doses already administered prior to this order: _____ IU/Dose: _____	
Deliver product to: <input type="checkbox"/> Patient's home <input type="checkbox"/> MD office <input type="checkbox"/> Clinic	
<input type="checkbox"/> Needles/syringes: quantity sufficient for factor supply	
Prescriber's Signature: _____	Date: _____



HEPATITIS C MEDICATIONS – Peg-Interferon/Ribavirin

Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address			City
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address			City
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

**3 Department of Vermont Health Access
 HEPATITIS C MEDICATIONS – Peg-Interferon/Ribavirin
 PRIOR AUTHORIZATION REQUEST**

Patient Diagnosis:	Genotype:
If requesting prescriber is not a Hepatologist, Gastroenterologist or ID Specialist, has one of these specialties been consulted on this case? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Specialist name: _____ Specialist Type: _____	
Requested DVHA PREFERRED Oral Hepatitis C Product? <input type="checkbox"/> Ribavirin 200 mg Tab (compare to Copegus®) <input type="checkbox"/> Ribavirin 200 mg Cap (compare to Rebetol®)	
For any DVHA NON-PREFERRED Oral Hepatitis C Product or Strength, please explain the medical necessity for this product: Product: _____ Medical justification: _____	
Requested DVHA PREFERRED Injectable Hepatitis C Product? <input type="checkbox"/> Pegasys® Prefilled Syringe <input type="checkbox"/> Pegasys® Single Dose Vial	
For any DVHA NON-PREFERRED Injectable Hepatitis C Product, please explain the medical necessity for this product: Product: _____ Medical justification: _____	
Patient will also be receiving (Please complete Hepatitis C Protease Inhibitors PA Form) <input type="checkbox"/> Incivek® <input type="checkbox"/> Victrelis® <input type="checkbox"/> Neither	

4 PRESCRIPTION

Oral:
 Ribavirin 200 mg Tablet or Capsule
 Other (Specify): _____
 Dose: _____ Frequency: _____ Qty: 28 days supply Refill X: _____

Injectable:
 Pegasys® Prefilled Syringe 180 mcg/0.5 ml "Convenience Kit" (4 syringes/box)
or
 Pegasys® 180 mcg/1 ml Single Dose Vial
or
 Other (choose): PEG-Intron® RediPen PEG-Intron® Kit Infergen®
 Specify Strength of above: _____
 Sig: Dose/Route/Frequency: _____
 Dispense Quantity: 28 days supply Refill X: _____

Needles/syringes: quantity sufficient for drug supply with refills as above
 Deliver product to: Patient's home MD office Clinic
Prescriber's Signature: _____ **Date:** _____



HEPATITIS C PROTEASE INHIBITORS (INCIVEK®/VICTRELIS®)

Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address		City	
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address		City	
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

**3 Department of Vermont Health Access
HEPATITIS C PROTEASE INHIBITORS
PRIOR AUTHORIZATION REQUEST**

Patient Diagnosis:	Genotype:
If requesting prescriber is not a Hepatologist, Gastroenterologist or ID Specialist, has one of these specialties been consulted on this case? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Specialist name: _____ Specialist Type: _____	
Requested Hepatitis C Protease Inhibitor? <input type="checkbox"/> Incivek®: 375 mg tablet <input type="checkbox"/> Victrelis®: 200 mg capsule	
Patient is treatment naive? <input type="checkbox"/> Yes <input type="checkbox"/> No	
If no, previous response to peg-interferon/ribavirin <input type="checkbox"/> Null responder <input type="checkbox"/> Partial responder <input type="checkbox"/> Relapser	
Patient has had previous therapy with Incivek® or Victrelis®? <input type="checkbox"/> Yes <input type="checkbox"/> No	
If yes, please specify: _____ (agent) ___/___/___ (date) _____ (response)	
Most recent HCV-RNA level: _____ IU/mL Date: ___/___/_____	
Patient has cirrhosis? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Ribavirin/peg-interferon will be used concomitantly <input type="checkbox"/> Yes <input type="checkbox"/> No	
Ribavirin/peg-interferon PA form included <input type="checkbox"/> Yes <input type="checkbox"/> No or	
Patient has had started Ribavirin/peg-interferon therapy <input type="checkbox"/> Yes <input type="checkbox"/> No	
If yes, date therapy initiated: ___/___/_____	
Prescriber Additional Comments:	

4 PRESCRIPTION

<input type="checkbox"/> Incivek®: 375 mg tablet	Sig: 750 mg PO TID with food	Qty: 168 tablets (28 days)
<input type="checkbox"/> Victrelis®: 200 mg capsule	Sig: 800 mg PO TID with food	Qty: 336 capsules (28 days)
Refill X _____	Note: TID is q 7 – 9 hours	
** HCV-RNA levels will be required per protocol (required for certain refills) **		
Deliver product to: <input type="checkbox"/> Patient's home <input type="checkbox"/> MD office <input type="checkbox"/> Clinic		
Prescriber's Signature: _____		Date: _____



HUMIRA® (adalimumab) - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address		City	
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address		City	
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

**3 Department of Vermont Health Access
HUMIRA® (adalimumab)
PRIOR AUTHORIZATION REQUEST**

Patient Diagnosis:

Rheumatoid Arthritis Psoriatic Arthritis Juvenile Idiopathic Arthritis
 Ankylosing Spondylitis Plaque Psoriasis Crohn's Disease

If requesting prescriber is not a Rheumatologist, Dermatologist or Gastroenterologist, has one of these specialties been consulted on this case? Yes No

Specialist name: _____ Specialist Type: _____

List previous medications/therapies tried and failed for this condition: (include oral, injectable, topical, phototherapy etc.)

Therapy (and dates)	Reason for discontinuation
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

Prescriber Additional Comments: _____

4 PRESCRIPTION

Dosage Form and Quantity:

Humira 40 mg/0.8 ml prefilled syringe Dispense Quantity: 2
or
 Humira PEN 40 mg/0.8 ml Dispense Quantity: 2
or
 Humira 40 mg/0.8 ml (Crohn's Starter kit-6) Dispense Quantity: 6 (1 kit)
or
 Humira PED 20 mg/0.4 ml prefilled syringe Dispense Quantity: 2

Sig: Dose/Route/Frequency: _____

Refill X: _____

Deliver product to: Patient's home MD office Clinic

Prescriber's Signature: _____ **Date:** _____



KINERET® (anakinra) - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address			City
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address			City
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

3 Department of Vermont Health Access KINERET® (anakinra) PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:
 Rheumatoid Arthritis

If requesting prescriber is not a Rheumatologist, has one been consulted on this case?
 Yes No

Specialist name: _____ Specialist Type: _____

List previous medications/therapies tried and failed for this condition: (include oral and injectable, etc.)

Therapy (and dates)	Reason for discontinuation
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

Prescriber Additional Comments:

4 PRESCRIPTION

Dosage Form and Quantity:
 Kineret 100 mg/0.67 ml prefilled syringe

Dispense Quantity:
 28 syringes

Sig: Dose/Route/Frequency: _____

Refill X: _____

Deliver product to: Patient's home MD office Clinic

Prescriber's Signature: _____ Date: _____

~ LONG ACTING NARCOTICS ~

Prior Authorization Request Form

Vermont Medicaid has established coverage limits and criteria for prior authorization of long acting narcotics. These limits and criteria are based on concerns about safety and the potential for abuse and diversion. In order for beneficiaries to receive coverage for this drug, it will be necessary for the prescriber to telephone or complete and fax this form to MedMetrics Health Partners. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

 Name: _____
 Phone #: _____
 Fax #: _____
 Address: _____

Beneficiary:

 Name: _____
 Medicaid ID #: _____
 Date of Birth: _____ Sex: _____
 Contact Person at Office: _____

Drug Requested:

 Please indicate: Brand Name or Generic Equivalent
Dose /Frequency and Length of Therapy:
Diagnosis or Indication for Use::

Has the member previously tried any of the following preferred medications?

Check all <input type="checkbox"/> that apply:	Re <input type="checkbox"/> sponse, check all that apply:
<input type="checkbox"/> Duragesic Patches	<input type="checkbox"/> side-effect <input type="checkbox"/> non-response <input type="checkbox"/> allerg <input type="checkbox"/>
<input type="checkbox"/> Methadone <input type="checkbox"/>	<input type="checkbox"/> side-effect <input type="checkbox"/> non-response <input type="checkbox"/> allergy
<input type="checkbox"/> Morphine Sulfate SR 12 hr	<input type="checkbox"/> side-effect <input type="checkbox"/> non-response <input type="checkbox"/> a <input type="checkbox"/> lergy

 Is this an initial request or a subsequent request? Initial Subsequent

Prescriber comments:

Prescriber Signature: _____

Date of this request: _____



MULTIPLE SCLEROSIS SELF INJECTABLES - Patient Enrollment/Order Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address			City
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address			City
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

**3 Department of Vermont Health Access
PRESCRIPTION
MULTIPLE SCLEROSIS SELF INJECTABLES**

Patient Diagnosis:

- Product:**
- Avonex 30 mcg/0.5 ml Prefilled Syringe (4 per box)
 - Avonex 30 mcg Kit (Single Dose Vials) (4 per box)
 - Betaseron 0.3 mg Prefilled Syringe
 - Copaxone 20 mg Prefilled Syringe (30 per kit)
 - Rebif Titration Pack X 1 (**Therapy initiation ONLY-No Refills**) (contains 6 - 8.8 mcg and 6 – 22 mcg Prefilled Syringes)
 - Rebif 22 mcg/0.5 ml Prefilled Syringes
 - Rebif 44 mcg/0.5 ml Prefilled Syringes

(Please Note: This form not to be used for Tysabri PA request or ordering)

Quantity: _____ **Refills:** _____

Dose / Route/ Frequency Instructions (Sig):

- Deliver product to: Patient's home MD office Clinic
- Needles/syringes: quantity sufficient for drug supply with refills as above

Prescriber's Signature: _____ **Date:** _____

~NUTRITIONALS ~
ORAL NUTRITION TAKEN BY MOUTH
 Prior Authorization Request Form

Effective February 2002, Vermont Medicaid established coverage limits and criteria for prior authorization of Nutritional supplements. These limits and criteria are based on concerns about safety and appropriate use. In order for beneficiaries to receive coverage for nutritionals, it will be necessary for the prescriber to telephone or complete and fax this form to MedMetrics Health Partners. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

 Name: _____
 Phone #: _____
 Fax #: _____
 Address: _____

Beneficiary:

 Name: _____
 Medicaid ID #: _____
 Date of Birth: _____ Sex: _____
 Contact Person at Office: _____

Diagnosis: _____

Baseline: Date: ___/___/___ Height: _____ Weight: _____ BMI: _____

Current: Date: ___/___/___ Height: _____ Weight: _____ BMI: _____

Children: Mid-Upper Arm Circumference: _____ Head Circumference: _____

Laboratory Values: Date: ___/___/___ Albumin: _____ Pre-Albumin: _____

Answer the following questions:

Caloric/protein intake is <u>not</u> obtainable through regular liquefied or pureed foods.	<input type="checkbox"/> Agree <input type="checkbox"/> Disagree
Requested nutritional supplement will be taken by <u>mouth</u> (not administered via tube feeding)	<input type="checkbox"/> Yes <input type="checkbox"/> No
Oral nutritional supplement is being requested due to:	<input type="checkbox"/> Unplanned weight loss (see complete definition by age in clinical criteria manual) <input type="checkbox"/> Low serum protein levels (nutritional deficiency as defined by albumin or pre-albumin levels)
Underlying cause of unplanned weight loss or low serum protein levels: Circle or describe specifics: <ul style="list-style-type: none"> ▪ Increased metabolic need resulting from severe trauma (i.e.: burns, infection, major bone fractures) ▪ Malabsorption syndrome (as related to cystic fibrosis, renal disease, short gut syndrome, Crohn's disease and other unspecified disorders of the gut) ▪ Nutritional wasting due to chronic disease (i.e.: cancer, AIDS, conditions resulting in dysphagia, pulmonary insufficiency, renal disease) 	<input type="checkbox"/> Yes <input type="checkbox"/> No
	<input type="checkbox"/> Yes <input type="checkbox"/> No
	<input type="checkbox"/> Yes <input type="checkbox"/> No

<p>▪ Other: Explain:</p> <p>_____</p> <p>_____</p>	<p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
--	--

Additional clinical information to support PA request:

<p>Requested Supplement: _____</p> <p>Strength & Frequency: _____</p> <p>Anticipated duration of supplementation: _____</p>
--

Prescriber Signature: _____ **Date of this request:** _____



ORAL ONCOLOGY/SELECT ADJUNCT - Patient Enrollment/Order Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address		City	
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address		City	
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

**3 Department of Vermont Health Access
PRESCRIPTION
ORAL ONCOLOGY/SELECT ADJUNCT**

Patient Diagnosis: _____

BSA(m2) _____ Patient height (cm) _____ Patient weight(kg) _____

Maintenance Therapy # of Refills _____

Cycle Specific Therapy NO REFILLS Cycle # _____

Treatment / Dosage Change Reason : Toxicity Progression of Disease

Change in BSA Other: _____

MEDICATION	Normalized Dose	Strength/ Frequency/ Route of Administration	QTY
<input type="checkbox"/> ARIMIDEX*			
<input type="checkbox"/> AROMASIN*			
<input type="checkbox"/> CASODEX			
<input type="checkbox"/> FEMARA*			
<input type="checkbox"/> GLEEVEC			
<input type="checkbox"/> HEXALEN			
<input type="checkbox"/> LUPRON DEPOT*			
<input type="checkbox"/> MERCAPTOPYRINE*			
<input type="checkbox"/> MESNEX			
<input type="checkbox"/> NEULASTA*			
<input type="checkbox"/> NEUPOGEN*			
<input type="checkbox"/> SPRYCEL			
<input type="checkbox"/> SUTENT			
<input type="checkbox"/> TARCEVA			
<input type="checkbox"/> TEMODAR			
<input type="checkbox"/> TRETINOIN			
<input type="checkbox"/> VESANOID			
<input type="checkbox"/> XELODA			
Other:			

Additional RX Instructions: _____

Prescriber's Signature: _____ Date: _____

* Not required to use ICORE

~ REMICADE ~

Prior Authorization Request Form

Vermont Medicaid has established coverage limits and criteria for prior authorization of Remicade. In order for beneficiaries to receive Medicaid coverage for Remicade, it will be necessary for the prescriber to telephone or complete and fax this prior authorization request to MedMetrics Health Partners. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Use this form for Remicade prior authorization requests only.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name: _____

Phone #: _____

Fax #: _____

Address: _____

Contact Person at Office: _____

Beneficiary:

Name: _____

Medicaid ID #: _____

Date of Birth: _____ Sex: _____

Will this medication be billed through the: **pharmacy benefit** or **medical benefit** (J-code or other code)?
(Please check one)

Administering Provider if other than Prescriber (name): _____ NPI #: _____

Pharmacy (if known): _____ Phone: _____ &/or FAX: _____

Remicade Infusion: Dose: _____ Frequency: _____ Length of therapy: _____

Indication:

Crohn's Disease Ulcerative Colitis

Ankylosing Spondylitis Psoriasis (Plaque) Psoriatic Arthritis Rheumatoid Arthritis

List previous medications tried and failed for this condition:

Name of medication	Reason for failure	Date(s) attempted
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____

Please explain why self-injectables (if indicated but not trialed) can not be trialed?

Prescriber comments:

Prescriber Signature: _____ **Date of this request:** _____

~SEROQUEL® (QUETIAPINE) ~
Prior Authorization Request Form

Vermont Medicaid has established criteria for prior authorization of quetiapine (Seroquel®) when used in doses of 50 mg/day or less. These criteria are based on concerns about safety and cost. The prescriber must telephone or complete and fax this form to MedMetrics Health Partners. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing physician:

Name: _____
Phone #: _____
Fax #: _____
Address: _____
Contact Person at Office: _____

Beneficiary:

Name: _____
Medicaid ID #: _____
Date of Birth: _____ Sex: _____
Diagnosis: _____

Request is for: Seroquel® _____ mg (strength) _____ (frequency/directions for use)

Patient Clinical Information to Support Seroquel® Prior Authorization Request

Indication for use is schizophrenia. Indication for use is bipolar disorder.

Indication for use is adjunct treatment of Major Depressive Disorder (MDD).

Patient initiated therapy with Seroquel® for this indication on ___/___/___

Patient has responded inadequately to the antidepressants listed below (at least 2):

Medication Name and Dose	Dates
_____	_____
_____	_____
_____	_____

Indication for use is an anxiety disorder.

Patient initiated therapy with Seroquel® for this indication on ___/___/___

Patient has responded inadequately to the antidepressants listed below (at least 2):

Medication Name and Dose	Dates
_____	_____
_____	_____

Or one antidepressant above and buspirone (dates: _____)

Indication for use is another mental health disorder (not approved for insomnia).

Please specify: _____

Patient initiated therapy with Seroquel® for this indication on ___/___/___

Prescriber's Signature: _____ **Date:** _____



SIMPONI® (golimumab) - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1 PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address			City
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2 PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address			City
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

3 Department of Vermont Health Access SIMPONI® (golimumab) PRIOR AUTHORIZATION REQUEST

Patient Diagnosis:
 Rheumatoid Arthritis Psoriatic Arthritis Ankylosing Spondylitis

If requesting prescriber is not a Rheumatologist or Dermatologist, has one of these specialties been consulted on this case? Yes No

Specialist name: _____ Specialist Type: _____

Initial Request (please complete remainder of form below)
 Subsequent Request: Response/tolerability to Simponi: _____

Please explain outcomes of therapy with Enbrel and/or Humira (OVHA preferred products):

Therapy (and dates)	Reason for discontinuation
_____	_____
_____	_____
_____	_____
_____	_____

List previous medications/therapies tried and failed for this condition:
(include NSAIDs, DMARDs, TNF Blockers: oral and injectable)

Therapy (and dates)	Reason for discontinuation
_____	_____
_____	_____
_____	_____
_____	_____

Prescriber Additional Comments:

4 PRESCRIPTION

Dosage Form and Quantity:

Simponi 50 mg/0.5 ml prefilled syringe Dispense Quantity: 1

Simponi 50 mg/0.5 ml prefilled autoinjector Dispense Quantity: 1

Sig: Administer 50 mg (1 syringe/autoinjector) subcutaneously once monthly.

Refill X: _____

Deliver product to: Patient's home MD office Clinic

Prescriber's Signature: _____ **Date:** _____



STELARA® (ustekinumab) - Prior Authorization and Patient Enrollment Form

Complete form in its entirety and fax to number listed below

1

PATIENT INFORMATION

Last Name		First Name	Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #	
Allergies: <input type="checkbox"/> NKA or _____			
Street Address		City	
State	County	Zip Code	
Home Phone		Cell Phone	
Parent/Guardian		Day Telephone	Night Telephone
Emergency Contact		Relationship	Telephone

2

PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address		City	
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	



Fax Completed Form to:
Fax Number: 866-364-2673
Phone Number: 800-327-1392

3

Department of Vermont Health Access STELARA® (ustekinumab) PRIOR AUTHORIZATION REQUEST

Patient Diagnosis: <input type="checkbox"/> Plaque Psoriasis	Patient Weight: _____ (kg)
If requesting prescriber is not a Dermatologist, has one been consulted on this case? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Specialist name: _____ Specialist Type: _____	
<input type="checkbox"/> Initial Request (please complete remainder of form below)	
<input type="checkbox"/> Subsequent Request: Response/tolerability to Stelara _____	
Please explain outcomes of therapy with Enbrel and/or Humira (OVHA preferred products): Therapy (and dates) _____ Reason for discontinuation _____	
List previous medications/therapies tried and failed for this condition: (include oral, injectable, topical, phototherapy etc.) Therapy (and dates) _____ Reason for discontinuation _____	

Prescriber Additional Comments:

4

PRESCRIPTION

Dosage Form and Quantity: (90 mg dose only permitted for patients > 100 kg)

- Stelara 45 mg/0.5 ml prefilled syringe Dispense Quantity: 0.5 ml
 or
 Stelara 90 mg/1 ml prefilled syringe Dispense Quantity: 1 ml

Sig: Dose/Route/Frequency: _____

Refill X: _____

Note: Dosed as initial dose, then 4 weeks later, then every 12 weeks.

Deliver product to: MD office Clinic (Self administration not permitted at this time)

Prescriber's Signature: _____ Date: _____



Complete form in its entirety and fax to number listed below

1

PATIENT INFORMATION

Last Name		First Name		Middle Initial
Date of Birth	Sex M <input type="checkbox"/> F <input type="checkbox"/>	Medicaid ID #		
Allergies: <input type="checkbox"/> NKA or _____				
Street Address			City	
State	County	Zip Code		
Parent/Guardian		Day Telephone	Night Telephone	
Emergency Contact		Relationship	Telephone	

2

PRESCRIBER INFORMATION

Prescriber's Name		NPI Number	DEA Number
Telephone Number	Fax Number	Hospital/Clinic Name	
Street Address		City	
State	County	Zip Code	
Contact Person at Office		Prescriber Specialty	
Supervising Physician's Name (If Required for Mid-Level Practitioner)		NPI Number	

WILCOX MEDICAL

Wilcox Home Infusion
250 Stratton Road
Rutland, Vermont 05701
A subsidiary of **bio scrip**
Form Last Updated 09/2010

Fax Completed Form to:

Fax Number: 802-775-7824 ☎

Phone Number: 800-639-1210 ☎

3

**Department of Vermont Health Access PRIOR AUTHORIZATION REQUEST
SYNAGIS® (PALIVIZUMAB)**

Gestational Age: weeks: days:	Current Weight: (kg)	Dose: 15mg / kg (weight verified monthly)
Diagnosis:		
<input type="checkbox"/> Infants born at 28 weeks of gestation or earlier (i.e., ≤ 28 weeks, 6 days) and under 12 months of age at the start of the RSV season (maximum 5 doses)		
<input type="checkbox"/> Infants born at 29 - 32 weeks (i.e., between 29 weeks, 0 days and 31 weeks, 6 days) of gestation and under 6 months of age at the start of the RSV season (maximum 5 doses)		
<input type="checkbox"/> Infants born at 32 - 35 weeks (i.e., between 32 weeks, 0 days and 34 weeks, 6 days) of gestation who have at least one of the following risk factors and who have not reached 3 months of age: (dosing continues in the RSV season through the end of the month the infant reaches 3 months old – maximum 3 doses)		
<input type="checkbox"/> Infant attends child care <input type="checkbox"/> One or more siblings (or other child permanently in house) < 5 years of age		
<input type="checkbox"/> Children under 24 months of age with chronic lung disease of prematurity (bronchopulmonary dysplasia) who have received medical therapy (supplemental oxygen, bronchodilator, diuretic or chronic corticosteroid therapy) within 6 months prior to the start of the RSV season (maximum 5 doses)		
<input type="checkbox"/> Treatment: _____ <input type="checkbox"/> Dates of Use: _____		
<input type="checkbox"/> Children under 24 months of age with hemodynamically significant cyanotic or acyanotic heart disease(CHD)		
<input type="checkbox"/> Receiving medication to control congestive heart failure		
<input type="checkbox"/> Moderate to severe pulmonary hypertension (maximum 5 doses)		
<input type="checkbox"/> Have cyanotic heart disease		
<input type="checkbox"/> Infants under 12 months of age with either: (dosing continues in the RSV season through the end of the month the infant reaches 12 months old – maximum 5 doses)		
<input type="checkbox"/> Congenital abnormalities of the airways		
<input type="checkbox"/> Neuromuscular condition compromising handling of respiratory tract secretions		
<input type="checkbox"/> Other: _____		

NICU HISTORY

Did the patient spend time in the NICU?
 Yes No (If yes, please attach the NICU summary)

Was RSV prophylaxis recommended by the NICU/Hospital physician for this patient?
 Yes No

Was a NICU/Hospital /Clinic dose administered?
 Yes, Date(s): _____ No

4

PRESCRIPTION

Synagis (palivizumab) 50 and/or 100 mg vials and supplies for administration.

Sig: Inject 15 mg/kg IM once every 4 weeks; expected date of first home injection: _____

Dispense Quantity: Quantity sufficient for prophylaxis thru 03/2010

Deliver product to: MD office Patient's home Clinic

Home health nurse to administer injection Home Health Agency: _____

If delivery is to clinic, please give location: _____

Pediatric Anaphylaxis: Administer 0.01 ml/kg (max 0.3ml) of 1:1000 epinephrine solution subcutaneously or intramuscularly, and contact EMS or physician, as appropriate.

Other: _____

Sig: _____

Physician will monitor patient's response to therapy. Any complications in therapy will be reported to the physician either by the patient's caregiver, or the skilled nursing service (If other than physician's office or Wilcox Home Infusion)

Prescriber's Signature: _____ **Date:** _____

Supervising Physician's Signature: _____

This order is valid for the entire upcoming season if signed prior to the November dose, or for the remainder of the present season if signed after November.

~VIVITROL~

Prior Authorization Request Form

Vermont Medicaid has established criteria for prior authorization of Vivitrol (naltrexone for IM extended release suspension). These criteria are based on concerns about safety. In order for beneficiaries to receive coverage for Vivitrol, it will be necessary for the prescriber to complete and fax this prior authorization request to MedMetrics Health Partners. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information.

Submit request via Fax: 1-866-767-2649

Prescribing physician:

Name: _____

Phone #: _____

Fax #: _____

Address: _____

Contact Person at Office: _____

Beneficiary:

Name: _____

Medicaid ID #: _____

Date of Birth: _____ Sex: _____

Diagnosis: _____

Administering physician:

Name: _____

Address: _____

Pharmacy (required): _____ **Phone:** _____ **&/or FAX:** _____

QUALIFICATIONS

MDs	Prescribers must secure direct delivery of Vivitrol from the pharmacy to the physician's office. Pharmacies may not dispense Vivitrol directly to the patient. Vivitrol may not be billed through the Medical Benefit as a J-Code J2315.
------------	---

PROCESS

► Please answer the following questions:

Patient diagnosis ?	<input type="checkbox"/> Alcohol dependence <input type="checkbox"/> Prevention of relapse to opioid dependency
Has the patient been opiate free for > 7 – 10 days	<input type="checkbox"/> Yes <input type="checkbox"/> No
For alcohol dependence:	
(1) Has the patient tried any of the following? Please document below.	
oral naltrexone: <input type="checkbox"/> side-effect <input type="checkbox"/> non-response <input type="checkbox"/> allergy	<input type="checkbox"/> Yes <input type="checkbox"/> No
acamprosate: <input type="checkbox"/> side-effect <input type="checkbox"/> non-response <input type="checkbox"/> allergy	
disulfiram: <input type="checkbox"/> side-effect <input type="checkbox"/> non-response <input type="checkbox"/> allergy	
(2) Has patient had a recent hospital admission for alcohol detoxification?	<input type="checkbox"/> Yes <input type="checkbox"/> No If yes, date: ____/____/____
For prevention of relapse to opioid dependency	
(1) Has the patient failed buprenorphine therapy?	<input type="checkbox"/> Yes <input type="checkbox"/> No
(2) Is the patient not a candidate for buprenorphine therapy?	<input type="checkbox"/> Yes <input type="checkbox"/> No
(3) Patient requires injectable therapy?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Comments and additional patient history:	

Prescriber Signature: _____ **Date of request:** _____

~ XOLAIR ~

Prior Authorization Request Form

Vermont Medicaid has established coverage limits and criteria for prior authorization of Xolair. In order for beneficiaries to receive Medicaid coverage for Xolair, it will be necessary for the prescriber to telephone or complete and fax this prior authorization request to MedMetrics Health Partners. Please complete this form as directed and sign and date below. Incomplete requests will be returned for additional information.

Submit request via: Fax: 1-866-767-2649 or Phone: 1-800-918-7549

Prescribing Physician:

Name: _____

Phone #: _____

Fax #: _____

Address: _____

Specialty: _____

Contact Person at Office: _____

Beneficiary:

Name: _____

Medicaid ID #: _____

Date of Birth: _____ Sex: _____

 Patient Diagnosis: Moderate/Severe Persistent Asthma

 Other: _____

If requesting prescriber is not a pulmonologist, allergist, or immunologist, date of last visit to one (required yearly):

Specialist name: _____ **Specialist Type:** _____ **Date:** _____

 Initial Prior Authorization Request: Please complete all portions of form below

 Subsequent PA Request: Has patient shown marked clinical improvement **Yes** **No**

List all previous therapies tried and failed for this condition:

Therapy	Specific Drug	Reason for Discontinuation
Inhaled Corticosteroid		
Chronic Oral Corticosteroid		
Leukotriene Receptor Antagonist		
Long-Acting Beta Agonist		

Has the member tested positive to at least one perennial aeroallergen by a skin or blood test (i.e. RAST, CAP, intracutaneous test)? **Yes** **No**

Please explain: _____

 Is the member's IgE level ≥ 30 and ≤ 700 IU/ml? **Yes** **No** Please provide IgE level: _____

Prescriber Signature: _____

Date of this request: _____